Official Title: A Phase 2, Double-blind, Placebo-controlled, Randomized Study  
Evaluating The Efficacy, Safety, And Tolerability Of SAGE-324 In 
The Treatment Of Individuals With Essential Tremor
Study ID: [REMOVED]  
Document Date: Protocol Version 5.0: 18-December-2020
Protocol Version 4.0: 11-June-2020 
Protocol Version 3.0: 24-February-2020 
Protocol Version 2.0: 20-December-2019 
Protocol Version 1.0: 23-October-2019
Clinical Study Report  324-ETD -201
16.1 Study Information 
1 1. PROTOCOL AND AMENDMENTS
Version Number  Date Title 
1.0 23 October  2019 A Phase 2, Double-Blind, Placebo -Controlled, Randomized 
Study Evaluating the Efficacy, Safety, and Tolerability of 
SAGE -324 in the Treatment of Individuals with Essential 
Tremor  
2.0 20 December 2019  
3.0 24 February  2020  
4.0 10 June 2020  
5.0 17 December 2020  
Adminis
trative Letter dated 16 November 2020 
A PHASE 2, DOUBLE -BLIND, PLACEBO -CONTROL LED, 
RANDOMIZED, DOSE -RAN GING STUDY EVALUATIN G THE 
EFFICACY, SAFETY, AN D TOLERABILITY OF SA GE-324 
MONOTHERAPY AND ADJU NCTIVE THERAPY WITH 
PROPRANOLOL IN THE T REATMENT OF INDIVIDU ALS 
WITH ESSENTIAL TREMOR   
324-ETD -201
Investigational Product  
Clinical Phase  
Sponsor  
Sponsor Contact  
Sponsor Medical Monitor  SAGE-32 4 Oral Table t 
Phase 2  
Sage Therapeutics, Inc. 
215 First Street 
Cambrid ge, MA 0
2142 
, MD 
, MD, PhD
23 October 2019Date of Original Protocol  
Confidentiality Statement  
The confidential information in this document is provided to you as an investigator or consultant for 
review by you, your staff, and the applicable Institutional Review Board/Independent Ethics Committee . 
Your acceptance of this document constitutes agreement that you will not disclose the information 
contained herein to others without written authorization from Sage Therapeutics , Inc. 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
3 INVESTIGATORâ€™S AGREE MENT  
I have received and read the Investigatorâ€™s Brochure for SAGE -324. I have read the 324-ETD -
201 protocol and agree to conduct the study as outlined . I agree to maintain the confidentiality of 
all information received or developed in connection with this protocol.  
 
 
             
Printed Name of Investigator  
 
             
Signature of I nvestigator  
 
        
Date  (DD/MMM/YYYY)  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
4 PROCEDURES IN CASE O F EMERGENCY  
Table 1: Emergency Contact Information  
Role in Study  Name  Address and Telephone N umber  
Sage  Study Physician  , MD  
 Phone US:  
Sage  Medical Monitor  and 
24-hour Emergency Contact, MD, PhD  Office phone:  
Mobile:  
E-mail: 
SAE Reporting Information  IQVIA Lifecycle Safety  4820 Emperor Boulevard  
Durham, NC 27703   
E-mail:  Sage.Safety@iqvia.com
Fax: 1 -855-638-1674
SAE Hotline: 1 -855-564-2229  
Product Complaints  Sage Therapeutics, Inc.  E-mail:
productcomplaints@sagerx.com
Phone: 1 -833-554-7243

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
5 1. SYNOPSIS  
Name of Sponsor/Company:  
Sage Therapeutics, Inc. (hereafter referred to as Sage Therapeutics, or Sage)  
Name of Investigational Product : 
SAGE -324 Oral Tablet  
Name of Active Ingredient:  
SAGE -324 
Title of Study:  
A Phase 2, Double -blind, Placebo -controlled, Randomized, Dose -ranging Study Evaluating the 
Efficacy, Safety, and Tolerability of SAGE -324 Mono therapy  and Adjunctive Therapy  with 
Propranolol  in the Treatment of Individuals  with Essential Tremor  
Number of Sites and Study Location: This study will take place at  approximately 30 site s in the 
United States.  
Phase of D evelopment: Phase 2  
Planned Duration for each Study Participant:  
The duration of  participation (from Screening through the final follow -up visit) for each participant is 
estimated to be up to  72 days.  
Objectives and Endpoints : 
Objectives  Endpoints  
Primary   
To assess the effect of SAGE -324 compared 
to placebo on tremor reduction in 
individuals with essential tremor (ET)  Change from baseline compared to placebo in 
Kinesia ONE â„¢ accelerometer scores  after 28 days 
of treatment  
Secondary   
â€¢ To assess the effect of SAGE -324 
compared to placebo on activities of 
daily living (ADLs), total 
performance, and upper extremities  
 
 
 
 
 
 
 
â€¢ To evaluate the safety and 
tolerability of SAGE -324 â€¢ Change from baseline compared to placebo 
in Kinesia ONE accelerometer scores at all 
other timepoints  
â€¢ Change from baseline compared to placebo 
in the following:  
- The Essential Tremor Rating 
Assessment (TETRAS) Scale ADL 
score  
- TETRAS total performance score  
- TETRAS performance subscale part 4 
upper limb tremor  score  
â€¢ Incidence of treatment -emergent adverse 
events (TEAEs)  
 
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
6  
 
Study Description : 
This is a randomized, double -blind, placebo -controlled, parallel group dose -ranging study to evaluate 
the efficacy, safety, and tolerability of SAGE -324 as mono therapy  and adjunctive therapy with 
propranolol in individuals with ET. Participants, site staff, and sponsor personnel will be masked to 
treatment allocation.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
7 This study includes a Screening Period of up to 28 days, a 2 9-day treatment period  (28 days of 
dosing) , and a 14 -day follow up period. After providing informed consent,  participants will undergo 
screening assessments as outlined in Table 2  to determine eligibility.  
Screening Period: The Screening Period begins with the signing of the informed consent form (ICF). 
Following completion of screening, on Day 1, eligible participants will visit the study center and will 
be randomized to 1 of 3 treatment groups (SAGE -324 30 mg  daily , SAGE -324 60 mg daily , or 
placebo) in a 1:1:1  ratio. Randomization will be stratified based on the use of propranolol for the 
treatment of ET (Y/N). Participants who are on a propranolol regimen must have been on a stable 
dose for at least 1 month prior to Day 1 and will continue to be on a stable dose during the Treatment 
Period. Participants will complete baseline assessments of safety and efficacy, including the clinician -
rated TETRAS and quantitative Kinesia ONE assessments  of tremor, as specified in the Schedule of 
Assessments (Table 2 ). 
Double -Blind Treatment Period:  Starting on Day 1, participants will receive a single d ose of 
investigational product (IP) once daily for  28 days on an outpatient basis. Doses occurring on 
scheduled clinic visits will be administered in the clinic, and doses occurring on all other days may be 
self-administered by the participant at home duri ng the 2 9-day Treatment Period  (28 days of dosing) . 
During the Treatment Period, participants will return to the study center approximately once per week 
for efficacy and safety assessments as specified in  Table 2 . Participants will be trained on the use of 
software applications and devices necessary to complete questionnaires or other assessments as 
required.  
Follow Up Period:  Follow up visits will be conducted on an outpatient basis. Participants will 
continue to complete  questionnaires as indicated in  Table 2  and will receive  a phone call 
approximately 7 days after the last dose of IP (ie, Day 3 6) for safety monitoring. Participants will 
return to the study center for an end of study visit approximately 14 days following the last dose of IP 
(ie, Day 4 2). 
Participants who disco ntinue IP during the Treatment Period will be asked to return to the clinic as 
soon as possible for an end of treatment (EOT) visit. Follow -up visits should take place as scheduled , 
or relative to the last dose of IP if discontinuing treatment early . If at  any time after the EOT visit, a 
participant  decides to withdraw from the study, the participant  should return for an early termination 
visit (ETV) . The EOT and  ETV  can be on the same day if a participant  discontinues IP and withdraws 
from the study on the same day during a clinic visit; in this case, all events scheduled for the EOT 
visit will be conducted . 
During the study, a phone call will be conducted  once  per week (preferably mid -week) in between  
clinic visits , to review current status  of participant . 
Number of Participants  (planned):  Up to 120 participants, with up to 40 participants per arm.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
8 Eligibility Criteria:  
Inclusion Criteria:  
1. Participant has s igned an ICF before any study -specific procedures or washout of drugs i s 
performed.  
2. Participant is 18 to 80 years of age, inclusive, at the time informed consent is obtained.  
3. Participant  has a diagnosis of ET, as defined by all of the following criteria:  
a. Isolated tremor syndrome consisting of bilateral upper limb action tremo r 
b. At least 3 years duration  
c. With or without tremor in other locations (eg, head, voice, or lower limbs)  
d. Absence of other neurological signs, such as dystonia, ataxia, or parkinsonism , isolated 
focal tremors (eg, voice, head) , task- and position -specific tr emors , sudden tremor onset 
or evidence of step -wise deterioration of tremor  
4. Participant has a combined t otal upper extremity TETRAS score of â‰¥8 with at least 1 upper 
extremity TETRAS score >4.  
5. Participant is willing to discontinue medications taken for the  treatment of ET, with the 
exception of propranolol , within 14 days or 5 half -lives (whichever is longer) prior to 
receiving  IP. 
6. Participants taking propranolol for the treatment of ET must be on a stable dose for at least 
1 month prior to Day 1 and must b e willing to maintain their stable dose through Day 2 9. 
7. Participant is willing to discontinue the use of alcohol and drugs of abuse within  at least â‰¥1 
week  prior to Day 1  and through Day 2 9 of the study.  
8. Female participant agrees to use at least one method of highly effective contraception as 
listed in Section  8.2.4  during participation in the study and for 30 days following the last dose 
of study drug, unless she  is postmenopausal (at least 12 months of spontaneous amenorrhea 
without an alternative medica l cause, with confirmatory follicle stimulating hormone 
>40 mIU/mL), and/or surgically sterile (bilateral oophorectomy, hysterectomy, and/or 
bilateral salpingectomy), or does not engage in sexual relations which carry a risk of 
pregnancy (do es include abst inence).  
9. Male participant agrees to use an acceptable method of effective contraception for the 
duration of the study and for 13 weeks after receiving study drug, unless the participant  does 
not engage in sexual relation(s) which carry a risk of pregnancy . Acceptable methods of 
effective contraception are listed in Section  8.2.4 .  
10. Male participant  is willing to abstain from sperm donation for the duration  of the study and 
for 13 weeks after receiving study drug.  
11. Female participant must have a pregnancy test result that is confirmed as negative at 
Screening and  Day 1 . 
12. At the discretion of the Investigator, participant is medically stable and ambulatory, and  has 
been on  stable dose(s) of any necessary prescription or over the counter medication(s) for at 
least 30 days  prior to Day 1, or changes/discontinues their use prior to Day 1 with the 
appropriate washout , as applicable  per investigator judgement .  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
9 13. Participant has no clinically significant findings, as determined by the investigator, on 
physical examination  including mental state examination (MSE) and neurologic examination , 
12-lead ECG, or clinical laboratory tests.  
Exclusion Criteria:  
1. Participant has presence of known causes of enhanced physiological tremor.  
2. Participant has had r ecent exposure (14 days prior to Day 1) to tremorgenic drugs or presence 
of a drug  or alcohol  withdrawal state.  
3. Participant has h ad direct or indirect injury or  trauma to the nervous system within 3 months 
before the onset of tremor . 
4. Participant  has had a previous procedure  for the treatment of ET, deep brain stimulation, 
brain lesioning, or magnetic resonance (MR) guided procedure, eg, MR -guided focused 
ultrasou nd. 
5. Participant has h istorical or clinical evidence of tremor with psychogenic origin (including 
but not limited to eating disorders, major depression, etc.)  
6. Participant has s ignificant history and/or presence of hepatic, renal, cardiovascular, 
pulmonary, gastrointestinal, hematological, immunologic, ophthalmologic, metabolic 
(hypothyroidism with stable thyroid replacement is acceptable), or oncological disease.  
7. Participant has h istory, presence, and/or current evidence of serologic positive results for 
hepatitis B surface antigen (HBsAg), hepatitis C antibodies (anti -HCV), or human 
immunodeficiency virus (HIV) 1 or 2 antibodies.  
8. Participant has history of alcohol or drug abuse  within 6 months prior to Screening , or a  
positive screen for alcohol o n the Day 1  visit, or a positive screen for drugs of abuse at 
Screening or at the Day 1 visit.  
9. Participant has a k nown allergy to SAGE -324 or any excipient.  
10. Participant has had e xposure to another investigational drug or device within 30 days prior to 
the Day 1 visi t. 
11. Participant has h istory or suicidal behavior within 2 years or answers â€œYESâ€ to questions 3, 
4, or 5 on the C -SSRS at Screening or at Day 1 or is currently at risk or suicide in the opinion 
of the investigator  
12. Participant has d onated one or more units (1 unit  = 450 mL) of blood or experienced acute 
loss of an equivalent amount of blood within 60 days prior to Day 1.  
13. Participant is unable to perform Kinesia O NE assessments or unable to use the device 
required to perform the assessment.  
14. Participant  has any condition or comorbidity that in the opinion of the investigator would 
limit or interfere with the participantâ€™s ability to complete or partake in the study.  
15. Participant is unwilling or unable to comply with study procedures  and required training . 
16. Participant has used any known moderate or strong cytochrome P 450 3A4 or P450 2D6 
inhibitors and/or inducers within 14 days or 5 half -lives (whichever is longer) prior to Day 1  
or consumed grapefruit juice, grapefruit, Seville orang es, pomegranates, tangelos, or St. 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
10 Johnâ€™s Wort or products containing these within 30 days prior to Day 1 . Use of mild 
cytochrome inhibitors and/or inducers may be permitted.  
17. Participant has concurrent or recent exposure (14 days prior to the Day 1 visit)  to 
sedative/hypnotic drugs, stimulants, eg, opioids, highly -caffeinated beverages or dietary 
supplements containing high doses of caffeine , or recent increase  above  regular daily  
consumption of coffee . 
18. Participant has concurrent or recent exposure ( 30 days prior to the Day 1 visit) to long-acting 
benzodiazepines . 
19. Participant plans to undergo elective surgery or relocate during participation in the study.  
20. Participant is investigative site personnel or a member of their immediate families (spouse, 
parent , child or sibling whether biological or legally adopted).   
Investigational Product  Dosage and Mode of Administration:  
Study drug , SAGE -324 or matched placebo oral tablet(s) will be administered in the clinic or self -
administer ed once  daily , in the morning  with food . The following dose levels of SAGE -324 will be 
evaluated:  
â€¢ 30 mg daily in the morning  
â€¢ 60 mg daily in the morning  
Duration of Treatment:  
Each participant will receive a single dose of SAGE -324 oral tablet or matching placebo administered 
once  daily for 28 days.   
Statistical Methods:   
A separate statistical analysis plan ( SAP) will provide a detailed description of the data analyses to be 
performed in the study . The SAP will be finalized and approved prior to database lock .  
General Considerations  
For the purpose of all efficacy and safety analyses where applicable, baseline is  defined as the last 
measurement prior to the start of IP administration.  
Continuous endpoints will be summarized with number (n), mean, standard deviation, median, 
minimum, and maximum. In addition, change from baseline values will be calculated at each t ime 
point and summarized descriptively. For categorical endpoints, descriptive summaries will include 
counts and percentages.  
Analysis Sets  
The Randomized Set is defined as all participants who are randomized.  
The Safety Set will include all participants who were administered IP.  
The Full Analysis Set will include  all randomized participants who received any amount of IP and 
have a baseline and at least one postbaseline clinic -based Kinesia  ONE  accelerometer score.  
 
 
The Per Protocol Set will include all participants in the F ull Analysis Set  without any major protocol 
deviations that could affect efficacy. The review of major protocol deviation s will be completed, and 
the decision on whether the deviation affects efficacy will be documented before database unblinding.  
Determination of Sample Size  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
11 The sample size of this study is based on the assumption of a 3 points difference in the mean change 
from baseline Kinesia ONE accelerometer  scores  between SAGE -324 and placebo with a standard 
deviation of 3 .5 point s and a 1:1:1 randomization schedule. Under these assumptions, a sample size of 
30 evaluable subjects per group would provide 90% power  assuming a  2-sided test at Î± level of 0.05. 
By including  3 treatment groups and using a 1:1 :1 randomization ratio, a total of 90 evaluable 
subjects are required. Assuming a nonevaluability rate of  25%, at least 1 20 subjects will be 
randomized.    
Analysis of Primary Efficacy Endpoint  
The estimand for the primary efficacy analysis is the treatment difference between either dose of 
SAGE -324 and placebo in mean change from baseline in clinic -based Kinesia ONE accelerometer 
scores at Day 2 9 based on F ull Analysis Set . This will be analyzed  using a mixed effects model for 
repeated measures (MMRM); the model will include treatment, baseline Kinesia  ONE accelerometer 
score, stratification factor, assessment timepoint, and timepoint -by-treatment as explanatory variables. 
All explanatory variabl es will be treated as fixed effects. All postbaseline clinic visits will be included 
in the model. The main comparison will be between SAGE -324 and placebo at the 2 9-day timepoint. 
Model -based point estimates (ie, least squares means, 95% confidence interv als, and p -values) will be 
reported where applicable. An unstructured covariance structure will be used to model the within -
subject errors. If there is a convergence issue with the unstructured covariance model, Toeplitz 
compound symmetry or Autoregressive  (1) [AR(1)] covariance structure will be used, following this 
sequence until convergence is achieved. If the model still does not converge with AR(1) structure, no 
results will be reported. When the covariance structure is not unstructured , the sandwich e stimator for 
the variance covariance matrix will be derived, using the EMPIRICAL option in the PROC MIXED 
statement in SAS.  
Analysis of Secondary Efficacy Endpoints  
Similar to those methods described above for the primary endpoint, an MMRM will be used to 
analy ze of the change from baseline in TETRAS total performance score s, TETRAS Performance 
subscale part 4 upper limb tremor  score s and TETRAS ADL score s.  
Safety Analysis  
Safety and tolerability of study drug will be evaluated by incidence of TEAEs /serious adverse events, 
 
  
 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
12 Table 2: Schedule of Assessments  
Assessment  Screening  Treatment Period  Follow -up Period  
Study Day  -28 to -1 1 5  
(Â±1) 
Phone
Call 8 
(Â±1) 12 
(Â±1) 
Phone
Call 15  
(Â±1) 19 
(Â±1) 
Phone
Call 22  
(Â±1) 26 
(Â±1) 
Phone
Call 29 
(+1) 
EOT  32 
(Â±1) 
Phone
Call 35  
Safety  
Phone
Call 38 
(Â±1) 
Phone
Call 42 
(Â±1) 
EOS / 
ETVa 
Informed Consent  X              
Inclusion/Exclusion  X              
Demographics  X              
Medical History  X              
Hepatitis/HIV screen  X              
Pregnancy Test  
(all women)  X  
(serum ; all 
women ) X  
(urine ; 
WOCBP  
only)   
 X  
(urine ; 
WOCBP  
only)    X  
(urine ; 
WOCBP  
only)    X  
(urine ; 
WOCBP  
only) 
FSH (postmenopausal 
women only)  X              
Randomizationb  X             
Drug/alcohol screens  X X  X  X  X  X    X 
Physical examinationc X X  X  X  X  X    X 
Neurological 
examination including 
MSEc X X  X  X  X  X    
X 
Body height  X         X    X 
Body weight  X X  X  X  X  X    X 
Vital signsd X X  X  X  X  X    X 
12-Lead ECGe X X  X  X  X  X    X 
Chemistry/hematology/
coagulation/urinalysis  X X  X  X  X  X    X 

&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7' &21),'(17,$/
$VVHVVPHQW 6FUHHQLQJ 7UHDWPHQW3HULRG )ROORZXS3HULRG
6WXG\'D\ WR  
Â“
3KRQH
&DOO
Â“
Â“
3KRQH
&DOO
Â“
Â“
3KRQH
&DOO
Â“
Â“
3KRQH
&DOO

(27
Â“
3KRQH
&DOO
6DIHW\
3KRQH
&DOO
Â“
3KRQH
&DOO
Â“
(26
(79D
.LQHVLDJ ; ; ;; ;;;
,QYHVWLJDWLRQDO3URGXFW
'LDU\WUDLQLQJK ;       
7(75$6L; ; ;; ; ; ;
3DWLHQW3HUFHSWLRQRI
5HVSRQVH%XUGHQ   ;;
3DUWLFLSDQWWUDLQLQJM;         PPD
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7' &21),'(17,$/
$VVHVVPHQW 6FUHHQLQJ 7UHDWPHQW3HULRG )ROORZXS3HULRG
6WXG\'D\ WR  
Â“
3KRQH
&DOO
Â“
Â“
3KRQH
&DOO
Â“
Â“
3KRQH
&DOO
Â“
Â“
3KRQH
&DOO

(27
Â“
3KRQH
&DOO
6DIHW\
3KRQH
&DOO
Â“
3KRQH
&DOO
Â“
(26
(79D
'LVSHQVHVWXG\GUXJ ;;;; 
,3DGPLQLVWUDWLRQ  $GPLQLVWHUHGRQFHGDLO\IRUGD\V 1RWDSSOLFDEOH
$(V6$(V ;
3ULRUDQGFRQFRPLWDQW
PHGLFDWLRQDQGKLVWRU\N;
$EEUHYLDWLRQV $'/ DFWLYLWLHVRIGDLO\OLYLQJ $( DGYHUVHHYHQW
(&* HOHFWURFDUGLRJUDP (26 HQGRIVWXG\(27  HQGRIWUHDWPHQW  
(79 HDUO\WHUPLQDWLRQYLVLW )6+ IROOLFOHVWLPXODWLQJKRUPRQH+,9  KXPDQLPPXQRGHILFLHQF\
YLUXV,&) LQIRUPHGFRQVHQWIRUP PLQ PLQXWHV,3 LQYHVWLJDWLRQDOSURGXFW 06( PHQWDOVWDWHH[DPLQDWLRQ
 
6$( VHULRXVDGYHUVHHYHQW 7(75$6  7KH(VVHQWLDO7UHPRU5DWLQJ$VVHVVPHQW6FDOH:2&%3  ZRPHQRIFKLOGEHDULQJSRWHQWLDO 

1RWH
x$SKRQHFDOOZLOOEHSHUIRUP HGRQFHPLGZHHNEHWZHHQFOLQLFYLVLWVGXULQJWKH7UHDWPHQW3HULRGD QGRQFHSHUZHHNGXULQJWKH )ROORZ8S3HULRG
'XULQJWKHSKRQHFDOOWKHFXUUHQWVW DWXVRIWKHSDUWLFLSDQWZLOOEHUHYLHZHGLQFOXGLQJEXWQ RWOLPLWHGWR$(UHSRUWLQJDQGFKDUDFWHUL]DWLRQ,3
FRPSOLDQFHUHYLHZDQGDVVHVVPHQWRIJHQHUD OZHOOEHLQJ'D\V DQGDUHFOLQLFYLVLWV
x7KHVXJJHVWHGRUGHURIDVVHVVPHQWVGXULQJFOLQLFYLVLWVLV YLWDOVLJQV.LQHVLD7(75$6(&*EORRGVDPSOHFROOHFWLRQIRU FOLQLFDOODERUDWRU\
DVVHVVPHQWVDQGTXHVWLRQQDLUHV 
x$OO'D\DVVHVVPHQWVZLOOEHSHUIRUPHGSUHGRVH

D3DUWLFLSDQWVZKRGLVFRQWLQXH,3GXULQJWKHWUHDWPHQWSHULRGVK RXOGUHWXUQWRWKHVLWHIRUDQ(27YLVLWDVVRRQDVSRVVLEOH3 DUWLFLSDQWVZKRGLVFRQWLQXH,3ZLOO
EHHQFRXUDJHGWRFRQWLQXHRQVWXG\DQGFRPSOHWHVDIHW\DVVHVVPHQWVDQGIROORZXSYLVLWV)ROO RZXSYLVLWVVKRXOGWDNHSODFHDVVFKHGXOHGUHODWLYHWRWKHODVW
GRVHRI,3,IDWDQ\WLPHDIWHU WKH(27YLVLWDSDUWLFLSDQWG HFLGHVWRZLWKGUDZIURPWKHVWX G\WKHSDUWLFLSDQWVKRXOGUHWXU QIRUDQ(797KH(27DQG(79V
FDQEHRQWKHVDPHGD\LIDSDUWLF LSDQWGLVFRQWLQXHV,3DQGZLWKGUDZVIURPWKHVWXG\RQWKHVDPHGD \GXULQJDFOLQLFYLVLW,Q VXFKFDVHDOOSURFHGXUHV
VFKHGXOHGIRU(27DQG( 79ZLOOEHFRQGXFWHG
E5DQGRPL]DWLRQZLOORFFXURQ'D\RQO\, QDGGLWLRQWRPHHWLQJ DOORWKHUHOLJLELOLW\FULWHULD HOLJLELOLW\L VGHWHUPLQHGEDVHGRQWKHWRWDOXSSHUH[WUHPLW\
7(75$6VFRUHRIÂ•ZLWKDWOHDVWXSSHUH[WUHPLW\7(75$6VFRUH !DW6FUHHQLQJ
F&RPSOHWHSK\VLFDOH[DPLQDWLRQ VLQFOXGLQJ06(DQGQHXURORJLFH [DPLQDWLRQDVSDUWVRISK\VLFDOH[DPLQDWLRQVKRXOGEHSHUIRUPH GDVVSHFLILHGDQGDV
FOLQLFDOO\QHFHVVDU\VHH6HFWLRQ PPD
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
15 d Vital signs without orthostat ic blood pressure  and heart rate  will be collected  predose in the beginning of each visit  and again  prior to departing the clinic, at 
approximately  5 hours (Â±30 min) . Postdose  vital signs to includ e orthostatic blood pressure and heart rate , measured after the participant has been in the supine 
position for at least 5 minutes and then repeated 1 minute and 3 minutes after standing.  
e ECGs will be collected and read centrally. ECGs will be performed approximately  5 hours  (Â±30 min)  postdose. All ECGs must be performed after the 
participant has been in a supine position for at least 5 minutes.  
 
  
g Kinesia ONE will be assessed simultaneous to TETRAS Performance subscale part 4 upper limb tremor . On clinic dosing days, pa rticipants will perform 
Kinesia ONE assessments approximately 30 to 60 minutes prior to dosing  in the morning . In addition, on Day 15 , Kinesia ONE assessments will be performed 
at 5 and 8 hours ( Â±30 min) postdose.  
h Training specific to  the Investigational Product Diary  will be performed prior to randomization .  
i The TETRAS Performance and TETRAS ADL subscales will be assessed at Screening and predose at each clinic visit  postrandomization . The TETRAS 
Performance subscale part 4 upper limb t remor will be assessed simultaneous to Kinesia ONE. In addition, on Day 15,  the TETRAS Performance  subscale  will 
be assessed  at 5 and 8 hours (Â± 30 min) postdose.  Eligibility is determined based on the combined TETRAS performance subscale part 4 upper limb tremor total 
score â‰¥8, with at least 1 upper limb score >4 at Screening.  
j Participants will be trained on the use of software applications and devices necessary for the conduct of the study by site p ersonnel.  
k Prior and concomitant medications will be re corded during Screening and will include all medications and supplements  taken within the 30 days prior to 
signing the ICF  through the first dose of IP.  Concomitant medications will be recorded thereafter throughout the duration of the study. At Screening,  this will 
include year of diagnosis and history of treatments for ET since year of diagnosis  and use of antidepressant medications taken in the prior 12 months .  
 

&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7' &21),'(17,$/
7$%/(2)&217(176
  6<1236,6   
  7$%/(2)&217(176   
  /,672)$%%5(9,$7,216$1''(),1,7,2162)7(506   
  ,1752'8&7,21   
  'RVH-XVWLILFDWLRQ   
  %HQHILW5LVN$VVHVVPHQW   
  678'<2%-(&7,9(6$1'(1'32,176   
  ,19(67,*$7,21$/3/$1   
  2YHUDOO6WXG\'HVLJQ   
  1XPEHURI3DUWLFLSDQWV   
  7UHDWPHQW$VVLJQPHQW   
  'RVH$GMXVWPHQW&ULWHULD   
  &ULWHULDIRU6WXG\7HUPLQDWLRQ   
  6(/(&7,21$1':,7+'5$:$/2)3$57,&,3$176   
  3DUWLFLSDQW,QFOXVLRQ&ULWHULD   
  3DUWLFLSDQW([FOXVLRQ&ULWHULD   
  6FUHHQ)DLOXUHV   
  ,QYHVWLJDWLRQDO3URGXFW'LVFRQWLQXDWLRQDQG(DUO\7HUPLQDWLRQI URPWKH
6WXG\    
  ,QYHVWLJDWLRQDO3URGXFW'LVFRQWLQXDWLRQ   
  (DUO\7HUPLQDWLRQIURPWKH6WXG\   
  /RVVWR)ROORZXS   
  5HSODFHPHQWRI3DUWLFLSDQWV   
  75($70(172)3$57,&,3$176   
  'HVFULSWLRQRI,QYHVWLJDWLRQDO3URGXFW   
  3ULRU0HGLFDWLRQV&RQFRPLWDQW0HGLFDWLRQV5HVWULFWLRQVDQG
&RQWUDFHSWLRQ5HTXLUHPHQWV   
  3ULRUDQG&RQFRPLWDQW0HGLFDWLRQVDQGRU6XSSOHPHQWV   
  3URKLELWHG0HGLFDWLRQV   
  2WKHU5HVWULFWLRQV   
  $FFHSWDEOH)RUPVRI&RQWUDFHSWLRQ   
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7' &21),'(17,$/
  ,QWHUYHQWLRQDIWHUWKH(QGRIWKH6WXG\   
  7UHDWPHQW$GKHUHQFH   
  5DQGRPL]DWLRQDQG%OLQGLQJ   
  (PHUJHQF\8QEOLQGLQJ   
  ,19(67,*$7,21$/352'8&70$7(5,$/6$1'0$1$*(0(17   
  ,QYHVWLJDWLRQDO3URGXFW   
  ,QYHVWLJDWLRQDO3URGXFW3DFNDJLQJDQG/DEHOLQJ   
  ,QYHVWLJDWLRQDO3URGXFW6WRUDJH   
  ,QYHVWLJDWLRQDO3URGXFW3UHSDUDWLRQ   
  ,QYHVWLJDWLRQDO3URGXFW$GP LQLVWUDWLRQ   
  ,QYHVWLJDWLRQDO3URGXFW$FFRXQWDELOLW\+DQGOLQJDQG'LVSRVDO   
  3URGXFW&RPSODLQWV   
  ()),&$&<$66(660(176$1'&/,1,&$ /3+$50$&2/2*<
$66(660(176   
  (IILFDF\$VVHVVPHQWV   
  .LQHVLD21(ÂŒ$FFHOHURPHWHU6FRUH   
  7KH(VVHQWLDO7UHPRU5DWLQJ$VVHVVPHQW6FDOH   
   
   
   
   
   
   
   
   
   
   
   
   
   
  2WKHU3DWLHQW5HSRUWHG$VVHVVPHQWV   
  3DWLHQW3HUFHSWLRQRI5HVSRQVH%XUGHQ   
  6$)(7<$66(660(176   
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7' &21),'(17,$/
  6DIHW\3DUDPHWHUV   
  'HPRJUDSK\DQG0HGLFDO+LVWRU\   
  :HLJKWDQG+HLJKW   
  3K\VLFDO([DPLQDWLRQ   
  9LWDO6LJQV    
  (OHFWURFDUGLRJUDP   
  /DERUDWRU\$VVHVVPHQWV   
  'UXJVRI$EXVH$OFRKRO&RWLQLQH   
  3UHJQDQF\6FUHHQ   
   
  6DIHW\3KRQH&DOO   
  $GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV   
  $GYHUVH(YHQW'HILQLWLRQ   
  6HULRXV$GYHUVH(YHQW6$('HILQLWLRQ   
  'HILQLWLRQRI$GYHUVH(YHQW VRI6SHFLDO,QWHUHVW   
  5HODWLRQVKLSWR,QYHVWLJDWLRQDO3URGXFW   
  5HFRUGLQJ$GYHUVH(YHQWV   
  5HSRUWLQJ6HULRXV$GYHUVH(YHQWV   
  3UHJQDQF\    
  2YHUGRVH    
  67$7,67,&6   
  'DWD$QDO\VLV6HWV   
  +DQGOLQJRI0LVVLQJ'DWD   
  *HQHUDO&RQVLGHUDWLRQV   
  'HPRJUDSKLFVDQG%DVHOLQH&KDUDFWHULVWLFV   
  (IILFDF\$QDO\VLV   
  6DIHW\$QDO\VHV   
  $GYHUVH(YHQWV   
   
  3K\VLFDO([DPLQDWLRQV   
   
   
  3ULRUDQG&RQFRPLWDQW0HGLFDWLRQV   
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7' &21),'(17,$/
   
   
  6DPSOH6L]HDQG3RZHU   
  ,QWHULPDQG'DWD0RQLWRULQJ&RPPLWWHH'0&$QDO\VHV   
  ',5(&7$&&(66726285&('$7$'2&80(176   
  6WXG\0RQLWRULQJ   
  $XGLWVDQG,QVSHFWLRQV   
  ,QVWLWXWLRQDO5HYLHZ%RDUGRU(WKLFV&RPPLWWHH   
  48$/,7<&21752/$1'48$/,7<$6685$1&(   
  (7+,&6    
  (WKLFV5HYLHZ   
  (WKLFDO&RQGXFWRIWKH6WXG\   
  :ULWWHQ,QIRUPHG&RQVHQW   
  '$7$+$1'/,1*$1'5(&25'.((3,1*   
  ,QVSHFWLRQRI5HFRUGV   
  5HWHQWLRQRI5HFRUGV   
  38%/,&$7,2132/,&<   
  /,672)5()(5(1&(6   

/,672)7$%/(6
7DEOH  (PHUJHQF\&RQWDFW,QIRUPDWLRQ   
7DEOH  6FKHGXOHRI$VVHVVPHQWV   
7DEOH  ,QYHVWLJDWLRQDO3URGXFW   
7DEOH  6XPPDU\RI&OLQLFDO/DERUDWRU\$QDO\WHV   

/,672)),*85(6
)LJXUH  6WXG\'HVLJQ   

&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7' &21),'(17,$/
/,672)$%%5(9,$7,216$1''(),1,7,2162)7(506

$EEUHYLDWLRQ 'HILQLWLRQ
$( DGYHUVHHYHQW
$'/ DFWLYLWLHVRIGDLO\OLYLQJ
$8&LQI DUHDXQGHUWKHFXUYHIURPWRLQILQLW\
$8&WDXDUHDXQGHUWKHFRQFHQWUDWLRQWLPHFXUYHIURPWRHQGRIWKHGRVLQJSHULRG
%0, ERG\PDVVLQGH[
 
&PD[ PD[LPXPREVHUYHGFRQFHQWUDWLRQ
&52 FRQWUDFWUHVHDUFKRUJDQL]DWLRQ
(& HWKLFVFRPPLWWHH
(&* HOHFWURFDUGLRJUDP
H&5) HOHFWURQLFFDVHUHSRUWIRUP
(26 (QGRI6WXG\
 
 
(7 HVVHQWLDOWUHPRU
 
(79 HDUO\WHUPLQDWLRQYLVLW
)'$ )RRGDQG'UXJ$GPLQLVWUDWLRQ
*&3 *RRG&OLQLFDO3UDFWLFH
*03 *RRG0DQXIDFWXULQJ3UDFWLFH
,% LQYHVWLJDWRUÂ¶VEURFKXUH
,&) LQIRUPHGFRQVHQWIRUP
,&+ ,QWHUQDWLRQDO&RXQFLOIRU+DUPRQLVDWLRQRI7HFKQLFDO5HTXLUHPHQ WVIRU
3KDUPDFHXWLFDOVIRU+XPDQ8VH
,3 LQYHVWLJDWLRQDOSURGXFW
,5% LQVWLWXWLRQDOUHYLHZERDUG
0HG'5$ 0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV
3' SKDUPDFRG\QDPLF
 
3, SULQFLSDOLQYHVWLJDWRU
3. SKDUPDFRNLQHWLF
 PPD PPD
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
21 Abbreviation  Definition  
  
PV pharmacovigilance  
QTcF  QT corrected according to Fridericia â€™s formula  
  
SAE  serious adverse event  
SAP statistical analysis plan 
SOP standard operating procedure  
tÂ½  terminal elimination half -life  
TEAE  treatment -emergent adverse event  
TETRAS  The Essential Tremor Rating Assessment Scale  
tmax time of occurrence of C max 
WHO  World Health Organization  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
22 4. INTRODUCTION  
SAGE -324 is a positive allosteric modulator (PAM) of A-type Î³ -aminobutyric acid -gated 
chloride channel (GABA A) receptors, the major class of inhibitory neurotransmitter receptors in 
the brain.  In addition to being developed as an adjunctive therapy in epilepsy and other seizure 
disorders  under IND 139201, SA GE-324 is also being developed for the treatment of Essential 
Tremor (ET).  
Essential tremor is a permanently debilitating, neurologically determined, common movement 
disorder characterized by involuntary rhythmic oscillation of a body part due to intermitt ent 
muscle contractions typically occurring when not at rest, thus interfering with fine motor skills 
associated with daily activities ( Olanow 2008 , Deuschl 2011 , Hopfner 201 6, NIH 2019 ). 
Although the pathophysiology and etiology of ET is not fully understood, it is postulated that 
approximately 50% of ET patients feature an autosomal dominant pattern of familial inheritance 
and that non -inherited cases may have toxin -based or other causali ty (Olanow 2008 , Hopfner 
2016). ET is the most common movement disorder in the US, with prevalence estimated to be 
approximately 2.2% of the population, representing a substantial societal medical burden with 
over an estimated 7 million ET patients in the US alone ( Louis 2014 ).  
In general, active tasks of daily life are adversely impacted by ET, including but not limited to 
speech, handwriting, household tasks, and occupational demands, contributing negatively to 
psychosocial well -being, general anxiety, a nd overall quality of life  (Koller, 1989 ). Although 
benign in term of its effect on life expectancy, ET is a progressive neurodegenerative condition 
whose symptoms are typically disabling, often forcing patients to change jobs or seek early 
retirement ( Zappia, 2013 ). In some cases, serious disability may ensue.   
The pharmacological profile  of SAGE -324 is theorized to  induce therapeutic effect  in the 
treatment of ET. Based on preclinical studies of  SAGE -324, which features a different 
mechanism of action tha n that of propranolol, the pharmacokinetic (PK)/ pharmacodynamic (PD) 
profile suggests SAGE -324 may safely ameliorate symptoms in patients suffering from ET, 
regardless of propranolol use . 
There are currently ongoing Phase 1 clinical studies of SAGE -324 in  healthy adults  and in adults 
with ET . These studies , in addition to preclinical studies of SAGE -324, are detailed in the 
investigatorâ€™s brochure.  
With a GABA A receptor -based mechanism of action  featuring  positive allosteric modulation  
capability , SAGE -324 represents a novel approach to treatment of ET with possible utility  as 
monotherapy or adjunctive  to propranolol, which may help address the unmet medical need of 
the ET population , warranting further st udy of SAGE -324 as a potential treatment for this 
common movement disorder.  
Henceforth, this double -blind, placebo -controlled efficacy and safety study of SAGE -324 will be 
conducted in adults  with and without concomitant use of propranolol and  is designed to assess 
the effect of SAGE -324 on a variety of outcome measures specific to ET disease characteristics  
and associate d quality of life  domains . 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
23 4.1. Dose Justification  
Doses of SAGE -324 planned for  this study  are 30 mg and 60 mg given as oral tablets, to be  
administered once daily in the morning with food. Th e doses  were selected based on preliminary 
data from 3 active studies of SAGE -324, which included : unblinded data from completed cohorts 
in 324 -CLP-101 Pa rt A (oral solution SAGE -324 doses of 3 mg, 10 mg, 30 mg, 45 mg, 60 mg) ; 
Part C (oral solution SAGE -324 doses of 30 mg) ; Part D (oral suspension SAGE -324 doses of 
30 mg) in healthy subjects ; and  preliminary data from open -label Part E (oral suspension SAGE -
324 doses of 45 mg and 60 mg) in participants with ET; additional preliminary data from 324 -
CLP-102 cohorts 1 through 6  (cohorts 1 to 5 unblinded, cohort 6 blinded) , which evaluated oral 
suspension doses ranging from 5 mg to 60 mg; and preliminary unblind ed data from 324 -CLP-
104, which compared the relative bioavailability of the oral tablet (30 mg) vs oral suspension (30 
mg) formulations of SAGE -324 and separately the effect of food on the PK of the SAGE -324 
oral tablet.  In 324 -CLP-101 and 324 -CLP-102 st udies, doses were administered in a fasted state. 
The preliminary data from all of these active studies collectively informed the route of 
administration (oral) and dose strengths of 30 mg and 60 mg as oral tablets planned for further 
evaluation in  this study .  
SAGE -324 was generally well -tolerated in participants with ET and in healthy volunteers, as was 
shown in the preliminary data of 324 -CLP-101 Part E at single administration doses of 45 mg 
and 60 mg, and in 324 -CLP-102 through once -daily admin istered doses of up to 60 mg  for 
14 days. In addition, tremor reduction was observed at both doses on TETRAS and Kinesia 
accelerometry, with greater improvement seen at 60  mg compared to 45  mg.  
In the clinically complete  study 324-CLP-104, preliminary dat a showed that SAGE -324 oral 
tablets, when coadministered with a meal, resulted in exposures approximately equivalent to that 
of SAGE -324 oral suspension under fasted conditions. Therefore, the SAGE -324 oral tablets are 
recommended to be administered with f ood. 
4.2. Benefit/Risk Assessment  
Based on the mechanism of action of SAGE -324 and the results of completed nonclinical studies 
and preliminary data of currently ongoing clinical studies of SAGE -324, it is theorized that 
participants  may have  symptomatic ameliorat ion, ie, tremor reduction and possibly improved 
quality of life  from potentially stabilizing disease characteristics associated with ET. 
Potential risks anticipated in this study are based on available data from toxicology studies of 
SAGE -324 in a ddition to preliminary data from 3 ongoing, currently active Phase 1 clinical 
studies of SAGE -324.   
As of 18 October 2019, based on the preliminary clinical data available, there have been no 
deaths, SAEs  related to IP , or confirmed  clinically significant  trends in clinical laboratory 
evaluations, vital signs, or physical examinations. Available preliminary clinical data is 
summarized in the Investigatorâ€™s Brochure.  
Based on available preliminary clinical data  from SAGE -324 active clinical studies , AEs of 
somnolence and feeling of relaxation are considered adverse drug reactions.  In addition to 
scheduled clinic visits, the current status of study participants will be reviewed via weekly phone 
calls, in between clinic visits.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
24 5. STUDY  OBJECTIVES AND ENDPOINTS  
Objectives  Endpoints  
Primary   
â€¢ To assess the effect of SAGE -324 
compared to placebo on tremor 
reduction in individuals with 
essential tremor (ET)  â€¢ Change from baseline compared to 
placebo in Kinesia  ONE â„¢ accelerometer 
scores  after 28 days of treatment  
Secondary   
â€¢ To assess the effect of SAGE -324 
compared to placebo on activities 
of daily living (ADLs) , total 
performance, and upper 
extremities  
 
 
 
 
 
 
â€¢ To evaluate the safety and 
tolerability of SAGE -324 â€¢ Change from baseline compared to 
placebo in Kinesia ONE accelerometer 
scores at all other timepoints  
â€¢ Change from baseline compared to 
placebo in the following:  
- The Essential Tremor Rating 
Assessment (TETRAS) Scale ADL 
score  
- TETRAS Total Performance Score  
- TETRAS Performance Subscale Part 4 
Upper Limb Tremor  
â€¢ Incidence of treatment -emergent adverse 
events (TEAEs)  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
25  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
26 6. INVESTIGATIONAL PLAN  
6.1. Overall Study Design  
This is a randomized, double -blind, placebo -controlled, parallel group dose -ranging study to 
evaluate the efficacy, safety, and tolerability of SAGE -324 as monotherapy and adjunctive 
therapy with propranolol in individuals with ET. Participants, site staff , and sponsor personnel 
will be masked to treatment allocation  (see Section  8.5). 
This study includes a Screening Period of up to 28 days, a 2 9-day treat ment period consisting of 
28 days of dosing with the end of treatment visit  intended to be on Day 29 at trough , and a 
14-day follow -up period  relative to final dose  (Figure 1). After providing informed consent, 
participants will undergo screening assessments as outlined in Table 2  to determine eligibility .  
The Screening Period begins with the signing of the informed consent form (ICF). Following 
completion of screening , on Day 1, eligible participants will visit the st udy center and will be 
randomized to 1 of 3 treatment groups (SAGE -324 30 mg , SAGE -324 60 mg , or placebo) in a 
1:1:1 ratio. Randomization will be stratified based on the use of propranolol for the treatment of 
ET (Y/N). Participants who are on a propranolo l regimen must have been on a stable regimen for 
at least 1 month prior to Day 1 and will continue to be on that stable regimen during the 
Treatment Period. Participants will complete baseline assessments of safety and efficacy, 
including the clinician -rated TETRAS and quantitative Kinesia ONE assessments of tremor, as 
specified in the Schedule of Assessments ( Table 2 ). 
During the double -blind Treatment Period, s tarting on Day 1, participants will receive a single 
dose of investigational product (IP) once daily for 28 days on an outpatient basis. Doses 
occurring on scheduled clinic visits will be administered in the clini c, and doses occurring on all 
other days will be self -administered by the participant at home  as specified in Table 2 . During 
the Treatment Period, partic ipants will return to the study center approximately once per week 
for efficacy and safety assessments as specified in  Table 2 . In addition, a phone call  will be 
conducted once per week (preferably mid -week) in  between clinic visits, to review current status 
of the participant.  
In addition to Kinesia ONE -specific training, c linical study center staff and study p articipants 
will be trained on the use of software applications and devices necessary to complete 
questionnaires or  other assessments as required.  During in-clinic visits, c linical study center staff 
will be available to assist participants as needed , to ensure they can  access and us e the software  
applications and devices  correctly according to the training . 
During the fo llow-up period, visits will be conducted on an outpatient basis. In addition to the 
phone calls to review current status, p articipants will receive a phone call approximately 7 day s 
after the last dose of IP (ie, Day 35) for safety monitoring. Participants will return to the study 
center for an end of study visit approximately 14 days following the last dose of IP (ie, Day 42) . 
Participants who discontinue IP during the Treatment Period will be asked to return to the clinic 
as soon as possible for an end of treatment (EOT) visit. Follow -up visits should take place as 
scheduled, or relative to the last dose of IP if discontinuing treatment early. If at any time after 
the EO T visit, a participant decides to withdraw from the study, the participant should return for 
an early termination visit  (ETV) . The EOT and ETV  can be on the same day if a participant 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
27 discontinues IP and withdraws from the study on the same day during a cli nic visit; in this case, 
all events scheduled for the EOT visit will be conducted.   
Figure 1: Study Design   
 
Abbreviation:  EOT = end of treatment  
6.2. Number of Participant s 
Up to approximately 120 participants  are planned , with up to  40 participants enrolled per arm , to 
produce an estimated 30  participants per arm who will complete the study . Additional 
participants may be randomized if the drop -out rate is higher than anticipated ( ie, >25%).  
6.3. Treatment Assignment  
Participants will be assigned to 30 mg or 60  mg IP (active or placebo) in accordance with the 
randomization schedule on Day 1. Additional details on randomization and blinding  are provided 
in Section  8.5.  
6.4. Dose Adjustment  Criteria  
Doses will not be adjusted for this study except as clinically necessary , eg, interrupting dose due 
to an AE or serious adverse event ( SAE ) considered related to IP , or as recomm ended by the 
medical monitor in consultation with the investigator.  
6.5. Criteria for Study Termination  
Sage Therapeutics may terminate this study or any portion of the study at any time for safety 
reasons including the occurrence of AEs or other findings suggesting unacceptable risk to 
participant s, or for administrative reasons . In the event of study termi nation, Sage Therapeutics 
will provide written notification to the investigator . Investigational sites must promptly notify 
their IRB/ ethics committee  (EC) , where required,  and initiate withdrawal procedures for 
participating participant s.  
 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
28 7. SELECTION AND WITHDRAWAL OF PARTICIPANT S 
7.1. Participant  Inclusion Criteria  
Participants must  meet all of the following criteria to qualify for  participation in this study:  
1. Participant has signed an ICF before any study -specific procedures or washout of drugs is 
performed.  
2. Participant is 18 to 80 years of age, inclusive, at the time informed consent is obtained.  
3. Participant has a diagnosis of ET, as defined by all of the following criteria:  
a. Isolated tremor syndrome consisting of bilateral upper limb acti on tremor  
b. At least 3 years duration  
c. With or without tremor in other locations (eg, head, voice, or lower limbs)  
d. Absence of other neurological signs, such as dystonia, ataxia, or parkinsonism, 
isolated focal tremors (eg, voice, head), task - and position -specific tremors, sudden 
tremor onset or evidence of step -wise deterioration of tremor  
4. Participant has a combined total upper extremity TETRAS score of â‰¥8 with at least 1 
upper extremity TETRAS score >4.  
5. Participant is willing to discontinue medications taken  for the treatment of ET, with the 
exception of propranolol, within 14 days or 5 half -lives (whichever is longer) prior to 
receiving IP.  
6. Participants taking propranolol for the treatment of ET must be on a stable dose for at 
least 1  month prior to Day 1 an d must be willing to maintain their stable dose through 
Day 2 9. 
7. Participant is willing to discontinue the use of alcohol and drugs of abuse within at least 
â‰¥1 week prior to Day 1 and through Day 2 9 of the study.  
8. Female participant agrees to use at least on e method of highly effective contraception as 
listed in Section  8.2.4  during participation in the study and for 30 days following the last 
dose of study drug, unless she is postmenopausal (at least 12 months of spontaneous 
amenorrhea without an alternative medical cause, with confirmatory follicle stimulating 
hormone >40  mIU/mL), and/or surgically sterile (bilateral oophorectomy, hysterectomy, 
and/or bilat eral salpingectomy), or does not engage in sexual relations which carry a risk 
of pregnancy (does include abstinence).  
9. Male participant agrees to use an acceptable method of effective contraception for the 
duration of the study and for 13 weeks after rece iving study drug, unless the participant 
does not engage in sexual relation(s) which carry a risk of pregnancy. Acceptable 
methods of effective contraception are listed in Section  8.2.4 .  
10. Male participant is willing to abstain from sperm donation for the duration of the study 
and for 13 weeks after receiving study drug.  
11. Female participant must have a pregnancy test result that is confirmed as negative at 
Screening and Day 1.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
29 12. At the discretion of the investigator, participant is medically stable and ambulatory, and 
is on stable dose(s) of any necessary prescription or over -the-counter medication(s) for at 
least 30 Days  prior to Day 1, or changes/discontinues  their use prior to Day 1 with the 
appropriate washout, as applicable per investigator judgement.  
13. Participant has no clinically significant findings, as determined by the investigator, on 
physical examination including mental state examination (MSE) and neurologic 
examination, 12 -lead ECG, or clinical laboratory tests . 
7.2. Participant Exclusion Criteria  
Participant s who meet any of the following criteria are disqualified from participation in this 
study:  
1. Participant has presence of known causes of enhance d physiological tremor.  
2. Participant has had recent exposure (14 days prior to Day 1) to tremorgenic drugs or 
presence of a drug or alcohol withdrawal state.  
3. Participant has had direct or indirect injury or trauma to the nervous system within 3 
months before the onset of tremor.  
4. Participant has had a previous procedure for the treatment of ET, deep brain stimulation, 
brain lesioning, or magnetic resonance (MR) guided procedure, eg, MR -guided focused 
ultrasound.  
5. Participant has historical or clinical evi dence of tremor with psychogenic origin 
(including but not limited to eating disorders, major depression, etc.)  
6. Participant has significant history and/or presence of hepatic, renal, cardiovascular, 
pulmonary, gastrointestinal, hematological, immunologic, ophthalmologic, metabolic 
(hypothyroidism with stable thyroid replacement is acceptable), or oncological disease.  
7. Participant has history, presence, and/or current evidence of serologic positive results for 
hepatitis B surface antigen (HBsAg), hepatitis C antibodies (anti -HCV), or human 
immunodeficiency virus (HIV) 1 or 2 antibodies.  
8. Participant has history of alcohol or drug abuse within 6 months prior to Screening, or a 
positive screen for alcohol on the Day 1 visit, or a positive screen for drugs of abus e at 
Screening or at the Day 1 visit.  
9. Participant has a known allergy to SAGE -324 or any excipient.  
10. Participant has had exposure to another investigational drug or device within 30 days 
prior to the Day 1 visit.  
11. Participant has history or suicidal behavio r within 2 years or answers â€œYESâ€ to questions 
3, 4, or 5 on the C -SSRS at Screening or at Day 1 or is currently at risk or suicide in the 
opinion of the investigator  
12. Participant has donated one or more units (1 unit  = 450 mL) of blood or experienced 
acute  loss of an equivalent amount of blood within 60 days prior to Day 1.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
30 13. Participant is unable to perform Kinesia O NE assessments or unable to use the device 
required to perform the assessment.  
14. Participant has any condition or comorbidity that in the opinion  of the investigator would 
limit or interfere with the participantâ€™s ability to complete or partake in the study.  
15. Participant is unwilling or unable to comply with study procedures and required training.  
16. Participant has used any known moderate or strong cy tochrome P450 3A4 or P450 2D6 
inhibitors and/or inducers within 14 days or 5 half -lives (whichever is longer) prior to 
Day 1 or consumed grapefruit juice, grapefruit, Seville oranges, pomegranates, tangelos, 
or St. Johnâ€™s Wort or products containing these within 30 days prior to Day 1. Use of 
mild cytochrome inhibitors and/or inducers may be permitted.  
17. Participant has concurrent or recent exposure (14 days prior to the Day 1 visit) to 
sedative/hypnotic drugs, stimulants, eg, opioids, highly -caffeinated bev erages or dietary 
supplements containing high doses of caffeine, or recent increase above regular daily 
consumption of coffee.  
18. Participant has concurrent or recent exposure (30 days prior to the Day 1 visit) to long -
acting benzodiazepines  
19. Participant plans  to undergo elective surgery or relocate during participation in the study.  
20. Participant is investigative site personnel or a member of their immediate families 
(spouse, parent, child or sibling whether biological or legally adopted) . 
7.3. Screen Failures  
Screen  failures are defined as participants who consent to participate in the clinical study but are 
not subsequently assigned IP or entered in the study , ie, a participant who does not meet 1 or 
more of the eligibility criteria  after providing consent  and prior to randomization  (Day 1) . A 
minimal set of screen failure information will be collected, including  demography, screen failure 
details, eligibility criteria, and any SAE.   
Individuals who do not meet the criteria for parti cipation in this study (screen failure) may be 
rescreened.  
7.4. Investigational Product  Discontinuation and Early Termination from 
the Study  
7.4.1.  Investigational Product  Discontinuation  
A participant may withdraw from the study at any time at his/her own request for  any reason. 
The investigator may discontinue a participant from the study and/or from IP for safety, 
behavioral, compliance, or administrative reasons. Participants who elect to discontinue IP will 
be encouraged by the Investigator to remain on study and complete the 14 -day follow -up safety 
assessments.  
The reason for IP discontinuation and/or the reason for early termination from the study must be 
documented in the participantâ€™s study record and recorded in the participantâ€™s electronic case 
report form (e CRF).  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
31 The investigator must notify the sponsor and/or the medical monitor when a participant stops 
participation in the study for any reason.  
If a participant  is persistently noncompliant, the investigator should discuss with the sponsor the 
potential discontinuation of the participant . Any reasons for unwillingness or inability to adhere 
to the protocol must be recorded in the participant â€™s eCRF, including:  
â€¢ missed visits;  
â€¢ interruptions in the sc hedule of study drug administration;  
â€¢ nonpermitted medications  
Participant s who discontinue IP due to an AE, regardless of investigator -determined causality, 
should be followed until the event is resolved, considered stable, or the investigator determines 
the event is no longer clinically significant.  
7.4.2.  Early Termination from the Study  
At the time of study withdrawal/stopping study participation, if possible  within 48 hours of final 
IP dose , an ETV/EOT  visit should be conducted  as specified in the Schedule of Assessments 
(Table 2 ). The participant will be permanently discontinued both from the IP and from the study 
at that time.  
If the participant withdraws co nsent for disclosure of future information, the sponsor will retain 
and continue to use any data collected before such a withdrawal of consent.  
If a participant withdraws from the study, he/she may request destruction of any samples taken 
and not tested, a nd the investigator must document this in the site study records.  
7.4.3.  Loss to Follow -up 
A participant will be deemed lost to follow -up after 3 attempts at contacting the participant have 
been unsuccessful .  
7.4.4.  Replacement of Participants  
Participants will not be replaced.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
32 8. TREATMENT OF PARTICIPANT S 
8.1. Description of Investigational Product  
SAGE -324 is an orally administered tablet provided in  5 mg tablets totaling  30-mg and 60-mg 
doses, to be administered once daily for 28 days, proceeded by a  14-day follow -up period. IP 
doses are to be administered in the morning  with food . 
Participants in all cohorts will receive the appropriate dose of IP ( 30 mg total dose of SAGE -324 
tablets , 60 mg total dose of SAGE -324 tablets , or appearance -matched place bo tablets) according to 
the randomization schedule. Additional details regarding IP preparation, formulation, and storage are 
included in Section  9. 
8.2. Prior  Medications , Concomitant Medications , Restrictions , and 
Contraception  Requirements  
8.2.1.  Prior and Concomitant Medications  and/or Supplements  
The start and end dates, route, dose/units, frequency, and indication for all medications  and/or 
supplements  taken  within 30 days prior to signing the informed consent through the first dose of 
IP will be recorded . Use of antidepressant medications taken in the prior  12 months will be 
recorded at Screening; all other medications taken within the 30 days prior to Screening will be 
recorded.  
All medications and/or supplements taken from the first dose of IP through the Day  42 (Â±1 days) 
visit (including start and end dates route, dose/units, frequency, and indication) will be recorded 
on the eCRF . Any concomitant medication determined necessary for the welfare of the 
participant  may be given at the discretion of the investigator at any time dur ing the study .  
8.2.2.  Prohibited Medications  
Use or consumption of the following is prohibited for the timeframes specified:  
â€¢ Treatment with an investigational drug or device during the 30 days or 5 half-lives (if 
known) of the investigational drug, whichever is longer, prior to Screening or during 
the study  
â€¢ Use of any prescription or over -the-counter medication ( except for prop ranolol use as 
prescribed , and /or up to 3 g/day of acetaminophen), herbal medication, vitamins, or 
mineral supplements within 14 days prior to first IP administration , or during the 
study period  
â€¢ Use of tremorgenic drugs or agents known to affect SAGE -324 drug metabolism (any 
known CYP450 3A4 inhibitors and/or inducers) within the 28 days or 5 terminal half-
lives (whichever is longer) prior to first IP administration  or during the study period  
8.2.3.  Other Restrictions  
In addition to alcohol and drugs of abuse, the following are not permitted during the study, or 
within 14 days of the first IP dose:  sedative/hypnotic drugs, stimulants, eg, opioids, 
benzodiazepines, highly -caffeinated beverages or dietary supplements con taining caffeine . 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
33 8.2.4.  Acceptable Forms of Contraception  
Acceptable forms of highly effective contraception for participants of childbearing potential or 
for partners of male participants who are of childbearing potential include:  
â€¢ Combined (estrogen and progest ogen containing) oral, intravaginal, or transdermal 
hormonal contraception associated with inhibition of ovulation  
â€¢ Oral, injectable, or implantable progestogen -only hormonal contraception associated 
with inhibition of ovulation  
â€¢ Intrauterine device  
â€¢ Intraut erine hormone -releasing system  
â€¢ Bilateral tubal ligation  or bilateral tubal occlusion  (performed at least 3 months prior 
to Screening)  
â€¢ Vasectomized partner  (performed at least 3 months prior to Screening)  
â€¢ Sexual abstinence (no sexual intercourse)  
Acceptable  forms of contraception for male participants include:  
â€¢ Sexual abstinence (no sexual intercourse)  
â€¢ History of vasectomy  (performed at least 3 months prior to Screening)  
â€¢ Condom with spermicide used together with highly effective female contraceptive 
methods i f the female partner(s) is of childbearing potential (see above for list of 
acceptable female contraceptive methods)  
8.3. Intervention after the End of the Study  
There is n o planned  intervention following the end of the study.  
8.4. Treatment Adherence  
The first dose of IP will be received and administered by participants in the clinic . Participant s 
will be dispensed a  7-day supply of IP to orally self -administer  at home with instructions 
specifying to administer in the morning with food. Treatment adherence will be monitored by the 
site staff at each in-clinic visit  by direct questioning  and counting  returned tablets  and will be 
documented . Details on drug accountability are included in  Section  9.6. 
8.5. Randomization and Blinding  
This is a  randomized, double -blind, placebo -controlled study. Participants will be random ized in 
a stratified manner based on propranolol for the treatment of ET (Y/N); randomization will be 
done within each stratum in a 1:1:1 ratio  to treatment group s (SAGE -324 30 mg, 
SAGE -324 60 mg, or placebo) . Participants, site staff, and the sponsor will  be blinded to 
treatment allocation. Randomization schedules will be generated by an independent statistician . 
The randomization schedules will be kept strictly confidential, accessible only to authorized  
personnel until the time of unblinding. The blindi ng of the study  will be broken after the 
database has been locked.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
34 8.5.1.  Emergency Unblinding  
During the study, the blind is to be broken only when the safety of a participant  is at risk and the 
treatment plan is dependent on the study treatment received. Unless a participant  is at immediate 
risk, the Investigator should  make diligent attempts to contact Sage prior to unblinding the study 
treatment administered to a participant . Request s from the investigator about the treatment 
administered to study participant s should  be discussed with the Sage  Medical Monitor . If the 
unblinding occurs without Sageâ€™s knowledge, the investigator must notify Sage within 24 hours 
of breaking the blind. All circumstances surrounding a premature unblinding must be clearly 
documented in the source records.  
In all cases where the IP allocation for a participant  is unblinded, pertinent information 
(including the reason for unblinding) must be document ed in the participant â€™s records and on the 
eCRF. At the time of withdrawal  from the study /stopping participation , if possible, an EOT 
and/or ETV  should be conducted .  
If a participant or study personnel become unblinded to treatment, the participant will b e 
excluded from the Per Protocol analysis set, as detailed further in the statistical analysis plan. 
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
35 9. INVESTIGATIONAL PROD UCT  MATERIALS AND 
MANAGEMENT  
9.1. Investigational Product  
Table 3: Investigational Product  
 Investigational Product  
Product Name:  SAGE -324 Placebo  
Dosage Form:  Tablet  Tablet  
Tablet Strength  5 mg  0 mg 
Route of Administration  Oral Oral 
Physical Description  Immediate release white to off -
white, round, film -coated tablet 
containing 5 mg of SAGE -324 
drug substance , and composed 
of lactose, microcrystalline 
cellulose, croscarmellose 
sodium, sodium stearyl fumarate 
and fumed silica , featuring  
OpadryÂ® II white  as the coating 
agent.  Immediate release white to off -
white, round, film -coated tablet 
containing no drug substance, 
composed of lactose, 
microcrystalline cellulose, 
croscarmellose sodium, sodium 
stearyl fumarate and fumed 
silica, featuring  OpadryÂ® II  
white as the coating agent.   
Manufacturer  Sage Therapeutics , Inc.  
9.2. Investigational Product  Packaging and Labeling  
SAGE -324 Oral Tablets and Placebo Tablets will be  packaged in blinded, high density 
polyethylene (HDPE) containers.  The containers used for SAGE -324 and placebo will be 
identical in appearance.  The package labeling conforms to FDA and GMP requirements.  
9.3. Investigational Product  Storage  
Upon receipt of the IP, the investigator, or the responsible pharmacist or designee, will inspect 
the product and acknowledge receipt in accordance with the study -specific process.  
The IP must be carefully stored at the temperature specified in the investigatorâ€™s brochure , 
securely a nd separately from other drugs. The IP may not be used for any purpose other than the 
present study. After the study is completed, all unused IP must be returned per the sponsorâ€™s 
instructions or destroyed locally  per the siteâ€™s procedure(s) . IP may not be  destroyed until 
accountability  and reconciliation  procedures  have been completed  and monitored . 
The Investigator or designee will be responsible for ensuring appropriate storage, dispensing, 
inventory, and accountability of the IP. An accurate, timely rec ord of the disposition of the IP 
must be maintained.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
36 9.4. Inves tigational Product  Preparation  
The IP will be  in tablet form and  provided in blinded packaging.  No preparation is required for 
the tablet , which is administered orally  as described below . 
9.5. Inves tigational Product  Administration  
The first dose of IP will be administered in the clinic, and at home thereafter  as specified in the 
Schedule of Assessments ( Table 2 ). The IP will be provided as tablets  in dosage according to the 
randomized dose cohort ( 30 mg  or 60 mg ) and will  be orally administered once daily  in the 
morning,  with food. 
9.6. Inves tigational Product  Accountability , Handling, and Disposal  
Upon receipt of IP, the investigator(s), or the responsible pharmacist or designee, will inspect the 
IP and complete and follow the instructions regarding receipt  and storage  in the investigatorâ€™s 
brochure and (where  applicable) in the Pharmacy Manual. A copy of the shipping documentation 
will be kept in the study files.  
The designated site staff will dispense the supplied participant -specific kits to participant s at the 
planned dispensation visit intervals outlined i n the Schedule of Assessments  (Table 2 ). 
Site staff will access the interactive response technology ( IRT) at the Screening Visit to obtain a 
participant  identification (ID) number for each participant  who has signed an ICF. On Day 1, site 
staff will access the IRT and provide the necessary participant -identifying information, including 
the participant  ID numb er assigned at Screening, to randomize the eligible participant  into the 
study and obtain the medication ID number for the IP to be dispensed to that participant . The 
medication ID number must be recorded.  
At the subsequent IP-dispensing visit, the investi gator or designee will access the IRT, providing 
the same participant  ID number assigned at Screening, to obtain the medication ID number for 
the IP to be dispensed at that visit. The medication ID number, and the number of tablets  
returned by the particip ant at this visit must be recorded.  
If dispensing errors or discrepancies are discovered by site staff or sponsorâ€™s designee, the 
sponsor must be notified immediately.  
The IP provided is for use only as directed in this protocol. The investigator or designee must 
keep a record of all IP received, used and returned/discarded.   
Sage Therapeutics  will be permitted access to the study  supplies at any time with appropriate 
notice during or after completion of the study to perform drug accountability reconciliation.   
The investigator, pharmacist, or qualified designee is responsible for drug accountability, 
reconciliation, and record mai ntenance (ie, receipt, reconciliation, and final disposition records).  
At the end of the study, any unused IP tablets will be returned to Sage Therapeutics for 
destruction or destroyed locally  per the siteâ€™s procedures ; disposition of IP will be documented . 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
37 9.7. Product Complaints  
A product complaint is any written, electronic, or verbal expression of dissatisfaction regarding 
the identity, quality, reliability, safety, purity, potency, effectiveness or performance (applicable 
for approved marketed products) of a drug product after it is released for distribution.  
In the course of conduct of the study, study personnel may become aware of a product complaint 
associated with the use of a Sage product. Personnel shall notify Sage within 24 hours by 
forwarding the p roduct complaint information via the contact information listed in Table 1  and in 
the Pharmacy Manual.  Where possible, personnel should segregate  and re tain any product, 
materials, or packaging  associated with the product complaint  until further instruction is 
provided by Sage or its designated representative (s). 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
38 10. EFFICACY ASSESSMENTS  AND CLINICAL PHARMA COLOGY 
ASSESSMENTS  
10.1. Efficacy Assessments  
10.1.1.  Kinesia ONEâ„¢ Accelerometer Score  
Kinesia ONEâ„¢ is an ISO -certified  wireless motion sensor worn distally on the index finger , 
which utilizes 3 orthogonal accelerometers and 3 orthogonal gyroscopes to monitor three -
dimensional motion. Data is transmitted wirelessly from the sensor to a Bluetooth  technology -
enabled device  to use with the  Kinesia ONE software  (eg, Apple iPad or similar device with 
preinstalled Kinesia ONE software) . The device has received FDA clearance . 
Via the Kinesia ONE software application,  measures of three -dimensional  motion  are converted 
to scores  ranging from 0 to 4 , per assessed maneuver ; higher scores indicate greater  tremor  
severity . Motion in both arms is captured.  
Participants will complete this assessment at each clinic visit as sp ecified in the Schedule of 
Assessments ( Table 2 ).  
10.1.2.  The Essential Tremor Rating Assessment Scale  
TETRAS is a validated , comprehensive clinical assessment of essential tremor  (Elble 2013).  
Three different components of TETRAS will be assesse d in this study. The TETRAS ADL 
subscale, total performance score, and performance subscale part 4 upper limb tremor  score , and 
will each be separately assessed  at each clinic visit as specified in the Schedule of Assessments 
(Table 2 ). 
The ADL subscale assesses how ET is impacting typical activities of daily li ving (ie, speech, 
eating, drinking, dressing, personal hygiene, writing, occupational impairment, social impact, 
and activities affected by upper limb tremor). It consists of 12 items that are  each rated in from 
0 (normal activity)  to 4 (severe abnormality ). The overall ADL score range is 0 to 48.  
The total performance score is based on overall rating  of the performance  subscale , which 
measures tremor amplitude in the voice, limbs , head, face,  trunk, and also  measures functional 
task capabilities, ie, handwriting, spirography,  and holding a pen over a dot . Each of these items 
is rated on a scale from 0  (no tremor) to 4 (severe tremor). Collectively, the performance items  
generate an  overall performance score fr om 0 to 64 .  
For the performance subscale part 4 upper limb tremor  score , all 3 maneuvers in the upper limb 
assessments  of part 4 (subscale items 4a, 4b, and 4c) will be completed for both arms, first for 
the left arm and then for the right . The part 4 sub scale ordinally rates postural  (limbs extended 
forward  maneuver, and wing -beating  [elbows flexed] maneuver) , and kinetic  (finger -nose-finger 
maneuver)  tremor on a 0 to 4  severity scale  in 0.5 -point increments.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
39 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
40 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
41  
 
  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
42 10.3. Other Patient -Reported Assessment s 
10.3.1.  Patient Perception of Response Burden  
The Patient Perception of Response Burden Questionnaire is a patient -reported measure that 
assesses the multidimensional construct of response burden ( Atkinson 2019 ). 
Participants r espond to 6 items assessing 1) how well the questions related to their actual 
concerns, 2) how comfortable the participants were with answering the questions, 3) how well 
the survey characterized their health and well -being, 4) the length of time to comple te the 
questionnaires, 5) whether questions seemed unimportant or repetitive, and 6) what additional 
information should have been gathered. Items 1 to 3 are assessed on a 0 to 10 scale, item 4 is 
assessed on a 1 to 3 scale, and items 5 and 6 are open -ended . Items 1 and 4 are reverse scored. A 
composite score can be calculated to create a weighted representative index of relevance, 
comfort, and well -being relative to time to completion (ie, items 1, 2, and 3 were summed and 
multiplied by item 4) for a range of 0 to 72, with higher scores indicative of elevated endorsed 
response burden. The open -ended items will be summarized thematically. The Patient Perception 
of Response Burden Questionnaire will be performed as specified in the Schedule of 
Assessments ( Table 2 ). 
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
43 11. SAFETY  ASSESSMENTS  
11.1. Safety Parameters  
All assessments will be conducted according to the Schedule of Assessments (Table 2 ). 
11.1.1.  Demograph y and Medical History  
Demographic characteristics (age, race, sex, ethnicity) and a full medical history will be 
documented . This  must  also additionally include  participant  recall of history of  ET, disease 
duration, past treatments  used, and responsiveness to  alcohol  and/or other treatments  with use 
intended  as off-label  treatment  of ET (eg, primidone  or similar t herapies ). 
11.1.2.  Weight and Height  
Height and weight wi ll be measured and documented . Body mass index (BMI) will be calculated 
and documented.   
11.1.3.  Physical Examination  
Whenever possible, the same individual should perform all physical examinations . Physical 
examinations will include assessment of body systems (eg, h ead, eye, ear, nose and throat; heart; 
lungs; abdomen; and extremities) as well as cognitive and neurological examination and MSE . 
Unscheduled physical examinations may also be conducted per the Investigatorâ€™s discretion.  
Any abnormality in physical examin ations will be interpreted by an investigator as abnormal, not 
clinically significant (NCS); or abnormal, clinically significant (CS) in source documents .  
11.1.4.  Vital Signs  
Vital signs comprise heart rate, respiratory rate, temperature, and blood pressure. Syst olic and 
diastolic blood pressure are to be measured after the participant  has been supine for at least 
5 minutes prior to the measurement. When assessed postdose,  orthostatic blood pressure and 
heart rate will also be measured after the participant  has be en in the supine position for at least 5 
minutes and then repeated approximately 1 and 3 minutes after standing .  
Any abnormality in vital signs will be interpreted by an Investigator as abnormal, NCS; or 
abnormal, CS in source documents . 
11.1.5.  Electrocardiogram  
A 12 -lead ECG will be performed . The standard intervals (heart rate, PR, QRS, QT, and QTcF ) 
as well as any rhythm abnormalities will be recorded.  
Electrocardiograms will be performed after the participant  has been resting in a supine posi tion 
for at least 5 minutes. When ECG measurement s coincide with safety assessments, vital signs 
assessment or blood draws, procedures should be carried out in said order  (vital  signs , ECG, 
blood draw) . 
All abnormal ECGs will be interpreted by an investiga tor as abnormal , NCS, or abnormal , CS in 
source documents . 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
44 11.1.6.  Laboratory Assessments  
Blood and urine samples for clinical labora tory assessments will be collected . Analytes to be 
evaluated are summarized in Table  4. 
Table  4: Summary of Clinical Laboratory Analytes  
Biochemistry  Renal Panel : glucose, calcium, phosphorus , blood urea nitrogen, creatinine, 
sodium, potassium, chloride, bicarbonate  
Hepatic Panel : albumin, ALT, AST, total bilirubin, direct bilirubin, indirect 
bilirubin, alkaline phosphatase, total protein, lactate dehydrogenase, gamma 
glutamyl transferase  
Othe r: triglycerides, cholesterol (low density lipoprotein [LDL], high density 
lipoprotein [HDL]), creatine phosphokinase , thyroid stimulating hormone (TSH)  
Coagulation  activated partial thromboplastin time, prothrombin time, and international 
normalized ratio  
Hematology  red blood cell count, hemoglobin, hematocrit, white blood cell count with 
differential, platelet count, and if red blood count  indices are abnormal, reflex red 
blood cell  morphology  as indicated  
Urinalysis  protein, glucose, pH, blood, leukocytes , leukocyte estrase, urobilinogen , bilirubin, 
ketones, nitrite  
Virus Serology 
(Screening only)  hepatitis B antigen; hepatitis C antibodies; HIV -1 and -2 antibodies  
All clinical laboratory test results outside the reference r ange will be interpreted by the 
Investigator as abnormal, NCS; or abnormal, CS in source documents.  
Follicle stimulating hormone testing will be conducted to confirm whether a participant  with 
â‰¥12 months of spontaneous amenorrhea meets the protocol -defined  criteria for being 
postmenopausal (Section  7.1). 
11.1.6.1.  Drugs of Abuse, Alcohol, Cotinine  
Separate urine samples for assessment of selected drugs of abuse (amphetamines, barbiturates, 
benzodiazepines, cannabinoids, cocaine, THC, stimulants, and opiates), cotinine, and alcohol 
will be collected .  
11.1.6.2.  Pregnancy Screen  
A serum  pregnancy test will be c onducted for all female participants at Screening ; a urine  
pregnancy test will be conducted for all participants of childbearing potential as specified in the 
Schedule of Assessments ( Table 2 ).  

&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7' &21),'(17,$/
6DIHW\3KRQH&DOO
$SKRQHFDOOZLOOEHFRQGXFWHGRQFH SHUZHHNSUHIHUDEO\PLGZHHNLQEHWZHHQFOLQLFYLVLWVDV
VSHFLILHGLQ 7DEOHWRFROOHFWLQIRUPDWLRQ DERXWFXUUHQWKHDOWKVWDWXVJHQHUDOZ HOOEHLQJ,3
FRPSOLDQFHRUWRJDWKHURWKHUSHUWLQHQWKHDOWKUHODWHGLQIRUPD WLRQDVSHULQYHVWLJDWRUMXGJHPHQW
$GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV
$GYHUVH(YHQW'HILQLWLRQ
$Q$(LVDQ\XQWRZDUGPHGLFDORFFXU UHQFHLQDSDWLHQWRUFOLQLF DOLQYHVWLJDWLRQSDUWLFLSDQW
DGPLQLVWHUHGDSKDUPDFHXWLFDOSURGXFWDQGWKDWGRHVQRWQHFHVVD ULO\KDYHDFDXVDOUHODWLRQVKLS
ZLWKWKLVWUHDWPHQW$Q$( FDQWKHUHIRUHEHDQ\XQIDYRUDEOHDQGXQLQWHQGHGVLJQLQFOXGLQJDQ
DEQRUPDOODERUDWRU\ILQGLQJV\P SWRPRUGLVHDVHWHPSRUDOO\DVV RFLDWHGZLWKWKHXVHRID
PHGLFLQDOLQYHVWLJDWLRQDOSURGXFWZ KHWKHURUQRWUHODWHGWRWKHPHGLFLQDOLQYHVWLJDWLRQDO
SURGXFW,QFOLQLFDOVWXGLHVDQ$(FDQLQFOXGHDQXQGHVLUDEOH PHGLFDOFRQGLWLRQRFFXUULQJDWDQ\
WLPHLQFOXGLQJEDVHOLQHRUZDVKRXWSHULRGVHYHQLIQRVWXG\WUHDWPHQWKDVEHHQDGPLQLVWHUHG
$7($(LVGHILQHGDVDQ$(ZLWKRQVHWDIWHUWKHVWDUWRI,3RU DQ\ZRUVHQLQJRIDSUHH[LVWLQJ
PHGLFDOFRQGLWLRQ$(ZLWKRQVH WDIWHUWKHVWDUWRI,3DQGWKURX JKRXWWKHVWXG\7KHWHUP,3
LQFOXGHVDQ\6DJH,3DFRPSDUDWRURUDSODFHERDGPLQLVWHUHGL QDFOLQLFDOWULDO
/DERUDWRU\DEQRUPDOLWLHV DUHFRQVLGHUHG$(V
LIWKH\UHVXOWLQGLVFRQWLQXDWLRQRUL QWHUUXSWLRQRIVWXG\WUHDWPHQWUHT XLUHWKHUDSHXWLFPHGLFDO
LQWHUYHQWLRQPHHWSURWRF ROVSHFLILFFULWHULDLIDSSOLFDEOHR ULIWKHLQYHVWLJDWRUFRQVLGHUVWKHPWR
EHFOLQLFDOO\VLJQLILFDQW$Q\DEQRUPDOLWLHVWKDWPHHWWKHFULW HULDIRUDQ6$(VKRXOGEHUHSRUWHG
LQDQH[SHGLWHGPDQQHU /DERUDWRU\ DEQRUPDOLWLHV 
WKDWDUHFOHDUO\DWWULEXWDEOHWRDQRWKHU $(GRQRWUHTXLUHGLVFUHWHUHSRUWLQJHJ HOHFWURO\WH
GLVWXUEDQFHVLQWKH FRQWH[WRIGHK\GUDWLRQFKHPLVWU\DQGKHPDWRORJLFGLVWXUEDQFHVLQWKH
FRQWH[WRIVHSVLV 
$OO$(VWKDWRFFXUDIWHUDQ\SDUWLFLSDQWKDVVLJQHGWKH,&)DQG WKURXJKRXWWKHGXUDWLRQRIWKH
VWXG\ZKHWKHURUQRWWKH\DUHUHODWHGWRWKHVWXG\PXVWEHUH SRUWHGWR6DJH7KHUDSHXWLFV
3DUWLFLSDQWVZKRGLVFRQWLQXHWKH,3G XHWRDQ$(UHJDUGOHVVRI LQYHVWLJDWRUGHWHUPLQHG
FDXVDOLW\VKRXOGEHIROORZHGXQWLOWK HHYHQWLVUHVROYHGFRQV LGHUHGVWDEOHRUWKHLQYHVWLJDWRU
GHWHUPLQHVWKHHYHQWLVQRORQJHUFOLQLFDOO\VLJQLILFDQW$Q\$ (VWKDWDUHXQUHVROYHGDWWKH
SDUWLFLSDQWÂ¶VODVW$(DVVHVVPHQWLQWKHVWXG\DUHIROORZHGXSE \WKHLQYHVWLJDWRUIRUDVORQJDV
PHGLFDOO\LQGLFDWHGEXWZLWKRXWIXUWKHUUHFRUGLQJLQWKHH&5) 7KHVSRQVRURULWVUHSUHVHQWDWLYH
UHWDLQVWKHULJKWWRUHTXHVWDGGLWLRQDOLQIRUPDWLRQIRUDQ\SDUWLFLSDQWZLWKRQJRLQJ$(V6$(V
DWWKHHQGRIWKHVWXG\LIMXGJHGQHFHVVDU\PPD
PPD
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
46 11.2.2.  Serious Adverse Event (SAE)  Definition  
An SAE  is any untoward medical occurrence that at any dose : 
â€¢ Results in death  
â€¢ Places the participant  at immediate risk of death (a life -threatening event); however, 
this does not include an event that, had it occurred in a more severe form, might have 
caused death   
â€¢ Requires inpatient hospitalization or prolongation of existing hospitalization  
â€¢ Results in persistent or significant disability or incapacity  
â€¢ Results in a  congenital abnormality or birth defect  
An SAE may also be any other medically important event that, in the opinion of the Investigator  
may jeopardize the participant  or may require medical intervention to prevent 1 of the outcomes 
listed above  (examples of such events include allergic bronchospasm requir ing intensive 
treatment in an emergency room or convulsions  occurring at hom e that do not require an 
inpatient hospi talization) . 
All SAEs that occur after any participant  has signed the ICF and throughout the duration of the 
study , whether or not they are related to the study, must be recorded on the SAE report form 
provided by Sage Therapeutics . Any SAE that is ongoing  when the participant  completes their 
final study visit, will be followed by the investigator until the event has resolved, stabilized, 
returned to baseline status , or until  the participant  dies or is lost to follow up . 
A prescheduled or elective procedure  or routinely scheduled treatment will not be considered an 
SAE, even if the participant  is hospitalized. The site must document all of the following:  
â€¢ The prescheduled or elective procedure or routinely scheduled treatment was 
scheduled (or on a waiting li st to be scheduled) prior to obtaining the participant â€™s 
consent to participate in the study.  
â€¢ The condition requiring the prescheduled or elective procedure or routinely scheduled 
treatment was present before and did not worsen or progress, in the opinion of an 
Investigator, between the participant â€™s consent to participate in the study and at the 
time of the procedure or treatment.  
11.2.3.  Definition of Adverse Events of Special Interest  
There are no known adverse event s of special inter est as of the date of signature approval of this 
clinical protocol.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
47 11.2.4.  Relationship to Inves tigational Product  
The investigator must make the determination of relationship to the IP for each AE (not related, 
related ). The following definitions should be considered when evaluating the relationship of AEs 
and SAEs to the IP.  
Not Related  An AE will be considered â€œnot relatedâ€ to the use of the IP if there is not a reasonable 
possibility  that the event has been caused by the IP. Factors pointing towards this 
assessment  include but are  not limited to : the lack of temporal relationship between 
administration of the IP and the event, the presence of biologically implausible 
relationship between the product and the AE, or the presence of a more likely 
alternative explanation for the AE  
Related  An AE will be considered â€œrelatedâ€ to the use of the IP if there is a reasonable 
possibility that the event may have been caused by the product under investigation. 
Factors that point towards this assessment include but are not limited to: a positive  
rechallenge, a reasonable temporal sequence between administration of the drug and 
the event, a known response pattern of the suspected drug, improvement following 
discontinuation or dose reduction, a biologically plausible relationship between the 
drug a nd the AE, or a lack of alternative explanation for the AE  
11.2.5.  Recording Adverse Events  
AEs spontaneously reported by the participant  and/or in response to an open question from the 
study personnel or revealed by observation will be recorded during the study at the 
investigational site . The AE term should be reported in standard medical terminology when 
possible . For each AE, the Invest igator will evaluate and report the onset (date and time), 
resolution (date and time), intensity, causality, action taken, outcome  and seriousness  (if 
applicable), and whether or not it caused the participant  to discontinue the IP or withdraw early 
from th e study . 
Intensity will be asses sed according to the following scale:  
â€¢ Mild : symptom(s) barely noticeable to participant  or does not make participant  
uncomfortable; does not influence performance or functioning; prescription drug not 
ordinarily needed for r elief of symptom(s)  
â€¢ Moderate : symptom(s) of a sufficient severity to make participant  uncomfortable; 
performance of daily activity is influenced; participant  is able to continue in study; 
treatment for symptom(s) may be needed  
â€¢ Severe : symptom(s) cause sev ere discomfort; symptoms cause incapacitation or 
significant impact on participant â€™s daily life; severity may cause cessation of 
treatment with IP; treatment for symptom(s) may be given and/or participant  
hospitalized   
It is important to distinguish betwee n serious and severe AEs . Severity is a measure  of intensity 
whereas seriousness is defined by the criteria under Section  11.2.2 . An AE of severe intensity 
may not necessarily be  considered serious.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
48 11.2.6.  Reporting Serious Adverse Events  
In order to adhere to all applicable laws and regulations for reporting an SAE(s), the study site 
must notify Sage or designee within 24 hours of the stud y site staff becoming aware of the 
SAE(s). The investigator must complete, sign and date the SAE report form , verify the accuracy 
of the information recorded on the SAE report form  with the corresponding source documents, 
and send a copy to  Sage or designe e.  
Additional follow -up information, if required or available, should all be sent to Sage or designee  
within 24 hours  of receipt on a follow -up SAE report form  and placed with the original SAE 
information and kept with the appropriate section of the eCRF and/or study file.  
SAEs occurring after the designated follow up time for the study, should be reported to Sage or 
designee according to the timelines noted above only if the Investigator considers the SAE 
related to IP.  
Sage , or designee,  is responsible for notifying the relevant regulatory authorities of certain 
events . It is the principal investigatorâ€™s responsibility to notify the IRB/EC of all SAEs that occur 
at his or her site . Investigators will also be notified of all suspected unexpected serious adverse 
reactions  (SUSARs ) that occur during the clinical study. Each site is responsible for notifying its 
IRB of all SUSARs .  
In addition, appropriate personnel in Sage  Drug Safety and Pharmacovigilance or designee will 
unblind SUSARs for the purpose of regulatory reporting. Sage  or designee will submit SUSARs 
(in blinded or unblinded fashion) to regulatory agencies according to local law. Sage , or 
designee, will submit S USAR s to investigators in a blinded fashion.  
11.3. Pregnancy  
If a participant  becomes pregnant after the first administration of IP, pregnancy information must 
be collected and recorded on the pregnancy form  and submitted to the sponsor within 24  hours of 
learni ng of the pregnancy. Details will be collected for all  pregnancies for which conception was 
likely  to have occur red after the start of IP administration until 5 terminal half -lives following 
the last administration of IP or until the completion of the stud y whichever is longer . Any 
pregnancy occurring in that time frame will be followed until delivery or termination of the 
pregnancy.  The investigator will also attempt to collect pregnancy information on any 
participant â€™s partner who becomes pregnant after t he participant has received the first 
administration of IP . After obtaining the necessary signed informed consent from the pregnan t 
partner directly, the investigator will follow the same pregnancy reporting procedures specified 
for pregnant participant s.  
The participant  or participant â€™s partner will be followed to determine the outcome of the 
pregnancy. The outcome of all pregnancies ( eg, spontaneous abortion , elective abortion , normal 
birth) must be followed and documented even if the participant  was discontinued  from the study. 
The investigator will collect follow -up information on the participant  or participant â€™s partner and 
the neonate , and the information will be forwarded to Sage or designee. Generally, follow -up 
will not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any 
termination of pregnancy will be reported, regardless of fetal status (presence or absence of 
anomalies) or indication for the procedure . 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
49 Pregnancy in itself is not regarded as an AE unless there is a su spicion that a n IP may have 
interfered with the effectiveness of a contraceptive medication. Any complication during 
pregnancy ( eg, anemia, infections, preeclampsia) should be reported as an AE/SAE. If the 
outcome of the pregnancy meets the criteria for im mediate classification as an SAE (ie,  
spontaneous abortion, stillbirth, neonatal death, ), the investigator should follow the procedures 
for reporting an SAE.  
11.4. Overdose  
An overdose is any dose of study treatment given to a participant  or taken by a participant  that 
exceeds more than one extra tablet within 24 hours as described in protocol. Overdoses are not 
considered AEs and should not be recorded as an AE on the eCRF; however , all overdoses must 
be recor ded on an overdose form and s ent to Sage or d esignee within 24 hours of the site 
becoming aware of the overdose.  An overdose must be reported to Sage or designee even if the 
overdose does not result in an AE. If an overdose results in an AE, the AE must be recorded .  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
50 12. STATISTICS  
Detail ed description of the analyses to be performed in the study will be provided in the 
statistical analysis plan (SAP). The SAP will be finalized and approved prior to database lock. 
Any changes  or additions to the SAP following database lock will be describe d in detail in the 
clinical study report.  
12.1. Data Analysis Sets  
The Randomized Set will include all participants who are randomized.   
The Safety Set will include all participant s administered IP.  
The Full Analysis Set will include all randomized participant s who received any amount of IP 
and have a baseline and at least one postbaseline Kinesia ONE accelerometer score .  
 
  
The Per Protocol Set will include  all participant s in t he Full Analysis Set without any major 
protocol deviations that could affect efficacy. The review of major protocol deviations will be 
completed, and the decision on whether the deviation affects efficacy will be documented before 
database unblinding.  
12.2. Hand ling of Missing Data  
Every attempt will be made to avoid missing data . All participant s will be used in the analyses, 
as per the analysis populations, using all nonmissing data available . No imputation process will 
be used to estimate missing data .  
12.3. General Considerations  
All participant  data, including those that are derived, that support the tables and figures will be 
presented in the participant  data listings. Some data may be presented only in participant  data 
listing, some may be presented with a  corresponding table or figure; these will be indicated in 
relevant sections below. Participants will be summarized according to treatment received.  
For the purpose of all primary and secondary analyses where applicable, baseline is defined as 
the last mea surement prior to receipt of IP.  
Continuous endpoints will be summarized with number (n), mean, standard deviation, median, 
minimum, and maximum. In addition, change from baseline values will be calculated at each 
time point and summarized descriptively. For categorical endpoints, descriptive summaries will 
include counts and percentages.  
12.4. Demographics and Baseline Characteristics  
Demographic data, such as age, race, and ethnicity, and baseline characteristics, such as height, 
weight, and BMI, will be summa rized using the Safety Set.  
Pregnancy  test results and drug screen results will be listed but not summarized .  
Medical history will be listed by participant .  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
51 12.5. Efficacy Analysis  
The estimand for the primary efficacy analysis is the treatment difference be tween either dose of 
SAGE -324 and placebo in mean change from baseline in clinic -based Kinesia ONE 
accelerometer scores at Day 2 9 based on the Full Analysis Set . This will be analyzed using a 
mixed effects model for repeated measures (MMRM); the model will include treatment, baseline 
Kinesia  ONE  accelerometer score, stratification factor, assessment timepoint, and timepoint -by-
treatment as explanatory variables. A ll explanatory variables will be treated as fixed effects. All 
postbaseline clinic visits will be included in the model. The main comparison will be between 
SAGE -324 and placebo at the 2 9-day timepoint. Model -based point estimates (ie, least squares  
means,  5% confidence intervals, and p -values) will be reported where applicable. An 
unstructured covariance structure will be used to model the within -subject errors. If there is a 
convergence issue with the unstructured covariance model, Toeplitz compound symme try or 
Autoregressive (1) [AR(1)] covariance structure will be used, following this sequence until 
convergence is achieved. If the model still does not converge with AR(1) structure, no results 
will be reported. When the covariance structure is not UN, the  sandwich estimator for the 
variance covariance matrix will be derived, using the EMPIRICAL option in the PROC MIXED 
statement in SAS.  
Similar to those methods described above for the primary endpoint, an MMRM will be used for 
the analysis of the change fr om baseline in TETRAS total performance score s, TETRAS 
performance subscale part 4 upper limb tremor scores  and TETRAS ADL score s.  
Other efficacy analyses will be specified in the SAP. In general, data will be analyzed using 
appropriate descriptive statis tics or prespecified statistical methods as applicable; participant  
listings will be provided for all efficacy data. Participant s will be analyzed according to 
randomized treatment for the purpose of efficacy unless otherwise specified.  
Sensitivity analyse s will be described in the SAP. 
12.6. Safety Analyses  
Safety and tolerability of SAGE -324 will be evaluated by AEs, concomitant medication usage, 
 
 Safety data will be listed by participant  and 
summarized by treatment group . All safety summaries will be performed on the Safety Set using 
treatment received.   
12.6.1.  Adverse Events  
AEs will be coded using Medical Dictionary for Regulato ry Activities (MedDRA) Version 22.1 
or higher. A treatment -emergent adverse event (TEAE) is defined as an AE with onset after the 
first dose of IP. The analysis of AEs will be based on the concept of TEAEs. The incidence of 
TEAEs will be summarized by Syst em Organ Class (SOC) and preferred term. In addition, 
summaries will be provided by intensity (mild, moderate, severe) and by causality (related, not 
related) to IP.  
Any TEAEs leading to discontinuation of treatment or withdrawal from the study and any 
treatment -emergent SAEs  will be summarized.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
52 All AEs and SAEs (including those with onset or worsening before the start of IP) through the 
end of the study will be listed.   
12.6.3.  Physical Examinations  
The occurrence of a physical examination , including MSE, (yes/no) and the date performed will 
be listed by participant . 
  
 
 
 
  
 
 
 
12.6.6.  Prior and Concomitant Medications  
Medications will be recorded at each study visit during the study and wil l be coded using World 
Health Organization -Drug dictionary (WHO -DD) September 2015, or later .  
All medications taken within 30 days prior to informed consent through the duration of the study 
will be recorded. In addition, all psychotropic medications take n in the previous 30 days prior to 
screening will be recorded. Those medications taken prior to the initiation of the start of IP will 
be denoted â€œPriorâ€. Those medications taken prior to the initiation of the IP and continuing 
beyond the initiation of the  IP or those medications started at the same time or after the initiation 
of the IP will be denoted â€œConcomitantâ€.  
Medications will be presented according to whether they are â€œPriorâ€ or â€œConcomitantâ€ as 
defined above. If medication dates are incomplete an d it is not clear whether the medication was 
concomitant, it will be assumed to be concomitant.  
Details of prior and concomitant medications will be listed by participant , start date, and 
verbatim term.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
53 12.8. Sample Size  and Power  
The sample size of this study is based on the assumption of a 3 points difference in the change 
from baseline Kinesia ONE accelerometer between SAGE -324 and placebo with a standard 
deviation of 3.5 points and a 1:1:1 randomization schedule. Under these ass umptions, a sample 
size of 30 evaluable participants per group would provide 90% power for detecting a placebo -
adjusted treatment difference of 3 points in Kinesia accele rometer assuming a 2 -sided test at 
Î±level  of 0.05. By including 3  treatment groups and  using a 1:1:1 randomization ratio, a total of 
90 evaluable participants are required.  Assuming a nonevaluability rate of  25%, at least 120 
subjects will be randomized.   
12.8.1.  Interim and Data Monitoring Committee (DMC) Analyses  
Not applicable.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
54 13. DIRECT ACCESS TO SOURCE DAT A/DOCUMENTS  
13.1. Study Monitoring  
Before an investigational site can enter a participant  into the study, a representative of Sage 
Therapeutics will visit the investigational study site  per Sage SOPs  to: 
â€¢ Determine the adequacy of the faciliti es 
â€¢ Discuss with the investigator(s) and other personnel their responsibilities with regard to 
protocol adherence, and the responsibilities of Sage Therapeutics  or its representatives . 
This will b e documented in a Clinical Trial  Agreement between Sage Thera peutics  and 
the investigator.  
During the study, a monitor from Sage Therapeutics  or representative will have regular contacts 
with the investigational site, for the following:  
â€¢ Provide information and support to the investigator(s)  
â€¢ Confirm that facilities r emain acceptable  
â€¢ Confirm that the investigational team is adhering to the protocol, that data are being 
accurately recorded in the case report forms, and that IP accountability checks are being 
performed  
â€¢ Perform source data verification . This includes a comparison of the data in the case report 
forms with the participant â€™s medical records at the hospital or practice, and other records 
relevant to the study . This will require direct access to all original records for each 
participant  (eg, clinic charts).  
â€¢ Record and report any protocol deviations not previously sent to Sage Therapeutics . 
â€¢ Confirm AEs and SAEs have been properly documented on eCRFs and confirm any 
SAEs have been forwarded to Sage Therapeutics  and those SAEs that met criteria fo r 
reporting have been forwarded to the IRB or EC. 
The monitor will be available between visits if the investigator(s) or other staff needs  
information or advice.  
13.2. Audits and Inspections  
Sage Therapeutics or a uthorized representatives of Sage Therapeutics , a regulatory authority, or 
an independent E C or an I RB may visit the site to perform an audit (s) or inspection (s), including 
source data verification . The purpose of a  Sage Therapeutics audit or a regulatory authority 
inspection is to systematically and independently examine all study -related activities and 
documents to determine whether these activities were conducted, and data were recorded, 
analyzed, and accurately reported according to the protocol, GCP/ICH GCP guid elines , and any 
applicable regulatory requirements . The Investigator should contact Sage Therapeutics  
immediately if contacted by a regulatory agency  or IRB/EC  about an  inspection.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
55 13.3. Institutional Review Board or Ethics Committee  
The principal investigator m ust obtain IRB (or EC) approval for the clinical study  prior to 
enrolling a participant . Initial IRB (or EC) approval, and all materials approved by the IRB (or 
EC) for this study including the participant  consent form and recruitment materials must be 
maintained by the investigator and made available for inspection.  
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
56 14. QUALITY CONTROL AND QUALITY ASSURANCE  
To ensure compliance with Good Clinical Practice and all applicable regulatory requirements, 
Sage Therapeutics may conduct a quality assurance audit (s) at the clinical site . Please see 
Section  13.2 for more details regarding the audit process.  
The Investigator must have adequate quality control pract ices to ensure that the study is 
performed in a manner consistent with the protocol, GCP/ICH GCP guidelines, and applicable 
regulatory requirements. The investigator is responsible for reviewing all identified protocol 
deviations.  Significant protocol devi ations should be reported to the IRB/EC per the IRB/ECâ€™s 
written procedures.  
The investigator is responsible for supervising any i ndividual or party to whom the investigator 
delegates trial-related duties and functions conducted at the trial site. When the  investigator 
retains the services of any individual or party to perform trial -related duties and functions , the 
Investigator  must ensure the individual or party is qualified to perform trial -related duties and 
functions and should implement procedures to ensure the integrity of the trial-related duties and 
functions performed,  and any data generated.  
The investigator must maintain adequate  and accurate source document s and trial records that 
include all pertinent observations  on each of the siteâ€™s trial participants. Source data  must be 
attributable, legible, contemporaneous, original, accurate, and complete. Changes to source data 
should b e traceable, should not obscure the original entry, and should be explained , if necessary  
to provide clarification . 
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
57 15. ETHICS  
15.1. Ethics Review  
The final study protocol, including the final version of the I CF, must be given a written and 
dated approval or favorable opinion by an IRB or EC as appropriate. The Investigator must 
obtain and document  approval before he or she can enroll any participant  into the study.  The IRB  
or EC  must  supply to the sponsor a list of the IR B/EC membership and a statement to confirm 
that the IRB /EC is organized and operates according to GCP and applicable laws and 
regulations.  
The principal investigator is responsible for informing the IRB or EC of any amendment to the 
protocol in accordance with local requirements. In addition, the IRB or EC must approve all 
advertising used to recruit participant s for the study. The protocol must be re -appro ved by the 
IRB or EC upon receipt of amendments and annually, as local regulations require.  
The principal investigator is also responsible for providing the IRB or EC with reports of any 
reportable serious adverse drug reactions from any other study conduc ted with the IP. Sage 
Therapeutics will provide this information to the principal investigator.  
Progress reports and notifications of serious adverse drug reactions will be provided to the IRB 
or EC according to local regulations and guidelines.  In additio n, the principal investigator must 
inform the IRB /EC and sponsor of any changes significantly affecting the conduct of the trial 
and/or increasing the risk to participant s (eg, violations to the protocol or urgent safety measures 
taken for participant  safety). 
15.2. Ethical Conduct of the Study  
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH  and GCP guidelines, as well as all  
applicable regional or national regulat ory requirements.  
15.3. Written Informed Consent  
Prior to enrolling a trial participant, t he investigator(s) will ensure that the participant  is given 
full and adequate oral and written information about the nature, purpose, possible risk and 
benefit of the stud y. Participant s must also be notified that they are free to discontinue from the 
study at any time . The participant  should be given the opportunity to ask questions and allowed 
time to consider the information provided.  
When the participant decides to participate in the trial, the participant  (or the participant â€™s, parent 
or legally authorized representative)  must  provide  signed and dated informed consent . The 
written consent  must be obtained before conducting any study p rocedures.  The investigator must 
document the consent process in the participantâ€™s source records. The investigator  must maintain 
the original, si gned ICF. A copy of the signed ICF must be given to the participant  or to the 
participantâ€™s  parent or  legal ly authorized  representative . 
Throughout the trial participants should be informed of any changes made to the study  and as 
new safety and or risk information  becomes known . The provision of this information  will be 
documented  in the participantâ€™s source records, and when applicable, an updated ICF will be 
provided . 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
58 16. DATA HANDLING AND RE CORDKEEPING  
16.1. Inspection of Records  
Sage Therapeutics  or its representative(s)  will be allowed to conduct site visits at the 
investigation facilities for the purpose of monitoring any aspect of the study . The investigator 
agrees to allow the monitor to inspect the facility, drug storage area, drug accountability records, 
participant  charts and study source documents, and other records relative to study cond uct. 
Inspection  of the study by a regulatory  authority may occur at any time. The investigator must 
agree to the inspection of study -related records  and source documents  by the regulatory authority  
representative (s).  
16.2. Retention of Records  
The principal investigator must maintain all documentation relating to the study for the period 
outlined in the site contract, or for a period of 2  years after the last marketing application 
approval , and until there are no pending or contemplated marketing app lication s in an ICH 
region  or at least 2 years have elapsed since the formal discontinuation of clinical development  
of the investigational product . Sage is responsible  to inform the Investigator/institution as to 
when study documents no longer need to be retained.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
59 17. PUBLICATION POLICY  
All information concerning SAGE -324 is considered confidential and shall remain the sole 
property of Sage Therapeutics. The investigator agrees to use this information only in conducting 
the study and shall not use it for any other purposes without written approval from Sage 
Therapeutics. No publication or disclosure of study results will be permitted except as specified 
in a separate, written, agreement between Sage Therapeutics and the investigator.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
60 18. LIST OF REFERENCES  
Atkinson TM, Schwartz CE, Goldstein L, et al. Assessments in Oncology. Value in Health . 
2019 ;22(2): 225-230. 
Belelli D, Casula A, Ling A, Lambert JJ. The influence of subunit composition on the interaction 
of neurosteroids with GABA(A) receptors. Neuropharmacology. 2002;43(4):651 -61. 
Deuschl G, R aethjen J, Hellriegel H, Elble R. Treatment of patients with essential tremor. Lancet 
Neuro. 2011. 10(2):148 . 
Elble R , Bain P, Forjaz MJ,  et al. Task force report: scales for screening and evaluating tremor: 
critique and recommendations.  Mov Disord. 2013 N ov;28(13):1793 -800. 
Genetics Home Reference; Essential Tremor.  Lister Hill National Center for Biomedical 
Communications ;U.S. National Library of Medicin e;National Institutes of Health , Department of 
Health & Human Services . Available from: https://ghr.nlm.nih.gov/condition/essential -tremor . 
Accessed  Sept 10, 2019 . 
 
 
 
Hopfner F, Haubenberger D, Galpern WR, et al. Knowledge gaps and research recommendations 
for essential tremor. Parkinsonism Relat Disord. 2016;33:27 -35. 
InderalÂ® (propranolol hydrochloride)  [package i nsert]. Philadelphia, PA: Wyeth 
Pharmaceuticals, Inc.; 2010. Accessed 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/016418s078lbl.pdf  
Koller W, Vetere -Overfield B. Acute and chronic effects of propranolol and primidone in 
essential tremor. Neur ology 1989;39:1587 -1588  
Louis ED, Ottman R. How many people in the USA have essential tremor? Deriving a 
population estimate based on epidemiological data. Tremor Other Hyperkinet Mov (N Y). 
2014;4:259.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201 CONFIDENTIAL  
61 Olanow CW. Hyperkinetic Movement Disorders: Essential  Tremor. In: Harrison's Principles of 
Internal Medicine. Vol 2. 17th ed. New York, NY: McGraw Hill; 2008:2560.  
Zappia M, Albanese A, Bruno E, et al. T reatment of essential tremor: a systematic review of 
evidence and recommendations from the Italian Movement Disorders Association.  Epub 2012 
Aug 11. Review. Erratum in: J Neurol. 2013 Mar;260(3):741  
 

 
1. TITLE PAGEA PHASE 2, DOUBLE -BLIND, PLACEBO -
CONTROLLED, RANDOMIZ ED STUDY EVALUATING 
THE EFFICACY, SAFETY , AND TOLERABILITY O F 
SAGE -324 MONOTHERAPY  AND ADJUNCTIVE 
THERAPY WITH PROPRAN OLOL IN THE 
TREATMENT OF INDIVID UALS WITH ESSENTIAL 
TREMOR   
324-ETD -201  
 
Investigational Product  SAGE -324 Oral Table t  
Clinical Phase  Phase 2  
Sponsor  Sage Therapeutics , Inc.  
215 First Street  
Cambridge, MA 02142  
Sponsor Contact  , MD  
Sponsor Medical Monitor  , MD, PhD  
Date of Original Protocol  23 October 2019  
Date of Amendment 1  20 December 2019  
 
 
Confidentiality Statement  
The confidential information in this document is provided to you as an investigator or consultant for 
review by you, your staff, and the applicable Institutional Review Board/Independent Ethics Committee . 
Your acceptance of this document constitutes agreement that you will not disclose the information 
contained herein to others without written authorization from Sage Therapeutics , Inc. 
 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
3 INVESTIGATORâ€™S AGREE MENT  
I have received and read the Investigatorâ€™s Brochure for SAGE -324. I have read the 324-ETD -
201 protocol and agree to conduct the study as outlined . I agree to maintain the confidentiality of 
all information received or developed in connection with this protocol.  
 
 
             
Printed Name of Investigator  
 
             
Signature of Investigator  
 
        
Date  (DD/MMM/YYYY)  
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
352&('85(6,1&$6(2)(0(5*(1&<

7DEOH (PHUJHQF\&RQWDFW,QIRUPDWLRQ
5ROHLQ6WXG\ 1DPH $GGUHVVDQG7HOHSKRQH1XPEHU
6DJH6WXG\3K\VLFLDQ0'
3KRQH 
6DJH0HGLFDO0RQLWRUDQG
KRXU(PHUJHQF\&RQWDFW0'3K' 0RELOH 
2IILFHSKRQH 
(PDLO 
6$(5HSRUWLQJ,QIRUPDWLRQ ,49,$/LIHF\FOH6DIHW\ (PSHURU%RXOHYDUG  
'XUKDP1&   
(PDLO6DJH6DIHW\#LTYLDFRP   
)D[  
6$(+RWOLQH
3URGXFW&RPSODLQWV  6DJH7KHUDSHXWLFV,QF (PDLO
SURGXFWFRPSODLQWV#VDJHU[FRP
3KRQH

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
5 2. SYNOPSIS  
Name of Sponsor/Company:  
Sage Therapeutics, Inc. (hereafter referred to as Sage Therapeutics, or Sage)  
Name of Investigational Product : 
SAGE -324 Oral Tablet  
Name of Active Ingredient:  
SAGE -324 
Title of Study:  
A Phase 2, Double -blind, Placebo -controlled, Randomized Study Evaluating the Efficacy, Safety, and 
Tolerability of SAGE -324 Mono therapy  and Adjunctive Therapy  with Propranolol  in the Treatment 
of Individuals  with Esse ntial Tremor  
Number of Sites and Study Location: This study will take place at  approximately 30 site s in the 
United States.  
Phase of D evelopment: Phase 2  
Planned Duration for each Study Participant:  
The duration of  participation (from Screening through the final follow -up visit) for each participant is 
estimated to be up to  72 days.  
Objectives and Endpoints : 
Objectives  Endpoints  
Primary   
To assess the effect of SAGE -324 compared 
to placebo on tremor reduction in 
individuals with essential tremor (ET)  Change from baseline compared to placebo in 
Kinesia ONE â„¢ accelerometer scores  after 28 days 
of treatment  
Secondary   
â€¢ To assess the effect of SAGE -324 
compared to placebo on activities of 
daily living (ADLs), total 
performance, and upper extremities  
 
 
 
 
 
 
 
 
â€¢ To evaluate the safety and 
tolerability of SAGE -324 â€¢ Change from baseline compared to placebo 
in Kinesia ONE accelerometer scores at all 
other timepoints  
â€¢ Change from baseline compared to placebo 
in the following:  
- The Essential Tremor Rating 
Assessment (TETRAS) Scale ADL 
score  
- TETRAS total performance score  
- TETRAS performance subscale part 4 
upper limb tremor  score  
 
â€¢ Incidence of treatment -emergent adverse 
events (TEAEs)  
 
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
6 Study Description : 
This is a randomized, double -blind, placebo -controlled, parallel group  study to evaluate the efficacy, 
safety, and tolerability of SAGE -324 as mono therapy  and adjunctive therapy with propranolol in 
individuals with ET. Participants, site staff , and sponsor personnel will be masked to treatment 
allocation.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
7 This study includes a Screening Period of up to 28 days, a 2 9-day treatment period  (28 days of 
dosing) , and a 14 -day follow up period. After providing informed consent, participants will under go 
screening assessments as outlined in Table 2  to determine eligibility.  
Screening Period: The Screening Period begins with the signing of the informed consent form (ICF). 
Following completion of screening, on Day 1, eligible participants  will visit the study center and will 
be randomized to 1 of 2 treatment groups (SAGE -324 60 mg daily , or placebo) in a 1:1 ratio. 
Randomization will be stratified based on the use of propranolol for the treatment of ET (Y/N). 
Participants who are on a prop ranolol regimen must have been on a stable dose for at least 1 month 
prior to Day 1 and will continue to be on a stable dose during the Treatment Period. Participants will 
complete baseline assessments of safety and efficacy, including the clinician -rated TETRAS and 
quantitative Kinesia ONE assessments of tremor, as specified in the Schedule of Assessments ( Table 
2). 
Double -Blind Treatment Period:  Starting on Day 1, participants will receive a single dose of 
investigational product (IP) once daily for  28 days on an outpatient basis. Doses occurring on 
scheduled clinic visits will be administered in the clinic, and doses occurring on all other days may be 
self-administered by the participant at home during the 2 9-day Treatment Period  (28 days of dosing) . 
During the Treatment Period, participants will return to the study center approximately once per week 
for efficacy and safety assessments as specifi ed in  Table 2 . Participants will be trained on the use of 
software applications and devices necessary to complete questionnaires or other assessments as 
required.  
Follow Up Period:  Follow up visits will be conducted on an outpatient basis. Participants will 
continue to complete  questionnaires as indicated in  Table 2  and will receive a phone call 
approximately 7 days after the last dose of IP (ie, Day 3 5) for safety monitoring. Participants will 
return to the study center for an end of study visit approxim ately 14 days following the last dose of IP 
(ie, Day 4 2). 
Participants who discontinue IP during the Treatment Period will be asked to return to the clinic as 
soon as possible for an end of treatment (EOT) visit. Follow -up visits should take place as scheduled , 
or relative to the last dose of IP if discontinuing treatment early . If at any time after the EOT visit, a  
participant  decides to withdraw from the study, the participant  should return for an early termination 
visit (ETV) . The EOT and  ETV  can be on the same day if a participant  discontinues IP and withdraws 
from the study on the same day during a clinic visit;  in this case, all events scheduled for the EOT 
visit will be conducted . 
During the study, a phone call will be conducted  once  per week (preferably mid -week) in between  
clinic visits , to review current status of participant . 
Number of Participants  (planned):  Approximately 60 participants, with approximately 30 per arm.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
8 Eligibility Criteria:  
Inclusion Criteria:  
1. Participant has s igned an ICF before any study -specific procedures or washout of drugs i s 
performed.  
2. Participant is 18 to 80 years of age, inclusive, at the time informed consent is obtained.  
3. Participant  has a diagnosis of ET, as defined by all of the following criteria:  
a. Isolated tremor syndrome consisting of bilateral upper limb action tremor  
b. At least 3 years duration  
c. With or without tremor in other locations (eg, head, voice, or lower limbs)  
d. Absence of other neurological signs, such as dystonia, ataxia, or parkinsonism , isolated 
focal tremors (eg, voice, head) , task- and position -specific tremors , sudden tremor onset 
or evi dence of step -wise deterioration of tremor  
4. Participant has a combined t otal upper extremity TETRAS score of â‰¥8 with at least 1 upper 
extremity TETRAS score >4.  
5. Participant is willing to discontinue medications taken for the treatment of ET, with the 
except ion of propranolol , within 14 days or 5 half -lives (whichever is longer) prior to 
receiving  IP. 
6. Participants taking propranolol for the treatment of ET must be on a stable dose for at least 
1 month prior to Day 1 and must be willing to maintain their stabl e dose through Day 2 9. 
7. Participant is willing to discontinue the use of alcohol and drugs of abuse within  at least â‰¥1 
week  prior to Day 1  and through Day 2 9 of the study.  
8. Female participant agrees to use at least one method of highly effective contraceptio n as 
listed in Section  8.2.4  during participation in the study and for 30 days following the last dose 
of study drug, unless she  is postmenopausal (at least 12 months of spontaneous amenorrhea 
without an alternative medica l cause, with confirmatory follicle stimulating hormone 
>40 mIU/mL), and/or surgically sterile (bilateral oophorectomy, hysterectomy, and/or 
bilateral salpingectomy), or does not engage in sexual relations which carry a risk of 
pregnancy (do es include abst inence).  
9. Male participant agrees to use an acceptable method of effective contraception for the 
duration of the study and for 13 weeks after receiving study drug, unless the participant  does 
not engage in sexual relation(s) which carry a risk of pregnancy . Acceptable methods of 
effective contraception are listed in Section  8.2.4 .  
10. Male participant  is willing to abstain from sperm donation for the duration  of the study and 
for 13 weeks after receiving study drug.  
11. Female participant must have a pregnancy test result that is confirmed as negative at 
Screening and  Day 1 . 
12. At the discretion of the Investigator, participant is medically stable and ambulatory, and  has 
been on  stable dose(s) of any necessary prescription or over the counter medication(s) for at 
least 30 days  prior to Day 1, or changes/discontinues their use prior to Day 1 with the 
appropriate washout , as applicable  per investigator judgement .  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
9 13. Participant has no clinically significant findings, as determined by the investigator, on 
physical examination  including mental state examination (MSE) and neurologic examination , 
12-lead ECG, or clinical laboratory tests.  
Exclusion Criteria:  
1. Participant has presence of known causes of enhanced physiological tremor.  
2. Participant has had r ecent exposure (14 days prior to Day 1) to tremorgenic drugs or presence 
of a drug  or alcohol  withdrawal state.  
3. Participant has h ad direct or indirect injury or  trauma to the nervous system within 3 months 
before the onset of tremor . 
4. Participant  has had a previous procedure  for the treatment of ET, deep brain stimulation, 
brain lesioning, or magnetic resonance (MR) guided procedure, eg, MR -guided focused 
ultrasou nd. 
5. Participant has h istorical or clinical evidence of tremor with psychogenic origin (including 
but not limited to eating disorders, major depression, etc.)  
6. Participant has s ignificant history and/or presence of hepatic, renal, cardiovascular, 
pulmonary, gastrointestinal, hematological, immunologic, ophthalmologic, metabolic 
(hypothyroidism with stable thyroid replacement is acceptable), or oncological disease.  
7. Participant has h istory, presence, and/or current evidence of serolog ic positive results for 
hepatitis B surface antigen (HBsAg), hepatitis C antibodies (anti -HCV), or human 
immunodeficiency virus (HIV) 1 or 2 antibodies.  
8. Participant has history of alcohol or drug abuse  within 6 months prior to Screening , or a  
positive scre en for alcohol o n the Day 1 visit , or a positive screen for drugs of abuse at 
Screening or at the Day 1 visit.  
9. Participant has a k nown allergy to SAGE -324 or any excipient.  
10. Participant has had e xposure to another investigational drug or device within 30 d ays prior to 
the Day 1 visit.  
11. Participant has h istory or suicidal behavior within 2 years or answers â€œYESâ€ to questions 3, 
4, or 5 on the C -SSRS at Screening or at Day 1 or is currently at risk or suicide in the opinion 
of the investigator  
12. Participant has d onated one or more units (1 unit  = 450 mL) of blood or experienced acute 
loss of an equivalent amount of blood within 60 days prior to Day 1.  
13. Participant is unable to perform Kinesia O NE assessments or unable to use the device 
required to  perform the assessment.  
14. Participant has any condition or comorbidity that in the opinion of the investigator would 
limit or interfere with the participantâ€™s ability to complete or partake in the study.  
15. Participant is unwilling or unable to comply with stu dy procedures  and required training . 
16. Participant has used any known moderate or strong cytochrome P 450 3A4 or P450 2D6 
inhibitors and/or inducers within 14 days or 5 half -lives (whichever is longer) prior to Day 1  
or consumed grapefruit juice, grapefruit, Seville oranges, pomegranates, tangelos, or St. 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
10 Johnâ€™s Wort or products containing these within 30 days prior to Day 1 . Use of mild 
cytochrome inhibitors and/or inducers may be permitted.  
17. Participant has concurrent or recent exposure (14 days prior to the  Day 1 visit) to 
sedative/hypnotic drugs, stimulants, eg, opioids, highly -caffeinated beverages or dietary 
supplements containing high doses of caffeine , or recent increase  above  regular daily  
consumption of coffee . 
18. Participant has concurrent or recent exposure ( 30 days prior to the Day 1 visit) to long-acting 
benzodiazepines . 
19. Participant plans to undergo elective surgery or relocate during participation in the study.  
20. Participant is investigative site personnel or a member of their immediate famil ies (spouse, 
parent, child or sibling whether biological or legally adopted).   
21. Participant has a positive urine cotinine screen at Screening or the Day 1 visit.  
Investigational Product  Dosage and Mode of Administration:  
SAGE -324 (60 mg) or matched placebo oral tablets will be administered in the clinic or self -
administer ed once  daily , in the morning  with food .  
Duration of Treatment:  
Each participant will receive a single dose of SAGE -324 oral tablet s or matching placebo 
administered once  daily for 28 days.   
Statistical Methods:  
A separate statistical analysis plan (SAP) will provide a detailed description of the data analyses to be 
performed in the study. The SAP will be finalized and approved prior to database lock.  
General Considerations  
For the purpose of all efficacy and safety analyses where applicable, baseline is defined as the last 
measurement prior to the start of IP administration.  
Continuous endpoints will be summarized with number (n), mean, standard deviation, median, 
minimum, and maximum. In addition, change from baseline values will be calculated at each time 
point and summarized descriptively. For categorical en dpoints, descriptive summaries will include 
counts and percentages.  
Analysis Sets  
The Randomized Set is defined as all participants who are randomized.  
The Safety Set will include all participants who were administered IP.  
The Full Analysis Set will include all randomized participants who received any amount of IP and 
have a baseline and at least one postbaseline clinic -based Kinesia  ONE  accelerometer score.  
 
 
The Per Protocol Set will include all participants in the F ull Analysis Set  without any major protocol 
deviations that could affect efficacy. The review of major protocol deviations will be completed, and 
the decision on whether the d eviation affects efficacy will be documented before database unblinding.  
Determination of Sample Size  
The sample size of this study is based on the assumption of a 3 points difference in the change from 
baseline Kinesia ONE accelerometer scores  between SAG E-324 and placebo with a standard 
deviation of 3.5 points. Under these assumptions, a sample size of 25 evaluable participants  per group 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
11 would provide 85% power for detecting a placebo -adjusted treatment difference of 3 points in Kinesia 
accelerometer assuming a  2-sided test at an alpha  level  of 0.05. By including  2 treatment groups and 
using a 1:1 randomization, a total of 50 evaluable participants  are required.  Assuming a 
nonevaluability rate of  15%, approximately 60 participants  will be randomized.  Additional 
participants  may be enrolled if the drop -out rate is higher than 15%.  
Analysis of Primary Efficacy Endpoint  
The estimand for the primary efficacy analysis is the treatment difference between SAGE -324 and 
placebo in mean change from baseline in c linic-based Kinesia ONE accelerometer scores at Day 2 9 
based on F ull Analysis Set . This will be analyzed using a mixed effects model for repeated measures 
(MMRM); the model will include treatment, baseline Kinesia  ONE accelerometer score, stratification 
factor, assessment timepoint, and timepoint -by-treatment as explanatory variables. All explanatory 
variables will be treated as fixed effects. All postbaseline clinic visits will be included in the model. 
The main comparison will be between SAGE -324 and plac ebo at the 2 9-day timepoint. Model -based 
point estimates (ie, least squares means, 95% confidence intervals, and p -values) will be reported 
where applicable. An unstructured covariance structure will be used to model the within -subject 
errors. If there is a convergence issue with the unstructured covariance model, Toeplitz compound 
symmetry or Autoregressive (1) [AR(1)] covariance structure will be used, following this sequence 
until convergence is achieved. If the model still does not converge with AR(1) s tructure, no results 
will be reported. When the covariance structure is not unstructured , the sandwich estimator for the 
variance covariance matrix will be derived, using the EMPIRICAL option in the PROC MIXED 
statement in SAS.  
Analysis of Secondary Effica cy Endpoints  
Similar to those methods described above for the primary endpoint, an MMRM will be used to 
analy ze of the change from baseline in TETRAS total performance score s, TETRAS Performance 
subscale part 4 upper limb tremor  score s and TETRAS ADL score s.  
Safety Analysis  
Safety and tolerability of study drug will be evaluated by incidence of TEAEs /serious adverse events, 
 
  
 
 
 
Interim Analysis  
The sponsor may conduct an interim analysis . Detailed descriptions of planned  data analyses will be 
provided in a  separate interim statistical analysis plan (SAP) , if applicable .  
 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
12 Table 2: Schedule of Assessments  
Assessment  Screening  Treatment Period  Follow -up Period  
Study Day  -28 to -1 1 5  
(Â±1) 
Phone
Call 8 
(Â±1) 12 
(Â±1) 
Phone
Call 15  
(Â±1) 19 
(Â±1) 
Phone
Call 22  
(Â±1) 26 
(Â±1) 
Phone
Call 29 
(+1) 
EOT  32 
(Â±1) 
Phone
Call 35  
Safety  
Phone
Call 38 
(Â±1) 
Phone
Call 42 
(Â±1) 
EOS / 
ETVa 
Informed Consent  X              
Inclusion/Exclusion  X              
Demographics  X              
Medical History  X              
Hepatitis/HIV screen  X              
Pregnancy Test  
(all women)  X  
(serum ; all 
women ) X  
(urine ; 
WOCBP  
only)   
 X  
(urine ; 
WOCBP  
only)    X  
(urine ; 
WOCBP  
only)    X  
(urine ; 
WOCBP  
only) 
FSH (postmenopausal 
women only)  X              
Randomizationb  X             
Drug/alcohol screens  X X  X  X  X  X    X 
Physical examinationc X X  X  X  X  X    X 
Neurological 
examination including 
MSEc X X  X  X  X  X    
X 
Body height  X         X    X 
Body weight  X X  X  X  X  X    X 
Vital signsd X X  X  X  X  X    X 
12-Lead ECGe X X  X  X  X  X    X 
Chemistry/hematology/
coagulation/urinalysis  X X  X  X  X  X    X 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
13 Assessment  Screening  Treatment Period  Follow -up Period  
Study Day  -28 to -1 1 5  
(Â±1) 
Phone
Call 8 
(Â±1) 12 
(Â±1) 
Phone
Call 15  
(Â±1) 19 
(Â±1) 
Phone
Call 22  
(Â±1) 26 
(Â±1) 
Phone
Call 29 
(+1) 
EOT  32 
(Â±1) 
Phone
Call 35  
Safety  
Phone
Call 38 
(Â±1) 
Phone
Call 42 
(Â±1) 
EOS / 
ETVa 
Kinesiag X X  X  X  X  X    X 
Investigational Product 
Diary  trainingh X              
TETRASi X X  X  X  X  X    X 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
14 Assessment  Screening  Treatment Period  Follow -up Period  
Study Day  -28 to -1 1 5  
(Â±1) 
Phone
Call 8 
(Â±1) 12 
(Â±1) 
Phone
Call 15  
(Â±1) 19 
(Â±1) 
Phone
Call 22  
(Â±1) 26 
(Â±1) 
Phone
Call 29 
(+1) 
EOT  32 
(Â±1) 
Phone
Call 35  
Safety  
Phone
Call 38 
(Â±1) 
Phone
Call 42 
(Â±1) 
EOS / 
ETVa 
Patient Perception of 
Response Burden           X    X 
Participant trainingj X              
Dispense study drug   X   X  X  X       
IP administration   Administered once daily for 28 days  Not applicable  
AEs/SAEs  X 
Prior and concomitant 
medication  and historyk X 
Abbreviations: ADL  = activities of daily living; AE = adverse event;
; ECG  = electrocardiogram; EOS  = end of study; EOT  = end of treatment;   
; ETV  = early termination visit; FSH = follicle stimulating hormone; HIV  = human immunodeficiency 
virus; ICF  = informed consent form; min = minutes; IP = investigational product; MSE  = mental state examination;  
; ;  
; SAE  = serious adverse event ; TETRAS  = The Essential Tremor Rating Assessment Scale; WOCBP  = women of childbearing potential  
 
Note:  
â€¢ IP doses will be administered in the clinic on Days 1  and 15. On all other days, IP doses may be administered at home.  
â€¢ A phone call  will be performed once, mid -week between clinic visits during the Treatment Period , and once per week during the Follow -Up Period.  
During the phone call, t he current status of the participant  will be reviewed , includi ng but not limited to, AE reporting and characterization, IP 
compliance review, and assessment of general we ll-being . Days 1, 8, 15, 22, and 2 9 are clinic visits.  
â€¢ The suggested order of assessments during clinic visits is: vital signs , Kinesia, TETRAS, EC G, blood sample collection for  and clinical laboratory 
assessments, and questionnaires . 
â€¢ All Day 1 assessments will be performed predose.  
 
a Participants who discontinue IP during the treatment period should return to the site for an EOT visit as soon as  possible. Participants who discontinue IP will 
be encouraged to continue on study and complete safety assessments and follow -up visits. Follow -up visits should take place as scheduled relative to the last 
dose of IP. If at any time after the EOT visit, a participant decides to withdraw from the study, the participant should return for an ETV . The EOT and ETV s 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
15 can be on the same day if a participant discontinues IP and withdraws from the study on the same day during a clinic visit . In such case, all procedures  
scheduled for EOT and E TV will be conducted.  
b Randomization will occur on Day 1 only.  In addition to meeting all other eligibility criteria , eligibility is determined based on the total upper extremity 
TETRAS score of â‰¥8 with at least  1 upper extremity TETRAS score >4  at Screening . 
c Complete physical examinations (including MS E and neurologic examination  as parts of physical examination ) should be performed as specified and as 
clinically necessary (see Section  11.1.3 ).  
d Vital signs without orthostat ic blood pressure  and heart rate  will be collected  predose in the beginning of each visit  and again  prior to departing the clinic, at 
approximately  5 hours (Â±30 min) . Postdose  vital signs to includ e orthostatic blood pressure and heart rate , measured after the participant has been in the supine 
position for at least 5 minutes and then repeated 1 minute and 3 minutes after standing.  
e ECGs will be collected and read centrally. ECGs will be performed approximately  5 hours  (Â±30 min)  postdose. All ECGs must be performed after the 
participant has been in a supine position for at least 5 minutes.  
 
 
  
g Kinesia ONE will be assessed simultaneous to TETRAS Performance subscale part 4 upper limb tremor . On clinic dosing days, participants will perform 
Kinesia ONE assessments approximately 30 to 60 minutes  prior to dosing  in the morning . In addition, on Day 15 , Kinesia ONE assessments will be performed 
at 5 and 8 hours ( Â±30 min) postdose.  
h Training specific to  the Investigational Product Diary  will be performed prior to randomization .  
i The TETRAS Perform ance and TETRAS ADL subscales will be assessed at Screening and predose at each clinic visit  postrandomization . The TETRAS 
Performance subscale part 4 upper limb tremor will be assessed simultaneous to Kinesia ONE. In addition, on Day 15,  the TETRAS Performance  subscale  will 
be assessed  at 5 and 8 hours (Â± 30 min) postdose.  Eligibility is determined based on the combined TETRAS performance subscale part 4 upper limb tremor total 
score â‰¥8, with at least 1 upper limb score >4 at Screening.  
j Participants  will be trained on the use of software applications and devices necessary for the conduct of the study by site personnel.  
k Prior and concomitant medications will be recorded during Screening and will include all medications and supplements  taken within t he 30 days prior to 
signing the ICF  through the first dose of IP.  Concomitant medications will be recorded thereafter throughout the duration of the study. At Screening, this will 
include year of diagnosis and history of treatments for ET since year of dia gnosis  and use of antidepressant medications taken in the prior 12 months .  
 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
16 3. TABLE OF CONTENTS  
1. TITLE PAGE  ................................ ................................ ................................ ................ 1 
2. SYNOPSIS  ................................ ................................ ................................ ................... 5 
3. TABLE OF CONTENTS  ................................ ................................ ........................... 16 
4. LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ............................. 20 
5. INTRODUCTION  ................................ ................................ ................................ ......22 
5.1. Dose Justific ation  ................................ ................................ ................................ ........ 23 
5.2. Benefit/Risk Assessment  ................................ ................................ ............................ 23 
6. STUDY OBJECTIVES AND  ENDPOINTS  ................................ .............................. 24 
7. INVESTIGATIONAL PLAN  ................................ ................................ ..................... 26 
7.1. Overall Study Design  ................................ ................................ ................................ ..26 
7.2. Number of Participants  ................................ ................................ ............................... 27 
7.3. Treatment Assignment  ................................ ................................ ................................ 27 
7.4. Dose Adjustment Criteria  ................................ ................................ ........................... 27 
7.5. Criteria for Study Termination  ................................ ................................ ................... 27 
8. SELECTION AND WITHDR AWAL OF PARTICIPANTS  ................................ .....28 
8.1. Participant Inclusion Criteria  ................................ ................................ ...................... 28 
8.2. Participant Exclusion Criteria  ................................ ................................ ..................... 29 
8.3. Screen Failures  ................................ ................................ ................................ ............ 30 
8.4. Investigational Product Discontinuation and Early Termination from the 
Study  ................................ ................................ ................................ ........................... 30 
8.4.1.  Investigational Product Discontinuation  ................................ ................................ .....30 
8.4.2.  Early Termination from the Study  ................................ ................................ .............. 31 
8.4.3.  Loss to Follow -up ................................ ................................ ................................ .......31 
8.4.4.  Replacement of Participants  ................................ ................................ ....................... 31 
9. TREATMENT OF PARTICI PANTS  ................................ ................................ ......... 32 
9.1. Description of Investigational Product  ................................ ................................ .......32 
9.2. Prior Medications, Concomitant Medications, Restrictions, and 
Contraception Requirements  ................................ ................................ ...................... 32 
9.2.1.  Prior and Concomitant Medications and/or Supplements  ................................ .......... 32 
9.2.2.  Prohibited Medications  ................................ ................................ ............................... 32 
9.2.3.  Other Restrictions  ................................ ................................ ................................ .......32 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
17 9.2.4.  Acceptable Forms of Contraception  ................................ ................................ ........... 32 
9.3. Intervention after the End of the Study  ................................ ................................ .......33 
9.4. Treatment Adherence  ................................ ................................ ................................ ..33 
9.5. Randomization and Blinding  ................................ ................................ ...................... 33 
9.5.1.  Emergency Unblinding  ................................ ................................ ............................... 33 
10. INVESTIGATIONAL PROD UCT MATERIALS AND MA NAGEMENT  ............. 35 
10.1.  Investigational Product  ................................ ................................ ............................... 35 
10.2.  Investigational Product Packaging and Labeling  ................................ ....................... 35 
10.3.  Investigational Product Storage  ................................ ................................ .................. 35 
10.4.  Investigational Product Preparation  ................................ ................................ ............ 36 
10.5.  Investigational Product Administration  ................................ ................................ ......36 
10.6.  Investigational Product Accountability, Handling, and Disposal  ............................... 36 
10.7.  Product Complaints  ................................ ................................ ................................ ....36 
11. EFFICACY ASSESSMENTS  AND CLINICAL PHARMA COLOGY 
ASSESSMENTS  ................................ ................................ ................................ ......... 38 
11.1.  Efficacy Assessments  ................................ ................................ ................................ .38 
11.1.1.  Kinesia ONEâ„¢ Accelerometer Score  ................................ ................................ .......... 38 
11.1.2.  The Essential Tremor Rating Assessment Scale  ................................ ........................ 38 
 38 
 39 
 39 
 39 
 40 
 40 
 40 
 40 
 41 
 41 
 41 
 41 
 41 
11.3.  Other Patient -Reported Assessments  ................................ ................................ .......... 42 
11.3.1.  Patient Perception of Response Burden  ................................ ................................ ......42 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
18 12. SAFETY ASSESSMENTS  ................................ ................................ ........................ 43 
12.1.  Safety Parameters  ................................ ................................ ................................ .......43 
12.1.1.  Demography and Medical History  ................................ ................................ .............. 43 
12.1.2.  Weight and Height  ................................ ................................ ................................ ......43 
12.1.3.  Physical Examination  ................................ ................................ ................................ .43 
12.1.4.  Vital Signs  ................................ ................................ ................................ .................. 43 
12.1.5.  Electrocardiogram  ................................ ................................ ................................ .......43 
12.1.6.  Laboratory Assessments  ................................ ................................ ............................. 44 
12.1.6.1.  Drugs of Abuse, Alcohol, Cotinine  ................................ ................................ ............ 44 
12.1.6.2.  Pregnancy Screen  ................................ ................................ ................................ ........ 44 
 44 
12.1.8.  Safety Phone Call  ................................ ................................ ................................ .......45 
12.2.  Adverse Events and Serious Adverse Events  ................................ ............................. 45 
12.2.1.  Adverse Event Definition  ................................ ................................ ........................... 45 
12.2.2.  Serious Adverse Event (SAE) Definition  ................................ ................................ ...46 
12.2.3.  Definition of Adverse Events of Special Interest  ................................ ....................... 46 
12.2.4.  Relationship to Investigational Product  ................................ ................................ ......47 
12.2.5.  Recording Adverse Events  ................................ ................................ ......................... 47 
12.2.6.  Reporting Serious Adverse Events  ................................ ................................ ............. 48 
12.3.  Pregnancy  ................................ ................................ ................................ ................... 48 
12.4.  Overdose  ................................ ................................ ................................ ..................... 49 
13. STATISTICS  ................................ ................................ ................................ .............. 50 
13.1.  Data Analysis Sets  ................................ ................................ ................................ ......50 
13.2.  Handling of Missing Data  ................................ ................................ ........................... 50 
13.3.  General Considerations  ................................ ................................ ............................... 50 
13.4.  Demographics and Baseline Characteristics  ................................ ............................... 50 
13.5.  Efficacy Analysis  ................................ ................................ ................................ ........ 51 
13.6.  Safety Analyses  ................................ ................................ ................................ .......... 51 
13.6.1.  Adverse Events  ................................ ................................ ................................ ........... 51 
 52 
13.6.3.  Physical Examinations  ................................ ................................ ................................ 52 
 52 
 52 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
19 13.6.6.  Prior and Concomitant Medications  ................................ ................................ ........... 52 
 52 
 53 
13.8.  Sample Size and Power  ................................ ................................ .............................. 53 
13.8.1 . Interim and Data Monitoring Committee (DMC) Analyses  ................................ .......53 
13.8.1.1.  Interim Analysis  ................................ ................................ ................................ .......... 53 
13.8.1.2.  DMC Analysis  ................................ ................................ ................................ ............ 53 
14. DIRECT ACCESS TO SOU RCE DATA/DOCUMENTS  ................................ ......... 54 
14.1.  Study Monitoring  ................................ ................................ ................................ ........ 54 
14.2.  Audits and Inspections  ................................ ................................ ................................ 54 
14.3. Institutional Review Board or Ethics Committee  ................................ ....................... 55 
15. QUALITY CONTROL AND QUALITY ASSURANCE  ................................ ......... 56 
16. ETHICS  ................................ ................................ ................................ ...................... 57 
16.1.  Ethics Review  ................................ ................................ ................................ ............. 57 
16.2.  Ethical Conduct of the Study  ................................ ................................ ...................... 57 
16.3.  Written Informed Consent  ................................ ................................ .......................... 57 
17. DATA HANDLING AND RE CORDKEEPING  ................................ ....................... 58 
17.1.  Inspection of Records  ................................ ................................ ................................ .58 
17.2.  Retention of Records  ................................ ................................ ................................ ..58 
18. PUBLICATION POLICY  ................................ ................................ .......................... 59 
19. LIST OF REFERENCES  ................................ ................................ ............................ 60 
 
LIST OF TABLES  
Table 1:  Emergency Contact Information  ................................ ................................ ................... 4 
Table 2:  Schedule of Assessments  ................................ ................................ ............................ 12 
Table 3:  Investigational Product  ................................ ................................ ............................... 35 
Table  4: Summary of Clinical Laboratory Analytes  ................................ ................................ .44 
 
LIST OF FIGURES  
Figure 1:  Study Design  ................................ ................................ ................................ ............... 27 
 

&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
/,672)$%%5(9,$7,216$1''(),1,7,2162)7(506

$EEUHYLDWLRQ 'HILQLWLRQ
$( DGYHUVHHYHQW
$'/ DFWLYLWLHVRIGDLO\OLYLQJ
$8&LQI DUHDXQGHUWKHFXUYHIURPWRLQILQLW\
$8&WDXDUHDXQGHUWKHFRQFHQWUDWLRQWLPHFXUYHIURPWRHQGRIWKHGRVLQJSHULRG
%0, ERG\PDVVLQGH[
 
&PD[ PD[LPXPREVHUYHGFRQFHQWUDWLRQ
&52 FRQWUDFWUHVHDUFKRUJDQL]DWLRQ
(& HWKLFVFRPPLWWHH
(&* HOHFWURFDUGLRJUDP
H&5) HOHFWURQLFFDVHUHSRUWIRUP
(26 (QGRI6WXG\
 
 
(7 HVVHQWLDOWUHPRU
 
(79 HDUO\WHUPLQDWLRQYLVLW
)'$ )RRGDQG'UXJ$GPLQLVWUDWLRQ
*&3 *RRG&OLQLFDO3UDFWLFH
*03 *RRG0DQXIDFWXULQJ3UDFWLFH
,% LQYHVWLJDWRUÂ¶VEURFKXUH
,&) LQIRUPHGFRQVHQWIRUP
,&+ ,QWHUQDWLRQDO&RXQFLOIRU+DUPRQLVDWLRQRI7HFKQLFDO5HTXLUHPHQ WVIRU
3KDUPDFHXWLFDOVIRU+XPDQ8VH
,3 LQYHVWLJDWLRQDOSURGXFW
,5% LQVWLWXWLRQDOUHYLHZERDUG
0HG'5$ 0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV
3' SKDUPDFRG\QDPLF
 
3, SULQFLSDOLQYHVWLJDWRU
3. SKDUPDFRNLQHWLF
 PPD
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
21 Abbreviation  Definition  
  
PV pharmacovigilance  
QTcF  QT corrected according to Fridericia â€™s formula  
  
SAE  serious adverse event  
SAP statistical analysis plan 
SOP standard operating procedure  
tÂ½  terminal elimination half -life  
TEAE  treatment -emergent adverse event  
TETRAS  The Essential Tremor Rating Assessment Scale  
tmax time of occurrence of C max 
WHO  World Health Organization  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
22 5. INTRODUCTION  
SAGE -324 is a positive allosteric modulator (PAM) of A -type Î³ -aminobutyric acid -gated 
chloride channel (GABA A) receptors, the major class of inhibitory neurotransmitter receptors in 
the brain.  In addition to being developed as an  adjunctive therapy in epilepsy and other seizure 
disorders  under IND 139201, SAGE -324 is also being developed for the treatment of Essential 
Tremor (ET).  
Essential tremor is a permanently debilitating, neurologically determined, common movement 
disorder c haracterized by involuntary rhythmic oscillation of a body part due to intermittent 
muscle contractions typically occurring when not at rest, thus interfering with fine motor skills 
associated with daily activities ( Olanow 2008 , Deuschl 2011 , Hopfner 201 6, NIH 2019 ). 
Although the pathophysiology and etiology of ET is not fully understood, it is postulated that 
approximately 50% of ET patients feature an autosomal dominant pattern of familial inheritance 
and that non -inherited cases may have toxin -based or o ther causality ( Olanow 2008 , Hopfner 
2016). ET is the most common movement disorder in the US, with prevalence estimated to be 
approximately 2.2% of the population, representing a substantial societal medical burden with 
over an estimated 7 million ET pati ents in the US alone ( Louis 2014 ).  
In general, active tasks of daily life are adversely impacted by ET, including but not limited to 
speech, handwriting, household tasks, and occupational demands, contributing negatively to 
psychosocial well -being, genera l anxiety, and overall quality of life  (Koller, 1989 ). Although 
benign in term of its effect on life expectancy, ET is a progressive neurodegenerative condition 
whose symptoms are typically disabling, often forcing patients to change jobs or seek early 
retirement ( Zappia, 2013 ). In some cases, serious disability may ensue.   
The pharmacological profile  of SAGE -324 is theorized to  induce therapeutic effect  in the 
treatment of ET. Based on preclinical studies of  SAGE -324, which features a different 
mechanism of action than that of propranolol, the pharmacokinetic (PK)/ pharmacodynamic (PD) 
profile suggests SAGE -324 may safely ameliorate symptoms in patients suffering from ET, 
regardless of propranolol use . 
There are currently ongoing Phase 1 clinical s tudies of SAGE -324 in healthy adults  and in adults 
with ET . These studies , in addition to preclinical studies of SAGE -324, are detailed in the 
investigatorâ€™s brochure.  
With a GABA A receptor -based mechanism of action  featuring  positive allosteric modulation  
capability , SAGE -324 represents a novel approach to treatment of ET with possible utility  as 
monotherapy or adjunctive  to propranolol, which may help address the unmet medical need of 
the ET population , warranting further study of SAGE -324 as a potential treatment for this 
common movement disorder.  
Henceforth, this double -blind, placebo -controlled efficacy and safety study of SAGE -324 will be 
conducted in adults  with and without concomitant use of propranolol and  is designed to assess 
the effect of SAGE -324 on a variety of outcome measures specific to ET disease characteristics  
and associate d quality of life  domains . 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
23 5.1. Dose Justification  
The d ose of SAGE -324 planned for  this study  is 60 mg given as oral tablets, to be  administered 
once daily in the morning with food. Th e dose  was selected based on preliminary data from 
3 active studies of SAGE -324, which included : unblinded data from completed cohorts in 
324-CLP-101 Part A (oral solution SAGE -324 doses of 3 mg, 10 mg, 30 mg, 45 mg, 60 mg) ; 
Part C (oral solution SAGE -324 doses of 30 mg) ; Part D (oral suspension SAGE -324 doses of 
30 mg) in healthy subjects ; and  preliminary data from open -label Part E (oral suspension SAGE -
324 doses of 45 mg and 60 mg) in participants with  ET; additional preliminary data from 
324-CLP-102 cohorts 1 through 6  (cohorts 1 to 5 unblinded, cohort 6 blinded) , which evaluated 
oral suspension doses ranging from 5 mg to 60 mg; and preliminary unblinded data from 
324-CLP-104, which compared the relati ve bioavailability of the oral tablet (30 mg) vs oral 
suspension (30 mg) formulations of SAGE -324 and separately the effect of food on the PK of the 
SAGE -324 oral tablet. In 324 -CLP-101 and 324 -CLP-102 studies, doses were administered in a 
fasted state. Th e preliminary data from all of these active studies collectively informed the route 
of administration (oral) and dose strength of 60 mg as oral tablets planned for further evaluation 
in this study .  
SAGE -324 was generally well -tolerated in participants wit h ET and in healthy volunteers, as was 
shown in the preliminary data of 324 -CLP-101 Part E at single administration doses of 45 mg 
and 60 mg, and in 324 -CLP-102 through once -daily administered doses of up to 60 mg  for 
14 days. In addition, tremor reduction was observed at both doses on TETRAS and Kinesia 
accelerometry, with greater improvement seen at 60  mg compared to 45  mg.  
In the clinically complete  study 324-CLP-104, preliminary data showed that SAGE -324 oral 
tablets, when coadministered with a meal, resulted in exposures approximately equivalent to that 
of SAGE -324 oral suspension under fasted conditions. Therefore, the SAGE -324 oral tablets are 
recommended to be administered with food.  
5.2. Benefit/Risk Assessment  
Based on the mechanism of action of SAGE -324 and the results of completed nonclinical studies 
and preliminary data of currently ongoing clinical studies of SAGE -324, it is theorized that 
participants  may have  symptomatic ameliorat ion, ie, tremor reduction and possibly improved 
quality of life  from potentially stabilizing disease characteristics associated with ET. 
Potential risks anticipated in this study are based on available data from toxicology studies of 
SAGE -324 in addition to preliminary data from 3 ongoing, currently active Phase 1 clinical 
studies of SAGE -324.  
As of  20 December 2019 , there have been no dea ths or SAEs  related to IP , and a s of 18 October 
2019, based on the preliminary clinical data available, there have been no confirmed  clinically 
significant trends in clinical laboratory evaluations, vital signs, or physical examinations. 
Available prelimin ary clinical data is summarized in the Investigatorâ€™s Brochure.  
Based on available preliminary clinical data  from SAGE -324 active clinical studies , AEs of 
somnolence and feeling of relaxation are considered adverse drug reactions.  In addition to 
scheduled clinic visits, the current status of study participants will be reviewed via weekly phone 
calls, in between clinic visits.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
24 6. STUDY  OBJECTIVES AND ENDPOINTS  
Objectives  Endpoints  
Primary   
â€¢ To assess the effect of SAGE -324 
compared to placebo on tremor 
reduction in individuals with 
essential tremor (ET)  â€¢ Change from baseline compared to 
placebo in Kinesia  ONE â„¢ accelerometer 
scores  after 28 days of treatment  
Secondary   
â€¢ To assess the effect of SAGE -324 
compared to placebo on activities 
of daily living (AD Ls), total 
performance, and upper 
extremities  
 
 
 
 
 
 
â€¢ To evaluate the safety and 
tolerability of SAGE -324 â€¢ Change from baseline compared to 
placebo in Kinesia ONE accelerometer 
scores at all other timepoints  
â€¢ Change from baseline compared to 
placebo in the following:  
- The Essential Tremor Rating 
Assessment (TETRAS) Scale ADL 
score  
- TETRAS Total Performance Score  
- TETRAS Performance Subscale Part 4 
Upper Limb Tremor  
â€¢ Incidence of treatment -emergent adverse 
events (TEAEs)  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
25  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
26 7. INVESTIGATIONAL PLAN  
7.1. Overall Study Design  
This is a randomized, double -blind, placebo -controlled, parallel group study to evaluate the 
efficacy, safety, and tolerability of SAGE -324 as monotherapy and adjunctive therapy with 
propranolol in individuals with ET. Participants, site staff, and sponsor  personnel will be masked 
to treatment allocation  (see Section  8.5). 
This study includes a Screening Period of up to 28 days, a 2 9-day treatment period consisting of 
28 days of dosing with the end of treatment visit  intended to be on Day 29 at trough , and a 
14-day follow -up period  relative to final dose  (Figure 1). After providing informed consent, 
participants will undergo screening assessments as outlined in Table 2  to determine eligibility .  
The Screening Period begins with the signing of the informed consent form (ICF). Following 
completion of screening , on Day 1, eligible participants will visit the study center and will be 
randomized to 1 of 2 treatment groups (SAGE -324 60 mg  or placebo) in a 1:1 ratio. 
Randomization will be stratified based on the use of propranolol for the treatment of ET (Y/N). 
Participants who are on a propranolol regimen must have been on a stable regimen for at least 1 
month  prior to Day 1 and will continue to be on that stable regimen during the Treatment Period. 
Participants will complete baseline assessments of safety and efficacy, including the clinician -
rated TETRAS and quantitative Kinesia ONE assessments of tremor, as specified in the Schedule 
of Assessments ( Table 2 ). 
During the double -blind Treatment Period, s tarting on Day 1, participants will receive a single 
dose of investigational product (IP) once daily for 28 days on an outpatient basis. Doses 
occu rring on scheduled clinic visits will be administered in the clinic, and doses occurring on all 
other days will be self -administered by the participant at home  as specified in Table 2 . During 
the Treatment Period, participants will return to the study center approximately once per week 
for efficacy and safety assessments as specified in  Table 2 . In addition, a phone call will be 
conducted once per week (preferably mid -week) in  between clinic visits, to review current status 
of the participant.  
In addition to Kinesia ONE -specific training, c linical study center staff and study p articipants 
will be trained on the use of software applications and devices necessary to complete 
questionnaires or  other assessments as required.  During in-clinic visits, c linical study center staff 
will be available to assis t participants as needed , to ensure they can  access and us e the software  
applications and devices  correctly according to the training . 
During the fo llow-up period, visits will be conducted on an outpatient basis. In addition to the 
phone calls to review cu rrent status, p articipants will receive a phone call approximately 7 days 
after the last dose of IP (ie, Day 35) for safety monitoring. Participants will return to the study 
center for an end of study visit approximately 14 days following the last dose of IP (ie, Day 42) . 
Participants who discontinue IP during the Treatment Period will be asked to return to the clinic 
as soon as possible for an end of treatment (EOT) visit. Follow -up visits should take place as 
scheduled, or relative to the last dose of IP if discontinuing treatment early. If at any time after 
the EOT visit, a participant decides to withdraw from the study, the participant should return for 
an early termination visit  (ETV) . The EOT and ETV  can be on the same day if a participant 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
27 discontin ues IP and withdraws from the study on the same day during a clinic visit; in this case, 
all events scheduled for the EOT visit will be conducted.   
Figure 1: Study Design   
 
Abbreviation:  EOT = end of treatment  
7.2. Number of Participa nts 
Approximately 60 participants  are planned , with approximately 30 participants enrolled per arm , 
to produce 25 evaluable participants per arm  for primary efficacy  analysis . Additional 
participants may be randomized if the drop -out rate is higher than anticipated ( ie, >15%). 
7.3. Treatment Assignment  
Participants will be assigned to IP (active or placebo) in accordance with the randomization 
schedule on Day 1. Additional details on randomization and blinding  are provided in Section  8.5.  
7.4. Dose Adjustment Criteria   
If participants report adverse events that are  considered by the investigator to be related to the IP 
and not tolerable , the investigator may reduce the dose of IP from 60 mg in 15 mg increments 
until tolerability is established.  The reduced  dose of IP will continue to be administered once 
daily at the  same schedule as specified in the Schedule of Assessments (Table 2). The dose of IP 
may not be increased for the remainder of the study . The dose may not be reduced below 30 mg: 
if intolerable adverse events persist at the 30 mg dose, the IP should be permanently stopped.  
Otherwise, IP doses will not be further adjusted for this study except as clinically necessary , eg, 
interrupting dose due to an AE or  serious adverse event ( SAE ) considered related to IP . 
7.5. Criteria for Study Termination  
Sage Therapeutics may terminate this study or any portion of the study at any time for safety 
reasons including the occurrence of AEs or other findings suggesting unaccep table risk to 
participant s, or for administrative reasons . In the event of study termination, Sage Therapeutics 
will provide written notification to the investigator . Investigational sites must promptly notify 
their IRB/ ethics committee  (EC) , where require d, and initiate withdrawal procedures for 
participating participant s.  
 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
28 8. SELECTION AND WITHDRAWAL OF PARTICIPANT S 
8.1. Participant  Inclusion Criteria  
Participants must  meet all of the following criteria to qualify for  participation in this study:  
1. Participant has signed an ICF before any study -specific procedures or washout of drugs is 
performed.  
2. Participant is 18 to 80 years of age, inclusive, at the time informed consent is obtained.  
3. Participant has a diagnosis of ET, as defined by all of the foll owing criteria:  
a. Isolated tremor syndrome consisting of bilateral upper limb action tremor  
b. At least 3 years duration  
c. With or without tremor in other locations (eg, head, voice, or lower limbs)  
d. Absence of other neurological signs, such as dystonia, ataxia, or parkinsonism, 
isolated focal tremors (eg, voice, head), task - and position -specific tremors, sudden 
tremor onset or evidence of step -wise deterioration of tremor  
4. Participant has a combined total upper extremity TETRAS score of â‰¥8 with at least 1 
upper e xtremity TETRAS score >4.  
5. Participant is willing to discontinue medications taken for the treatment of ET, with the 
exception of propranolol, within 14 days or 5 half -lives (whichever is longer) prior to 
receiving IP.  
6. Participants taking propranolol for th e treatment of ET must be on a stable dose for at 
least 1  month prior to Day 1 and must be willing to maintain their stable dose through 
Day 2 9. 
7. Participant is willing to discontinue the use of alcohol and drugs of abuse within at least 
â‰¥1 week prior to Da y 1 and through Day 2 9 of the study.  
8. Female participant agrees to use at least one method of highly effective contraception as 
listed in Section  8.2.4  during participation in the study and for 30 days following the last 
dose of study drug, unless she is postmenopausal (at least 12 months of spontaneous 
amenorrhea without an alternative medical cause, with confirmatory follicle stimulating 
hormone >40  mIU/mL), and/or surgically sterile (bilateral oophorectomy, hysterectomy, 
and/or bilateral salpingectomy), or does not engage in sexual relations which carry a risk 
of pregnancy (does include abstinence).  
9. Male participant agrees to use an acceptable method of effective contraception for the 
duration of the study and for 13 weeks after receiving study drug, unless the participant 
does not engage in sexual relation(s) which carry a risk of pregnancy. Acceptable 
methods of effective contracept ion are listed in Section  8.2.4 .  
10. Male participant is willing to abstain from sperm donation for the duration of the study 
and for 13 weeks after receivi ng study drug.  
11. Female participant must have a pregnancy test result that is confirmed as negative at 
Screening and Day 1.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
29 12. At the discretion of the investigator, participant is medically stable and ambulatory, and 
is on stable dose(s) of any necessary presc ription or over -the-counter medication(s) for at 
least 30 Days  prior to Day 1, or changes/discontinues their use prior to Day 1 with the 
appropriate washout, as applicable per investigator judgement.  
13. Participant has no clinically significant findings, as determined by the investigator, on 
physical examination including mental state examination (MSE) and neurologic 
examination, 12 -lead ECG, or clinical laboratory tests . 
8.2. Participant Exclusion Criteria  
Participant s who meet any of the following criteria are d isqualified from participation in this 
study:  
1. Participant has presence of known causes of enhanced physiological tremor.  
2. Participant has had recent exposure (14 days prior to Day 1) to tremorgenic drugs or 
presence of a drug or alcohol withdrawal state.  
3. Participant has had direct or indirect injury or trauma to the nervous system within 3 
months before the onset of tremor.  
4. Participant has had a previous procedure for the treatment of ET, deep brain stimulation, 
brain lesioning, or magnetic resonance (MR) guided procedure, eg, MR -guided focused 
ultrasound.  
5. Participant has historical or clinical evidence of tremor with psychogenic origin 
(including but not limited to eating disorders, major depression, etc.)  
6. Participant has significant history  and/or presence of hepatic, renal, cardiovascular, 
pulmonary, gastrointestinal, hematological, immunologic, ophthalmologic, metabolic 
(hypothyroidism with stable thyroid replacement is acceptable), or oncological disease.  
7. Participant has history, presence , and/or current evidence of serologic positive results for 
hepatitis B surface antigen (HBsAg), hepatitis C antibodies (anti -HCV), or human 
immunodeficiency virus (HIV) 1 or 2 antibodies.  
8. Participant has history of alcohol or drug abuse within 6 months pr ior to Screening, or a 
positive screen for alcohol on the Day 1 visit, or a positive screen for drugs of abuse at 
Screening or at the Day 1 visit.  
9. Participant has a known allergy to SAGE -324 or any excipient.  
10. Participant has had exposure to another invest igational drug or device within 30 days 
prior to the Day 1 visit.  
11. Participant has history or suicidal behavior within 2 years or answers â€œYESâ€ to questions 
3, 4, or 5 on the C -SSRS at Screening or at Day 1 or is currently at risk or suicide in the 
opinion of the investigator  
12. Participant has donated one or more units (1 unit  = 450 mL) of blood or experienced 
acute loss of an equivalent amount of blood within 60 days prior to Day 1.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
30 13. Participant is unable to perform Kinesia O NE assessments or unable to use th e device 
required to perform the assessment.  
14. Participant has any condition or comorbidity that in the opinion of the investigator would 
limit or interfere with the participantâ€™s ability to complete or partake in the study.  
15. Participant is unwilling or unabl e to comply with study procedures and required training.  
16. Participant has used any known moderate or strong cytochrome P450 3A4 or P450 2D6 
inhibitors and/or inducers within 14 days or 5 half -lives (whichever is longer) prior to 
Day 1 or consumed grapefruit  juice, grapefruit, Seville oranges, pomegranates, tangelos, 
or St. Johnâ€™s Wort or products containing these within 30 days prior to Day 1. Use of 
mild cytochrome inhibitors and/or inducers may be permitted.  
17. Participant has concurrent or recent exposure ( 14 days prior to the Day 1 visit) to 
sedative/hypnotic drugs, stimulants, eg, opioids, highly -caffeinated beverages or dietary 
supplements containing high doses of caffeine, or recent increase above regular daily 
consumption of coffee.  
18. Participant has conc urrent or recent exposure (30 days prior to the Day 1 visit) to long -
acting benzodiazepines  
19. Participant plans to undergo elective surgery or relocate during participation in the study.  
20. Participant is investigative site personnel or a member of their immediate families 
(spouse, parent, child or sibling whether biological or legally adopted) . 
21. Participant has a positive urine cotinine screen at Screening  or the Day 1 visit.  
8.3. Screen Failures  
Screen failures are defined as participants who consent to partic ipate in the clinical study but are 
not subsequently assigned IP or entered in the study , ie, a participant who does not meet 1 or 
more of the eligibility criteria  after providing consent  and prior to randomization  (Day 1) . A 
minimal set of screen failure information will be collected, including  demography, screen failure 
details, eligibility criteria, and any SAE.   
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened.  
8.4. Investigational Product  Discontinuation and Early Termination from 
the Study  
8.4.1.  Investigational Product  Discontinuation  
A participant may withdraw fro m the study at any time at his/her own request for any reason. 
The investigator may discontinue a participant from the study and/or from IP for safety, 
behavioral, compliance, or administrative reasons. Participants who elect to discontinue IP will 
be enco uraged by the Investigator to remain on study and complete the follow -up safety 
assessments  14 days after the last dose of study drug , in addition to the EOT  visit conducted as 
specified in the Schedule of Assessments ( Table 2).  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
31 The reason for IP discontinuation and/or the reason for early termination from the study must be 
documented in the participantâ€™s study record and recorded in the participantâ€™s ele ctronic case 
report form (eCRF).  
The investigator must notify the sponsor and/or the medical monitor when a participant stops 
participation in the study for any reason.  
If a participant  is persistently noncompliant, the investigator should discuss with the sponsor the 
potential discontinuation of the participant . Any reasons for unwillingness or inability to adhere 
to the protocol must be recorded in the participant â€™s eCRF, including:  
â€¢ missed visits;  
â€¢ interruptions in the sc hedule of study drug administration;  
â€¢ non-permitted medications  
Participant s who discontinue IP due to an AE, regardless of investigator -determined causality, 
should be followed until the event is resolved, considered stable, or the investigator determines 
the event is no longer clinically significant.  
8.4.2.  Early Termination from the Study  
At the time of study withdrawal/stopping study participation, if possible  within 48 hours of final 
IP dose , an EOS/ ETV  visit should be conducted  as specified in the Schedule of  Assessments 
(Table 2 ). The participant will be permanently discontinued both from the IP and from the study 
at that time.  
If the participant withdraws consent for disclosure of future information, the sponsor will retain 
and continue to use any data collected before such a withdrawal of consent.  
If a participant withdraws from the study, he/s he may request destruction of any samples taken 
and not tested, and the investigator must document this in the site study records.  
8.4.3.  Loss to Follow -up 
A participant will be deemed lost to follow -up after 3 attempts at contacting the participant have 
been uns uccessful .  
8.4.4.  Replacement of Participants  
Participants will not be replaced.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
32 9. TREATMENT OF PARTICIPANT S 
9.1. Description of Investigational Product  
SAGE -324 is an orally administered tablet provided in  5 mg  or 15 mg (when available)  dose 
strengths . Participants will receive IP (60 mg total dose of SAGE -324 tablets , or appearance -
matched placebo tablets) according to the randomization schedule. Additional details regarding 
IP preparation, formulation, and storage are included in Section  9. 
9.2. Prior  Medications , Concomitant Medications , Restrictions , and 
Contraception  Requirements  
9.2.1.  Prior and Concomitant Medications  and/or Supplements  
The start and end date s, route, dose/units, frequency, and indication for all medications  and/or 
supplements  taken within 30 days prior to signing the informed consent through the first dose of 
IP will be recorded . Use of all medications taken within the 30 days prior to Screening will be 
recorded.  
All medications and/or supplements taken from the first dose of IP through the Day  42 (Â±1 days) 
visit (including start and end dates route, dose/units, frequency, and indication)  will be recorded 
on the eCRF . Any concomitant medication determined necessary for the welfare of the 
participant  may be given at the discretion of the investigator at any time during the study .  
9.2.2.  Prohibited Medications  
Use or consumption of the following i s prohibited for the timeframes specified:  
â€¢ Treatment with an investigational drug or device during the 30 days or 5 half-lives (if 
known) of the investigational drug, whichever is longer, prior to Screening or during 
the study  
â€¢ Use of any prescription or over-the-counter medication ( except for propranolol use as 
prescribed , and /or up to 3 g/day of acetaminophen), herbal medication, vitamins, or 
mineral supplements within 14 days prior to first IP administration , or during the 
study period  
â€¢ Use of tremorgenic drugs or agents known to affect SAGE -324 drug metabolism (any 
known CYP450 3A4 inhibitors and/or inducers) within the 28 days or 5 terminal half-
lives (whichever is longer) prior to first IP administration  or during the study period  
9.2.3.  Other Restrictions  
In addition to alcohol and drugs of abuse, the following are not permitted during the study, or 
within 14 days of the first IP dose:  sedative/hypnotic drugs, stimulants, eg, opioids, 
benzodiazepines, highly -caffeinated beverages or dietary supplements containing caffeine . 
9.2.4.  Acceptable Forms of Contraception  
Acceptable forms of highly effective contraception for participants of childbearing potential or 
for partners of male participants who are of childbearing pot ential include:  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
33 â€¢ Combined (estrogen and progestogen containing) oral, intravaginal, or transdermal 
hormonal contraception associated with inhibition of ovulation  
â€¢ Oral, injectable, or implantable progestogen -only hormonal contraception associated 
with inhibi tion of ovulation  
â€¢ Intrauterine device  
â€¢ Intrauterine hormone -releasing system  
â€¢ Bilateral tubal ligation  or bilateral tubal occlusion  (performed at least 3 months prior 
to Screening)  
â€¢ Vasectomized partner  (performed at least 3 months prior to Screening)  
â€¢ Sexual abstinence (no sexual intercourse)  
Acceptable forms of contraception for male participants include:  
â€¢ Sexual abstinence (no sexual intercourse)  
â€¢ History of vasectomy  (performed at least 3 months prior to Screening)  
â€¢ Condom with spermicide used together with highly effective female contraceptive 
methods if the female partner(s) is of childbearing potential (see above for list of 
acceptable female contraceptive methods)  
9.3. Intervention after the End of the Study  
There is n o planned  intervention following the end of the study.  
9.4. Treatment Adherence  
The first dose of IP will be received and administered by participants in the clinic . Participant s 
will be dispensed a  7-day supply of IP to orally self -administer  at home with instructions 
specifying to administer in the morning with food. Treatment adherence will be monitored by the 
site staff at each in-clinic visit  by direct questioning  and counting  returned tablets  and will be 
documented . Details on drug accountability are included in  Section  9.6. 
9.5. Randomization and Blinding  
This is a  randomized, double -blind, placebo -controlled study. Participants will be random ized in 
a stratified  manner based on propranolol for the treatment of ET (Y/N); randomization will be 
done within each stratum in a 1:1 ratio  to treatment group s (SAGE -324, 60 mg or placebo) . 
Participants, site staff, and the sponsor will be blinded to treatment allocation. Randomization 
schedules will be generated by an independent statistician . The randomization schedules will be 
kept strictly confidential, accessible only to authorized  personnel until the time of unblinding. 
The blinding of the study  will be broken after the database has been locked.  
9.5.1.  Emergency Unblinding  
During the study, the blind is to be broken only when the safety of a participant  is at risk and the 
treatment plan is dependent on the study treatment received. Unless a participant  is at immediate 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
34 risk, the Investigator should  make diligent attempts to contact Sage prior to unblinding the study 
treatment administered to a participant . Request s from the investigator about the treatment 
administered to study participant s should  be discusse d with the Sage  Medical Monitor . If the 
unblinding occurs without Sageâ€™s knowledge, the investigator must notify Sage within 24 hours 
of breaking the blind. All circumstances surrounding a premature unblinding must be clearly 
documented in the source recor ds.  
In all cases where the IP allocation for a participant  is unblinded, pertinent information 
(including the reason for unblinding) must be documented in the participant â€™s records and on the 
eCRF. At the time of withdrawal  from the study /stopping partici pation , if possible, an EOT 
and/or ETV  should be conducted .  
If a participant or study personnel become unblinded to treatment, the participant will be 
excluded from the Per Protocol analysis set, as detailed further in the statistical analysis plan. 
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
35 10. INVESTIGATIONAL PROD UCT  MATERIALS AND 
MANAGEMENT  
10.1. Investigational Product  
Table 3: Investigational Product  
 Investigational Product  
Product Name:  SAGE -324 Placebo  
Dosage Form:  Tablet  Tablet  
Tablet Strength  5 mg , 15 mg  0 mg, appearance -matched to 
5 mg, and 15 mg, respectively  
Route of Administration  Oral Oral 
Physical Description  Immediate release white to off -
white, round, film -coated tablet 
containing 5 mg or 15 mg  of 
SAGE -324 drug substance , and 
composed of lactose, 
microcrystalline cellulose, 
croscarmellose sodium, sodium 
stearyl f umarate and fumed 
silica, featuring  OpadryÂ® II 
white as the coating agent.  White to off -white, round, film -
coated tablet containing no drug 
substance, composed of lactose, 
microcrystalline cellulose, 
croscarmellose sodium, sodium 
stearyl fumarate and fumed  
silica, featuring  OpadryÂ® II 
white as the coating agent.   
Manufacturer  Sage Therapeutics , Inc.  
10.2. Investigational Product  Packaging and Labeling  
SAGE -324 Oral Tablets and Placebo Tablets will be  packaged in blinded, high density 
polyethylene (HDPE) containers.  The containers used for SAGE -324 and placebo will be 
identical in appearance.  The package labeling conforms to FDA and GMP requirements.  
10.3. Investigational Product  Storage  
Upon receipt of the IP, the investigator, or the responsible pharmacist or designee, will inspect 
the product and acknowledge receipt in accordance with the study -specific process.  
The IP must be carefully stored at the temperature specified in the investigatorâ€™s brochure , 
securely and separately from other drugs. The IP may not  be used for any purpose other than the 
present study. Any unused IP must be returned per the sponsorâ€™s instructions or destroyed locally  
per the siteâ€™s procedure(s) . IP may not be destroyed until accountability  and reconciliation  
procedures  have been completed  and monitored . 
The Investigator or designee will be responsible for ensuring appropriate storage, dispensing, 
inventory, and accountability of the IP. An accurate, timely record of the disposition of the IP 
must be maintained.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
36 10.4. Inves tigational Product  Preparation  
The IP will be  in tablet form and  provided in blinded packaging.  No preparation is required for 
the tablet , which is administered orally  as described below . 
10.5. Inves tigational Product  Administration  
The IP will be administered in the clinic or at home as specified in the Schedule of Assessments 
(Table 2 ). The IP will be provided as tablets , sufficient in number to achieve a  dose of  60 mg . IP 
will be orally administered once daily  in the morning,  with food. 
10.6. Inves tigational Product  Accountabili ty, Handling, and Disposal  
Upon receipt of IP, the investigator(s), or the responsible pharmacist or designee, will inspect the 
IP and complete and follow the instructions regarding receipt  and storage  in the investigatorâ€™s 
brochure and (where applicable) in the Pharmacy Manual. A copy of the shipping documentation 
will be kept in the study files.  
The designated site staff will dispense the supplied participant -specific kits to participant s at the 
planned dispensation visit in tervals outlined in  the Schedule of Assessments  (Table 2 ). 
An interactive response technology (IRT) will be used to capture participant -identifying 
infor mation. The IRT will be used to randomize the eligible participant into the study and 
provides the kit number of the IP to be dispensed to that participant.   
If dispensing errors or discrepancies are discovered by site staff or sponsorâ€™s designee, the 
sponsor must be notified immediately.  
The IP provided is for use only as directed in this protocol. The investigator or designee must 
keep a record of all IP received, used and returned/discarded.   
Sage Therapeutics  will be permitted access to the study  supplies at any time with appropriate 
notice during or after completion of the study to perform drug accountability reconciliation.   
The investigator, pharmacist, or qualified designee is responsible for drug accountability, 
reconciliat ion, and  record maintenance (ie, receipt, reconciliation, and final disposition records).  
At the end of the study, any unused IP tablets will be returned to Sage Therapeutics for 
destruction or destroyed locally  per the siteâ€™s procedures ; disposition of IP will be documented.  
IP may not be destroyed until accountability and reconciliation procedures have been completed 
and monitored.  
10.7. Product Complaints  
A product complaint is any written, electronic, or verbal expression of dissatisfaction regarding 
the iden tity, quality, reliability, safety, purity, potency, effectiveness or performance (applicable 
for approved marketed products) of a drug product after it is released for distribution.  
In the course of conduct of the study, study personnel may become aware of a product complaint 
associated with the use of a Sage product. Personnel shall notify Sage within 24 hours by 
forwarding the product complaint information via the contact information listed in Table 1  and in 
the Pharmacy Manual.  Where possible, personnel should segregate  and retain  any product, 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
37 materials, or packaging  associated with the product complaint  until further instruction is 
provided by Sage or its designated representative (s). 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
38 11. EFFICACY ASSESSMENTS  AND CLINICAL PHARMA COLOGY 
ASSESSMENTS  
11.1. Efficacy Assessments  
11.1.1.  Kinesia ONEâ„¢ Accelerometer Score  
Kinesia ONEâ„¢ is an ISO -certified  wireless motion sensor wor n distally on the index finger , 
which utilizes 3 orthogonal accelerometers and 3 orthogonal gyroscopes to monitor three -
dimensional motion. Data is transmitted wirelessly from the sensor to a Bluetooth  technology -
enabled device  to use with the  Kinesia ONE software  (eg, Apple iPad or similar device with 
preinstalled Kinesia ONE software) . The device has received FDA clearance . 
Via the Kinesia ONE software application, m easures of three -dimensional  motion  are converted 
to scores  ranging from 0 to 4 , per assessed maneuver ; higher scores indicate greater  tremor  
severity . Motion in both arms is captured.  
Participants will complete this assessment at each clinic visit as specified in the Schedule of 
Assessments ( Table 2 ).  
11.1.2.  The Essential Tremor Rating Assessment Scale  
TETRAS is a validated , comprehensive clinical assessment of essential tremor  (Elble 2013).  
Three different components of TETRAS will be assessed in this study. The TETRAS ADL 
subscale, total performance score, and performance subscale part 4 upper limb tremor  score , and 
will each be separately assessed  at each clinic visit as specified in the Sc hedule of Assessments 
(Table 2 ). 
The ADL subscale assesses how ET is impacting typical activities of daily living (ie, speech, 
eating, drinking, dressing, personal hygiene, writing, occupational impairment, social impact, 
and activities affected by upper limb tremor). It consists of 12 items that are  each rated in from 
0 (normal activity)  to 4 (severe abnormality) . The overall ADL score range is 0 to 48.  
The total performance score is based on overall rating  of the performance  subscale , which 
measures tremor amplitude in the voice, limbs , head, face,  trunk, and also  measures functional 
task capabilities, ie, handwriting, spirography,  and h olding a pen over a dot . Each of these items 
is rated on a scale from 0  (no tremor) to 4 (severe tremor). Collectively, the performance items  
generate an  overall performance score from 0 to 64 .  
For the performance subscale part 4 upper limb tremor  score , all 3 maneuvers in the upper limb 
assessments  of part 4 (subscale items 4a, 4b, and 4c) will be completed for both arms, first for 
the left arm and then for the right . The part 4 subscale ordinally rates postural  (limbs extended 
forward  maneuver, and wing -beating  [elbows flexed] maneuver) , and kinetic  (finger -nose-finger 
maneuver)  tremor on a 0 to 4  severity scale  in 0.5 -point increments.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
39 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
40 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
41  
 
  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
42 11.3. Other Patient -Reported Assessment s 
11.3.1.  Patient Perception of Response Burden  
The Patient Perception of Response Burden Questionnaire is a patient -reported measure that 
assesses the multidimensional construct of response burden ( Atkinson 2019 ). 
Participants respond t o 6 items assessing 1) how well the questions related to their actual 
concerns, 2) how comfortable the participants were with answering the questions, 3) how well 
the survey characterized their health and well -being, 4) the length of time to complete the 
questionnaires, 5) whether questions seemed unimportant or repetitive, and 6) what additional 
information should have been gathered. Items 1 to 3 are assessed on a 0 to 10 scale, item 4 is 
assessed on a 1 to 3 scale, and items 5 and 6 are open -ended. Items 1 and 4 are reverse scored. A 
composite score can be calculated to create a weighted representative index of relevance, 
comfort, and well -being relative to time to completion (ie, items 1, 2, and 3 were summed and 
multiplied by item 4) for a range of 0 to 72, with higher scores indicative of elevated endorsed 
response burden. The open -ended items will be summarized thematically. The Patient Perception 
of Response Burden Questionnaire will be performed as specified in the Schedule of 
Assessments ( Table 2 ). 
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
43 12. SAFETY  ASSESSMENTS  
12.1. Safety Parameters  
All assessments will be conducted according to the Schedule of Assessments (Table 2). 
12.1.1.  Demograph y and Medical History  
Demographic characteristics (age, race, sex, ethnicity) and a full medical history will be 
documented . This  must  also additionally include  participant  recall of history of  ET, disease 
duration, past treatments  used, and responsiveness to  alcohol  and/or other treatments  with use 
intended  as off-label  treatment  of ET (eg, primidone  or similar t herapies ). 
12.1.2.  Weight and Height  
Height and weight wi ll be measured and documented . Body mass index (BMI) will be calculated 
and documented.   
12.1.3.  Physical Examination  
Whenever possible, the same individual should perform all physical examinations . Physical 
examinations will include assessment of body systems (eg, head, eye, ear, nose and throat; heart; 
lungs; abdomen; and extremities) as well as cognitive and neurological examination and MSE . 
Unscheduled physical examinations may also be conducted p er the Investigatorâ€™s discretion.  
Any abnormality in physical examinations will be interpreted by an investigator as abnormal, not 
clinically significant (NCS); or abnormal, clinically significant (CS) in source documents .  
12.1.4.  Vital Signs  
Vital signs comprise  heart rate, respiratory rate, temperature, and blood pressure. Systolic and 
diastolic blood pressure are to be measured after the participant  has been supine for at least 
5 minutes prior to the measurement. When assessed postdose,  orthostatic blood pressu re and 
heart rate will also be measured after the participant  has been in the supine position for at least 
5 minutes and then repeated approximately 1 and 3 minutes after standing .  
Any abnormality in vital signs will be interpreted by an Investigator as a bnormal, NCS; or 
abnormal, CS in source documents . 
12.1.5.  Electrocardiogram  
A 12 -lead ECG will be performed . The standard intervals (heart rate, PR, QRS, QT, and QTcF ) 
as well as any rhythm abnormalities will be recorded.  
Electrocardiograms will be performed after the participant  has been resting in a supine position 
for at least 5 minutes. When ECG measurement s coincide with safety assessments, vital signs 
assessment or blood draws, procedures should be carried out in said  order  (vital  signs , ECG, 
blood draw) . 
All abnormal ECGs will be interpreted by an investigator as abnormal , NCS, or abnormal , CS in 
source documents . 
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
/DERUDWRU\$VVHVVPHQWV
%ORRGDQGXULQHVDPSOHVIRUFOLQLFDO ODERUDWRU\DVVHVVPHQWVZLOOEHFROOHFWHG$QDO\WHVWREH
HYDOXDWHGDUHVXPPDUL]HGLQ7DEOH 
7DEOH 6XPPDU\RI&OLQLFDO/DERUDWRU\$QDO\WHV
%LRFKHPLVWU\ 5HQDO3DQHO JOXFRVHFDOFLXPSKRVSKRUXVEORRGXUHDQLWURJHQFUHDWLQLQH 
VRGLXPSRWDVVLXPFKORULGHELFDUERQDWH 
+HSDWLF3DQHO DOEXPLQ$/7$67WRWDOE LOLUXELQGLUHFWELOLUXELQLQGLUHF W
ELOLUXELQDONDOLQHSKRVSKD WDVHWRWDOSURWHLQ ODFWDWHGHK\GURJHQDVHJDPPD
JOXWDP\OWUDQVIHUDVH 
2WKHUWULJO\FHULGHVFKROHVWHUROORZG HQVLW\OLSRSURWHLQ>/'/@KL JKGHQVLW\
OLSRSURWHLQ>+'/@ FUHDWLQHSKRVSKRNLQDVH WK\URLGVWLPXODWLQJ KRUPRQH76+
&RDJXODWLRQ DFWLYDWHGSDUWLDOWKURPERSODVWLQWLPHSURWKURPELQWLPHDQGLQ WHUQDWLRQDO
QRUPDOL]HGUDWLR
+HPDWRORJ\ UHGEORRGFHOOFRXQWKHPRJORELQKHPDWRFULWZKLWHEORRGFHOO FRXQWZLWK
GLIIHUHQWLDOSODWHOHWFRXQW DQGLIUHGEORRGFRXQWLQG LFHVDUHDEQRUPDOUHIOH[ UHG
EORRGFHOOPRUSKRORJ\DVLQGLFDWHG
8ULQDO\VLV SURWHLQJOXFRVHS+EORRGOHXN RF\WHVOHXNRF\WHHVWUDVHXUR ELOLQRJHQELOLUXELQ
NHWRQHVQLWULWH
9LUXV6HURORJ\
6FUHHQLQJRQO\KHSDWLWLV%DQWLJHQKHSDWLWLV&DQWLERG LHV+,9DQGDQWLE RGLHV
$OOFOLQLFDOODERUDWRU\WHVWUHVXOW VRXWVLGHWKHUHIHUHQFHUDQJ HZLOOEHLQWHUSUHWHGE\WKH
,QYHVWLJDWRUDVDEQRUPDO1&6RUDEQRUPDO&6LQVRXUFHGRFXPH QWV
)ROOLFOHVWLPXODWLQJKRUPRQHWHVWL QJZLOOEHFRQGXFWHGWRFRQILUPZKHWKHUDSDUWLFLSDQWZLWK
Â•PRQWKVRIVSRQWDQHRXVDPHQRUUKH DPHHWVWKHSURWRFROGHILQHGFULWHULDIRUEHLQJ
SRVWPHQRSDXVDO6HFWLRQ 
'UXJVRI$EXVH$OFRKRO&RWLQLQH
6HSDUDWHXULQHVDPSOHVIRUDVVHVVPHQWRIVHOHFWHGGUXJVRIDEXV HDPSKHWDPLQHVEDUELWXUDWHV
EHQ]RGLD]HSLQHVFDQQDELQRLGVFRFDLQH 7+&VWLPXODQWVDQGRSLDWHVFRWLQLQHDQGDOFRKRO
ZLOOEHFROOHFWHG
3UHJQDQF\6FUHHQ
$VHUXPSUHJQDQF\WHVWZLOOEHFRQGXFWHGIRUDOOIHPDOHSDUWLFL SDQWVDW6FUHHQLQJDXULQH
SUHJQDQF\WHVWZLOOEHFRQGXFWHGIRUDOOSDUWLFLSDQWVRIFKLOGE HDULQJSRWHQWLDODVVSHFLILHGLQWKH
6FKHGXOHRI$VVHVVPHQWV 7DEOH
PPD
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
6DIHW\3KRQH&DOO
$SKRQHFDOOZLOOEHFRQGXFWHGRQFH SHUZHHNSUHIHUDEO\PLGZHHNLQEHWZHHQFOLQLFYLVLWVDV
VSHFLILHGLQ 7DEOHWRFROOHFWLQIRUPDWLRQ DERXWFXUUHQWKHDOWKVWDWXVJHQHUDOZ HOOEHLQJ,3
FRPSOLDQFHRUWRJDWKHURWKHUSHUWLQHQWKHDOWKUHODWHGLQIRUPD WLRQDVSHULQYHVWLJDWRUMXGJHPHQW
$GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV
$GYHUVH(YHQW'HILQLWLRQ
$Q$(LVDQ\XQWRZDUGPHGLFDORFFXU UHQFHLQDSDWLHQWRUFOLQLF DOLQYHVWLJDWLRQSDUWLFLSDQW
DGPLQLVWHUHGDSKDUPDFHXWLFDOSURGXFWDQGWKDWGRHVQRWQHFHVVD ULO\KDYHDFDXVDOUHODWLRQVKLS
ZLWKWKLVWUHDWPHQW$Q$(FDQWKHUHIRUHEHDQ\XQIDYRUDEOHDQG XQLQWHQGHGVLJQLQFOXGLQJDQ
DEQRUPDOODERUDWRU\ILQGLQJV\P SWRPRUGLVHDVHWHPSRUDOO\DVV RFLDWHGZLWKWKHXVHRID
PHGLFLQDOLQYHVWLJDWLRQDOSURGXFWZ KHWKHURUQRWUHODWHGWRWKHPHGLFLQDOLQYHVWLJDWLRQDO
SURGXFW,QFOLQLFDOVWXGLHVDQ$(FDQLQFOXGHDQXQGHVLUDEOH PHGLFDOFRQGLWLRQRFFXUULQJDWDQ\
WLPHLQFOXGLQJEDVHOLQHRUZDVKRXWSHULRGVHYHQLIQRVWXG\WUHDWPHQWKDVEHHQDGPLQLVWHUHG
$7($(LVGHILQHGDVDQ$(ZLWKRQVHWDIWHUWKHVWDUWRI,3RU DQ\ZRUVHQLQJRIDSUHH[LVWLQJ
PHGLFDOFRQGLWLRQ$(ZLWKRQVHWDIWHUWKHVWDUWRI,3DQGWKURX JKRXWWKHVWXG\7KHWHUP,3
LQFOXGHVDQ\6DJH,3DFRPSDUDWRURUDSODFHERDGPLQLVWHUHGL QDFOLQLFDOWULDO
/DERUDWRU\DEQRUPDOLWLHV DUHFRQVLGHUHG$(V
LIWKH\UHVXOWLQGLVFRQWLQXDWL RQRULQWHUUXSWLRQRIVWXG\WUHD WPHQWUHTXLUHWKHUDSHXWLFPHGLFDO
LQWHUYHQWLRQPHHWSURWRF ROVSHFLILFFULWHULDLIDSSOLFDEOHR ULIWKHLQYHVWLJDWRUFRQVLGHUVWKHPWR
EHFOLQLFDOO\VL JQLILFDQW$Q\DEQRUPDOLWLHVWKDWPHHWWKHFULWHULDIRUD Q6$(VKRXOGEHUHSRUWHG
LQDQH[SHGLWHGPDQQHU /DERUDWRU\ DEQRUPDOLWLHV 
WKDWDUHFOHDUO\DWWULEXWDEOHWRDQRWKHU $(GRQRWUHTXLUHGLVFUHWHUHSRUWL QJHJHOHFWURO\WH
GLVWXUEDQFHVLQWKHFRQWH[WRIGHK\GUDWLRQFKHPLVWU\DQGKHPDWRORJLFGLVWXUEDQFHVLQWKH
FRQWH[WRIVHSVLV 
$OO$(VWKDWRFFXUDIWHUDQ\SDUWLFLSDQWKDVVLJQHGWKH,&)DQG WKURXJKRXWWKHGXUDWLRQRIWKH
VWXG\ZKHWKHURUQRWWKH\DUHUHODWHGWRWKHVWXG\PXVWEHUH SRUWHGWR6DJH7KHUDSHXWLFV
3DUWLFLSDQWVZKRGLVFRQWLQXHWKH,3G XHWRDQ$(UHJDUGOHVVRI LQYHVWLJDWRUGHWHUPLQHG
FDXVDOLW\VKRXOGEHIROORZHGXQWLOWK HHYHQWLVUHVROYHGFRQV LGHUHGVWDEOHRUWKHLQYHVWLJDWRU
GHWHUPLQHVWKHHYHQWLVQRORQJHUFOLQLFDOO\VLJQLILFDQW$Q\$ (VWKDWDUHXQUHVROYHGDWWKH
SDUWLFLSDQWÂ¶VODVW$(DVVHVVPHQWLQWKHVWXG\DUHIROORZHGXSE \WKHLQYHVWLJDWRUIRUDVORQJDV
PHGLFDOO\LQGLFDWHGEXWZLWKRXWIXUWKHUUHFRUGLQJLQWKHH&5) 7KHVSRQVRURULWVUHSUHVHQWDWLYH
UHWDLQVWKHULJKWWRUHTXHVWDGGL WLRQDOLQIRUPDWLRQIRUDQ\SDUWLFLSDQWZLWKRQJRLQJ$(V6$(V
DWWKHHQGRIWKHVWXG\LIMXGJHGQHFHVVDU\PPD
PPD
PPD
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
46 12.2.2.  Serious Adverse Event (SAE)  Definition  
An SAE  is any untoward medical occurrence that at any dose : 
â€¢ Results in death  
â€¢ Places the participant  at immediate risk of death (a life -threatening event); however, 
this does no t include an event that, had it occurred in a more severe form, might have 
caused death   
â€¢ Requires inpatient hospitalization or prolongation of existing hospitalization  
â€¢ Results in persistent or significant disability or incapacity  
â€¢ Results in a  congenital abnormality or birth defect  
An SAE may also be any other medically important event that, in the opinion of the Investigator  
may jeopardize the participant  or may require medical intervention to prevent 1 of the outcomes 
listed above  (examples of such events include allergic bronchospasm requir ing intensive 
treatment in an emergency room or convulsions  occurring at hom e that do not require an 
inpatient hospitalization) . 
All SAEs that occur after any participant  has signed the ICF and throughout the duration of the 
study , whether or not they are related to the study, must be recorded on the SAE report form 
provided by Sage Therapeutics . Any SAE that is ongoing when the participant  completes their 
final study visit, will be followed by the investigator until the event has resolved, stabilized, 
returned to baseline status , or until  the participant  dies or is lost to follow up . 
A prescheduled or elective procedure or routinely scheduled treatment will not be considered an 
SAE, even if the participant  is hospitalized. The site must document all of the following:  
â€¢ The prescheduled or elective procedure or routinely scheduled treatment was 
scheduled (or on a waiting list to be scheduled) prior to obtaining the participant â€™s 
consent to participate i n the study.  
â€¢ The condition requiring the prescheduled or elective procedure or routinely scheduled 
treatment was present before and did not worsen or progress, in the opinion of an 
Investigator, between the participant â€™s consent to participate in the study  and at the 
time of the procedure or treatment.  
12.2.3.  Definition of Adverse Events of Special Interest  
There are no known adverse event s of special inter est as of the date of signature approval of this 
clinical protocol.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
47 12.2.4.  Relationship to Inves tigational Product  
The investigator must make the determination of relationship to the IP for each AE (not related, 
related ). The following definitions should be considered when evaluating the relationship of AEs 
and SAEs to the IP.  
Not Related  An AE will be conside red â€œnot relatedâ€ to the use of the IP if there is not a reasonable 
possibility  that the event has been caused by the IP. Factors pointing towards this 
assessment  include but are not limited to : the lack of temporal relationship between 
administration of t he IP and the event, the presence of biologically implausible 
relationship between the product and the AE, or the presence of a more likely 
alternative explanation for the AE  
Related  An AE will be considered â€œrelatedâ€ to the use of the IP if there is a re asonable 
possibility that the event may have been caused by the product under investigation. 
Factors that point towards this assessment include but are not limited to: a positive 
rechallenge, a reasonable temporal sequence between administration of the dru g and 
the event, a known response pattern of the suspected drug, improvement following 
discontinuation or dose reduction, a biologically plausible relationship between the 
drug and the AE, or a lack of alternative explanation for the AE  
12.2.5.  Recording Adverse Events  
AEs spontaneously reported by the participant  and/or in response to an open question from the 
study personnel or revealed by observation will be recorded during the study at the 
investigational site . The AE term should be reported in standar d medical terminology when 
possible . For each AE, the Investigator will evaluate and report the onset (date and time), 
resolution (date and time), intensity, causality, action taken, outcome  and seriousness  (if 
applicable), and whether or not it caused the participant  to discontinue the IP or withdraw early 
from the study . 
Intensity will be asses sed according to the following scale:  
â€¢ Mild : symptom(s) barely noticeable to participant  or does not make participa nt 
uncomfortable; does not influence performance or functioning; prescription drug not 
ordinarily needed for relief of symptom(s)  
â€¢ Moderate : symptom(s) of a sufficient severity to make participant  uncomfortable; 
performance of daily activity is influenced;  participant  is able to continue in study; 
treatment for symptom(s) may be needed  
â€¢ Severe : symptom(s) cause severe discomfort; symptoms cause incapacitation or 
significant impact on participant â€™s daily life; severity may cause cessation of 
treatment with IP; treatment for symptom(s) may be given and/or participant  
hospitalized   
It is important to distinguish between serious and severe AEs . Severity is a measure  of intensity 
whereas seriousness is defined by the criteria under Section  11.2.2 . An AE of severe intensity 
may not necessarily be  considered serious.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
48 12.2.6.  Reporting Serious Adverse Events  
In order to adhere to all applicable laws and regulations for reporting an SAE(s), the study site 
must notify Sage or designee within 24 hours of the study site staff becoming aware of the 
SAE(s). The investigator must complete, sign and date the SAE repor t form , verify the accuracy 
of the information recorded on the SAE report form  with the corresponding source documents, 
and send a copy to  Sage or designee.  
Additional follow -up information, if required or available, should all be sent to Sage or designee  
within 24 hours  of receipt on a follow -up SAE report form  and placed with the original SAE 
information and kept with the appropriate section of the eCRF and/or study file.  
SAEs occurring after the designated follow up time for the study, should be reporte d to Sage or 
designee according to the timelines noted above only if the Investigator considers the SAE 
related to IP.  
Sage , or designee,  is responsible for notifying the relevant regulatory authorities of certain 
events . It is the principal investigatorâ€™ s responsibility to notify the IRB/EC of all SAEs that occur 
at his or her site . Investigators will also be notified of all suspected unexpected serious adverse 
reactions  (SUSARs ) that occur during the clinical study. Each site is responsible for notifying  its 
IRB of all SUSARs .  
In addition, appropriate personnel in Sage  Drug Safety and Pharmacovigilance or designee will 
unblind SUSARs for the purpose of regulatory reporting. Sage  or designee will submit SUSARs 
(in blinded or unblinded fashion) to regulato ry agencies according to local law. Sage , or 
designee, will submit SUSAR s to investigators in a blinded fashion.  
12.3. Pregnancy  
If a participant  becomes pregnant after the first administration of IP, pregnancy information must 
be collected and recorded on the pregnancy form  and submitted to the sponsor within 24  hours of 
learning of the pregnancy. Details will be collected for all  pregnancies for which conception was 
likely  to have occur red after the start of IP administration until 5 terminal half -lives following 
the last administration of IP or until the completion of the study whichever is longer . Any 
pregnancy occurring in that time frame will be followed until delivery or termination of the 
pregn ancy.  The investigator will also attempt to collect pregnancy information on any 
participant â€™s partner who becomes pregnant after the participant has received the first 
administration of IP . After obtaining the necessary signed informed consent from the pr egnan t 
partner directly, the investigator will follow the same pregnancy reporting procedures specified 
for pregnant participant s.  
The participant  or participant â€™s partner will be followed to determine the outcome of the 
pregnancy. The outcome of all preg nancies ( eg, spontaneous abortion , elective abortion , normal 
birth) must be followed and documented even if the participant  was discontinued  from the study. 
The investigator will collect follow -up information on the participant  or participant â€™s partner and 
the neonate , and the information will be forwarded to Sage or designee. Generally, follow -up 
will not be required for longer than 6 to 8 weeks beyond the estimat ed delivery date. Any 
termination of pregnancy will be reported, regardless of fetal status (presence or absence of 
anomalies) or indication for the procedure . 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
49 Pregnancy in itself is not regarded as an AE unless there is a suspicion that a n IP may have 
interfered with the effectiveness of a contraceptive medication. Any complication during 
pregnancy ( eg, anemia, infections, preeclampsia) should be reported as an AE/SAE. If the 
outcome of the pregnancy meets the criteria for immediate classification as an SA E (ie,  
spontaneous abortion, stillbirth, neonatal death ), the investigator should follow the procedures 
for reporting an SAE.  
12.4. Overdose  
An overdose is any dose of study treatment given to a participant  or taken by a participant  that 
exceeds more than one e xtra tablet within 24 hours as described in protocol. Overdoses are not 
considered AEs and should not be recorded as an AE on the eCRF; however , all overdoses must 
be recor ded on an overdose form and sent to Sage or d esignee within 24 hours of the site 
becoming aware of the overdose.  An overdose must be reported to Sage or designee even if the 
overdose does not result in an AE. If an overdose results in an AE, the AE must be recorded .  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
50 13. STATISTICS  
Detailed description of the analyses to be performed in th e study will be provided in the 
statistical analysis plan (SAP). The SAP will be finalized and approved prior to database lock. 
Any changes  or additions to the SAP following database lock will be described in detail in the 
clinical study report.  
13.1. Data Analy sis Sets  
The Randomized Set will include all participants who are randomized.   
The Safety Set will include all participant s administered IP.  
The Full Analysis Set will include all randomized participant s who received any amount of IP 
and have a baseline and at least one postbaseline Kinesia ONE accelerometer score .  
 
  
The Per Protocol Set will include  all participant s in t he Full Analysis Set without any major 
protocol deviations that could affect efficacy. The review of major protocol deviations will be 
completed, and the decision on whether the deviation affects efficacy will be documented before 
database unblinding.  
13.2. Hand ling of Missing Data  
Every attempt will be made to avoid missing data . All participant s will be used in the analyses, 
as per the analysis populations, using all nonmissing data available . No imputation process will 
be used to estimate missing data .  
13.3. Genera l Considerations  
All participant  data, including those that are derived, that support the tables and figures will be 
presented in the participant  data listings. Some data may be presented only in participant  data 
listing, some may be presented with a corresponding table or figure; these will be indicated in 
relevant sections below. Participants will be summarized according to treatment received.  
For the purpose of all primary and secondary analyses where appl icable, baseline is defined as 
the last measurement prior to receipt of IP.  
Continuous endpoints will be summarized with number (n), mean, standard deviation, median, 
minimum, and maximum. In addition, change from baseline values will be calculated at eac h 
time point and summarized descriptively. For categorical endpoints, descriptive summaries will 
include counts and percentages.  
13.4. Demographics and Baseline Characteristics  
Demographic data, such as age, race, and ethnicity, and baseline characteristics, suc h as height, 
weight, and BMI, will be summarized using the Safety Set.  
Pregnancy  test results and drug screen results will be listed but not summarized .  
Medical history will be listed by participant .  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
51 13.5. Efficacy Analysis  
The estimand for the primary effic acy analysis is the treatment difference between SAGE -324 
and placebo in mean change from baseline in clinic -based Kinesia ONE accelerometer scores at 
Day 2 9 based on the Full Analysis Set . This will be analyzed using a mixed effects model for 
repeated mea sures (MMRM); the model will include treatment, baseline Kinesia  ONE  
accelerometer score, stratification factor, assessment timepoint, and timepoint -by-treatment as 
explanatory variables. All explanatory variables will be treated as fixed effects. All postbaseline 
clinic visits will be included in the model. The main compa rison will be between SAGE -324 and 
placebo at the 2 9-day timepoint. Model -based point estimates (ie, least squares  means, 5% 
confidence intervals, and p -values) will be reported where applicable. An unstructured 
covariance structure will be used to model t he within -subject errors. If there is a convergence 
issue with the unstructured covariance model, Toeplitz compound symmetry or Autoregressive 
(1) [AR(1)] covariance structure will be used, following this sequence until convergence is 
achieved. If the mode l still does not converge with AR(1) structure, no results will be reported. 
When the covariance structure is not UN, the sandwich estimator for the variance covariance 
matrix will be derived, using the EMPIRICAL option in the PROC MIXED statement in SAS.  
Similar to those methods described above for the primary endpoint, an MMRM will be used for 
the analysis of the change from baseline in TETRAS total performance score s, TETRAS 
performance subscale part 4 upper limb tremor scores  and TETRAS ADL score s.  
Other efficacy analyses will be specified in the SAP. In general, data will be analyzed using 
appropriate descriptive statistics or prespecified statistical methods as applicable; participant  
listings will be provided for all efficacy data. Participant s will be analyzed according to 
randomized treatment for the purpose of efficacy unless otherwise specified.  
Sensitivity analyses will be described in the SAP. 
13.6. Safety Analyses  
Safety and tolerability of SAGE -324 will be evaluated by AEs, concomitant medication us age, 
 
 Safety data will be listed by participant  and 
summarized by treatment group . All safety summaries will be performed on the Safety Set using 
treatment received.   
13.6.1.  Adverse Events  
AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 22.1 
or higher. A treatment -emergent adverse event (TEAE) is defined as  an AE with onset after the 
first dose of IP. The analysis of AEs will be based on the concept of TEAEs. The incidence of 
TEAEs will be summarized by System Organ Class (SOC) and preferred term. In addition, 
summaries will be provided by intensity (mild, m oderate, severe) and by causality (related, not 
related) to IP.  
Any TEAEs leading to discontinuation of treatment or withdrawal from the study and any 
treatment -emergent SAEs  will be summarized.  
All AEs and SAEs (including those with onset or worsening b efore the start of IP) through the 
end of the study will be listed.   

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
52 13.6.3.  Physical Examinations  
The occurrence of a physical examinatio n, including MSE, (yes/no) and the date performed will 
be listed by participant . 
  
 
 
 
  
 
 
 
13.6.6.  Prior and Concomitant Medications  
Medications will be recorded at each study visit during the study and will be coded using World 
Health Organization -Drug dictionary (WHO -DD) September 2015, or later .  
All medi cations taken within 30 days prior to informed consent through the duration of the study 
will be recorded. In addition, all psychotropic medications taken in the previous 30 days prior to 
screening will be recorded. Those medications taken prior to the ini tiation of the start of IP will 
be denoted â€œPriorâ€. Those medications taken prior to the initiation of the IP and continuing 
beyond the initiation of the IP or those medications started at the same time or after the initiation 
of the IP will be denoted â€œCo ncomitantâ€.  
Medications will be presented according to whether they are â€œPriorâ€ or â€œConcomitantâ€ as 
defined above. If medication dates are incomplete and it is not clear whether the medication was 
concomitant, it will be assumed to be concomitant.  
Detail s of prior and concomitant medications will be listed by participant , start date, and 
verbatim term.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
53 13.8. Sample Size  and Power  
The sample size of this study is based on the assumption of a 3 points difference i n the change 
from baseline Kinesia ONE accelerometer between SAGE -324 and placebo with a standard 
deviation of 3.5 points. Under these assumptions, a sample size of 25 evaluable participants per 
group would provide 85% power for detecting a placebo -adjuste d treatment difference of 3 
points in Kinesia accele rometer assuming a 2 -sided test at an alpha level  of 0.05. By including 
2 treatment groups and using a 1:1  randomization, a total of 50 evaluable participants are 
required. Assuming a nonevaluability rate of  15%, approximately  60 participants  will be 
randomized.  Additional participants may be enrolled if the dropout rate is greater than 15%.  
13.8.1.  Interim and Data Monitoring Committee (DMC) Analyses 
13.8.1.1.  Interim Analysis  
The sponsor may conduct an interim analysis. Detailed description s of planned data analyses will 
be provided in a separate interim statistical analysis plan (SAP) , if applicable . 
13.8.1.2.  DMC Analysis  
Not applicable  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
54 14. DIRECT ACCESS TO SOURCE DATA/DOCUMENT S 
14.1. Study Monitoring  
Before an investigational site can enter a participant  into the study, a representative of Sage 
Therapeutics will visit the investigational study site  per Sage SOPs  to: 
â€¢ Determine the adequacy of the facilities  
â€¢ Discuss with the investigator(s) and other personnel their responsibilities with regard to 
protocol adherence, and the responsibilities of Sage Therapeutics  or its representatives . 
This will b e documented in a Clinical Trial  Agreement between Sage Therapeutics  and 
the investigator.  
During the study, a monitor from Sage Therapeutics  or representative will have regular contacts 
with the investigational site, for the following:  
â€¢ Provide information and support to the investigator(s)  
â€¢ Confirm that faci lities remain acceptable  
â€¢ Confirm that the investigational team is adhering to the protocol, that data are being 
accurately recorded in the case report forms, and that IP accountability checks are being 
performed  
â€¢ Perform source data verification . This inclu des a comparison of the data in the case report 
forms with the participant â€™s medical records at the hospital or practice, and other records 
relevant to the study . This will require direct access to all original records for each 
participant  (eg, clinic char ts). 
â€¢ Record and report any protocol deviations not previously sent to Sage Therapeutics . 
â€¢ Confirm AEs and SAEs have been properly documented on eCRFs and confirm any 
SAEs have been forwarded to Sage Therapeutics  and those SAEs that met criteria for 
reportin g have been forwarded to the IRB or EC. 
The monitor will be available between visits if the investigator(s) or other staff needs  
information or advice.  
14.2. Audits and Inspections  
Sage Therapeutics or a uthorized representatives of Sage Therapeutics , a regulator y authority, or 
an independent E C or an I RB may visit the site to perform an audit (s) or inspection (s), including 
source data verification . The purpose of a  Sage Therapeutics audit or a regulatory authority 
inspection is to systematically and independently examine all study -related activities and 
documents to determine whether these activities were conducted, and data were recorded, 
analyzed, and accurately reported according to the protocol, GCP/ICH GCP guid elines , and any 
applicable regulatory requirements . The Investigator should contact Sage Therapeutics  
immediately if contacted by a regulatory agency  or IRB/EC  about an  inspection.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
55 14.3. Institutional Review Board or Ethics Committee  
The principal investigator m ust obtain IRB (or EC) approval for the clinical study  prior to 
enrolling a participant . Initial IRB (or EC) approval, and all materials approved by the IRB (or 
EC) for this study including the participant  consent form and recruitment materials must be 
maintained by the investigator and made available for inspection.  
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
56 15. QUALITY CONTROL AND QUALITY ASSURANCE  
To ensure compliance with Good Clinical Practice and all applicable regulatory requirements, 
Sage Therapeutics may conduct a quality assurance audit (s) at the clinical site . Please see 
Section  13.2 for more details regarding the audit process.  
The Investigator must have adequate quality control practices to ensure that the study is 
performed in a manner consistent with the protocol, GCP/ICH GCP guidelines, and applicable 
regulatory requirements. The investigator is responsible for reviewing all identified protocol 
deviations.  Significant protocol deviation s should be reported to the IRB/EC per the IRB/ECâ€™s 
written procedures.  
The investigator is responsible for supervising any i ndividual or party to whom the investigator 
delegates trial-related duties and functions conducted at the trial site. When the investigator 
retains the services of any individual or party to perform trial -related duties and functions , the 
Investigator  must ensure the individual or party is qualified to perform trial -related duties and 
functions and should implement proced ures to ensure the integrity of the trial-related duties and 
functions performed,  and any data generated.  
The investigator must maintain adequate and accurate source document s and trial records that 
include all pertinent observations  on each of the siteâ€™s  trial participants. Source data  must be 
attributable, legible, contemporaneous, original, accurate, and complete. Changes to source data 
should be traceable, should not obscure the original entry, and should be explained , if necessary,  
to provide clarific ation . 
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
57 16. ETHICS  
16.1. Ethics Review  
The final study protocol, including the final version of the I CF, must be given a written and 
dated approval or favorable opinion by an IRB or EC as appropriate. The Investigator must 
obtain and document  approval before he or s he can enroll any participant  into the study.  The IRB  
or EC  must  supply to the sponsor a list of the IRB /EC membership and a statement to confirm 
that the IRB /EC is organized and operates according to GCP and applicable laws and 
regulations.  
The principal investigator is responsible for informing the IRB or EC of any amendment to the 
protocol in accordance with local requirements. In addition, the IRB or EC must a pprove all 
advertising used to recruit participant s for the study. The protocol must be re -approved by the 
IRB or EC upon receipt of amendments and annually, as local regulations require.  
The principal investigator is also responsible for providing the IRB  or EC with reports of any 
reportable serious adverse drug reactions from any other study conducted with the IP. Sage 
Therapeutics will provide this information to the principal investigator.  
Progress reports and notifications of serious adverse drug react ions will be provided to the IRB 
or EC according to local regulations and guidelines.  In addition, the principal investigator must 
inform the IRB /EC and sponsor of any changes significantly affecting the conduct of the trial 
and/or increasing the risk to participant s (eg, violations to the protocol or urgent safety measures 
taken for participant  safety) . 
16.2. Ethical Conduct of the Study  
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and ar e consistent with ICH  and GCP guidelines, as well as all  
applicable regional or national regulatory requirements.  
16.3. Written Informed Consent  
Prior to enrolling a trial participant, t he investigator(s) will ensure that the participant  is given 
full and adequate oral and written information about the nature, purpose, possible risk and 
benefit of the study . Participant s must also be notified that they are free to discontinue from the 
study at any time . The participant  should be given the  opportunity to ask questions and allowed 
time to consider the information provided.  
When the participant decides to participate in the trial, the participant  (or the participant â€™s, parent 
or legally authorized representative)  must  provide  signed and dated  informed consent . The 
written consent  must be obtained before conducting any study procedures.  The investigator must 
document the consent process in the participantâ€™s source records. The investigator  must maintain 
the original, si gned ICF. A copy of the s igned ICF must be given to the participant  or to the 
participantâ€™s  parent or  legal ly authorized  representative . 
Throughout the trial participants should be informed of any changes made to the study  and as 
new safety and or risk information  becomes known . The provision of this information  will be 
documented  in the participantâ€™s source records, and when applicable, an updated ICF will be 
provided . 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
58 17. DATA HANDLING AND RE CORDKEEPING  
17.1. Inspection of Records  
Sage Therapeutics  or its representative(s)  will be allowed to conduct site visits at the 
investigation facilities for the purpose of monitoring any aspect of the study . The investigator 
agrees to allow the monitor to inspect the facility, drug storage area, drug accountability records, 
participant  charts and study source documents, and other records relative to study conduct.  
Inspection  of the study by a regulatory  authority may occur at any time. The investigator must 
agree to the inspection of study -related records  and source documents  by the regulatory authority  
representative (s).  
17.2. Retention of Records  
The principal investigator must maintain all documentation relating to the study for the period 
outlined in the site contract, or for a period of 2  years after the last marketing application 
approval , and until there are no pending or contemplated marketing application s in an ICH 
region  or at least 2 years have elapsed since the formal discontinuation of clinical development  
of the investigational product . Sage is res ponsible  to inform the Investigator/institution as to 
when study documents no longer need to be retained.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
59 18. PUBLICATION POLICY  
All information concerning SAGE -324 is considered confidential and shall remain the sole 
property of Sage Therapeutics. The investigator agrees to use this information only in conducting 
the study and shall not use it for any other purposes without written approval from Sage 
Therapeutics. No publication or disclosure of study results will be permitted except as specified 
in a se parate, written, agreement between Sage Therapeutics and the investigator.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
60 19. LIST OF REFERENCES  
Atkinson TM, Schwartz CE, Goldstein L, et al. Assessments in Oncology. Value in Health . 
2019 ;22(2): 225-230. 
Belelli D, Casula A, Ling A, Lambert JJ. The influence of subunit composition on the interaction 
of neurosteroids with GABA(A) receptors. Neuropharmacology. 2002;43(4):651 -61. 
Deuschl G, Raethjen J, Hellriegel H, Elble R. Treatment of patients with essential tremor. Lancet 
Neuro. 2011. 10(2):148 . 
Elble R , Bain P, Forjaz MJ,  et al. Task force report: scales for  screening and evaluating tremor: 
critique and recommendations.  Mov Disord. 2013 Nov;28(13):1793 -800. 
Genetics Home Reference; Essential Tremor.  Lister Hill National Center for Biomedical 
Communications ;U.S. National Library of Medicin e;National Institutes of Health , Department of 
Health & Human Services . Available from: https://ghr.nlm.nih.gov/condition/essential -tremor . 
Accessed  Sept 10, 2019 . 
Hopfner F, Haubenberger D, Galpern WR, et al. Knowledge gaps and research recommendations 
for essential tremor. Parkin sonism Relat Disord. 2016;33:27 -35. 
InderalÂ® (propranolol hydrochloride)  [package insert]. Philadelphia, PA: Wyeth 
Pharmaceuticals, Inc.; 2010. Accessed 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/016418s078lbl.pdf  
Koller W, Vetere -Overfield B. Acute and chronic effects of propranolol and primidone in 
essential tremor. Neurology 1989;39:1587 -1588  
Louis ED, Ottman R. How many people in the USA have essential tremor? Deriving a 
population estimate based on epidemiological data. Tremor Other Hype rkinet Mov (N Y). 
2014;4:259.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 2  CONFIDENTIAL  
61 Olanow CW. Hyperkinetic Movement Disorders: Essential Tremor. In: Harrison's Principles of 
Internal Medicine. Vol 2. 17th ed. New York, NY: McGraw Hill; 2008:2560.  
Zappia M, Albanese A, Bruno E, et al. T reatment of essential tremor: a systematic review  of 
evidence and recommendations from the Italian Movement Disorders Association.  Epub 2012 
Aug 11. Review. Erratum in: J Neurol. 2013 Mar;260(3):741  
 

 
1. TITLE PAGE A PHASE 2, DOUBLE -BLIND, PLACEBO -
CONTROLLED, RANDOMIZ ED STUDY EVALUATING 
THE EFFICACY, SAFETY , AND TOLERABILITY O F 
SAGE -324 IN THE TREATMENT OF  INDIVIDUALS 
WITH ESSENTIAL TREMO R  
324-ETD -201  
 
Investigational Product  SAGE -324 Oral Table t  
Clinical Phase  Phase 2  
Sponsor  Sage Therapeutics , Inc.  
215 First Street  
Cambridge, MA 02142  
Sponsor Contact  , MD  
Sponsor Medical Monitor  , MD, PhD  
Date of Original Protocol  23 October 2019  
Date of Amendment 1  20 December 2019  
Date of Amendment 2  24 February 2020  
 
 
Confidentiality Statement  
The confidential information in this document is provided to you as an investigator or consultant for 
review by you, your staff, and the applicable Institutional Review Board/Independent Ethics Committee . 
Your acceptance of this document constitutes agreem ent that you will not disclose the information 
contained herein to others without written authorization from Sage Therapeutics , Inc. 
 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
3 INVESTIGATORâ€™S AGREE MENT  
I have received and read the Investigatorâ€™s Brochure for SAGE -324. I have read the 324-ETD -
201 protocol and agree to conduct the study as outlined . I agree to maintain the confidentiality of 
all information received or developed in connection with this pro tocol.  
 
 
             
Printed Name of Investigator  
 
             
Signature of Investigator  
 
        
Date  (DD/MMM/YYYY)  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
4 PROCEDURES IN CASE O F EMERGENCY  
 
Table 1: Emergency Contact Information  
Role in Study  Name  Address and Telephone N umber  
Sage  Study Physician  , MD  Phone  
Sage  Medical Monitor  and 
24-hour Emergency Contact  , MD, PhD  Mobile: 1 
Office phone:  
E-mail:  
SAE Reporting Information  IQVIA Lifecycle Safety   4820 Emperor Boulevard   
Durham, NC 27703   
E-mail:  Sage.Safety@iqvia.com   
Fax: +1-855-638-1674   
SAE Hotline: +1-855-564-2229   
Product Complaints  Sage Therapeutics, Inc.  E-mail: 
productcomplaints@sagerx.com  
Phone: +1-833-554-7243  
 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
5 2. SYNOPSIS  
Name of Sponsor/Company:  
Sage Therapeutics, Inc. (hereafter referred to as Sage Therapeutics, or Sage)  
Name of Investigational Product : 
SAGE -324 Oral Tablet  
Name of Active Ingredient:  
SAGE -324 
Title of Study:  
A Phase 2, Double -blind, Placebo -controlled, Randomized Study Evaluating the Efficacy, Safety, and 
Tolerability of SAGE -324 in the Treatment of Individuals  with Essential Tremor  
Number of Sites and Study Location: This study will take place at  approximately 30 site s in the 
United States.  
Phase of D evelopment: Phase 2  
Planned Duration for each Study Participant:  
The duration of  participation (from Screening through the final follow -up visit) for each participant is 
estimated to be up to  71 days.  
Objectives and Endpoints : 
Objectives  Endpoints  
Primary   
To assess the effect of SAGE -324 compared to 
placebo on upper limb tremor reduction in 
individuals with essential tremor (ET) after 
28 days of treatment  Change from baseline compared to placebo in 
The Essential Tremor Rating Assessment 
(TETRAS) performance subscale part 4 upper 
limb tremor score on Day 29  
Secondary   
To assess the effect of SAGE -324 compared to 
placebo on overall upper limb tremor reduction  â€¢ Change from baseline compared to placebo in 
TETRAS performance subscale part 4 upper 
limb tremor score at all other timepoints  
â€¢ Change from baseline compared to placebo in 
Kinesia  ONE accelerometer scores  
To assess the effect of SAGE -324 compared to 
placebo on activities of daily living (ADLs)  â€¢ Change from baseline compared to placebo in 
TETRAS Scale ADL score  
To assess the effect of SAGE -324 compared to 
placebo on overall tremor  â€¢ Change from baseline compared to placebo in 
TETRAS total performance score  
To evaluate the safety and tolerability of 
SAGE -324 â€¢ Incidence of treatment -emergent adverse 
events (TEAEs)  
 
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
6 Study Description : 
This is a randomized, double -blind, placebo -controlled, parallel group  study to evaluate the efficacy, 
safety, and tolerability of SAGE -324 in individuals with ET. Participants, site staff, and sponsor 
personnel will be masked to treatment allocation.  
This study includes a Screening Period of up to 28 days, a 2 9-day treatment period  (28 days of dosing) , 
and a 14 -day follow up period. After providing informed consent, participants will undergo screening 
assessments as outlined in Table 2  to determine eligibility.  
Screening Period: The Screening Period begins with the signing of the inf ormed consent form (ICF). 
Eligible participants will visit the study center on Day 1 and complete additional eligibility  and baseline  
assessments, as specified in the Schedule of Assessments ( Table 2 ). Following completion of screening  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
7 and Day 1  eligibility check s, participants will be randomized to 1 of 2 treatment groups ( SAGE -324 60 
mg daily , or placebo) in a 1:1 ratio.   
Double -Blind Treatment Period:  Starting on Day 1, participants will receive a single dose of 
investigational product (IP) once daily for  28 days on an outpatient basis , to be taken  in the morning 
with food that comprises a minimum of 400 calories . Doses occurring on scheduled clinic visits will be 
administered in the clinic, and doses occurring on all other days will be self -administered by the 
participant at home. During the Treatment Period, participants will r eturn to the study center 
approximately once per week for efficacy and safety assessments as specified in  Table 2 . Participants 
will be trained on the use  of software applications and devices necessary to complete questionnaires or 
other assessments.  During the study, a phone call will be conducted once per week , preferably midw ay 
between clinic visits,  to review current status of participant . 
Follow -Up Per iod: Follow -up visits will be conducted on an outpatient basis. Participants will continue 
to complete  questionnaires as indicated in Table 2  and will receive a phone call approximately 7 days 
after the last dose of IP (ie, Day 3 5) for safety monitoring. Participants will return to the study center for 
an end of study visit approxim ately 14 days following the last dose of IP (ie, Day 4 2). 
Number of Participants  (planned):  Approximately 60 participants, with approximately 30 per arm.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
8 Eligibility Criteria:  
Inclusion Criteria:  
1. Participant has s igned an ICF before any study -specific procedures or washout of drugs i s 
performed.  
2. Participant is ambulatory and is 18 to 80 years of age, inclusive, at the time informed consent is 
obtained.  
3. Participant  has a diagnosis of ET, as defined by all of the following criteria:  
a. Isolat ed tremor syndrome consisting of bilateral upper limb action tremor  
b. At least 3 years duration  
c. With or without tremor in other locations (eg, head, voice, or lower limbs)  
d. Absence of other neurological signs, such as dystonia, ataxia, or parkinsonism , isolated 
focal tremors (eg, voice, head) , task- and position -specific tremors , sudden tremor onset or 
evidence of stepwise  deterioration of tremor  
4. Participant scores at least 1.5 for each of the six items that comprise the combined t otal upper 
limb TETRAS (total performance subscale  part 4)  with the total score for the dominant upper 
limb (the sum of the 3 items for either the right or left upper limb, whichever is dominant) 
being at least 5.5, at bo th Screening and predose on Day 1 . 
5. Participant is willing to discontinue medications taken for the treatment of ET  within 14 days or 
5 half -lives (whichever is longer) prior to receiving  IP. Medications taken for the treatment of 
ET that were discontinued prior to receiving IP may be resumed following Day 29.  
6. Participant is willing to discontinue the use of alcohol and products that contain nicotine  within  
at least 1 week  prior to Day 1  and through Day 2 9 of the study.  
7. Female participant agrees to use at least one method of highly effective contraception as listed 
in Section  9.2.4 during participation in the study and f or 30 days following the last dose of 
study drug, unless she  is postmenopausal (at least 12 months of spontaneous amenorrhea 
without an alternative medical cause, with confirmatory follicle stimulating hormone 
>40 mIU/mL), and/or surgically sterile (bilate ral oophorectomy, hysterectomy, and/or bilateral 
salpingectomy), or does not engage in sexual relations which carry a risk of pregnancy (do es 
include abstinence).  
8. Male participant agrees to use an acceptable method of effective contraception for the durat ion 
of the study and for 13 weeks after receiving study drug, unless the participant  does not engage 
in sexual relation(s) which carry a risk of pregnancy. Acceptable methods of effective 
contraception are listed in Section  9.2.4 .  
9. Male participant  is willing to abstain from sperm donation for the duration of the study and for 
13 weeks after receiving study drug.  
10. Participant has no clinically significant findings, as de termined by the investigator, on 
Screening and predose Day 1 physical examination  including mental state examination (MSE) 
and neurologic examination , 12-lead ECG, or screening clinical laboratory tests.  
Exclusion Criteria:  
1. Participant has presence of kno wn causes of enhanced physiological tremor.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
9 2. Participant has had r ecent exposure (14 days prior to Day 1) to tremorgenic drugs or presence 
of alcohol  withdrawal state.  
3. Participant has h ad direct or indirect injury or trauma to the nervous system within 3 mo nths 
before the onset of tremor . 
4. Participant  has had a previous procedure  for the treatment of ET, deep brain stimulation, brain 
lesioning, or magnetic resonance (MR) guided procedure, eg, MR -guided focused ultrasound . 
5. Participant has h istorical or clinical evidence of tremor with psychogenic origin (including but 
not limited to eating disorders, major depression, etc.)  
6. Participant has s ignificant history and/or presence of hepatic, renal, cardiovascular, pulmonary, 
gastrointestinal, hematological, i mmunologic, ophthalmologic, metabolic (hypothyroidism with 
stable thyroid replacement is acceptable), or oncological disease.  
7. Participant has history of substance  abuse  prior to Screening , has a positive screen for drugs of 
abuse at Screening or predose on  Day 1 , or has a positive screen for alcohol predose on Day 1 . 
8. Participant has a k nown allergy to SAGE -324 or any excipient.  
9. Participant has had e xposure to another investigational drug or device within 30 days  or 5 half -
lives (if known) of the investigat ional drug, whichever is longer,  prior to the Day 1 visit.  
10. Participant has h istory o f suicidal behavior within 2 years or answers â€œYESâ€ to questions 3, 4, 
or 5 on the C -SSRS at Screening or at Day 1 or is currently at risk o f suicide in the opinion of 
the investigator  
11. Participant has d onated one or more units (1 unit  = 450 mL) of blood or experienced acute loss 
of an equivalent amount of blood within 60 days prior to Day 1.  
12. Participant has any condition or comorbidity that in the opinion of the investigator would limit 
or interfere with the participantâ€™s ability to complete or partake in the study.  
13. Participant is unwilling or unable to comply with study procedures  and required training . 
14. Participant has used any known moderate or strong cytochrome P 450 3A4 inhibitors and/or 
inducers within 14 days or 5 half -lives (whichever is longer) prior to Day 1  or consumed 
grapefruit juice, grapefruit, Seville oranges, pomegran ates, tangelos, or St. Johnâ€™s Wort or 
products containing these within 30 days prior to Day 1 . Use of mild cytochrome inhibitors 
and/or inducers may be permitted.  
15. Participant has concurrent or recent exposure (14 days or five half -lives, whichever is long er, 
prior to the Day 1 visit) to sedative/hypnotic drugs, stimulants, highly caffeinated  beverages or 
dietary supplements containing high doses of caffeine , or recent increase  above  regular daily  
consumption of caffeine . 
16. Participant plans to undergo elective surgery or relocate during participation in the study.  
17. Participant is investigative site personnel or a member of their immediate families (spouse, 
parent, child or sibling whether biological or legally adopted).   
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
10 18. Participant currently uses or has used within 14 days or 5 half -lives (whichever is 
longer) prior to Day 1 , any prescription or over -the-counter medication that is a substrate of 
the OATP1B1 transporter.  
19. Female p articipant has a positive pregnancy test  or confirmed pregnancy . 
Investigati onal Product  Dosage and Mode of Administration:  
SAGE -324 (60 mg) or matched placebo oral tablets will be administered in the clinic or self -
administer ed once  daily , in the morning  with food  that comprises a minimum of 400 calories .  
Duration of Treatment:  
Each participant will receive a single dose of SAGE -324 oral tablet s or matching placebo administered 
once  daily for 28 days.   
Statistical Methods:  
A separate statistical analysis plan (SAP) will provide a detailed description of the data analyses to be 
performed in the study. The SAP will be finalized and approved prior to database lock.  
General Considerations  
For the purpose of all efficacy and safety analyses where applicable, baseline is defined as the last 
measurement prior to the start of IP administration.  
Continuous endpoints will be summarized with number (n), mean, standard deviation, median, 
minimum, and maximum. In addition, change from baseline values will be calculated at each time point 
and summari zed descriptively. For categorical endpoints, descriptive summaries will include counts and 
percentages.  
Analysis Sets  
The Randomized Set is defined as all participants who are randomized.  
The Safety Set will include all participants who were administered  IP.  
The Full Analysis Set will include all randomized participants who received any amount of IP and have 
a baseline and at least one postbaseline TETRAS performance subscale part 4 upper limb tremor score .  
 
 
The Per Protocol Set will include all participants in the F ull Analysis Set  without any major protocol 
deviations that could affect efficacy. The review of major protocol deviations will be completed, and 
the decision on whether the deviation affects efficacy will be documented before database unblinding.  
Determination of Sample Size  
The sample size of this study is based on the assumption of a 3 -point difference in the change from 
baseline TETRAS performance subscale part 4 upper limb tremor scores  between  SAGE -324 and 
placebo with a standard deviation of 3.5 points. Under these assumptions, a sample size of 25 evaluable 
participants  per group would provide 85% power for detecting a placebo -adjusted treatment difference 
of 3 points in TETRAS performance subscale par t 4 upper limb tremor score , assuming a  2-sided test at 
an alpha  level  of 0.05. By including  2 treatment groups and using a 1:1 randomization, a total of 
50 evaluable participants  are required.  Assuming a nonevaluability rate of  15%, approximately 
60 participants  will be randomized.  Additional participants  may be enrolled if the drop -out rate is higher 
than 15%.  
Analysis of Primary Efficacy Endpoint  
The estimand for the primary efficacy analysis is the treatment difference between SAGE -324 and 
placebo in me an change from baseline in clinic -based TETRAS performance subscale part 4 upper limb 
tremor score at Day 2 9 based on the Full Analysis Set . This will be analyzed using a mixed -effects 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
11 model for repeated measures (MMRM); the model will include treatment, baseline TETRAS 
performance subscale part 4 upper limb tremor score , assessment timepoint, and timepoint -by-treatment 
as explanatory variables. All explanatory variables will be treated as fixed effects. All postbaseline 
clinic visits will be included in the model. The main comparison will be between SAGE -324 and 
placebo at the 2 9-day timepoint. Model -based point estimates (ie, least squares means, 95% confidence 
intervals, and p -values) will be reported where applicable. An unstructured covariance structure will be 
used to model the within -subject errors. If there is a convergence issue with the unstructured covariance 
model, Toeplitz compound symmetry or Autoregressive (1) [AR(1)] covari ance structure will be used, 
following this sequence until convergence is achieved. If the model still does not converge with AR(1) 
structure, no results will be reported. When the covariance structure is not unstructured , the sandwich 
estimator for the va riance covariance matrix will be derived, using the EMPIRICAL option in the 
PROC MIXED statement in SAS.  
Analysis of Secondary Efficacy Endpoints  
Similar to those methods described above for the primary endpoint, an MMRM will be used to analy ze 
of the chan ge from baseline in TETRAS total performance score s, Kinesia ONE accelerometer scores  
and TETRAS ADL score s. Individual items of the TETRAS subscales will be summarized.  
Safety Analysis  
Safety and tolerability of study drug will be evaluated by incidence of TEAEs /serious adverse events, 
Interim Analysis  
The sponsor may conduct an interim analysis . Detailed descriptions of planned  data analyses will be 
provided in a  separate interim statistical analysis plan (SAP) , if applicable .  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
12 Table 2: Schedule of Assessments  
Assessment  Screening  Treatment Period  Follow -up Period  
Study Day  -28 to -1 1 5 (Â±1)  
Phone 
Call 8 (Â±1)  12 (Â±1)  
Phone 
Call 15(Â±1)  19 (Â±1) 
Phone 
Call 22 (Â±1)  26 (Â±1) 
Phone 
Call 29 (+1) 
EOT  
 35 (Â±1) 
Safety 
Phone Call  42 (Â±1) 
EOS/ETV  
Informed Consent  X            
Inclusion/Exclusion  X X           
Demographics  X            
Medical History  X            
Pregnancy Testl X  
(serum ; all 
women ) X  
(urine ; 
WOCBP  
only)   
 X  
(urine ; 
WOCBP  
only)    X  
(urine ; 
WOCBP  
only)  X  
(urine ; 
WOCBP  only) 
FSH (postmenopausal 
women only)  X            
Randomizationa  X           
Alcohol /cotinine  screens   X  X  X  X  X   
Drug screen  X X           
Physical examinationb X X  X  X  X  X  X 
Neurological examination 
including MSEb X X  X  X  X  X  X 
Body height  X            
Body weight  X            
Vital signsc X X  X  X  X  X  X 
12-Lead ECGd X X  X  X  X  X  X 
Chemistry/hematology/  
coagulation/urinalysis  X X  X  X  X  X  X 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
13 Assessment  Screening  Treatment Period  Follow -up Period  
Study Day  -28 to -1 1 5 (Â±1)  
Phone 
Call 8 (Â±1)  12 (Â±1)  
Phone 
Call 15(Â±1)  19 (Â±1) 
Phone 
Call 22 (Â±1)  26 (Â±1) 
Phone 
Call 29 (+1) 
EOT  
 35 (Â±1) 
Safety 
Phone Call  42 (Â±1) 
EOS/ETV  
Kinesiaf X X  X  X  X  X  X 
TETRASg X X  X  X  X  X  X 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
14 Assessment  Screening  Treatment Period  Follow -up Period  
Study Day  -28 to -1 1 5 (Â±1)  
Phone 
Call 8 (Â±1)  12 (Â±1)  
Phone 
Call 15(Â±1)  19 (Â±1) 
Phone 
Call 22 (Â±1)  26 (Â±1) 
Phone 
Call 29 (+1) 
EOT  
 35 (Â±1) 
Safety 
Phone Call  42 (Â±1) 
EOS/ETV  
Patient Perception of 
Response Burden           X  X 
Participant trainingh X X           
Dispense study drug   X   X  X  X     
IP administration   Administered once daily for 28 days  Not applicable  
AEs/SAEs  X 
Prior and concomitant 
medication  and historyi X 
Abbreviations: ADL  = activities of daily living; AE  = adverse event;  
; ECG  = electrocardiogram; EOS  = end of study; EOT  = end of treatment;  ; 
; ETV  = early termination visit; FSH = follicle stimulating hormone; HIV  = human immunodeficiency 
virus; ICF  = informed consent form; min  = minutes; IP = investigational product; MSE  = mental state examination;  
 
; SAE  = serious adverse event; TETRAS  = The Essential Tremor Rating Assessment 
Scale; WOCBP  = women of childbearing potential  
Note s:  
â€¢ The suggested order of assessments during clinic visits is: vital signs , TETRAS, Kinesia, ECG, blood sample collection for  and clinical laboratory 
assessments, and questionnaires . 
â€¢ All assessments will be performed predose  unless specified in a footnote . 
 
a Randomization  will occur on Day 1 after meeting all eligibility crite ria. 
b Complete physical examinations (including MS E and neurologic examination  as parts of physical examination ) should be performed as specified and as 
clinically necessary (see Section  12.1.3 ).  
c Predose on Day 1, supine and standing blood pressure and heart rate will be collected in triplicate at least 15 minutes apart, measur ed after the participant has 
been in the supine position for at least 5 minutes and then repeated 1 minute and 3 minutes after standing. Respiratory rate and temperature are collected once 
predose on Day 1. Vital signs will be collected once predose at all other visits. All postdose vital signs will be collected once at approx imately 3 hours (Â±60 
min) after dosing . 
d ECGs will be collected and read centrally. ECGs will be performed predose and approximately  3 hours  (Â±60 min)  postdose. All ECGs must be performed after 
the participant has been in a supine position for at least 5 minutes.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
15 f Kinesia ONE will be assessed simultaneous ly to TETRAS Performance subscale part 4 upper limb tremor .  
g The TETRAS Performance and TETRAS ADL subscales will be assessed at Screening and predose at each clinic visit. The TETRAS Performance subscale 
part 4 upper limb tremor will be assessed simultaneous ly to Kin esia ONE. In addition, on Day 15,  the TETRAS Performance  subscale  will be assessed  at 5 and 
8 hours (Â± 30 min) postdose . A videographer will record each TETRAS administration.  
h Participants will be trained by study personnel on the use of software applicat ions, Investigational Product Diary,  and devices necessary for the conduct of the 
study.  
i Prior medications will be recorded during Screening and will include all medications and supplements  taken within the 30 days prior to signing the ICF  through 
the fi rst dose of IP , as well as a complete history of all treatments for ET since the year of diagnosis . Concomitant medications will be recorded thereafter 
throughout the duration of the study.  
   

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
16 3. TABLE OF CONTENTS  
1. TITLE PAGE  ................................ ................................ ................................ ................ 1 
INVESTIGATORâ€™S AGREE MENT  ................................ ................................ ............................... 3 
PROCEDURES IN CASE O F EMERGENCY  ................................ ................................ ............... 4 
2. SYNOPSIS  ................................ ................................ ................................ ................... 5 
3. TABLE OF CONTENTS  ................................ ................................ ........................... 16 
LIST OF TABLES  ................................ ................................ ................................ ......................... 20 
LIST OF FIGURES  ................................ ................................ ................................ ....................... 20 
4. LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS ............................. 21 
5. INTRODUCTION  ................................ ................................ ................................ ......23 
5.1. Dose Justification  ................................ ................................ ................................ ........ 23 
5.2. Benefit/Risk Assessment  ................................ ................................ ............................ 24 
6. STUDY OBJECTIVES AND  ENDPOINTS  ................................ .............................. 25 
7. INVESTIGATIONAL PLAN  ................................ ................................ ..................... 27 
7.1. Overall Study Design  ................................ ................................ ................................ ..27 
7.2. Number of Participants  ................................ ................................ ............................... 28 
7.3. Treatment Assignment  ................................ ................................ ................................ 28 
7.4. Dose Adjustment Criteria  ................................ ................................ ........................... 28 
7.5. Criteria for Study Termination  ................................ ................................ ................... 28 
8. SELECTION AND WITHDR AWAL OF PARTICIPANTS ................................ .....29 
8.1. Participant Inclusion Criteria  ................................ ................................ ...................... 29 
8.2. Participant Exclusion Criteria  ................................ ................................ ..................... 30 
8.3. Screen Failures  ................................ ................................ ................................ ............ 31 
8.4. Investigational Product Discontinuation and Early Termination from the 
Study  ................................ ................................ ................................ ........................... 31 
8.4.1.  Investigational Product Discontinuation  ................................ ................................ .....31 
8.4.2.  Early Termination from the Study  ................................ ................................ .............. 32 
8.4.3.  Loss to Follow -up ................................ ................................ ................................ .......32 
8.4.4.  Replacement of Partic ipants  ................................ ................................ ....................... 32 
9. TREATMENT OF PARTICI PANTS  ................................ ................................ ......... 33 
9.1. Description of Investigational Product  ................................ ................................ .......33 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
17 9.2. Prior Medications, Concomitant Medications, Restrictions, and 
Contraception Requirements  ................................ ................................ ...................... 33 
9.2.1.  Prior and Concomitant Medications and/or Supplements  ................................ .......... 33 
9.2.2.  Prohibited Medications  ................................ ................................ ............................... 33 
9.2.3.  Other Restrictions  ................................ ................................ ................................ .......33 
9.2.4.  Acceptable Forms of Contraception  ................................ ................................ ........... 34 
9.3. Intervention after the End of the Study  ................................ ................................ .......34 
9.4. Treatment Adherence  ................................ ................................ ................................ ..35 
9.5. Randomization and Blinding  ................................ ................................ ...................... 35 
9.5.1. Emergency Unblinding  ................................ ................................ ............................... 35 
10. INVESTIGATIONAL PROD UCT MATERIALS AND MA NAGEMENT  ............. 36 
10.1.  Investigational Product  ................................ ................................ ............................... 36 
10.2. Investigational Product Packaging and Labeling  ................................ ....................... 36 
10.3.  Investigational Product Storage  ................................ ................................ .................. 36 
10.4.  Investigational Product Preparation  ................................ ................................ ............ 37 
10.5.  Investigational Product Administration  ................................ ................................ ......37 
10.6.  Investigational Product Accountability, Handling, and Disposal  ............................... 37 
10.7.  Product Complaints  ................................ ................................ ................................ ....37 
11. EFFI CACY ASSESSMENTS AND  CLINICAL PHARMACOLO GY 
ASSESSMENTS ................................ ................................ ................................ ......... 39 
11.1.  Efficacy Assessments  ................................ ................................ ................................ .39 
11.1.1 . The Essential Tremor Rating Assessment Scale  ................................ ........................ 39 
11.1.2.  Kinesia ONEâ„¢ Accelerometer Score  ................................ ................................ .......... 39 
 40 
 40 
 40 
 40 
 41 
 41 
 41 
 42 
 42 
 42 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
18  42 
 42 
 42 
11.3.  Other Patient -Reported Assessments  ................................ ................................ .......... 43 
11.3.1.  Patient Perception of Response Burden  ................................ ................................ ......43 
12. SAFETY ASSESSMENTS  ................................ ................................ ........................ 44 
12.1.  Safety Parameters  ................................ ................................ ................................ .......44 
12.1.1.  Demography and Medical History  ................................ ................................ .............. 44 
12.1.2.  Weight and Height  ................................ ................................ ................................ ......44 
12.1.3.  Physical Examination  ................................ ................................ ................................ .44 
12.1.4.  Vital Signs  ................................ ................................ ................................ .................. 44 
12.1.5.  Electrocardiogram  ................................ ................................ ................................ .......44 
12.1.6.  Laboratory Assessments  ................................ ................................ ............................. 45 
12.1.6.1.  Drugs of Abuse, Alcohol, Nicotine (Cotinine)  ................................ ........................... 45 
12.1.6.2.  Pregnancy Screen  ................................ ................................ ................................ ........ 45 
 46 
 46 
12.1.9.  Safety Phone Call  ................................ ................................ ................................ .......46 
12.2.  Adverse Events and Serious Adverse Events  ................................ ............................. 46 
12.2.1.  Adverse Event Definition  ................................ ................................ ........................... 46 
12.2.2.  Serious Adverse Event (SAE) Definition  ................................ ................................ ...47 
12.2.3.  Definition of Adverse Events of Special Interest  ................................ ....................... 48 
12.2.4.  Relationship to Investigational Product  ................................ ................................ ......48 
12.2.5.  Recording Adverse Events  ................................ ................................ ......................... 48 
12.2.6.  Reporting Serious Adverse Events  ................................ ................................ ............. 49 
12.3.  Pregnancy  ................................ ................................ ................................ ................... 49 
12.4.  Overdose  ................................ ................................ ................................ ..................... 50 
13. STATISTICS  ................................ ................................ ................................ .............. 51 
13.1.  Data Analysis Sets  ................................ ................................ ................................ ......51 
13.2.  Handling of Missing Data  ................................ ................................ ........................... 51 
13.3.  General Considerations  ................................ ................................ ............................... 51 
13.4.  Demographics and Baseline Characteristics  ................................ ............................... 51 
13.5.  Efficacy Analysis  ................................ ................................ ................................ ........ 52 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
19 13.6.  Safety Analyses  ................................ ................................ ................................ .......... 52 
13.6.1.  Adve rse Events  ................................ ................................ ................................ ........... 52 
 53 
13.6.3.  Physical Examinations  ................................ ................................ ................................ 53 
 53 
 53 
13.6.6.  Prior and Concomitant Medications  ................................ ................................ ........... 53 
 54 
 54 
 54 
13.8.  Sample Size and Power  ................................ ................................ .............................. 54 
13.8.1 . Interim and Data Monitoring Committee (DMC) Analyses  ................................ .......54 
13.8.1.1.  Interim Analysis  ................................ ................................ ................................ .......... 54 
13.8.1.2.  DMC Analysis  ................................ ................................ ................................ ............ 55 
14. DIRECT ACCESS TO SOU RCE DATA/DOCUMENTS ................................ ......... 56 
14.1.  Study Monitoring  ................................ ................................ ................................ ........ 56 
14.2.  Audits and Inspections  ................................ ................................ ................................ 56 
14.3.  Institutional Review Board or Ethics Committee  ................................ ....................... 57 
15. QUALITY CONTROL AND QUALITY ASSURANCE  ................................ ......... 58 
16. ETHICS  ................................ ................................ ................................ ...................... 59 
16.1.  Ethics Review  ................................ ................................ ................................ ............. 59 
16.2.  Ethical Conduct of the Study  ................................ ................................ ...................... 59 
16.3.  Written Informed Consent  ................................ ................................ .......................... 59 
17. DATA HANDLING AND RE CORDKEEPING  ................................ ....................... 60 
17.1.  Inspection of Records  ................................ ................................ ................................ .60 
17.2.  Retention of Records  ................................ ................................ ................................ ..60 
18. PUBLICATION POLICY  ................................ ................................ .......................... 61 
19. LIST OF REFERENCES  ................................ ................................ ............................ 62 
 
  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
20 LIST OF TABLES  
Table 1:  Emergency Contact Information  ................................ ................................ ................... 4 
Table 2:  Schedule of Assessments  ................................ ................................ ............................ 12 
Table 3:  Investigational Product  ................................ ................................ ............................... 36 
Table  4: Summary of Clinical Laboratory Analytes  ................................ ................................ .45 
 
LIST OF FIGURES  
Figure 1:  Study Design  ................................ ................................ ................................ ............... 27 
 
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
/,672)$%%5(9,$7,216$1' '(),1,7,2162)7(506

$EEUHYLDWLRQ 'HILQLWLRQ
$( DGYHUVHHYHQW
$'/ DFWLYLWLHVRIGDLO\OLYLQJ
$8&LQI DUHDXQGHUWKHFXUYHIURPWRLQILQLW\
$8&WDXDUHDXQGHUWKHFRQFHQWUDW LRQWLPHFXUYHIURPWRHQGRIWKHGR VLQJSHULRG
%0, ERG\PDVVLQGH[
 
&PD[ PD[LPXPREVHUYHGFRQFHQWUDWLRQ
&52 FRQWUDFWUHVHDUFKRUJDQL]DWLRQ
(& HWKLFVFRPPLWWHH
(&* HOHFWURFDUGLRJUDP
H&5) HOHFWURQLFFDVHUHSRUWIRUP
(26 (QGRI6WXG\
 
 
(7 HVVHQWLDOWUHPRU
 
(79 HDUO\WHUPLQDWLRQYLVLW
)'$ )RRGDQG'UXJ$GPLQLVWUDWLRQ
*&3 *RRG&OLQLFDO3UDFWLFH
*03 *RRG0DQXIDFWXULQJ3UDFWLFH
,% LQYHVWLJDWRUÂ¶VEURFKXUH
,&) LQIRUPHGFRQVHQWIRUP
,&+ ,QWHUQDWLRQDO&RXQFLOIRU +DUPRQLVDWLRQRI7HFKQLFDO5HTXLUHPHQ WVIRU
3KDUPDFHXWLFD OVIRU+XPDQ8VH
,3 LQYHVWLJDWLRQDOSURGXFW
,5% LQVWLWXWLRQDOUHYLHZERDUG
0HG'5$ 0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV
 
3' SKDUPDFRG\QDPLF
 
3, SULQFLSDOLQYHVWLJDWRU
3. SKDUPDFRNLQHWLFPPD
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
22 Abbreviation  Definition  
PV Pharmacovigilance  
QTcF  QT corrected according to Fridericia â€™s formula  
  
SAE  serious adverse event  
SAP statistical analysis plan 
SOP standard operating procedure  
tÂ½  terminal elimination half -life  
TEAE  treatment -emergent adverse event  
TETRAS  The Essential Tremor Rating Assessment Scale  
tmax time of occurrence of C max 
WHO  World Health Organization  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
23 5. INTRODUCTION  
SAGE -324 is a positive allosteric modulator (PAM) of A -type Î³ -aminobutyric acid -gated 
chloride channel (GABA A) receptors, the major class of inhibitory neurotransmitter receptors in 
the brain.  In addition to being developed as an adjunctive therapy in epilepsy and other seizure 
disorders  under IND 139201, SAGE -324 is also being developed for the treatment of Essential 
Tremor (ET).  
Essential tremor is a permanently debilitating, neurologically determined, common movement 
disor der characterized by involuntary rhythmic oscillation of a body part due to intermittent 
muscle contractions typically occurring when not at rest, thus interfering with fine motor skills 
associated with daily activities ( Olanow 2008 , Deuschl 2011 , Hopfner 2016, NIH 2019 ). 
Although the pathophysiology and etiology of ET is not fully understood, it is postulated that 
approximately 50% of ET patients feature an autosomal dominant pattern of familial inheritance 
and that non -inherited cases may have toxin -based  or other causality ( Olanow 2008 , Hopfner 
2016). ET is the most common movement disorder in the US, with prevalence estimated to be 
approximately 2.2% of the population, representing a substantial societal medical burden with 
over an estimated 7 million ET  patients in the US alone ( Louis 2014 ). 
In general, active tasks of daily life are adversely impacted by ET, including but not limited to 
speech, handwriting, household tasks, and occupational demands, contributing negatively to 
psychosocial well -being, ge neral anxiety, and overall quality of life  (Koller, 1989 ). Although 
benign in term of its effect on life expectancy, ET is a progressive neurodegenerative condition 
whose symptoms are typically disabling, often forcing patients to change jobs or seek early  
retirement ( Zappia, 2013 ). In some cases, serious disability may ensue.   
The pharmacological profile  of SAGE -324 is theorized to  induce therapeutic effect  in the 
treatment of ET. Based on preclinical studies of  SAGE -324, which features a different 
mechanism of action than that of propranolol, the pharmacokinetic (PK)/ pharmacodynamic (PD) 
profile suggests SAGE -324 may safely ameliorate symptoms in patients suffering from ET, 
regardless of propranolol use . 
There are current ly ongoing Phase 1 clinical studies of SAGE -324 in healthy adults  and in adults 
with ET . These studies , in addition to preclinical studies of SAGE -324, are detailed in the 
investigatorâ€™s brochure.  
With a GABA A receptor -based mechanism of action  featuring  positive allosteric modulation  
capability , SAGE -324 represents a novel approach to the treatment of ET, which may help 
address the unmet medical need of the ET population , warranting further study of SAGE -324 as 
a potential treatment for this common movement disorder.  
Henceforth, this double -blind, placebo -controlled efficacy and safety study of SAGE -324 will be 
conducted in adults  and is designed to assess the effect of SAGE -324 on a variety of outcome 
measures specific to ET disease characte ristics  and associate d quality of life  domains . 
5.1. Dose Justification  
The d ose of SAGE -324 planned for  this study  is 60 mg given as oral tablets, to be  administered 
once daily in the morning with food. Th e dose  was selected based on preliminary data from 
3 active studies of SAGE -324, which included : unblinded data from completed cohorts in 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
24 324-CLP-101 Part A (oral solution SAGE -324 doses of 3 mg, 10 mg, 30  mg, 45 mg, 60 mg) ; 
Part C (oral solution SAGE -324 doses of 30 mg) ; Part D (oral suspension SAGE -324 doses of 
30 mg) in healthy subjects ; and  preliminary data from open -label Part E (oral suspension 
SAGE -324 doses of 45 mg and 60 mg) in participants with ET; additional preliminary data from 
324-CLP-102 cohorts 1 through 6  (cohorts 1 to 5 unblinded, cohort 6 blinded) , which evaluated 
oral suspension doses ranging from 5 mg to 60 mg; and preliminary unblinded data from 
324-CLP-104, which compared the relative bioavailability of the oral tablet (30 mg) vs oral 
suspension (30 mg) formulations of SAGE -324 and separately the effect of food on the PK of the 
SAGE -324 oral tablet. In 324 -CLP-101 and 324 -CLP-102 studies, doses were administered in a 
fasted state. The preliminary data from all of these active studies collectively info rmed the route 
of administration (oral) and dose strength of 60 mg as oral tablets planned for further evaluation 
in this study .  
SAGE -324 was generally well -tolerated in participants with ET and in healthy volunteers, as was 
shown in the preliminary data of 324 -CLP-101 Part E at single administration doses of 45 mg 
and 60 mg, and in 324 -CLP-102 through once -daily administered doses of up to 60 mg  for 
14 days. In addition, tremor reduction was observed at both doses on TETRAS and Kinesia 
accelerometry, with greater improvement seen at 60  mg compared to 45  mg.  
In the clinically complete  study 324-CLP-104, preliminary data showed that SAGE -324 oral 
tablets, when coadministered with a meal, resulted in exposures approximately equivalent to t hat 
of SAGE -324 oral suspension under fasted conditions. Therefore, the SAGE -324 oral tablets are 
recommended to be administered with food.  
5.2. Benefit/Risk Assessment  
Based on the mechanism of action of SAGE -324 and the results of completed nonclinical studies 
and preliminary data of currently ongoing clinical studies of SAGE -324, it is theorized that 
participants  may have  symptomatic ameliorat ion, ie, tremor reduction and possibly improved 
quality of life  from p otentially stabilizing disease characteristics associated with ET. 
Potential risks anticipated in this study are based on available data from toxicology studies of 
SAGE -324 in addition to preliminary data from 3 ongoing, currently active Phase 1 clinical 
studies of SAGE -324.  
Available preliminary clinical data are summarized in the SAGE -324 Investigatorâ€™s Brochure.  
There have been no deaths or SAEs  related to IP , and  based on the preliminary clinical data 
available , there have been  no confirmed  clinically significant trends in clinical laboratory 
evaluations, vital signs, or physical examinations.  
Based on available preliminary clinical data  from SAGE -324 active clinical studies , AEs of 
somnolence and feel ing of relaxation are considered adverse drug reactions.  In addition to 
scheduled clinic visits, the current status of study participants will be reviewed via weekly phone 
calls, in between clinic visits.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
25 6. STUDY  OBJECTIVES AND ENDPOINTS  
Objectives  Endpoints  
Primary   
To assess the effect of SAGE -324 compared 
to placebo on upper limb tremor reduction in 
individuals with essential tremor (ET) after 
28 days of treatment  Change from baseline compared to placebo in 
The Essential Tremor Rating Assessment 
(TETRAS) performance subscale part 4 upper 
limb tremor score on Day 29  
Secondary   
To assess the effect of SAGE -324 compared 
to placebo on overall upper limb tremor 
reduction  â€¢ Change from baseline compared to placebo 
in TETRAS performance subsca le part 4 
upper limb tremor score at all other 
timepoints  
â€¢ Change from baseline compared to placebo 
in Kinesia ONE accelerometer scores  
To assess the effect of SAGE -324 compared 
to placebo on activities of daily living (ADLs)  â€¢ Change from baseline compared to 
placebo in TETRAS Scale ADL score  
To assess the effect of SAGE -324 compared 
to placebo on overall tremor  â€¢ Change from  baseline compared to 
placebo in TETRAS total performance 
score  
To evaluate the safety and tolerability of 
SAGE -324 â€¢ Incidence of treatment -emergent adverse 
events (TEAEs)  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
26  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
27 7. INVESTIGATIONAL PLAN  
7.1. Overall Study Design  
This is a randomized, double -blind, placebo -controlled, parallel group study to evaluate the 
efficacy, safety, and tolerability of SAGE -324 in individuals with ET. Participants, site staff, and 
sponsor personnel will be masked to treatment allocation  (see Section  9.5). 
This study includes a Screening Period of up to 28 days, a 2 9-day treatment period consisting of 
28 days of dosing with the end of treatment visit  intended to be on Day 29 at trough , and a 
14-day follow -up period  relative to final dose  (Figure 1). After providing informed consent, 
participants will undergo screening assessments as outlined in Table 2  to determine eligibility .  
The Screening Period begins with the signing of the informed consent form (ICF). Eligible 
participants will visit the study center on Day 1 and complete additional eligibility assessments 
of safety and efficacy,  as specified in the Schedule of Assessments ( Table 2 ). Following 
completion of screening and Day 1 eligibility checks, participants will be randomized to 1 of 2 
treatment groups ( SAGE -324 60 mg daily, or placebo) in a 1:1 ratio.   
During the double -blind Treatment Period, s tarting on Day 1, participants will receive a single 
dose of investigational product (IP) once daily in the morning with f ood for 28 days on an 
outpatient basis. Doses occurring on scheduled clinic visits will be administered in the clinic,  and 
doses occurring on all other days will be self -administered by the participant at home  as 
specified in Table 2 . During the Treatment Period, participants will return to the study center 
approximately once per week for efficacy and safety assessments as specified in  Table 2 . In 
addition, a phone call will be conducted once per week , preferably mid -way between clinic 
visits, to review current status of the participant.  
In addition to Kinesia ONE -specific training, c linical study center staff and study p articipants 
will be trained on the use of software applications and devices necessary to complete 
quest ionnaires or  other assessments as required.  During in-clinic visits, c linical study center staff 
will be available to assist participants as needed , to ensure they can  access and us e the software  
applications and devices  correctly according to the training . 
During the fo llow-up period, visits will be conducted on an outpatient basis. In addition to the 
phone calls to review current status, p articipants will receive a phone call approximately 7 days 
after the last dose of IP (ie, Day 35) for safety monitoring. Participants will return to the study 
center for an end of study visit approximately 14 days following the last dose of IP (ie, Day 42) . 
Figure 1: Study Design   
 
Abbreviation:  EOT = end of treatment  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
28 7.2. Number of Participan ts 
Approximately 60 participants  are planned , with approximately 30 participants enrolled per arm , 
to produce 25 evaluable participants per arm  for primary efficacy  analysis . Additional 
participants may be randomized if the drop -out rate is higher than anticipated ( ie, >15%). 
7.3. Treatment Assignment  
Participants will be assigned to IP (active or placebo) in accordance with the randomization 
schedule on Day 1. Additional details on randomization and blinding  are provided in Section  9.5.  
7.4. Dose Adjustment Criteria   
If participants report adverse events that are  considered by the investigator to be related to the IP 
and not tolerable , the investigator may reduce the dose of IP from 60 mg in 15 mg decrements 
(ie, 60 , to 45 , to 30 mg) , as medically appropriate . The dose may not be reduced below 30 mg: if 
intolerable adverse events persist at the 30 mg dose, the IP should be per manently stopped.  The 
reduced dose of IP will continue to be administered once daily at the same schedule as specified 
in the Schedule of Assessments (Table 2). The dose of IP may not be increased for the remainder 
of the study .  
Otherwise, IP doses will not be further adjusted for this study except as clinically necessary , eg, 
interrupting dose due to an AE or serious adverse event ( SAE ) considered related to IP . 
7.5. Criteria for Study Termination  
Sage Therapeutics may terminate this study or any portion of the study at any time for safety 
reasons including the occurrence of AEs or other findings suggesting unacceptable risk to 
participant s, or for administrative reasons . In the event of study termination, Sage Therapeutics 
will provide written notification to the investigator . Investigational sites must promptly notify 
their IRB, where required,  and initiate withdrawal procedures for participa ting participant s.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
29 8. SELECTION AND WITHDRAWAL OF PARTICIPANT S 
8.1. Participant  Inclusion Criteria  
Participants must  meet all of the following criteria to qualify for  participation in this study:  
1. Participant has signed an ICF before any study -specific procedures or washout of drugs is 
performed.  
2. Participant  is ambulatory and  is 18 to 80 years of age, inclusive, at the time informed 
consent is obtained.  
3. Participant has a diagnosis of ET, as defined by all of the following criteria:  
a. Isolated tremor syndrome consisting of bilateral upper limb action tremor  
b. At least 3 years duration  
c. With or without tremor in other locations (eg, head, voice, or lower limbs)  
d. Absence of other neurological signs, such as dystonia, ataxia, or parkinsonism, 
isolated focal tremors (eg, voice, head), task - and position -specific tremors, sudden 
tremor onset or evidence of stepwise  deterioration of tremor  
4. Participant scores at least 1.5 for each of the six items that comprise the combined total 
upper limb TETRAS (total performance subscale part 4)  with the total score for the 
dominant  upper limb (the sum of the three items for either the right or left upper limb, 
whichever is dominant ) being at least 5.5, at both Screening and predose on Day 1 . 
5. Participant is willing to discontinue medications taken for the treatment of ET within 
14 days or 5 half -lives (whichever is longer) prior to receiving IP. Medications taken for 
the treatment of  ET that were discontinued prior to receiving IP may be resumed 
following Day 29.  
6. Participant is willing to discontinue the use of alcohol and products that contain nicotine  
within at least 1 week prior to Day 1 and through Day 29 of the study.  
7. Female part icipant agrees to use at least one method of highly effective contraception as 
listed in Section  9.2.4  during participation in the study and for 30 days following the last 
dose of study drug, unless she is postmenopausal (at least 12 months of spontaneous 
amenorrhea without an alternative medica l cause, with confirmatory follicle stimulating 
hormone >40  mIU/mL), and/or surgically sterile (bilateral oophorectomy, hysterectomy, 
and/or bilateral salpingectomy), or does not engage in sexual relations which carry a risk 
of pregnancy (does include abst inence).  
8. Male participant agrees to use an acceptable method of effective contraception for the 
duration of the study and for 13 weeks after receiving study drug, unless the participant 
does not engage in sexual relation(s) which carry a risk of pregnancy . Acceptable 
methods of effective contraception are listed in Section  9.2.4 .  
9. Male participant is willing to abstain from sperm donation for the duration  of the study 
and for 13 weeks after receiving study drug.  
10. Participant has no clinically significant findings, as determined by the investigator, on 
Screening and predose Day 1 physical examination including mental state examination 
(MSE) and neurologic ex amination, 12 -lead ECG, or screening clinical laboratory tests.   
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
30 8.2. Participant Exclusion Criteria  
Participant s who meet any of the following criteria are disqualified from participation in this 
study:  
1. Participant has presence of known causes of enhanced phys iological tremor.  
2. Participant has had recent exposure (14 days prior to Day 1) to tremorgenic drugs or 
presence of alcohol withdrawal state.  
3. Participant has had direct or indirect injury or trauma to the nervous system within 3 
months before the onset of t remor.  
4. Participant has had a previous procedure for the treatment of ET, deep brain stimulation, 
brain lesioning, or magnetic resonance (MR) guided procedure, eg, MR -guided focused 
ultrasound.  
5. Participant has historical or clinical evidence of tremor with psychogenic origin 
(including but not limited to eating disorders, major depression, etc.)  
6. Participant has significant history and/or presence of hepatic, renal, cardiovascular, 
pulmonary, gastrointestinal, hematological, immunologic, ophthalmologic, metab olic 
(hypothyroidism with stable thyroid replacement is acceptable), or oncological disease.  
7. Participant has history of substance  abuse prior to Screening  or has  a positive screen for 
drugs of abuse at Screening or predose on Day 1 or has a positive screen  for alcohol 
predose on Day 1 . 
8. Participant has a known allergy to SAGE -324 or any excipient.  
9. Participant has had exposure to another investigational drug or device within 30 days or 5 
half-lives (if known) of the investigational drug, whichever is longer, prior to the Day 1 
visit.  
10. Participant has history or suicidal behavior within 2 years or answ ers â€œYESâ€ to questions 
3, 4, or 5 on the C -SSRS at Screening or at Day 1 or is currently at risk or suicide in the 
opinion of the investigator  
11. Participant has donated one or more units (1 unit  = 450 mL) of blood or experienced 
acute loss of an equivalent a mount of blood within 60 days prior to Day 1.  
12. Participant has any condition or comorbidity that in the opinion of the investigator would 
limit or interfere with the participantâ€™s ability to complete or partake in the study.  
13. Participant is unwilling or unable to comply with study procedures and required training.  
14. Participant has used any known moderate or strong cytochrome P450 3A4 inhibitors 
and/or inducers within 14 days or 5 half -lives (whichever is longer) prior to Day 1 or 
consumed grap efruit juice, grapefruit, Seville oranges, pomegranates, tangelos, or St. 
Johnâ€™s Wort or products containing these within 30 days prior to Day 1. Use of mild 
cytochrome inhibitors and/or inducers may be permitted.  
15. Participant has concurrent or recent expo sure (14 days or 5 half-lives, whichever is 
longer, prior to the Day 1 visit) to sedative/hypnotic drugs, stimulants, highly  caffeinated 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
31 beverages or dietary supplements containing high doses of caffeine, or recent increase 
above regular daily consumption of caffeine . 
16. Participant plans to undergo elective surgery or relocate during participation in the study.  
17. Participant is investigative site personnel or a member of their immediate families 
(spouse, parent, child or sibling whether biological or legally ad opted).   
18. Participant currently uses or has used within 14 days or 5 half -lives (whichever is longer) 
prior to Day 1 , any prescription or over -the-counter medication that is a substrate of the 
OATP1B1 transporter.  
19. Female participant has a positive pregnancy  test or confirmed pregnancy . 
8.3. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently assigned IP or entered in the study , ie, a participant who does not meet 1 or 
more of the el igibility criteria  after providing consent  and prior to randomization  (Day 1) . A 
minimal set of screen failure information will be collected, including  demography, screen failure 
details, eligibility criteria, and any SAE.   
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened.  
8.4. Investigational Product  Discontinuation and Early Termination from 
the Study 
8.4.1.  Investigational Product  Discontinuation  
A participant may discontinue IP at any time at his/her own request for any reason. The 
investigator may discontinue a participant from IP for safety, behavioral, compliance, or 
administrative reasons. Participant s who discontinue IP will be encouraged by the investigator to 
remain on study and complete the EOT visit , the safety phone call 7 days later , and then , after a 
further 7 days,  the End of Study /Early Termination visit (EOS/ETV) , as specified in the 
Schedul e of Assessments ( Table 2). If the participant withdraw s consent to collect protected 
health information , the EOS/ETV will be conducted . 
The reason for IP discontinuation must be documented in the participantâ€™s study r ecord and 
recorded in the participantâ€™s electronic case report form (eCRF).  
The investigator must notify the sponsor and/or the medical monitor when a participant stops IP 
for any reason.  
Participant s who discontinue IP due to an AE, regardless of invest igator -determined causality, 
should be followed until the event is resolved, considered stable, or the investigator determines 
the event is no longer clinically significant.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
32 8.4.2.  Early Termination from the Study  
A participant may withdraw from the study at any time at his/her own request for any reason. 
The investigator may discontinue a participant from the study for safety, behavioral, compliance, 
or administrative reasons.  
The reason for early termination from the study must be documented in the participantâ€™s study 
record and recorded in the participantâ€™s electronic case report form (eCRF).  
The investigator must notify the sponsor and/or the medical monitor when a participa nt stops 
participation in the study for any reason.  
If a participant  is persistently noncompliant, the investigator should discuss with the sponsor the 
potential discontinuation of the participant . Any reasons for unwillingness or inability to adhere 
to the protocol must be recorded in the participant â€™s eCRF, including:  
â€¢ missed visits;  
â€¢ interruptions in the schedule of study drug administration;  
â€¢ non-permitted medications  
If the participant withdraws from the study after completing 28 days of dosing with IP, they will 
be encouraged to attend follow -up visits for safety assessments at Day 35 and Day 42 , as 
specified in the Schedule of Assessments ( Table 2 ). If the participant withdraw s their consent to 
collect protected health information , the EOS/ETV  visit will be conducted  and t he participant 
will be permanently discontinued from the study at that time . 
If the participant withdraws consent for disclosure of future information, the sponsor will retain 
and continue to use any data collected before such a withdrawal of consent.  
If a participant withdraws from the stu dy, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the site study records.  
8.4.3.  Loss to Follow -up 
A participant will be deemed lost to follow -up after 3 attempts at contacting the participant have 
been unsuccessful .  
8.4.4.  Replacement of Participants  
Participants will not be replaced.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
33 9. TREATMENT OF PARTICIPANT S 
9.1. Description of Investigational Product  
SAGE -324 is an orally administered tablet provided in  5 mg  or 15 mg (when available)  dose 
strengths . Participants will receive IP (60 mg total dose of SAGE -324 tablets , or appearance -
matched placebo tablets) according to the randomization schedule. Additional details regarding 
IP preparation, formulation, and storage are included in Section  10. 
9.2. Prior  Medications , Concomitant Medications , Restrictions , and 
Contraception  Requirements  
9.2.1.  Prior and Concomitant Medications  and/or Supplements  
The start and end dates, route, dose/units, frequency, and indication for all medications  and/or 
supplements  taken within 30 days prior to signing the informed consent through the first dose of 
IP will be recorded .  
All medications and/or supplements taken from the firs t dose of IP through the Day  42 (Â±1 days) 
visit (including start and end dates route, dose/units, frequency, and indication) will be recorded 
on the eCRF . Any concomitant medication determined necessary for the welfare of the 
participant  may be given at th e discretion of the investigator at any time during the study .  
9.2.2.  Prohibited Medications  
Use or consumption of the following is prohibited for the timeframes specified:  
â€¢ Treatment with an investigational drug or device during the 30 days or 5 half-lives (if 
known) of the investigational drug, whichever is longer, prior to Day 1  or during the 
study .  
â€¢ Use of tremorgenic drugs within the 14 days or 5 half -lives (whichever is longer) of 
Day 1  or during the study . 
â€¢ Use of  agents known to affect SAGE -324 drug metabolism (any known cytochrome 
P450  3A4 inhibitors and/or inducers) within the 14 days or 5 half-lives (whichever is 
longer) of Day 1  and through Day 29 of  the study period . Use of mild cytochrome P 
inhibitors and/or inducers may be permitted.  
â€¢ Concomitant u se of any prescription or over -the-counter medication that is a substrate 
of the OATP1B1 transporter for 14 days or 5 half -lives prior to Day 1  and during the 
28-day dosing period . 
â€¢ Concomitant  use of sedative/hypnotic drugs  for 14 days or 5 half -lives prior to Day 1 
and during the 28-day dosing period . 
9.2.3.  Other Restrictions  
â€¢ Use of any drugs of abuse during the study period  is prohibited. Note: participants 
with a history of drug abuse prior to screening should not be enrolled in the study.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
34 â€¢ Use of alcohol within 1 week prior to Day 1 and through Day 29 of the study period  
is prohibited . If the alcohol test is positive on Day s 1, 8, 15, 22 , or 29, the participant  
will not be administered further IP and will be withdrawn from the study ; no further 
efficacy assessments such as TETRAS will be undertaken.  
â€¢ Use of products that contain nicotine within 1 week prior to Day 1 and throu gh 
Day 29 of the study period is prohibited.  Positive cotinine testing on Days 1, 8, 15, 
22, or 29 would be considered a major  protocol deviation and the participant will be 
excluded from the Per Protocol Analysis Set.  
â€¢ Consumption of grapefruit juice, grap efruit, Seville oranges, pomegranates, tangelos, 
or St. Johnâ€™s Wort or products containing these within 30 days prior to Day 1 and 
through Day 29 of  the study period  is prohibited .  
â€¢ Use of stimulants, highly caffeinated beverages or dietary supplements containing 
high doses of caffeine  within 14 days prior to the Day  1 visit and through Day 29 of 
the study period is prohibited . Note: participants should not increase their regular 
daily consumption of caffeine during the study period.  
9.2.4.  Acceptable Forms of Contraception  
Acceptable forms of highly effective contraception for participants of childbearing potential or 
for partners of male participants who are of childbearing potential include:  
â€¢ Combined (estrog en and progestogen containing) oral, intravaginal, or transdermal 
hormonal contraception associated with inhibition of ovulation  
â€¢ Oral, injectable, or implantable progestogen -only hormonal contraception associated 
with inhibition of ovulation  
â€¢ Intrauterine device  
â€¢ Intrauterine hormone -releasing system  
â€¢ Bilateral tubal ligation  or bilateral tubal occlusion  (performed at least 3 months prior 
to Screening)  
â€¢ Vasectomized partner  (performed at least 3 months prior to Screening)  
â€¢ Sexual abstinence (no sexual intercour se) 
Acceptable forms of contraception for male participants include:  
â€¢ Sexual abstinence (no sexual intercourse)  
â€¢ History of vasectomy  (performed at least 3 months prior to Screening)  
â€¢ Condom with spermicide used together with highly effective female contracep tive 
methods if the female partner(s) is of childbearing potential (see above for list of 
acceptable female contraceptive methods)  
9.3. Intervention after the End of the Study  
There is n o planned  intervention following the end of the study.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
35 9.4. Treatment Adherence  
The first dose of IP will be received and administered by participants in the clinic . Participant s 
will be dispensed a  7-day supply of IP to orally self -administer  at home with instructions 
specifying to administer in the morning with food. Treatment adherence will be monitored by the 
site staff at each in-clinic visit  by direct questioning  and counting  returned tablets  and will be 
documented . Details on drug accountability are included in  Section  10.6. 
Patients will be asked to record the dates and times of their IP dose administrations  at home in a 
diary. They will also record details around how well they complied with the study instructions 
for self -administering IP at home . 
9.5. Randomization and Blinding  
This is a  randomized, double -blind, placebo -controlled study. Participants will be random ized in 
a 1:1 rat io to treatment group s (SAGE -324, 60 mg or placebo) . Participants, site staff, and the 
sponsor will be blinded to treatment allocation. Randomization schedules will be generated by an 
independent statistician . The randomization schedules will be kept stri ctly confidential, 
accessible only to authorized  personnel until the time of unblinding. The blinding of the study  
will be broken after the database has been locked.  
9.5.1.  Emergency Unblinding  
During the study, the blind is to be broken only when the safety of a participant  is at risk and the 
treatment plan is dependent on the study treatment received. Unless a participant  is at immediate 
risk, the investigator should  make diligent attempts to c ontact Sage prior to unblinding the study 
treatment administered to a participant . Request s from the investigator about the treatment 
administered to study participant s should  be discussed with the Sage  Medical Monitor . If the 
unblinding occurs without Sag eâ€™s knowledge, the investigator must notify Sage within 24 hours 
of breaking the blind. All circumstances surrounding a premature unblinding must be clearly 
documented in the source records.  
In all cases where the IP allocation for a participant  is unblin ded, pertinent information 
(including the reason for unblinding) must be documented in the participant â€™s records and on the 
eCRF.  
If a participant or any study personnel become unblinded to treatment, the participant will be 
excluded from the Per Protocol  analysis set, as detailed further in the statistical analysis plan. 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
36 10. INVESTIGATIONAL PROD UCT  MATERIALS AND 
MANAGEMENT  
10.1. Investigational Product  
Table 3: Investigational Product  
 Investigational Product  
Product Name:  SAGE -324 Placebo  
Dosage Form:  Tablet  Tablet  
Tablet Strength  5 mg , 15 mg  0 mg, appearance -matched to 
5 mg, and 15 mg, respectively  
Route of Administration  Oral Oral 
Physical Description  Immediate release white to off -
white, round, film -coated tablet 
containing 5 mg or 15 mg  of 
SAGE -324 drug substance , and 
composed of lactose, 
microcrystalline cellulose, 
croscarmellose sodium, sodium 
stearyl fumarate and fumed 
silica, featuring  OpadryÂ® II 
white as the coating agent.  White to off -white, round, film -
coated tablet containing no drug 
substance, composed of lactose, 
microcrystalline cellulose, 
croscarmellose sodium, sodium 
stearyl fumarate and fumed 
silica, featuring  OpadryÂ® II 
white as the coat ing agent.   
Manufacturer  Sage Therapeutics , Inc.  
10.2. Investigational Product  Packaging and Labeling  
SAGE -324 Oral Tablets and Placebo Tablets will be  packaged in blinded, high density 
polyethylene (HDPE) containers.  The containers used for SAGE -324 and placebo will be 
identical in appearance.  The package labeling conforms to FDA and GMP requirements.  
10.3. Investigational Product  Storage  
Upon receipt of the IP, the investigator, or the responsible pharmacist or designee, w ill inspect 
the product and acknowledge receipt in accordance with the study -specific process.  
The IP must be carefully stored at the temperature specified in the investigatorâ€™s brochure , 
securely and separately from other drugs. The IP may not be used fo r any purpose other than the 
present study. Any unused IP must be returned per the sponsorâ€™s instructions or destroyed locally  
per the siteâ€™s procedure(s) . IP may not be destroyed until accountability  and reconciliation  
procedures  have been completed  and monitored . 
The investigator or designee will be responsible for ensuring appropriate storage, dispensing, 
inventory, and accountability of the IP. An accurate, timely record of the disposition of the IP 
must be maintained.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
37 10.4. Inves tigational Pr oduct  Preparation  
The IP will be  in tablet form and  provided in blinded packaging.  No preparation is required for 
the tablet , which is administered orally  as described below . 
10.5. Inves tigational Product  Administration  
The IP will be administered in the clinic or at home as specified in the Schedule of Assessments 
(Table 2 ). The IP will be provided as tablets , sufficient in number to achieve a  dose of  60 mg . IP 
will be orally administered once daily  in the morning,  with food. Patients will be instructed to 
take the IP with food that comprises a minimum of  400 calories.  
10.6. Inves tigational Product  Accountability , Handling, and Disposal  
Upon receipt of IP, the investigator(s), or the responsible pharmacist or designee, will inspect the 
IP and complete and follow the instructions regarding receipt  and storage  in the investigatorâ€™s 
brochure and (where applicable) in the Pharmacy Manual. A copy of the shipping docum entation 
will be kept in the study files.  
The designated site staff will dispense the supplied participant -specific kits to participant s at the 
planned dispensation visit intervals outlined in  the Schedule of Assessments  (Table 2 ). 
An interactive response technology (IRT) will be used to capture participant -identifying 
information. The IRT will be used to randomize the eligible participant into the study an d 
provides the kit number of the IP to be dispensed to that participant.   
If dispensing errors or discrepancies are discovered by site staff or sponsorâ€™s designee, the 
sponsor must be notified immediately.  
The IP provided is for use only as directed in thi s protocol. The investigator or designee must 
keep a record of all IP received, used and returned/discarded.   
Sage Therapeutics  will be permitted access to the study  supplies at any time with appropriate 
notice during or after completion of the study to perform drug accountability reconciliation.   
The investigator, pharmacist, or qualified designee is responsible for drug accountability, 
reconciliation, and  record mai ntenance (ie, receipt, reconciliation, and final disposition records).  
At the end of the study, any unused IP tablets will be returned to Sage Therapeutics for 
destruction or destroyed locally  per the siteâ€™s procedures ; disposition of IP will be documented . 
IP may not be destroyed until accountability and reconciliation procedures have been completed 
and monitored.  
10.7. Product Complaints  
A product complaint is any written, electronic, or verbal expression of dissatisfaction regarding 
the identity, quality, reli ability, safety, purity, potency, effectiveness or performance (applicable 
for approved marketed products) of a drug product after it is released for distribution.  
In the course of conduct of the study, study personnel may become aware of a product compla int 
associated with the use of a Sage product. Personnel shall notify Sage within 24 hours by 
forwarding the product complaint information via the contact information listed in Table 1  and in 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
38 the Pharmacy Manual.  Where possible, personnel should segregate  and retain  any product, 
materials, or packaging  associated with the product complaint  until further instruction is 
provided by Sage or its designated representative (s). 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
39 11. EFFICACY ASSESSMENTS  AND CLINICAL PHARMA COLOGY 
ASSESSMENTS  
11.1. Efficacy Assessments  
11.1.1.  The Essential Tremor Rating Assessment Scale  
TETRAS is a validated , comprehensive clinical assessment of essential tremor  (Elble 2013).  
Three different components of TETRAS will be assessed in this study. The TETRAS ADL 
subscale, total performance score, and performance subscale part 4 upper limb tremor  score  will 
each be separately assessed  at each clinic visit as specified in the Schedule of Assessments 
(Table 2 ). 
The ADL subscale assesses how ET is impacting typical activities of daily living (ie, speech, 
eating, drinking, dressing, personal hygiene, writing, occupational impairment, social impact, 
and activities affected by upper limb tremor). It consists of 12 items that are  each rated on a scale 
from 0  (normal activity)  to 4 (severe abnormality) . The overall ADL score range is 0 to 48.  
The total performance score is based on overall rating  of tremor amplitude in the voice, limbs , 
head, face,  trunk, while performing pre -specified tasks, and also  measures functional task 
capabi lities, ie, handwriting, spirography,  and holding a pen over a dot . Each of these items is 
rated on a scale from 0  (no tremor) to 4 (severe tremor). Collectively, the performance items  
generate an  overall performance score from 0 to 64 .  
For the performanc e subscale part 4 upper limb tremor  score , all 3 maneuvers in the upper limb 
assessments  of part 4 (subscale items 4a, 4b, and 4c) will be completed for both arms, first for 
the left arm and then for the right . The part 4 subscale ordinally rates postural  (limbs extended 
forward  maneuver, and wing -beating  [elbows flexed] maneuver) , and kinetic  (finger -nose-finger 
maneuver)  tremor on a 0 to 4  severity scale  in 0.5 -point increments.  
In this study, a videographer  will video tape each TETRAS administration . 
11.1.2.  Kinesia ONEâ„¢ Accelerometer Score  
Kinesia ONEâ„¢ is an ISO -certified wireless motion sensor worn distally on the index finger, 
which utilizes 3 orthogonal accelerometers and 3 orthogonal gyroscopes to monitor 
3-dimensional mot ion. Data is transmitted wirelessly from the sensor to a Bluetooth technology -
enabled device to use with the Kinesia ONE software (eg,  Apple iPad or similar device with 
preinstalled Kinesia ONE software). The device has received FDA clearance.  
Via the Kine sia ONE software application, measures of 3-dimensional motion are converted to 
scores ranging from 0 to 4, per assessed maneuver; higher scores indicate greater tremor severity. 
Motion in both arms is captured.  
Participants will complete this assessment a t each clinic visit as specified in the Schedule of 
Assessments ( Table 2 ).  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
40 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
41 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
42 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
43 11.3. Other Patient -Reported Assessment s 
11.3.1.  Patient Perception of Res ponse Burden  
The Patient Perception of Response Burden Questionnaire is a patient -reported measure that 
assesses the multidimensional construct of response burden ( Atkinson 2019 ). 
Participants respond to 6 items assessing 1) how well the questions related to their actual 
concerns, 2) how comfortable the participants were with answering the questions, 3) how well 
the survey characterized their health and well -being, 4) the length of time to complete the 
questionnaires, 5) whether questions seemed unimportant  or repetitive, and 6) what additional 
information should have been gathered. Items 1 to 3 are assessed on a 0 to 10 scale, item 4 is 
assessed on a 1 to 3 scale, and items 5 and 6 are open -ended. Items 1 and 4 are reverse scored. A 
composite score can be c alculated to create a weighted representative index of relevance, 
comfort, and well -being relative to time to completion (ie, items 1, 2, and 3 were summed and 
multiplied by item 4) for a range of 0 to 72, with higher scores indicative of elevated endorsed  
response burden. The open -ended items will be summarized thematically. The Patient Perception 
of Response Burden Questionnaire will be performed as specified in the Schedule of 
Assessments ( Table 2 ). 
 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
44 12. SAFETY  ASSESSMENTS  
12.1. Safety Parameters  
All assessments will be conducted according to the Schedule of Assessments (Table 2 ). 
12.1.1.  Demograph y and Medical History  
Demographic characteristics (age, race, sex, ethnicity) and a full medical history will be 
documented . Whether the participant is left -handed or right -handed will be recorded. This must  
also additionally include  participant  recall of history of  ET, disease duration, past treatments  
used, and responsiveness to  alcohol  and/or other treatments  with use intended  as off-label  
treatment  of ET (eg, primidone  or similar t herapies ). 
12.1.2.  Weight and Height  
Height and weight wi ll be measured and documented . Body mass index (BMI) will be calculated 
and documented.   
12.1.3.  Physical Examination  
Whenever possible, the  same individual should perform all physical examinations . Physical 
examinations will include assessment of body systems (eg, head, eye, ear, nose and throat; heart; 
lungs; abdomen; and extremities) as well as cognitive and neurological examination and MSE . 
Unscheduled physical examinations may also be conducted p er the Investigatorâ€™s discretion.  
Any abnormality in physical examinations will be interpreted by an investigator as abnormal, not 
clinically significant (NCS); or abnormal, clinically significant (CS) in source documents .  
12.1.4.  Vital Signs  
Vital signs comprise  blood pressure and heart rate  (supine and standing) , respiratory rate, and 
temperature. Systolic and diastolic blood pressure and heart rate are to be measured after the 
participant  has been supine for at least 5  minutes  and then repeated 1 minute and 3 m inutes after  
standing .  
Vital signs are measured once at each timepoint with the exception of predose on Day 1, when 
blood pressure and heart rate are measured supine and standing in triplicate at least 15 minutes 
apart . 
Any abnormality in vital signs will be interpreted by an Investigator as abnormal, NCS; or 
abnormal, CS in source documents . 
12.1.5.  Electrocardiogram  
A 12 -lead ECG will be performed . The standard intervals (heart rate, PR, QRS, QT, and QTcF ) 
as well as any rhythm abnormalities will be recorded.  
Electrocardiograms will be performed after the participant  has been resting in a supine position 
for at least 5 minutes. When ECG measurement s coincide with safety assessments, vital signs 
assessment or blood draws, procedures should be carried o ut in said order  (vital  signs , ECG, 
blood draw) . 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
45 All abnormal ECGs will be interpreted by an investigator as abnormal , NCS, or abnormal , CS in 
source documents . 
12.1.6.  Laboratory Assessments  
Blood and urine samples for clinical labora tory assessments will be coll ected . Analytes to be 
evaluated are summarized in Table  4. 
Table  4: Summary of Clinical Laboratory Analytes  
Biochemistry  Renal Panel : glucose, calcium, phosphorus, blood urea nitrogen, creatinine, 
sodium, potassium, chloride, bicarbonate  
Hepatic Panel : albumin, ALT, AST, total bilirubin, direct bilirubin, indirect 
bilirubin, alkaline phosphatase, total protein, lactate dehydrogenase, gamma 
glutamyl transferase  
Other : triglycerides, cholesterol (low density lipoprotein [LDL], high density 
lipoprotein [HDL]), creatine phosphokinase , thyroid stimulating hormone (TSH)  
Coagulation  activated partial thromboplastin time, prothrombin time, and international 
normalized ratio  
Hematology  red blood cell count, hemoglobin, hematocrit, white blood cell count with 
differential, platelet count, and if red blood count  indices are abnormal, reflex red 
blood cell  morphology  as indicated  
Urinalysis  protein, glucose, pH, blood, leukocyte est erase, urobilinogen , bilirubin, ketones, 
nitrite  
All clinical laboratory test results outside the reference range will be interpreted by the 
Investigator as abnormal, NCS; or abnormal, CS in source documents.  
Follicle stimulating hormone testing will be conducted to confirm whether a participant  with 
â‰¥12 months of spontaneous amenorrhea meets the protocol -defined criteria for being 
postmenopausal ( Section  8.1). 
12.1.6.1.  Drugs of Abuse, Alcohol,  Nicotine  (Cotinine)  
A urine sample will be collected for assessment of the following selected drugs of abuse per the 
Schedule of Assessments  (Table 2 ): amphetamines, barbiturates, benzodiazepines,  
cannabinoids /THC , cocaine, methadone , MDMA, methamphetamines, opiates, oxycodone, 
tricyclic  antidepressants , and PCP. 
Urine samples will  be colle cted and tested for cotinin e. Either urine dipstick or breathalyzer will 
be used for alcohol testing.  
12.1.6.2.  Pregnancy Screen  
A serum  pregnancy test will be conducted for all female participants at Screening ; subsequently, 
a urine  pregnancy test will be conducted for all participants of childbearing potential as specified 
in the Schedule of Assessments ( Table 2 ).  
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
 6DIHW\3KRQH&DOO
$SKRQHFDOOZLOOEHFRQGXFWHGRQFH SHUZHHNSUHIHUDEO\PLGZHHNLQEHWZHHQFOLQLFYLVLWVDV
VSHFLILHGLQ 7DEOHDQGDJDLQDW'D\WRFROOHFWLQIRUPDWLRQDERXWFXUUHQWKHD OWKVWDWXV
JHQHUDOZHOOEHLQJ,3F RPSOLDQFHRUWRJDWKHURWKHUSHUWLQHQWKHDOWKUHODWHGLQIRUPDWLRQDVSHU
LQYHVWLJDWRUMXGJHPHQW
$GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV
 $GYHUVH(YHQW'HILQLWLRQ
$Q$(LVDQ\XQWRZDUGPHGLFDORFFXUUHQFHLQDSDWLHQWRUFOLQLF DOLQYHVWLJDWLRQSDUWLFLSDQW
DGPLQLVWHUHGDSKDUPDFHXWL FDOSURGXFWDQGWKDWGRHVQRWQHFHVVD ULO\KDYHDFDXVDOUHODWLRQVKLS
ZLWKWKLVWUHDWPHQW$Q$(FDQWKHUH IRUHEHDQ\XQIDYRUDEOHDQG XQLQWHQGHGVLJQLQFOXGLQJDQ
DEQRUPDOODERUDWRU\ILQG LQJV\PSWRPRUGLVHDVHWHPSRUDOO\DVV RFLDWHGZLWKWKHXVHRID
PHGLFLQDOLQYHVWLJDWLRQDOSURGXF WZKHWKHURUQRWUHODWHGWRW KHPHGLFLQDOLQYHVWLJDWLRQDO
SURGXFW,QFOLQLFDOVWXGLHVD Q$(FDQLQFOXGHDQXQGHVLUDEOH PHGLFDOFRQGLWLRQRFFXUULQJDWDQ\
WLPHLQFOXGLQJEDVHOLQHRUZ DVKRXWSHULRGVHYHQLIQRVWXG\W UHDWPHQWKDVEHHQDGPLQLVWHUHG
$7($(LVGHILQHGDVDQ$(ZLWKRQVHWDIWHUWKHVWDUWRI,3RU DQ\ZRUVHQLQJRIDSUHH[LVWLQJ
PHGLFDOFRQGLWLRQ$(ZLWKRQVHWDI WHUWKHVWDUWRI,3DQGWKURXJKRXWWKHVWXG\7KHWHUP,3
LQFOXGHVDQ\6DJH,3DFRPSDUD WRURUDSODFHERDGPLQLVWHUHGLQDFOLQLFDOWULDO
/DERUDWRU\DEQRUPDOLWLHV DUHFRQVLGHUHG$(V
LIWKH\UHVXOWLQGLVFRQWLQXDWLRQRU LQWHUUXSWLRQRIVWXG\WUHD WPHQWUHTXLUHWKHUDSHXWLFPHGLFDO
LQWHUYHQWLRQPHHWSURWRFROVSHFLILFF ULWHULDLIDSSOLFDEOHR ULIWKHLQYHVWLJDWRUFRQVLGH UVWKHPWRPPD
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
EHFOLQLFDOO\VLJQLILFDQW$Q\D EQRUPDOLWLHVWKDWPHHWWKHFULW HULDIRUDQ6$(VKRXOGEHUHSRUWHG
LQDQH[SHGLWHGPDQQHU /DERUDWRU\ DEQRUPDOLWLHV 
WKDWDUHFOHDUO\D WWULEXWDEOHWRDQRWKHU $(GRQRWUHTXLUHGLVFUHWHUHSRUWLQJHJ HOHFWURO\WH
GLVWXUEDQFHVLQWKHFRQWH[WRIGHK\GUDWLRQFKHPLVWU\DQGKHPDWRORJLFGLVWXUEDQFHVLQWKH
FRQWH[WRIVHSVLV 
$OO$(VWKDWRFFXUDIWHUDQ\SDUWLF LSDQWKDVVLJQHGWKH,&)DQG WKURXJKRXWWKHGXUDWLRQRIWKH
VWXG\ZKHWKHURUQRWWKH\DUHUHODWHGWRWKHVWXG\PXVWEHUH SRUWHGWR6DJH7KHUDSHXWLFV
3DUWLFLSDQWVZKRGLVFRQWLQXHWKH,3 GXHWRDQ$(UHJDUGOHVVRI LQYHVWLJDWRUGHWHUPLQHG
FDXVDOLW\VKRXOGEHIROORZHGXQWLOW KHHYHQWLVUHVROYHGFRQVLGHUHGVWDEOHRUWKHLQYHVWLJDWRU
GHWHUPLQHVWKHHYHQWLVQRORQJH UFOLQLFDOO\VLJQLILFDQW$Q\$(VWKDWDUHXQUHVROYHGDWWKH
SDUWLFLSDQWÂ¶VODVW$(DVVHVVPHQWLQWKHVWXG\DUHIROORZHGXSE \WKHLQYHVWLJDWRUIRUDVORQJDV
PHGLFDOO\LQGLFDWHGEXWZLWKRXWIXUWKHUUHFRUGLQJLQWKHH&5) 7KHVSRQVRURULWVUHSUHVHQWDWLYH
UHWDLQVWKHULJKWWRUHTXHVWDGGLWLRQDOLQIRUPDWLRQIRUDQ\SDU WLFLSDQWZLWKRQJRLQJ$(V6$(V
DWWKHHQGRIWKHVWXG\LIMXGJHGQHFHVVDU\
 6HULRXV$GYHUVH(YHQW6$('HILQLWLRQ
$Q6$(LVDQ\XQWRZDUGPHGLFDORFFXUUHQFHWKDWDWDQ\GRVH
x5HVXOWVLQGHDWK
x3ODFHVWKHSDUWLFLSDQWDWLPPH GLDWHULVNRIGHDWKDOLIHWKUHD WHQLQJHYHQWKRZHYHU
WKLVGRHVQRWLQFOXGHDQHYHQWW KDWKDGLWRFFXUUHGLQDPRUH VHYHUHIRUPPLJKWKDYH
FDXVHGGHDWK
x5HTXLUHVLQSDWLHQWKRVSLWDOL]DW LRQRUSURORQJDWLRQRIH[LVWLQJ KRVSLWDOL]DWLRQ
x5HVXOWVLQSHUVLVWHQWRUVLJQLILFDQWGLVDELOLW\RULQFDSDFLW\
x5HVXOWVLQDFRQJHQLWD ODEQRUPDOLW\RUELUWKGHIHFW
$Q6$(PD\DOVREHDQ\RWKHUPHGLFDOO\LPSRUWDQWHYHQWWKDWLQWKHRSLQLRQRIWKH,QYHVWLJDWRU
PD\MHRSDUGL]HWKHSDUWLFLSDQWRUPD\UHTXLUHPHGLFDOLQWHUYHQW LRQWRSUHYHQWRIWKHRXWFRPHV
OLVWHGDERYHH[DPSOHVRIVXFKH YHQWVLQFOXGHDOOHUJLFEURQFKRVSDVPUHTXLULQJLQWHQVLYH
WUHDWPHQWLQDQHPHUJHQF\URR PRUFRQYXOVLRQVRFFXUULQJDWKRPH WKDWGRQRWUHTXLUHDQ
LQSDWLHQWKRVSLWDOL]DWLRQ
$OO6$(VWKDWRFFXUDIWHUDQ\ SDUWLFLSDQWKDVVLJQHGWKH,&)DQ GWKURXJKRXWWKHGXUDWLRQRIWKH
VWXG\ZKHWKHURUQRWWKH\DUHU HODWHGWRWKHVWXG\PXVWEHUHFRUGHGRQWKH6$(UHSRUWIRUP
SURYLGHGE\6DJH7KHUDSHXWLFV$Q\6$(WKDWLVRQJRLQJZKHQWKH SDUWLFLSDQWFRPSOHWHVWKHLU
ILQDOVWXG\YLVLWZLOOEHIROORZHGE\WKHLQYHVWLJDWRUXQWLOW KHHYHQWKDVUHVROYHGVWDELOL]HG
UHWXUQHGWREDVHOLQHVWDWXVRUXQWLOWKHSDUWLFLSDQWGLHVRUL VORVWWRIROORZXS
$SUHVFKHGXOHGRUHOHFWLYHSURF HGXUHRUURXWLQHO\VFKHGXOHGWUH DWPHQWZLOOQRWEHFRQVLGHUHGDQ
6$(HYHQLIWKHSDUWLFLSDQWLVKRV SLWDOL]HG7KHVLWHPXVWGRF XPHQWDOORIWKHIROORZLQJ
x7KHSUHVFKHGXOHGRUHOHFWLYHSURFHGXUHRUURXWLQHO\VFKHGXOHGW UHDWPHQWZDV
VFKHGXOHGRURQDZDLW LQJOLVWWREHVFKHGXOHGSULRUWRREWDL QLQJWKHSDUWLFLSDQWÂ¶V
FRQVHQWWRSDUWLFLSDWHLQWKHVWXG\PPD
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
48 â€¢ The condition requiring the prescheduled or elective procedure or routinely scheduled 
treatment was present before and did not worsen or progress, in the opinion of an 
Investigator, between the participant â€™s consent to participate in the study and at the 
time of the procedure or treatment.  
12.2.3.  Definition of Adverse Events of Special Interest  
There are no kno wn adverse event s of special inter est as of the date of signature approval of this 
clinical protocol.  
12.2.4.  Relationship to Inves tigational Product  
The investigator must make the determination of relationship to the IP for each AE (not related, 
related ). The following definitions should be considered when evaluating the relationship of AEs 
and SAEs to the IP.  
Not Related  An AE will be considered â€œnot rela tedâ€ to the use of the IP if there is not a reasonable 
possibility  that the event has been caused by the IP. Factors pointing towards this 
assessment  include but are not limited to : the lack of temporal relationship between 
administration of the IP and the  event, the presence of biologically implausible 
relationship between the product and the AE, or the presence of a more likely 
alternative explanation for the AE  
Related  An AE will be considered â€œrelatedâ€ to the use of the IP if there is a reasonable 
possibility that the event may have been caused by the product under investigation. 
Factors that point towards this assessment include but are not limited to: a positive 
rechallenge, a reasonable temporal sequence between administration of the drug and 
the eve nt, a known response pattern of the suspected drug, improvement following 
discontinuation or dose reduction, a biologically plausible relationship between the 
drug and the AE, or a lack of alternative explanation for the AE  
12.2.5.  Recording Adverse Events  
AEs spontaneously reported by the participant  and/or in response to an open question from the 
study personnel or revealed by observation will be recorded during the study at the 
investigational site . The AE term should be reported in standard medical terminology when 
possible . For each AE, the investigator will evaluate and report the onset (date and time), 
resolution (date and time), intensity, causality, action taken, outcome  and seriousness  (if 
applicable), and whether or not it caused the participa nt to discontinue the IP or withdraw early 
from the study . 
Intensity will be asses sed according to the following scale:  
â€¢ Mild : symptom(s) barely noticeable to participant  or does not make participant  
uncomfortable; does not influence performance or function ing; prescription drug not 
ordinarily needed for relief of symptom(s)  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
49 â€¢ Moderate : symptom(s) of a sufficient severity to make participant  uncomfortable; 
performance of daily activity is influenced; participant  is able to continue in study; 
treatment for sym ptom(s) may be needed  
â€¢ Severe : symptom(s) cause severe discomfort; symptoms cause incapacitation or 
significant impact on participant â€™s daily life; severity may cause cessation of 
treatment with IP; treatment for symptom(s) may be given and/or participant  
hospitalized   
It is important to distinguish between serious and severe AEs . Severity is a measure  of intensity 
whereas seriousness is defined by the criteria under Section  12.2.2 . An AE of severe intensity 
may not necessarily be  considered serious.  
12.2.6.  Reporting Serious Adverse Events  
In order to adhere to all applicable laws and regulations for reporting an SAE(s), the study site 
must notify Sage or designee within 24 hours of the study site staff becoming aware of the 
SAE(s). The investigator must complete, sign and date the SAE repor t form , verify the accuracy 
of the information recorded on the SAE report form  with the corresponding source documents, 
and send a copy to  Sage or designee.  
Additional follow -up information, if required or available, should all be sent to Sage or designee  
within 24 hours  of receipt on a follow -up SAE report form  and placed with the original SAE 
information and kept with the appropriate section of the eCRF and/or study file.  
SAEs occurring after the designated follow up time for the study, should be reporte d to Sage or 
designee according to the timelines noted above only if the investigator considers the SAE 
related to IP.  
Sage , or designee,  is responsible for notifying the relevant regulatory authorities of certain 
events . It is the principal investigatorâ€™ s responsibility to notify the IRB/EC of all SAEs that occur 
at his or her site . Investigators will also be notified of all suspected unexpected serious adverse 
reactions  (SUSARs ) that occur during the clinical study. Each site is responsible for notifying  its 
IRB of all SUSARs .  
In addition, appropriate personnel in Sage  Drug Safety and Pharmacovigilance or designee will 
unblind SUSARs for the purpose of regulatory reporting. Sage  or designee will submit SUSARs 
(in blinded or unblinded fashion) to regulatory agencies according to local law. Sage , or 
designee, will submit SUSAR s to investigators in a blinded fashion.  
12.3. Pregnancy  
If a participant  becomes pregnant after the first adminis tration of IP, pregnancy information must 
be collected and recorded on the pregnancy form  and submitted to the sponsor within 24  hours of 
learning of the pregnancy. Details will be collected for all  pregnancies for which conception was 
likely  to have occur red after the start of IP administration until 5 terminal half -lives following 
the last administration of IP or until the completion of the study whichever is longer . Any 
pregnancy occurring in that time frame will be followed until delivery or termination  of the 
pregnancy.  The investigator will also attempt to collect pregnancy information on any 
participant â€™s partner who becomes pregnant after the participant has received the first 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
50 administration of IP . After obtaining the necessary signed informed consen t from the pregnan t 
partner directly, the investigator will follow the same pregnancy reporting procedures specified 
for pregnant participant s.  
The participant  or participant â€™s partner will be followed to determine the outcome of the 
pregnancy. The outcome of all pregnancies ( eg, spontaneous abortion , elective abortion , normal 
birth) must be followed and documented even if the participant  was discontinued  from the study. 
The investigator will collect follow -up information on the participant  or partic ipant â€™s partner and 
the neonate , and the information will be forwarded to Sage or designee. Generally, follow -up 
will not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any 
termination of pregnancy will be reported, regardless  of fetal status (presence or absence of 
anomalies) or indication for the procedure . 
Pregnancy in itself is not regarded as an AE unless there is a suspicion that a n IP may have 
interfered with the effectiveness of a contraceptive medication. Any complicat ion during 
pregnancy ( eg, anemia, infections, preeclampsia) should be reported as an AE/SAE. If the 
outcome of the pregnancy meets the criteria for immediate classification as an SAE (ie,  
spontaneous abortion, stillbirth, neonatal death ), the investigator should follow the procedures 
for reporting an SAE.  
12.4. Overdose  
An overdose is any dose of study treatment given to a participant  or taken by a participant  that 
exceeds more than one extra tablet within 24 hours as described in protocol. Overdoses are not 
considered AEs and should not be recorded as an AE on the eCRF; however , all overdoses must 
be recor ded on an overdose form and sent to Sage or d esignee within 24 hours of the site 
becoming aware of the overdose.  An overdose must be reported to Sage or designee even if the 
overdose does not result in an AE. If an overdose results in an AE, the AE must be recorded .  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
51 13. STATISTICS  
Detailed description of the analyses to be performed in the study will be provided in the 
statistical analysis plan (SAP). The SAP will be finalized and approved prior to database lock. 
Any changes  or additions to the SAP following database lock will be described in detail in the 
clinical study report.  
13.1. Data Analysis Sets  
The Randomized Set will include all participants who are randomized.   
The Safety Set will include all participant s administered IP.  
The Full Analysis Set will include all randomized participant s who received any amount of IP 
and have a baseline and at least one postbaseline TETRAS performance subscale part 4 upper 
limb tremor score .  
 
  
The Per Protocol Set will in clude  all participant s in the Full Analysis Set without any major 
protocol deviations that could affect efficacy. The review of major protocol deviations will be 
completed, and the decision on whether the deviation affects efficacy will be documented befor e 
database unblinding.  Note that a positive cotinine test on Days 1, 8, 15, 22 or 29 constitutes a 
major protocol deviation.  
13.2. Handling of Missing Data  
Every attempt will be made to avoid missing data . All participant s will be used in the analyses, 
as per the analysis populations, using all nonmissing data available . No imputation process will 
be used to estimate missing data .  
13.3. General Considerations  
All participant  data, including those that are derived, that support the tables and figures will be 
presente d in the participant  data listings. Some data may be presented only in participant  data 
listing, some may be presented with a corresponding table or figure; these will be indicated in 
relevant sections below. Participants will be summarized according to tr eatment received.  
For the purpose of all primary and secondary analyses where applicable, baseline is defined as 
the last measurement prior to receipt of IP.  
Continuous endpoints will be summarized with number (n), mean, standard deviation, median, 
minimu m, and maximum. In addition, change from baseline values will be calculated at each 
time point and summarized descriptively. For categorical endpoints, descriptive summaries will 
include counts and percentages.  
13.4. Demographics and Baseline Characteristics  
Dem ographic data, such as age, race, and ethnicity, and baseline characteristics, such as height, 
weight, and BMI, will be summarized using the Safety Set.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
52 Pregnancy  test results and drug screen results will be listed but not summarized .  
Medical history wil l be listed by participant .  
13.5. Efficacy Analysis  
The estimand for the primary efficacy analysis is the treatment difference between SAGE -324 
and placebo in mean change from baseline in clinic -based TETRAS performance subscale part 4 
upper limb tremor  scores at Day 2 9 based on the Full Analysis Set . This will be analyzed using a 
mixed effects model for repeated measures (MMRM); the model will include treatment, baseline 
TETRAS performance subscale part 4 upper limb tremor score , assessment timepoint, and 
timepoint -by-treatment as explanatory variables. All explanatory variables will be treated as 
fixed effects. All postbaseline clinic visits will be included in the model. The main comparison 
will be between SAGE -324 and placebo at the 2 9-day timepoint. Model -based point estimates 
(ie, least squares  means, 5% confidence intervals, and p -values) will be reported where 
applicable. An unstructured covariance structure will be used to model the within -subject errors. 
If there is a con vergence issue with the unstructured covariance model, Toeplitz compound 
symmetry or Autoregressive (1) [AR(1)] covariance structure will be used, following this 
sequence until convergence is achieved. If the model still does not converge with AR(1) 
struct ure, no results will be reported. When the covariance structure is not UN, the sandwich 
estimator for the variance covariance matrix will be derived, using the EMPIRICAL option in 
the PROC MIXED statement in SAS.  
Similar to those methods described above fo r the primary endpoint, an MMRM will be used for 
the analysis of the change from baseline in TETRAS total performance score s, Kinesia ONE 
accelerometer  scores  and TETRAS ADL score s.  
Other efficacy analyses will be specified in the SAP. In general, data wi ll be analyzed using 
appropriate descriptive statistics or prespecified statistical methods as applicable; participant  
listings will be provided for all efficacy data. Participant s will be analyzed according to 
randomized treatment for the purpose of effic acy unless otherwise specified.  
Sensitivity analyses will be described in the SAP. 
13.6. Safety Analyses  
Safety and tolerability of SAGE -324 will be evaluated by AEs, concomitant medication usage, 
 
 
 Safety data will be listed by participant  and summarized by treatment group . All 
safety summaries will be perf ormed on the Safety Set using treatment received.   
13.6.1.  Adverse Events  
AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 22.1 
or higher. A treatment -emergent adverse event (TEAE) is defined as an AE with onset after the 
first dose of IP. The analysis of AEs will be based on the concept of TEAEs. The incidence of 
TEAEs will be summarized by System Organ Class (SOC) and preferred term. In addition, 
summaries will be provided by intensity (mild, moderate, severe) and by causality  (related, not 
related) to IP.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
53 Any TEAEs leading to discontinuation of treatment or withdrawal from the study and any 
treatment -emergent SAEs  will be summarized.  
All AEs and SAEs (including those with onset or worsening before the start of IP) through th e 
end of the study will be listed.   
13.6.3.  Physical Examinations  
The occurrence of a physical examination , including MSE, (yes/no) and the date performed will 
be listed by participant . 
13.6.6.  Prior and Concomitant Medications  
Medications will be recorded at each study visit during the study and wil l be coded using World 
Health Organization -Drug dictionary (WHO -DD) September 2015, or later .  
All medications taken within 30 days prior to informed consent through the duration of the study 
will be recorded. In addition, all psychotropic medications take n in the previous 30 days prior to 
screening will be recorded. Those medications taken prior to the initiation of the start of IP will 
be denoted â€œPriorâ€. Those medications taken prior to the initiation of the IP and continuing 
beyond the initiation of the IP or those medications started at the same time or after the initiation 
of the IP will be denoted â€œConcomitantâ€.  
Medications will be presented according to whether they are â€œPriorâ€ or â€œConcomitantâ€ as 
defined above. If medication dates are incomplete and it is not clear whether the medication was 
concomitant, it will be assumed to be concomitant.  
Details of prior and concomitant medications will be listed by participant , start date, and 
verbatim term.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
54 13.8. Sample Size  and Power  
The sample size of this study is based on the assumption of a 3 points difference in the change 
from baseline TETRAS performance subscale part 4 upper limb tremor score  between 
SAGE -324 and placebo with a standard deviation of 3.5 points. Under these assum ptions, a 
sample size of 25 evaluable participants per group would provide 85% power for detecting a 
placebo -adjusted treatment difference of 3 points in TETRAS performance subscale part 4 upper 
limb tremor score  assuming a 2 -sided test at an alpha level  of 0.05. By including 2 treatment 
groups and using a 1:1  randomization, a total of 50 evaluable participants are required. Assuming 
a nonevaluability rate of  15%, approximately  60 participants  will be randomized.  Additional 
participants may be enrolled if t he dropout rate is greater than 15%.  
13.8.1.  Interim and Data Monitoring Committee (DMC) Analys es 
13.8.1.1.  Interim Analysis  
The sponsor may conduct an interim analysis. Detailed description s of planned data analyses will 
be provided in a separate interim statistical analysis plan (SAP) , if applicable . 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
55 13.8.1.2.  DMC Analysis  
Not applicable  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
56 14. DIRECT ACCESS TO SOU RCE DATA/DOCUMENTS  
14.1. Study Monitoring  
Before an investigational site can enter a participant  into the study, a representative of Sage 
Therapeutics will visit the investigational study site  per Sage SOPs  to: 
â€¢ Determine the adequacy of the facilities  
â€¢ Discuss with the investigator(s) and other personnel their responsibilities with regard to 
protocol adherence, and the responsibilities of Sage Therapeutics  or its repres entatives . 
This will b e documented in a Clinical Trial  Agreement between Sage Therapeutics  and 
the investigator.  
During the study, a monitor from Sage Therapeutics  or representative will have regular contacts 
with the investigational site, for the followin g: 
â€¢ Provide information and support to the investigator(s)  
â€¢ Confirm that facilities remain acceptable  
â€¢ Confirm that the investigational team is adhering to the protocol, that data are being 
accurately recorded in the case report forms, and that IP accountabil ity checks are being 
performed  
â€¢ Perform source data verification . This includes a comparison of the data in the case report 
forms with the participant â€™s medical records at the hospital or practice, and other records 
relevant to the study . This will require direct access to all original records for each 
participant  (eg, clinic charts).  
â€¢ Record and report any protocol deviations not previously sent to Sage Therapeutics . 
â€¢ Confirm AEs and SAEs have been properly documented on eCRFs and confirm any 
SAEs have been forwarded to Sage Therapeutics  and those SAEs that met criteria for 
reporting have been forwarded to the IRB or EC. 
The monitor will be available between visits if the investigator(s) or other staff needs  
information or advice.  
14.2. Audits and Inspect ions 
Sage Therapeutics or a uthorized representatives of Sage Therapeutics , a regulatory authority, or 
an independent E C or an I RB may visit the site to perform an audit (s) or inspection (s), including 
source data verification . The purpose of a  Sage Therapeu tics audit or a regulatory authority 
inspection is to systematically and independently examine all study -related activities and 
documents to determine whether these activities were conducted, and data were recorded, 
analyzed, and accurately reported accord ing to the protocol, GCP/ICH GCP guidelines , and any 
applicable regulatory requirements . The investigator should contact Sage Therapeutics  
immediately if contacted by a regulatory agency  or IRB/EC  about an  inspection.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
57 14.3. Institutional Review Board or Ethics Committee  
The principal investigator must obtain IRB (or EC) approval for the clinical study  prior to 
enrolling a participant . Initial IRB (or EC) approval, and all materials approved by the IRB (or 
EC) for this study i ncluding the participant  consent form and recruitment materials must be 
maintained by the investigator and made available for inspection.  
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
58 15. QUALITY CONTROL AND QUALITY ASSURANCE  
To ensure compliance with Good Clinical Practice and all applicable regulatory requirements, 
Sage Therapeutics may conduct a quality assurance audit (s) at the clinical site . Please see 
Section  14.2 for more details regarding the audit process.  
The investigator must have adequate quality control practices to ensure that the study is 
performed in a manner consistent with the protocol, GCP/ICH GCP guidelines, and applicable 
regulatory requirements. The investigator is responsible for reviewing all identified protocol 
deviations.  Significant protocol deviation s should be reported to the IRB/EC per the IRB/ECâ€™s 
written procedures.  
The investigator is responsible for supervising any i ndividual or party to whom the investigator 
delegates trial-related duties and functions conducted at the trial site. When the investigator 
retains the services of any individual or party to perform trial -related duties and functions , the 
investigator  must ensure the individual or party is qualified to perform trial -related duties and 
functions and should implement procedures to ensur e the integrity of the trial-related duties and 
functions performed,  and any data generated.  
The investigator must maintain adequate and accurate source document s and trial records that 
include all pertinent observations  on each of the siteâ€™s trial participants. Source data  must be 
attributable, legible, contemporaneous, original, accurate, and complete. Changes to source data 
should be traceable, should not obscure the original entry, and should be explained , if necessar y, 
to provide clarification . 
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
59 16. ETHICS  
16.1. Ethics Review  
The final study protocol, including the final version of the I CF, must be given a written and 
dated approval or favorable opinion by an IRB or EC as appropriate. The investigator must 
obtain and document  approval before he or she can enroll any participant  into the study.  The IRB  
or EC  must  supply to the sponsor a list of the IRB /EC membership and a statement to confirm 
that the IRB /EC is organized and operates according to GCP and applicable laws and 
regul ations.  
The principal investigator is responsible for informing the IRB or EC of any amendment to the 
protocol in accordance with local requirements. In addition, the IRB or EC must approve all 
advertising used to recruit participant s for the study. The pr otocol must be re -approved by the 
IRB or EC upon receipt of amendments and annually, as local regulations require.  
The principal investigator is also responsible for providing the IRB or EC with reports of any 
reportable serious adverse drug reactions from  any other study conducted with the IP. Sage 
Therapeutics will provide this information to the principal investigator.  
Progress reports and notifications of serious adverse drug reactions will be provided to the IRB 
or EC according to local regulations and guidelines.  In addition, the principal investigator must 
inform the IRB /EC and sponsor of any changes significantly affecting the conduct of the trial 
and/or increasing the risk to participant s (eg, violations to the protocol or urgent safe ty measures 
taken for participant  safety) . 
16.2. Ethical Conduct of the Study  
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH  and GCP guidelines, as well as all  
applicable regional or national regulatory requirements.  
16.3. Written Informed Consent  
Prior to enrolling a trial participant, t he investigator(s) will ensure that the participant  is given 
full and adequate oral and written information about the nature, purpose,  possible risk and 
benefit of the study . Participant s must also be notified that they are free to discontinue from the 
study at any time . The participant  should be given the opportunity to ask questions and allowed 
time to consider the information provided . 
When the participant decides to participate in the trial, the participant  (or the participant â€™s, parent 
or legally authorized representative)  must  provide  signed and dated informed consent . The 
written consent  must be obtained before conducting any study procedures.  The investigator must 
document the consent process in the participantâ€™s source records. The investigator  must maintain 
the original, si gned ICF. A copy of the signed ICF must be given to the partici pant or to the 
participantâ€™s  parent or  legal ly authorized  representative . 
Throughout the trial participants should be informed of any changes made to the study  and as 
new safety and or risk information  becomes known . The provision of this information  will be 
documented  in the participantâ€™s source records, and when applicable, an updated ICF will be 
provided . 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
60 17. DATA HANDLING AND RE CORDKEEPING  
17.1. Inspection of Records  
Sage Therapeutics  or its representative(s)  will be allowed to conduct site visit s at the 
investigation facilities for the purpose of monitoring any aspect of the study . The investigator 
agrees to allow the monitor to inspect the facility, drug storage area, drug accountability records, 
participant  charts and study source documents, an d other records relative to study conduct.  
Inspection  of the study by a regulatory  authority may occur at any time. The investigator must 
agree to the inspection of study -related records  and source documents  by the regulatory authority  
representative (s).  
17.2. Retention of Records  
The principal investigator must maintain all documentation relating to the study for the period 
outlined in the site contract, or for a period of 2  years after the last marketing application 
approval , and until there are no pending or contemplated marketing application s in an ICH 
region  or at least 2 years have elapsed since the formal discontinuation of clinical development  
of the investigational product . Sage is responsible  to inform the investigator/institution as to 
when study documents no longer need to be retained.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
61 18. PUBLICATION POLICY  
All information concerning SAGE -324 is considered confidential and shall remain the sole 
property of Sage Therapeutics. The investigator agrees to use this information only in conducting 
the study and shall not use it for any other purposes without written approval from Sage 
Therapeutics. No publication or disclosure of study results will be permitted except as specified 
in a separate, written, agreement between Sage Therapeutics and the investigator.  
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
/,672)5()(5(1&(6
$WNLQVRQ706FKZDUW]&(*ROGVW HLQ/HWDO$VVHVVPHQWVLQ2Q FRORJ\9DOXHLQ+HDOWK

%HOHOOL'&DVXOD$/LQJ$/DPEHU W--7KHLQIOXHQFHRIVXEXQLWFRPSRVLWLRQRQWKHLQWHUDFWLRQ
RIQHXURVWHURLGVZLWK*$%$$UH FHSWRUV1HXURSKDUPDFRORJ\ 
'HXVFKO*5DHWKMHQ-+HOOULH JHO+(OEOH57UHDWPHQWRISDWL HQWVZLWKHVVHQWLDOWUHPRU/DQFHW
1HXUR
(OEOH5%DLQ3)RUMD]0-HWDO7DVNIRUFHUHSRUWVFDOHVIRUVFUHHQLQJDQGHYDOXDWLQJWUHPRU
FULWLTXHDQGUHFRPPHQ GDWLRQV0RY'LVRUG1RY 
*HQHWLFV+RPH5HIHUHQFH(VVH QWLDO7UHPRU/LVWHU+LOO1DWLRQDO&HQWHUIRU%LRPHGLFDO
&RPPXQLFDWLRQV861DWLRQDO/LEUD U\RI0HGLFLQH1DWLRQDO,QVWL WXWHVRI+HDOWK'HSDUWPHQWRI
+HDOWK	+XPDQ6HUYLFHV$YD LODEOHIURPKWWSVJKUQOPQLKJR YFRQGLWLRQHVVHQWLDOWUHPRU
$FFHVVHG6HSW
+RSIQHU)+DXEHQEHUJHU'*D OSHUQ:5HWDO.QRZOHGJHJDSVDQGUHVHDUFKUHFRPPHQGDWLRQV
IRUHVVHQWLDOWUHPRU3DUNLQVRQLVP5HODW'LVRUG 
,QGHUDOÂŠSURSUDQROROK\GURFKORULGH>SDFNDJHLQVHUW@3KLODGHO SKLD3$:\HWK
3KDUPDFHXWLFDOV,QF$FFHVVHG
KWWSVZZZDFFHVVGDWDIGDJRYGUXJVD WIGDBGRFVODEHO VOEOSGI
.ROOHU:9HWHUH2YHUILHOG% $FXWHDQGFKURQLFHIIHFWVRISURS UDQRORODQGSULPLGRQHLQ
HVVHQWLDOWUHPRU1HXURORJ\
/RXLV('2WWPDQ5+RZPDQ\SHRSOHLQWKH86$KD YHHVVHQWLDOW UHPRU"'HULYLQJD
SRSXODWLRQHVWLPDWHEDVHGRQHSLGHPLRORJLFDOGDWD7UHPRU2WKHU +\SHUNLQHW0RY1<
PPD
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 3  CONFIDENTIAL  
63 Olanow CW. H yperkinetic Movement Disorders: Essential Tremor. In: Harrison's Principles of 
Internal Medicine. Vol 2. 17th ed. New York, NY: McGraw Hill; 2008:2560.  
 
Zappia M, Albanese A, Bruno E, et al. T reatment of essential tremor: a systematic review of 
evidence and recommendations from the Italian Movement Disorders Association.  Epub 2012 
Aug 11. Review. Erratum in: J Neurol. 2013 Mar;260(3):741 . 

 
1. TITLE PAGE A PHASE 2, DOUBLE -BLIND, PLACEBO -
CONTROLLED, RANDOMIZ ED STUDY EVALUATING 
THE EFFICACY, SAFETY , AND TOLERABILITY O F 
SAGE -324 IN THE TREATMENT OF  INDIVIDUALS 
WITH ESSENTIAL TREMOR  
324-ETD -201  
 
Investigational Product  SAGE -324 Oral Table t  
Clinical Phase  Phase 2  
Sponsor  Sage Therapeutics , Inc.  
215 First Street 
Cambridge, MA 02142  
Sponsor Contact  , MD  
Sponsor Medical Monitor  , MD, PhD  
Date of Original Protocol  23 October 2019  
Date of Amendment 1  20 December 2019  
Date of Amendment 2  24 February 2020  
Date of Amendment 3  10 June 2020  
 
 
Confidentiality Statement  
The confidential information in this document is provided to you as an investigator or consultant for 
review by you, your staff, and the applicable Institutional Review Board/Independent Ethics Committee . 
Your acceptance of this document constitutes agreem ent that you will not disclose the information 
contained herein to others without written authorization from Sage Therapeutics , Inc. 
 

&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
6321625$33529$/

3URWRFRO1XPEHU (7'
6WXG\7LWOH $3KDVH'RXEOH%OLQG3ODFHER
&RQWUROOHG5DQGRPL]HG6WXG\(YDOXDWLQJWKH(IILFDF\6DIHW\DQG7ROHUDELOLW\RI6$*(
LQWKH7UHDWPHQWRI,QGLYLGXDOV
ZLWK(VVHQWLDO7UHPRU
3URWRFRO9HUVLRQDQG'DWH 9HUVLRQ-XQH

B BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
'DWH

B BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
0' 'DWH


B BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
0' 'DWH


B BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
 'DWH



BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
3K' 'DWH


B BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
3K' 'DWH


BB BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
' D W H 
Æ–Æ–Æ–
Û¯	
Û¯
Û¯
Û¯








Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
3 INVESTIGATORâ€™S AGREEMENT 
I have received and read the Investigatorâ€™s Brochure for SAGE -324. I have read the 324-ETD -
201 protocol and agree to conduct the study as outlined. I agree to maintain the confidentiality of 
all information received or developed in connection wit h this protocol.  
 
 
             
Printed Name of Investigator  
 
             
Signature of Investigator  
        
Date  (DD/MMM/YYYY)  
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
&217$&7,1)250$7,21

7DEOH (PHUJHQF\&RQWDFW,QIRUPDWLRQ
5ROHLQ6WXG\ 1DPH $GGUHVVDQG7HOHSKRQH1XPEHU
6DJH6WXG\3K\VLFLDQ 0' 3KRQH 
6DJH0HGLFDO0RQLWRU0'3K'0RELOH 
2IILFHSKRQH 
(PDLO 
&520HGLFDO0RQLWRUDQG
+RXU(PHUJHQF\&RQWDFW0'
03+3KRQH 
(PDLO 
6$(5HSRUWLQJ,QIRUPDWLRQ ,49,$/LIHF\FOH6DIHW\(PSHURU%RXOHYDUG  
'XUKDP1&  
(PDLO6DJH6DIHW\#LTYLDFRP  
)D[  
6$(+RWOLQH
3URGXFW&RPSODLQWV 6DJH7KHUDSHXWLFV,QF(PDLOSURGXFWFRPSODLQWV#VDJHU[FRP
3KRQH

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
5 2. SYNOPSIS  
Name of Sponsor/Company:  
Sage Therapeutics, Inc. (hereafter referred to as Sage Therapeutics, or Sage)  
Name of Investigational Product: 
SAGE -324 Oral Tablet  
Name of Active Ingredient:  
SAGE -324 
Title of Study:  
A Phase 2, Double -blind, Placebo -controlled, Randomized Study Evaluating the Efficacy, Safety, and 
Tolerability of SAGE -324 in the Treatment of Individuals  with Essential Tremor  
Number of Sites and Study Location: This study will take place at  approximately 30 site s in the 
United States.  
Phase of D evelopment: Phase 2  
Planned Duration for each Study Participant:  
The duration of  participation (from Screening through the final follow -up visit) for each participant is 
estimated to be up to  71 days.  
Objectives and Endpoints : 
Objectives  Endpoints  
Primary   
To assess the effect of SAGE -324 compared to 
placebo on upper limb tremor reduction in 
individuals with essential tremor (ET) after 28 days of treatment  Change from baseline compared to placebo in The Essential Tremor Rating Assessment (TETRAS) performance subscale part 4 upper limb tremor score on Day 29  
Secondary   
To assess the effect of SAGE -324 compared to 
placebo on overall upper limb tremor reduction  â€¢ Change from baseline compared to placebo in 
TETRAS performance subscale part 4 upper limb tremor score at all other timepoints  
â€¢ Change from baseline compared to placebo in 
Kinesia ONE accelerometer scores  
To assess the effect of SAGE -324 compared to 
placebo on activities of daily living (ADLs)  â€¢ Change from baseline compared to placebo in 
TETRAS Scale ADL score  
To assess the effect of SAGE -324 compared to 
placebo on overall tremor  â€¢ Change from baseline compared to placebo in TETRAS total performance score  
To evaluate the safety and tolerability of 
SAGE -324 â€¢ Incidence of treatment-emergent adverse events (TEAEs)  
 
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
6 Study Description : 
This is a randomized, double -blind, placebo -controlled, parallel group  study to evaluate the efficacy, 
safety, and tolerability of SAGE -324 in individuals with ET. Participants, site staff, and sponsor 
personnel will be masked to treatment allocation.  
This study includes a Screening Period of up to 28 days, a 29-day treatment period  (28 days of dosing) , 
and a 14 -day follow up period. After providing informed consent, participants will undergo screening 
assessments as outlined in  Table 2  to determine eligibility.  
Screening Period: The Screening Period begins with the signing of the informed consent form (ICF). 
Eligible participants will visit the study center on Day 1 and complete additional eligibility  and baseline  
assessments, as specified in the Schedule of Assessments (Table 2 ). Following completion of screening  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
7 and Day 1  eligibility check s, participants will be randomized to 1 of 2 treatment groups ( SAGE -324 60 
mg daily , or placebo) in a 1:1 r atio.   
Double -Blind Treatment Period: Starting on Day 1, participants will receive a single dose of 
investigational product (IP) once daily for  28 days on an outpatient basis , to be taken  in the morning 
with food that comprises a minimum of 400 calories. Doses occurring on scheduled clinic visits will be 
administered in the clinic, and doses occurring on all other days will be self-administered by the 
participant at home. During the Treatment Period, participants will return to the study center 
approximately once per week for efficacy and safety assessments as specified in  Table 2 . Participants 
will be trained on the use of software applications and devices necessary to complete questionnaires or 
other assessments.  During the study, a phone call will be conducted once per week, preferably midw ay 
between clinic visits,  to review current status of participant . 
Follow -Up Period:  Follow -up visits will be conducted on an outpatient basis. Participants will continue 
to complete  questionnaires as indicated in Table 2  and will receive a phone call approximately 7 days 
after the last dose of IP (ie, Day 3 5) for safety monitoring. Participants will return to the study center for 
an end of study visit approximately 14 days following the last dose of IP (ie, Day 4 2). 
Number of Participants  (planned):  Approximately 60 participants, with approximately 30 per arm.  
Eligibility Criteria:  
Inclusion Criteria:  
1. Participant has signed an ICF before any study-specific procedures or washout of drugs i s 
performed. 
2. Participant is ambulatory and is 18 to 80 years of age, inclusive, at the time informed consent is 
obtained.  
3. Participant has a diagnosis of ET, as defined by all of the following criteria:  
a. Isolated tremor syndrome consisting of bilateral upper limb action tremor  
b. At least 3 years duration  
c. With or without tremor in other locations (eg, head, voice, or lower limbs) 
d. Absence of other neurological signs, such as dystonia, ataxia, or parkinsonism , isolated 
focal tremors (eg, voice, head), task- and position -specific tremors, sudden tremor onset or 
evidence of stepwise deterioration of tremor  
4. Participant scores at least 1.5 for each of the six items that comprise the combined total upper 
limb TETRAS (total performance subscale p art 4)  with the total s core for the dominant upper 
limb (the sum of the 3 items for either the right or left upper limb, whichever is dominant) 
being at least 5.5, at both S creening and predose on Day 1. 
5. Participant is willing to discontinue medications taken for the treatment o f ET within 14 days or 
5 half -lives (whichever is longer) prior to receiving IP.  Medications taken for the treatment of 
ET that were discontinued prior to receiving IP may be resumed following Day 29.  
6. Participant is willing to discontinue the use of alcohol and products that contain nicotine  within  
at least 1 week  prior to Day 1  and through Day 29 of the study.  
7. Female participant agrees to use at least one method of highly effective contraception as listed 
in Section  9.2.4 during participation in the study and for 30 days following the last dose of 
study drug, unless she  is postmenopausal (at least 12 months of spontaneous amenorrhea 
without an alternative medical cause, with confirmatory follicle stimulating hormone 
>40 mIU/mL), and/or surgically sterile (bilateral oophorectomy, hysterectomy, and/or bilateral 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
8 salpingectomy), or does not engage in sexual relations which carry a risk of pregnancy (do es 
include abstinence).  
8. Male participant agrees to use an acceptable method of effective contraception for the duration 
of the study and for 13 weeks after receiving study drug, unless the participant does not engage 
in sexual relation(s) which carry a risk of pregnancy. Acceptable methods of effective 
contraception are listed in Section  9.2.4.  
9. Male participant is willing to abstain from sperm donation for the duration of the study and for 
13 weeks after receiving study drug.  
10. Participant has no clinically significant findings, as determined by the investigator, on 
Screening and predose Day 1 physical examination  including mental state examination (MSE) 
and neurologic examination, 12 -lead ECG, or screening clinical laboratory tes ts.  
Exclusion Criteria:  
1. Participant has presence of known causes of enhanced physiological tremor.  
2. Participant has had r ecent exposure (14 days prior to Day 1) to tremorgenic drugs or presence 
of alcohol  withdrawal state.  
3. Participant has had direct or indirect injury or trauma to the nervous system within 3 months 
before the onset of tremor . 
4. Participant has had a previous procedure  for the treatment of ET, deep brain stimulation, brain 
lesioning, or magnetic resonance (MR) guided procedure,  eg, MR-guided focused ultrasound. 
5. Participant has h istorical or clinical evidence of tremor with psychogenic origin (including but 
not limited to eating disorders, major depression, etc.)  
6. Participant has significant history and/or presence of hepatic, renal, cardiovascular, pulmonary, 
gastrointestinal, hematological, immunologic, ophthalmologic, metabolic (hypothyroidism with 
stable thyroid replacement is acceptable), or oncological disease.  
7. Participant has history of substance abuse prior to Screening , has a positive screen for drugs of 
abuse at Screening or predose on Day 1 , or has a positive screen for alcohol predose on Day 1 . 
8. Participant has a k nown allergy to SAGE -324 or any excipient.  
9. Participant has had exposure to another investigational drug or device within 30 days  or 5 half -
lives (if known) of the investigational drug, whichever is longer,  prior to the Day 1 visit.  
10. Participant has h istory o f suicidal behavior within 2 years or answers â€œYESâ€ to questions 3, 4, 
or 5 on the C -SSRS at Screening or at Day 1 or is currently at risk of suicide in the opinion of 
the investigator . 
11. Participant has d onated one or more units (1 unit  = 450 mL) of blood or  experienced acute loss 
of an equivalent amount of blood within 60 days prior to Day 1.  
12. Participant has any condition or comorbidity that in the opinion of the investigator would limit 
or interfere with the participantâ€™s ability to complete or partake in the study.  
13. Participant is unwilling or unable to comply with study procedures  and required training. 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
9 14. Participant has used any known moderate or strong cytochrome P 450 3A4 inhibitors and/or 
inducers within 14 days or 5 half -lives (whichever is longer) prior to Day 1  or consumed 
grapefruit juice, grapefruit, Seville oranges, pomegranates, tangelos, or St. Johnâ€™s Wort or 
products containing these within 30 days prior to Day 1 . Use of mild cytochrome inhibitors 
and/or inducers may be permitted.  
15. Participant has concurrent or recent exposure (14 days or five half -lives, whichever is longer, 
prior to the Day 1 visit) to sedative/hypnotic drugs, stimulants, highly caffeinated  bever ages or 
dietary supplements containing high doses of caffeine , or recent increase above  regular daily  
consumption of caffeine . 
16. Participant plans to undergo elective surgery or relocate during participation in the study.  
17. Participant is investigative site personnel or a member of their immediate families (spouse, 
parent, child or sibling whether biological or legally adopted).   
18. [Removed ] 
19. Female p articipant has a positive pregnancy test  or confirmed pregnancy.  
Investigational Product  Dosage and Mode of Administration:  
SAGE -324 (60 mg) or matched placebo oral tablets will be administered in the clinic or self -
administer ed once  daily , in the morning, at approximately the same time each day , with food  that 
comprises a minimum of 400 calor ies.  
Duration of Treatment:  
Each participant will receive a single dose of SAGE -324 o ral tablets or matching placebo administered 
once  daily for 28 days.   
Statistical Methods:  
A separate statistical analysis plan (SAP) will provide a detailed description of the data analyses to be 
performed in the study. The SAP will be finalized and approved prior to database lock.  
General Considerations  
For the purpose of all efficacy and saf ety analyses where applicable, baseline is defined as the last 
measurement prior to the start of IP administration.  
Continuous endpoints will be summarized with number (n), mean, standard deviation, median, 
minimum, and maximum. In addition, change from ba seline values will be calculated at each time point 
and summarized descriptively. For categorical endpoints, descriptive summaries will include counts and 
percentages.  
Analysis Sets  
The Randomized Set is defined as all participants who are randomized.  
The Safety Set will include all participants who were administered IP.  
The Full Analysis Set will include all randomized participants who received any amount of IP and have 
a baseline and at least one postbaseline TETRAS performance subscale part 4 upper lim b tremor score.  
 
The Per Protocol Set will include all participants in the F ull Analysis Set  without any major protocol 
deviations that could  affect efficacy. The review of major protocol deviations will be completed, and 
the decision on whether the deviation affects efficacy will be documented before database unblinding.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
10 Determination of Sample Size  
The sample size of this study is based on the assumption of a 3-point difference in the change from 
baseline TETRAS performance subscale part 4 upper limb tremor scores between  SAGE -324 and 
placebo with a standard deviation of 3.5 points. Under these assumptions, a sample size of 25 evaluable 
participants  per group would provide 85% power for detecting a placebo -adjusted treatment difference 
of 3 points in TETRAS performance subscale part 4 upper limb tremor score , assuming a  2-sided test at 
an alpha  level of 0.05. By including  2 treatment groups and using a 1:1 randomization, a total of 
50 evaluable participants  are required.  Assuming a nonevaluability rate of  15%, approximately 
60 participants will be randomized.  Additional participants  may be enrolled if the drop- out rate is higher 
than 15%.  
Analysis of Primary Efficacy Endpoint  
The estimand for the primary efficacy analysis is the treatment difference between SAGE -324 and 
placebo in mean change from baseline in clinic -based TETRAS performance subscale part 4 upper limb 
tremor score at Day 2 9 based on the F ull Analysis Set . This will be analyz ed using a mixed -effects 
model for repeated measures (MMRM); the model will include treatment, baseline TETRAS 
performance subscale part 4 upper limb tremor score , assessment timepoint, and timepoint-by- treatment 
as explanatory variables. All explanatory v ariables will be treated as fixed effects. All postbaseline 
clinic visits will be included in the model. The main comparison will be between SAGE -324 and 
placebo at the 2 9-day timepoint. Model-based point estimates (ie, least squares means, 95% confidence 
intervals, and p -values) will be reported where applicable. An unstructured covariance structure will be 
used to model the within -subject errors. If there is a convergence issue with the unstructured covariance 
model, Toeplitz compound symmetry or Autoregr essive (1) [AR(1)] covariance structure will be used, 
following this sequence until convergence is achieved. If the model still does not converge with AR(1) 
structure, no results will be reported. When the covariance structure is not unstructured , the sand wich 
estimator for the variance covariance matrix will be derived, using the EMPIRICAL option in the 
PROC MIXED statement in SAS.  
Analysis of Secondary Efficacy Endpoints  
Similar to those methods described above for the primary endpoint, an MMRM will be us ed to analyze 
of the change from baseline in TETRAS total performance score s, Kinesia ONE accelerometer scores 
and TETRAS ADL score s. Individual items of the TETRAS subscales will be summarized.  
Safety Analysis  
Safety and tolerability of study drug will be evaluated by incidence of TEAEs /serious adverse events, 
 
 
 
 
 
 
Interim Analysis  
The sponsor may conduct an interim analysis . Detailed descriptions of planned  data analyses will be 
provided in a  separate interim statistical analysis plan (SAP), if applicable .  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
11 Table 2: Schedule of Assessments  
Assessment Screening  Treatment Period  Follow -up Period  
Study Day  -28 to -1 1 5 (Â±1)  
Phone 
Call 8 (Â±1)  12 (Â±1)  
Phone 
Call 15(Â±1) 19 (Â±1) 
Phone 
Call 22 (Â±1)  26 (Â±1) 
Phone 
Call 29 (+1) 
EOT 
 35 (Â±1) 
Safety 
Phone Call  42 (Â±1) 
EOS/ETV  
Informed Consent X            
Inclusion/Exclusion  X X           
Demographics  X            
Medical History  X            
Pregnancy Test  X  
(serum;  all 
women ) X  
(urine ; 
WOCBP  
only)    
 X  
(urine ; 
WOCBP  
only)     X  
(urine ; 
WOCBP  
only)   X  
(urine ; 
WOCBP  only)  
FSH (postmenopausal 
women only)  X            
Randomizationa  X           
Alcohol /cotinine  screens   X  X  X  X  X   
Drug screen  X X           
Physical examinationb X X  X  X  X  X  X 
Neurological examination 
including MSEb X X  X  X  X  X  X 
Body height  X            
Body weight  X            
Vital signsc X X  X  X  X  X  X 
12-Lead ECGd X X  X  X  X  X  X 
Chemistry/hematology/  
coagulation/urinalysis  X X  X  X  X  X  X 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
12 Assessment Screening  Treatment Period  Follow -up Period  
Study Day  -28 to -1 1 5 (Â±1)  
Phone 
Call 8 (Â±1)  12 (Â±1)  
Phone 
Call 15(Â±1) 19 (Â±1) 
Phone 
Call 22 (Â±1)  26 (Â±1) 
Phone 
Call 29 (+1) 
EOT 
 35 (Â±1) 
Safety 
Phone Call  42 (Â±1) 
EOS/ETV  
Kinesia  ONEf X X  X  X  X  X  X 
TETRASg X X  X  X  X  X  X 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
13 Assessment Screening  Treatment Period  Follow -up Period  
Study Day  -28 to -1 1 5 (Â±1)  
Phone 
Call 8 (Â±1)  12 (Â±1)  
Phone 
Call 15(Â±1) 19 (Â±1) 
Phone 
Call 22 (Â±1)  26 (Â±1) 
Phone 
Call 29 (+1) 
EOT 
 35 (Â±1) 
Safety 
Phone Call  42 (Â±1) 
EOS/ETV  
Patient Perception of 
Response Burden          X  X 
Participant trainingh X X           
Dispense study drug  X   X  X  X     
IP administration   Administered once daily for 28 days  Not applicable  
AEs/SAEs X 
Prior and concomitant 
medication  and historyi X 
Abbreviations: ADL  = activities of daily living; AE  = adverse event; 
; ECG  = electrocardiogram; EOS  = end of study; EOT  = end of treatment;   
; ETV  = early termination visit; FSH = follicle stimulating hormone; HIV  = human immunodeficiency 
virus; ICF  = informed consent form; min  = minutes; IP = investigational product; MSE  = mental state examination; 
; ; 
; ; SAE  = serious adverse event; TETRAS  = The Essential Tremor Rating Assessment 
Scale; WOCBP  = women of childbearing potential  
Note s:  
â€¢ The suggested order of assessments during clinic visits is: vital signs , TETRAS, Kinesia  ONE, ECG, blood sample collection for  and clinical 
laboratory assessments, and questionnaires . 
â€¢ All assessments will be performed predose  unless specified in a footnote . 
 
a Randomization  will occur on Day 1 after meeting all eligibility criteria.  
b Complete physical examinations (including MS E and comprehensive  neurologic examination) should be performed as specified and additionally as clinically 
necessary (see Section  12.1.3 ).  
c Predose on Day 1, supine and standing blood pressure and heart rate will be collected in triplicate a t least 15 minutes apart, measured after the participant has 
been in the supine position for at least 5 minutes and then repeated 1 minute and 3 minutes after standing. Respiratory rate and temperature are collected once 
predose on Day 1. Vital signs will be collected once predose at all other visits. All postdose vital signs will be collected once at approximately 3 hours (Â±60 
min) after dosing . 
d ECGs will be collected and read centrally. ECGs will be performed predose and approximately 3 hours  (Â±60 min)  postdose. All ECGs must be performed after 
the participant has been in a supine position for at least 5 minutes.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
14 e 
 
f Kinesia ONE will be assessed subsequently to TETRAS P erformance subscale part 4 upper limb tremor .  
g The TETRAS Performance and TETRAS ADL subscales will be assessed at Screening and predose at each cl inic visit. The TETRAS P erformance subscale 
part 4 upper limb tremor will be assessed before  Kinesia  ONE. In addition, on Day 15,  the TETRAS Performance  subscale will be assessed at 5 and 8 hours 
(Â±30 min) postdose . A videographer will record each TETRAS administration.  
h Participants will be trained by study personnel on the use of software applications , Investigational Product Diary,  and devices necessary for the conduct of the 
study.  
i Prior medications will be re corded during Screening and will include all medications and supplements  taken within the 30 days prior to signing the ICF  through 
the first dose of IP , as well as a complete history of all treatments for ET since the year of diagnosis . Concomitant medications will be recorded thereafter 
throughout the duration of the study.  
   

&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
7$%/(2)&217(176
  7,7/(3$*(   
,19(67,*$725Â¶6$*5((0(17   
&217$&7,1)250$7,21    
  6<1236,6   
  7$%/(2)&217(176   
/,672)7$%/(6    
/,672)),*85(6    
  /,672)$%%5(9,$7, 216$1''(),1,7,2162)7(506   
  ,1752'8&7,21   
  'RVH-XVWLILFDWLRQ   
  %HQHILW5LVN$VVHVVPHQW   
  678'<2%-(&7,9(6$1'(1'32,176   
  ,19(67,*$7,21$/3/$1   
  2YHUDOO6WXG\'HVLJQ   
  1XPEHURI3DUWLFLSDQWV   
  7UHDWPHQW$VVLJQPHQW   
  'RVH$GMXVWPHQW&ULWHULD   
  &ULWHULDIRU6WXG\7HUPLQDWLRQ   
  6(/(&7,21$1':,7+'5$:$/2)3$57,&,3$176   
  3DUWLFLSDQW,QFOXVLRQ&ULWHULD   
  3DUWLFLSDQW([FOXVLRQ&ULWHULD   
  6FUHHQ)DLOXUHV   
  ,QYHVWLJDWLRQDO3URGXFW'LVFRQ WLQXDWLRQDQG(DUO\7HUPLQDWLRQI URPWKH
6WXG\    
  ,QYHVWLJDWLRQDO3URGXFW'LVFRQWLQXDWLRQ   
  (DUO\7HUPLQDWLRQIURPWKH6WXG\   
  /RVVWR)ROORZXS   
  5HSODFHPHQWRI3DUWLFLSDQWV   
  75($70(172)3$57,&,3$176   
  'HVFULSWLRQRI,QYHVWLJDWLRQDO3URGXFW   
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
  3ULRU0HGLFDWLRQV&RQFRPLWDQW 0HGLFDWLRQV5HVWULFWLRQVDQG
&RQWUDFHSWLRQ5HTXLUHPHQWV   
  3ULRUDQG&RQFRPLWDQW0HGLF DWLRQVDQGRU6XSSOHPHQWV   
  3URKLELWHG0HGLFDWLRQV   
  2WKHU5HVWULFWLRQV   
  $FFHSWDEOH)RUPVRI&RQWUDFHSWLRQ   
  ,QWHUYHQWLRQDIWHUWK H(QGRIWKH6WXG\   
  7UHDWPHQW$GKHUHQFH   
  5DQGRPL]DWLRQDQG%OLQGLQJ   
  (PHUJHQF\8QEOLQGLQJ   
  ,19(67,*$7,21$/352'8&70$ 7(5,$/6$1'0$1$*(0(17   
  ,QYHVWLJDWLRQDO3URGXFW   
  ,QYHVWLJDWLRQDO3URGXFW 3DFNDJLQJDQG/DEHOLQJ   
  ,QYHVWLJDWLRQDO3URGXFW6WRUDJH   
  ,QYHVWLJDWLRQDO3U RGXFW3UHSDUDWLRQ   
  ,QYHVWLJDWLRQDO3URGXFW$GPLQLVWUDWLRQ   
  ,QYHVWLJDWLRQDO3U RGXFW$FFRXQWDELOLW\+ DQGOLQJDQG'LVSRVDO   
  3URGXFW&RPSODLQWV   
  ()),&$&<$66(660(176$1'&/,1,&$/3+$50$&2/2*<
$66(660(176   
  (IILFDF\$VVHVVPHQWV   
  7KH(VVHQWLDO7UHPRU5DWLQJ$VVHVVPHQW6FDOH   
  .LQHVLD21(ÂŒ$FFHOHURPHWHU6FRUH   
   
   
   
   
   
   
   
   
   
   
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
   
   
   
  2WKHU3DWLHQW5HSRUWHG$VVHVVPHQWV   
  3DWLHQW3HUFHSWLRQRI5HVSRQVH%XUGHQ   
  6$)(7<$66(660(176   
  6DIHW\3DUDPHWHUV   
  'HPRJUDSK\DQG0HG LFDO+LVWRU\   
  :HLJKWDQG+HLJKW   
  3K\VLFDO([DPLQDWLRQ   
  9LWDO6LJQV    
  (OHFWURFDUGLRJUDP   
  /DERUDWRU\$VVHVVPHQWV   
  'UXJVRI$EXVH$OFRKRO1LFRWLQH&RWLQLQH   
  3UHJQDQF\6FUHHQ   
   
   
  6DIHW\3KRQH&DOO   
  $GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV   
  $GYHUVH(YHQW'HILQLWLRQ   
  6HULRXV$GYHUVH(YHQW6$('HILQLWLRQ   
  'HILQLWLRQRI$GYHUVH(YHQWVRI6SHFLDO,QWHUHVW   
  5HODWLRQVKLSWR,QYHVWLJDWLRQDO3URGXFW   
  5HFRUGLQJ$GYHUVH(YHQWV   
  5HSRUWLQJ6HULRXV$GYHUVH(YHQWV   
  3UHJQDQF\    
  2YHUGRVH    
  67$7,67,&6   
  'DWD$QDO\VLV6HWV   
  +DQGOLQJRI0LVVLQJ'DWD   
  *HQHUDO&RQVLGHUDWLRQV   
  'HPRJUDSKLFVDQG%DVHOLQH&KDUDFWHULVWLFV   
  (IILFDF\$QDO\VLV   
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
  6DIHW\$QDO\VHV   
  $GYHUVH(YHQWV   
   
  3K\VLFDO([DPLQDWLRQV   
   
   
  3ULRUDQG&RQFRPLWDQW0HGLFDWLRQV   
   
   
   
  6DPSOH6L]HDQG3RZHU   
  ,QWHULPDQG'DWD0RQLWRULQJ&R PPLWWHH'0&$QDO\VHV   
  ,QWHULP$QDO\VLV   
  '0&$QDO\VLV   
  ',5(&7$&&(66726285&('$7$'2&80(176   
  6WXG\0RQLWRULQJ   
  $XGLWVDQG,QVSHFWLRQV   
  ,QVWLWXWLRQDO5HYLHZ%RDUGRU(WKLFV&RPPLWWHH   
  48$/,7<&21752/$1'48$/,7<$6685$1&(   
  (7+,&6    
  (WKLFV5HYLHZ   
  (WKLFDO&RQGXFWRIWKH6WXG\   
  :ULWWHQ,QIRUPHG&RQVHQW   
  '$7$+$1'/,1*$1'5(&25'.((3,1*   
  ,QVSHFWLRQRI5HFRUGV   
  5HWHQWLRQRI5HFRUGV   
  38%/,&$7,2132/,&<   
  /,672)5()(5(1&(6   

 
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
/,672)7$%/(6
7DEOH  (PHUJHQF\&RQWDFW,QIRUPDWLRQ   
7DEOH  6FKHGXOHRI$VVHVVPHQWV   
7DEOH  ,QYHVWLJDWLRQDO3URGXFW   
7DEOH  6XPPDU\RI&OLQLFDO/DERUDWRU\$QDO\WHV   

/,672)),*85(6
)LJXUH  6WXG\'HVLJQ   

&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
/,672)$%%5(9,$7,216$1''(),1,7,2162)7(506

$EEUHYLDWLRQ 'HILQLWLRQ
$( DGYHUVHHYHQW
$'/ DFWLYLWLHVRIGDLO\OLYLQJ
$8&LQI DUHDXQGHUWKHFXUY HIURPWRLQILQLW\
$8&WDX DUHDXQGHUWKHFRQFHQWUDWLRQ WLPHFXUYHIURPWRHQGRIWKHGRVLQJSHULRG
%0, ERG\PDVVLQGH[
 
&PD[ PD[LPXPREVHUYHGFRQFHQWUDWLRQ
&52 FRQWUDFWUHVHDUFKRUJDQL]DWLRQ
(& HWKLFVFRPPLWWHH
(&* HOHFWURFDUGLRJUDP
H&5) HOHFWURQLFFDVHUHSRUWIRUP
(26 (QGRI6WXG\
 

(7 HVVHQWLDOWUHPRU
 
(79 HDUO\WHUPLQDWLRQYLVLW
)'$ )RRGDQG'UXJ$GPLQLVWUDWLRQ
*&3 *RRG&OLQLFDO3UDFWLFH
*03 *RRG0DQXIDFWXULQJ3UDFWLFH
,% LQYHVWLJDWRUÂ¶VEURFKXUH
,&) LQIRUPHGFRQVHQWIRUP
,&+ ,QWHUQDWLRQDO&RXQFLOIRU+DUPRQL VDWLRQRI7HFKQLFDO5HTXLUHPHQWVIRU
3KDUPDFHXWLFDOVIRU+XPDQ8VH
,3 LQYHVWLJDWLRQDOSURGXFW
,5% LQVWLWXWLRQDOUHYLHZERDUG
0HG'5$ 0HGLFDO'LFWLRQDU\I RU5HJXODWRU\$FWLYLWLHV
 
3' SKDUPDFRG\QDPLF

3, SULQFLSDOLQYHVWLJDWRU
3. SKDUPDFRNLQHWLFPPD
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
21 Abbreviation  Definition  
PV Pharmacovigilance 
QTcF  QT corrected according to Fridericiaâ€™s formula  
  
SAE  serious adverse event  
SAP statistical analysis plan 
SOP standard operating procedure 
tÂ½  terminal elimination half -life  
TEAE  treatment- emergent adverse event  
TETRAS  The Essential Tremor Rating Assessment Scale  
tmax time of occurrence of C max 
WHO  World Health Organization 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
22 5. INTRODUCTION
SAGE -324 is a positive allosteric modulator (PAM) of A -type Î³- aminobutyric acid -gated 
chloride channel (GABA A) receptors, the major class of inhibitory neurotransmitter receptors in 
the brain. In addition to being developed as an adjunctive therapy in epilepsy and other seizure 
disorders under IND 139201, SAGE -324 is also being developed for the treatment of Essential 
Tremor (ET).  
Essential tremor is a permanently debilitating, neurologically determined, common movement disorder characterized by involuntary rhythmi c oscillation of a body part due to intermittent 
muscle contractions typically occurring when not at rest, thus interfering with fine motor skills 
associated with daily activities (Olanow 2008, Deuschl 2011, Hopfner 2016, NIH 2019).  
Although the pathophysiology and etiology of ET is not fully understood, it is postulated that 
approximately 50% of ET patients feature an autosomal dominant pattern of familial inheritance 
and that non- inherited cases may have toxin -based or other causality ( Olanow 2008, Hopfner 
2016). ET is the most common movement disorder in the US, with prevalence estimated to be 
approximately 2.2% of the population, representing a substantial societal medical burden with 
over an estimated 7 million ET patients in the US alone ( Louis 2014).  
In general, active tasks of daily life are adversely impacted by ET, including but not limited to 
speech, handwriting, household tasks, and occupational demands, contributing negatively to 
psychosocial well-being, general anxiety, and overall quality of life  (Koller, 1989). Although 
benign in term of its effect on life expectancy, ET is a progressive neurodegenerative condition 
whose symptoms are typically disabling, often forcing patients to change jobs or seek early 
retirement ( Zapp ia, 2013). In some cases, serious disability may ensue.   
The pharmacological profile of SAGE -324 is theorized to  induce therapeutic effect in the 
treatment of ET. Based on preclinical studies of  SAGE -324, which features a different 
mechanism of action than  that of propranolol, the pharmacokinetic (PK)/ pharmacodynamic (PD) 
profile suggests SAGE -324 may safely ameliorate symptoms in patients suffering from ET, 
regardless of propranolol use . 
There are currently ongoing Phase 1 clinical studies of SAGE -324 in healthy adults and in adults 
with ET . These studies, in addition to preclinical studies of SAGE -324, are detailed in the 
investigatorâ€™s brochure. 
With a GABA
A receptor -based mechanism of action  featuring  positive allosteric modulation  
capability , SAGE -324 represents a novel approach to the treatment of ET, which may help 
address the unmet medical need of the ET population, warranting further study of SAGE -324 as 
a potential treatment for this common movement disorder.  
Henceforth, this double -blind, placebo-controlled efficacy and safety study of SAGE -324 will be 
conducted in adults and is designed to assess the effect of SAGE -324 on a variety of outcome 
measures specific to ET disease characteristics and associate d quality of life domains. 
5.1. Dose Justification  
The d ose of SAGE -324 planned for this study is 60 mg given as oral tablets, to be administered 
once daily in the morning with food. Th e dose w as selected based on preliminary data from 
3 active studies of SAGE -324, which included : unblinded data from completed cohorts in 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
23 324-CLP-101 Part A (oral solution SAGE -324 doses of 3 mg, 10 mg, 30 mg, 45 mg, 60 mg); 
Part C (oral solution SAGE -324 doses of 30 mg); Part D (oral suspension SAGE -324 doses of 
30 mg) in healthy subjects ; and preliminary data from open- label Part E (oral suspension 
SAGE -324 doses of 45 mg and 60 mg) in participants with ET; additional preliminary data from 
324-CLP-102 cohorts 1 through 6 (cohorts 1 to 5 unblinded, cohort 6 blinded) , which evaluated 
oral suspension doses ranging from 5 mg to 60 mg; and preliminary unblinded data from 
324-CLP-104, which compared the relative bioavailability of the oral tablet (30 mg) vs oral 
suspension (30 mg) formulations of SAGE -324 and separately the effect of food on the PK of the 
SAGE -324 oral tablet. In 324- CLP-101 and 324- CLP-102 studies , doses were administered in a 
fasted state. The preliminary data from all of these active studies collectively informed the route 
of administration (oral) and dose strength of 60 mg as oral tablets planned for further evaluation 
in this study .  
SAGE -324 w as generally well -tolerated in participants with ET and in healthy volunteers, as was 
shown in the preliminary data of 324- CLP-101 Part E at single administration doses of 45 mg 
and 60 mg, and in 324- CLP-102 through once- daily administered doses of up to 60 mg for 
14 days. In addition, tremor reduction was observed at both doses on TETRAS and Kinesia ONE 
accelerometry, with greater improvement seen at 60  mg compared to 45 mg.  
In the clinically complete  study 324- CLP-104, preliminary data showed that SAGE -324 oral 
tablets, when coadministered with a meal, resulted in exposures approximately equivalent to that of SAGE -324 oral suspension under fasted conditions. Therefore, the SAGE -324 oral tablets are 
recommended to be admi nistered with food.  
5.2. Benefit/Risk Assessment  
Based on the mechanism of action of SAGE -324 and the results of completed nonclinical studies 
and preliminary data of currently ongoing clinical studies of SAGE -324, it is theorized that 
participants  may have symptomatic amelioration, ie, tremor reduction and possibly improved 
quality of life from p otentially stabilizing disease characteristics associated with ET. 
Potential risks anticipated in this study are based on available data from toxicology studies of SAGE -324 in addition to preliminary data from 3 ongoing, currently active Phase 1 clinical 
studies of SAGE -324.  
Available preliminary clinical data are summarized in the SAGE -324 Investigatorâ€™s Brochure.  
There have been no deaths or SAEs related to IP , and based on the preliminary clinical data 
available, there have been  no confirmed  clinically significant trends in clinical laboratory 
evaluations, vital signs, or physical examinations.  
Based on available preliminary clinical data from SAGE -324 active clinical studies, AEs of 
somnolence and feeling of relaxation are considered advers e drug reactions.  In addition to 
scheduled clinic visits, the current status of study participants will be reviewed via weekly phone 
calls, in between clinic visits.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
24 6. STUDY  OBJECTIVES AND ENDPOINTS  
Objectives  Endpoints  
Primary   
To assess the effect of SAGE -324 compared 
to placebo on upper limb tremor reduction in 
individuals with essential tremor (ET) after 28 days of treatment  Change from baseline compared to placebo in The Essential Tremor Rating Assessment (TETRAS) performance subscale part 4 upper 
limb tremor score on Day 29  
Secondary   
To assess the effect of SAGE -324 compared 
to placebo on overall upper limb tremor reduction â€¢ Change from baseline compared to placebo 
in TETRAS performance subscale part 4 upper limb tremor score at all other timepoints 
â€¢ Change from baseline compared to placebo 
in Kinesia ONE accelerometer scores  
To assess the effect of SAGE -324 compared 
to placebo on activities of daily living (ADLs) â€¢ Change from baseline compared to 
placebo in TETRAS Scale ADL score 
To assess the effect of SAGE -324 compared 
to placebo on overall tremor â€¢ Change from baseline compared to placebo in TETRAS total performance score  
To evaluate the safety and tolerability of 
SAGE -324 â€¢ Incidence of treatment -emergent adverse 
events (TEAEs)  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
25  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
26 7. INVESTIGATIONAL PLAN
7.1. Overall Study Design
This is a randomized, double-blind, placebo-controlled, parallel group study to evaluate the 
efficacy, safety, and tolerability of SAGE -324 in individuals with ET. Participants, site staff, and 
sponsor personnel will be masked to treatment allocation  (see Section  9.5). 
This study includes a Screening Period of up to 28 days, a 29-day treatment period consisting of 28 days of dosing with the end of treatment visit intended to be on Day 29 at trough, and a 14-day follow-up period relative to final dose  (Figure 1) . After providing informed consent,
participants will undergo screening assessments as outlined in  Table 2  to determine eligibility .
The Screening Perio d begins with the signing of the informed consent form (ICF). Eligible 
participants will visit the study center on Day 1 and complete additional eligibility assessments 
of safety and efficacy, as specified in the Schedule of Assessments (Table 2 ). Following 
completion of screening and Day 1 eligibility checks, participants will be randomized to 1 of 2 
treatment groups (SAGE -324 60 mg daily, or placebo) in a 1:1 ratio.   
During the double-blind T reatment Period, s tarting on Day 1, participants will receive a single 
dose of investigational product (IP) once daily in the morning with food for 28 days on an 
outpatient basis (see Section  10.5) . Doses occurring on scheduled clinic visits will be 
administered in the clinic,  and doses occurring on all other days will be self -administered by the 
participant at home as specified in  Table 2. During the T reatment Period, participants will return 
to the study center approximately once per week for efficacy and safety assessments as specified 
in Table 2 . In addition, a phone call will be conducted once per week , preferably mid -way 
between clinic visits, to review current status of the participant.  
In addition to Kinesia ONE- specific training, c linical study center staff and study p articipants 
will be trained on the use of software applications and devices necessary to complete 
questionnaires or other assessments as required.  During in -clinic visits, clinical study center staff 
will be available to assist participants as needed , to ensure they can  access and use the software  
applications and devices  correctly according to the training . 
During the follow -up period, visits will be conducted on an outpatient basis. In addition to the 
phone calls to review current status, participants will receive a phone call approximately 7 days 
after the last dose of IP (ie, Day 35) for safety monitoring. Participants will return to the study 
center for an end of study visit approximately 14 days following the last dose of IP (ie, Day 42). 
Figure 1: Study Design 
Abbreviation:  EOT = end of treatment  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
27 7.2. Number of Participants 
Approximately 60 participants  are planned , with approximately 30 participants enrolled per arm, 
to produce 25  evaluable participants per arm  for primary efficacy  analysis. Additional 
participants may be randomized if the drop-out rate is higher than anticipated (ie, >15 %). 
7.3. Treatment Assignment 
Participants will be assigned to IP  (active or placebo) in accordance with the randomization 
schedule on Day 1. Additional details on randomization and blinding are provided in Section  9.5.  
7.4. Dose Adjustment Criteria  
If participants report adverse events that are considered by the investigator to be related to the IP 
and not tolerable , the investigator may reduce the dose of IP from 60 mg in 15 mg de crements 
(ie, 60, to 45, to 30 mg), as medically appropriate. The dose may not be reduced below 30 mg: if 
intolerable adverse events persist at the 30 mg dose, the IP should be per manently stopped. The 
reduced dose of IP will continue to be administered once daily at the same schedule as specified 
in the Schedule of Assessments (Table 2 ). The dose of IP may not be increased for the remainder 
of the study.  
Otherwise, IP doses will not be further adjusted for this study except as clinically necessary , eg, 
interrupting dose due to an AE or serious adverse event ( SAE ) considered related to IP . 
7.5. Criteria for Study Termination  
Sage Therapeutics may terminate this study or any portion of the study at any time for safety reasons including the occurrence of AEs or other findings suggesting unacceptable risk to 
participant s, or for administrative reasons . In the event of study termination, Sage Therapeutics 
will provide written notification to the investigator. Investigational sites must promptly notify 
their IRB, where required, and initiate withdrawal procedures for participa ting participants.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
28 8. SELECTION AND WITHDRAWAL OF PARTICIPANT S 
8.1. Participant Inclusion Criteria 
Participants must meet all of the following criteria to qualify for participation in this study: 
1. Participant has signed an ICF before any study-specific procedures or washout of drugs is 
performed. 
2. Participant  is ambulatory and is 18 to 80 years of age, inclusive, at the time informed 
consent is obtained.  
3. Participant has a diagnosis of ET, as defined by all of the following criteria:  
a. Isolated tremor syndrome consisting of bilateral upper limb action tremor 
b. At least 3 years duration  
c. With or without tremor in other locations (eg, head, voice, or lower limbs) 
d. Absence of other neurological signs, such as dystonia, ataxia, or parkinsonism, 
isolated focal tremors (eg, voice, head), task - and position -specific tremors, sudden 
tremor onset or evidence of stepwise deterioration of tremor  
4. Participant scores at least 1.5 for each of the six items that comprise the combined total 
upper limb  TETRAS (total performance subscale part 4) with the total score for the 
dominant upper limb (the sum of the three items for either the right or left upper limb, 
whichever is dominant ) being at least 5.5, at both Screening and predose on Day 1. 
5. Participant is willing to discontinue medications taken for the treatment of ET within 
14 days or 5 half- lives (whichever is longer) prior to receiving IP. Medications taken for 
the treatment of  ET that were discontinued prior to receiving IP may be resumed 
following Day 29. 
6. Participant is willing to discontinue the use of alcohol and products that contain nicotine 
within at least 1 week prior to Day 1 and through Day 29 of the study. 
7. Female part icipant agrees to use at least one method of highly effective contraception as 
listed in Section  9.2.4 during participation in the study and for 30 days following the last 
dose of study drug, unless she is postmenopausal (at least 12 months of spontaneous 
amenorrhea without an alternative medica l cause, with confirmatory follicle stimulating 
hormone >40 mIU/mL), and/or surgically sterile (bilateral oophorectomy, hysterectomy, 
and/or bilateral salpingectomy), or does not engage in sexual relations which carry a risk 
of pregnancy (does include abst inence).  
8. Male participant agrees to use an acceptable method of effective contraception for the 
duration of the study and for 13 weeks after receiving study drug, unless the participant 
does not engage in sexual relation(s) which carry a risk of pregnancy. Acceptable methods of effective contraception are listed in Section  9.2.4.  
9. Male participant is willing to abstain from sperm donation for the duration  of the study 
and for 13 weeks after receiving study drug. 
10. Participant has no clinically significant findings, as determined by the investigator, on 
Screening and predose Day 1 physical examination including mental state examination 
(MSE) and neurologic examination, 12-lead ECG, or screening clinical laboratory tests.   
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
29 8.2. Participant Exclusion Criteria  
Participant s who meet any of the following criteria are disqualified from participation in this 
study: 
1. Participant has presence of known causes of enhanced physiological tremor.  
2. Participant has had recent exposure (14 days prior to Day 1) to tremorgenic drugs or 
presence of alcohol withdrawal state.  
3. Participant has had direct or indirect injury or trauma to the nervous system within 3 
months before the onset of t remor.  
4. Participant has had a previous procedure for the treatment of ET, deep brain stimulation, brain lesioning, or magnetic resonance (MR) guided procedure, eg, MR-guided focused ultrasound. 
5. Participant has historical or clinical evidence of tremor with psychogenic origin 
(including but not limited to eating disorders, major depression, etc.) 
6. Participant has significant history and/or presence of hepatic, renal, cardiovascular, 
pulmonary, gastrointestinal, hematological, immunologic, ophthalmologic, metabolic 
(hypothyroidism with stable thyroid replacement is acceptable), or oncological disease.  
7. Participant has history of substance abuse prior to Screening  or has  a positive screen for 
drugs of abuse at Screening or predose on Day 1 or has a positive screen  for alcohol 
predose on Day 1. 
8. Participant has a known allergy to SAGE -324 or any excipient.  
9. Participant has had exposure to another investigational drug or device within 30 days or 5 half-lives (if known) of the investigational drug, whichever is longer, prior to the Day 1 visit.  
10. Participant has history or suicidal behavior within 2 years or answ ers â€œYESâ€ to questions 
3, 4, or 5 on the C- SSRS at Screening or at Day 1 or is currently at risk o f suicide in the 
opinion of the investigator. 
11. Participant has donated one or more units (1 unit = 450 mL) of blood or experienced 
acute loss of an equivalent amount of blood within 60 days prior to Day 1.  
12. Participant has any condition or comorbidity that in the opinion of the investigator would 
limit or interfere with the participantâ€™s ability to complete or partake in the study.  
13. Participant is unwilling or unable to comply with study procedures and required training. 
14. Participant has used any known moderate or strong cytochrome P450 3A4 inhibitors and/or inducers within 14 days or 5 half-lives (whichever is longer) prior to Day 1 or 
consumed grapefruit juice, grapefruit, Seville oranges, pomegranates, tangelos, or St. Johnâ€™s Wort or products containing these within 30 days prior to Day 1. Use of mild 
cytochrome inhibitors and/or inducers may be permitted.  
15. Participant has concurrent or recent expo sure (14 days or 5 half -lives, whichever is 
longer, prior to the Day 1 visit) to sedative/hypnotic drugs, stimulants, highly caffeinated 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
30 beverages or dietary supplements containing high doses of caffeine, or recent increase 
above regular daily consumption of caffeine . 
16. Participant plans to undergo elective surgery or relocate during participation in the study.  
17. Participant is investigative site personnel or a member of their immediate families (spouse, parent, child or sibling whether biological or legally adopted).  
18. [Removed] 
19. Female participant has a positive pregnancy test or confirmed pregnancy. 
8.3. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study but are not subsequently assigned IP or entered in the study, ie , a participant who does not meet 1 or 
more of the eligibility criteria  after providing consent  and prior to randomization  (Day 1). A 
minimal set of screen failure information will be collected, including demography, screen failure 
details, eligibility criteria, and any SAE.  
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened.  
8.4. Investigational Product Discontinuation and Early Termination from 
the Study  
8.4.1.  Investigational Product Discontinuation  
A participant may discontinue IP at any time at his/her own request for any reason. The 
investigator may discontinue a participant from IP for safety, behavioral, compliance, or 
administrative reasons. Participant s who discontinue IP will be encouraged by the i nvestigator to 
remain on study and complete the EOT visit, the safety phone call 7 days later, and then, after a 
further 7 days, the End of Study/ Early Termination visit (EOS/ETV) , as specified in the 
Schedul e of Assessments (Table 2 ). If the participant withdraw s consent to collect protected 
health information , the EOS/ETV will be conducted . 
The reason for IP discontinuation must be documented in the participantâ€™s study record and 
recorded in the participantâ€™s electronic case report form (eCRF).  
The investigator must notify the sponsor and/or the m edical monitor when a participant stops IP  
for any reason.  
Participant s who discontinue IP  due to an AE, regardless of i nvest igator -determined causality, 
should be followed until the event is resolved, considered stable, or the i nvestigator determines 
the event is no longer clinically significant.  
8.4.2.  Early Termination from the Study  
A participant may withdraw from the study at any time at his/her own request for any reason. 
The investigator may discontinue a participant from the study for safety, behavioral, compliance, 
or administrative reasons.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
31 The reason for early termination from the study must be documented in the participantâ€™s study 
record and recorded in the participantâ€™s electronic case report form (eCRF).  
The investigator must notify the sponsor and/or the m edical monitor when a participant stops 
participation in the study for any reason.  
If a participant is persistently noncompliant, the investigator should discuss with the sponsor the 
potential discontinuation of the participant. Any reasons for unwillingness or inability to adhere 
to the protocol must be recorded in the participantâ€™s eCRF, including: 
â€¢ missed visits;  
â€¢ interruptions in the schedule of study drug administration; 
â€¢ non-permitted medications  
If the participant withdraws from the study after completing 28 days of dosing with IP, they will 
be encouraged to attend follow -up visits for safety assessments at Day 35 and Day 42 , as 
specified in the Schedule of Assessments (Table 2 ). If the participant withdraw s their consent to 
collect protected health information , the EOS/ETV  visit will be conducted and t he participant 
will be permanently discontinued from the study at that time . 
If the participant withdraws consent for disclosure of future information, the sponsor will retain 
and continue to use any data collected before such a withdrawal of consent. 
If a participant withdraws from the stu dy, he/she may request destruction of any samples taken 
and not tested, and the i nvestigator must document this in the site study records.  
8.4.3. Loss to Follow- up 
A participant will be deemed lost to follow -up after 3 attempts at contacting the participant have 
been unsuccessful .  
8.4.4. Replacement of Participants  
Participants will not be replaced.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
32 9. TREATMENT OF PARTICIPANT S 
9.1. Description of Investigational Product  
SAGE -324 is an orally administered tablet provided in  5 mg or  15 mg (when available) dose 
strengths . Participants will receive IP (60 mg total dose of SAGE -324 tablets, or appearance-
matched placebo tablets) according to the randomization schedule. Additional details regarding 
IP preparation, formulation, and storage are included in Section  10. 
9.2. Prior Medications, Concomitant Medications, Restrictions, and 
Contraception Requirements  
9.2.1. Prior and Concomitant Medications and/or Supplements  
The start and end dates, route, dose/units, frequency, and indication for all medications and/or 
supplements taken within 30 days prior to signing the informed consent through the first dose of 
IP will be recorded .  
All medications and/or supplements taken from the firs t dose of IP  through the Day 42 (Â± 1 days) 
visit (including start and end dates route, dose/units, frequency, and indication) will be recorded 
on the eCRF. Any concomitant medication determined necessary for the welfare of the 
participant  may be given at the discretion of the investigator at any time during the study.  
9.2.2. Prohibited Medications  
Use or consumption of the following is prohibited for the timeframes specified:  
â€¢ Treatment with an investigational drug or device during the 30 days or 5 half- lives (if 
known) of the investigational drug, whichever is longer, prior to Day 1  or during the 
study.  
â€¢ Use of tremorgenic drugs within the 14 days or 5 half- lives (whichever is longer) of 
Day 1  or during the study. 
â€¢ Use of  agents known to affect SAGE -324 drug metabolism (any known cytochrome 
P450 3A4 inhibitors and/or inducers) within the 14 days or 5 half- lives (whichever is 
longer) of Day 1  and through Day 29 of the study period. Use of mild cytochrome P 
inhibitors and/or inducers may be permitted. 
â€¢ Concomitant use of sedative/hypnotic drugs for 14 days or 5 half-lives prior to Day 1 
and during the 28-day dosing period. 
9.2.3. Other Restrictions  
â€¢ Use of any drugs of abuse during the study period is prohibited. Note: participants 
with a history of drug abuse prior to screening should not be enrolled in the study. 
â€¢ Use of alcohol within 1 week prior to Day 1 and through Day 29 of the study period is prohibited . If the alcohol test is positive on Day s 1, 8, 15, 22, or 29, the participant 
will not be administered further IP and will be withdrawn from the study; no further 
efficacy assessments such as TETRAS will be undertaken.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
33 â€¢ Use of products that contain nicotine within 1 week prior to Day 1 and through 
Day 29 of the study period is prohibited. Positive cotinine testing on Days 1, 8, 15, 
22, or 29 would be considered a major  protocol deviation and the participant will be 
excluded from the Per Protocol Analysis Set. 
â€¢ Consumption of grapefruit juice, grap efruit, Seville oranges, pomegranates, tangelos, 
or St. Johnâ€™s Wort or products containing these within 30 days prior to Day 1 and through Day 29 of the study period is prohibited.  
â€¢ Use of stimulants, highly caffeinated beverages or dietary supplements con taining 
high doses of caffeine within 14 days prior to the Day 1 visit and through Day 29 of the study period is prohibited . Note: participants should not increase their regular 
daily consumption of caffeine during the study period.  
9.2.4. Acceptable Forms of Contraception  
Acceptable forms of highly effective contraception for participants of childbearing potential or 
for partners of male participants who are of childbearing potential include:  
â€¢ Combined (estrogen and progestogen containing) oral, intravaginal, or transdermal 
hormonal contraception associated with inhibition of ovulation  
â€¢ Oral, injectable, or implantable progestogen -only hormonal contraception associated 
with inhibition of ovulation  
â€¢ Intrauterine device  
â€¢ Intrauterine hormone -releasing  system  
â€¢ Bilateral tubal ligation  or bilateral tubal occlusion (performed at least 3 months prior 
to Screening)  
â€¢ Vasectomized partner  (performed at least 3 months prior to Screening)  
â€¢ Sexual abstinence (no sexual intercourse)  
Acceptable forms of contraception  for male participants include:  
â€¢ Sexual abstinence (no sexual intercourse)  
â€¢ History of vasectomy  (performed at least 3 months prior to Screening)  
â€¢ Condom with spermicide used together with highly effective female contraceptive methods if the female partner(s) is of childbearing potential (see above for list of 
acceptable female contraceptive methods)  
9.3. Intervention after the End of the Study  
There is n o planned intervention following the end of the study. 
9.4. Treatment Adherence  
The first dose of IP  will be received  and administered by participants in the clinic . Participants 
will be dispensed a 7-day supply of IP  to orally self- administer  at home with instructions 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
34 specifying to administer in the morning with food. Treatment adherence will be monitored by the 
site staff at each in -clinic visit by direct questioning and counting returned tablets  and will be 
documented. Details on drug accountability are included in Section  10.6.  
Patients will be asked to record the dates and times of their IP dose administrations at home in a 
diary. They will also record details around how well they complied with the study instructions 
for self-administering IP  at home. 
9.5. Randomization and Blinding 
This is a randomized, double-blind, placebo-controlled study. Participants will be randomized in 
a 1:1 ratio  to treatment group s (SAGE -324, 60 mg  or placebo). Participants, site staff, and the 
sponsor will be blinded to treatment allocation. Randomization schedules will be generated by an 
independent statistician . The randomization schedules will be kept strictly confidential, 
accessible only to authorized  pers onnel until the time of unblinding. The blinding of the study 
will be broken after the database has been locked.  
9.5.1. Emergency Unblinding  
During the study, the blind is to be broken only when the safety of a participant  is at risk and the 
treatment plan is de pendent on the study treatment received. Unless a participant is at immediate 
risk, the investigator should make diligent attempts to contact Sage prior to unblinding the study 
treatment administered to a participant. R equest s from the investigator about the treatment 
administered to study participant s should be discussed with the Sage  Medical Monitor . If the 
unblinding occurs without Sageâ€™s knowledge, the investigator must notify Sage within 24 hours of breaking the blind. All circumstances surrounding a premature unblinding must be clearly 
documented in the source records.  
In all cases where the IP allocation for a participant is unblinded, pertinent information 
(including the reason for unblinding) must be documented in the participantâ€™s records and on the 
eCRF.  
If a participant or any study personnel become unblinded to treatment, the participant will be 
excluded from the Per Protocol analysis set, as detailed further in the statistical analysis plan. 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
35 10. INVESTIGATIONAL PRODUCT  MATERIALS  AND 
MANAGEMENT  
10.1. Investigational Product 
Table 3: Investigational Product  
 Investigational Product 
Product Name:  SAGE -324 Placebo  
Dosage Form:  Tablet Tablet  
Tablet Strength  5 mg , 15 mg  0 mg, appearance-matched to 
5 mg, and 15 mg, respectively  
Route of Administration  Oral Oral 
Physical Description Immediate release white to off -
white, round, film -coated tablet 
containing 5 mg or 15 mg of 
SAGE -324 drug substance, and 
composed of lactose, 
microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate and fumed 
silica, featuring  OpadryÂ® II 
white as the coating agent.  White to off -white, round, film -
coated tablet containing no drug 
substance, composed of lactose, 
microcrystalline cellulose, 
croscarmellose sodium, sodium stearyl fumarate and fumed silica, featuring  OpadryÂ® II 
white as the coating agent.   
Manufacturer  Sage Therapeutics, Inc.  
10.2. Investigational Product Packaging and Labeling 
SAGE -324 Oral Tablets and Placebo Tablets will be  packaged in blinded, high density 
polyethylene (HDPE) containers.  The containers used for SAGE -324 and placebo will be 
identical in appearance.  The package labeling conforms to FDA and GMP requirements. 
10.3. Investigational Product Storage  
Upon receipt of the IP , the investigator, or the responsible pharmacist or designee, will inspect 
the product and acknowledge receipt in accordance with the study- specific process.  
The IP must be carefully stored at the temperature specified in the investigatorâ€™s brochure, 
securely and separately from other drugs. The IP  may not be used for any purpose other than the 
present study. Any  unused IP  must be returned per the sponsorâ€™s instructio ns or destroyed locally  
per the siteâ€™s procedure(s). IP may not be destroyed until accountability and reconciliation 
procedures have been completed  and monitored . 
The investigator or designee will be responsible for ensuring appropriate storage, dispensing, 
inventory, and accountability of the IP. An accurate, timely record of the disposition of the IP  
must be maintained.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
36 10.4. Invest igational Product Preparation  
The IP will be  in tablet form and  provided in blinded packaging. No preparation is required for 
the tablet , which is administered orally as described below . 
10.5. Invest igational Product Administration 
The IP will be administered in the clinic or at home as specified in the Schedule of Assessments 
(Table 2 ). The IP will be provided as tablets , sufficient in number to achieve a dose of 60 mg. IP  
will be orally administered once daily  in the morning, with food. Participants will be instructed 
to take the IP with food that comprises a minimum of 400 calories , and to take the IP at 
approximately the same time each morning .  
10.6. Invest igational Product Accountability , Handling, and Disposal  
Upon receipt of IP , the inves tigator(s), or the responsible pharmacist or designee, will inspect the 
IP and complete and follow the instructions regarding receipt and storage in the i nvestigatorâ€™s 
brochure and (where applicable) in the Pharmacy Manual. A copy of the shipping documenta tion 
will be kept in the study files.  
The designated site staff will dispense the supplied participant -specific kits to participants at the 
planned dispensation visit intervals outlined in the Schedule of Assessments ( Table 2 ). 
An interactive response technology (IRT) will be used to capture participant- identifying 
information. The IRT will be used to randomize the eligible participant into the study and 
provides the kit number of the IP to be dispensed to that participant.  
If dispensing errors or discrepancies are discovered by site staff or sponsorâ€™s designee, the 
sponsor must be notified immediately. The IP provided is for use only as directed in this protocol. The investigator or designee must 
keep a record of all IP  received, used and returned/discarded.  
Sage Therapeutics will be permitted access to the study supplies at any time with appropriate 
notice during or after completion of the study to perform drug accountability reconciliation.  The investigator, pharmacist, or qualified designee is responsible for drug accountability, 
reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records). At the end of the study, any unused IP  tablets will be returned to Sage Therapeutics for 
destruction or destroyed locally per the siteâ€™s procedures ; disposition of IP will be  documented. 
IP may not be destroyed until accountability and reconciliation procedures have been completed 
and monitored. 
10.7. Product Complaints  
A product complaint is any written, electronic, or verbal expression of dissatisfaction regarding the identity, quality, reliability, safety, purity, potency, effectiveness or performance (applicable for approved marketed products) of a drug product after it is released for distribution.  
In the course of conduct of the study, study personnel may become aware of a product complaint 
associated with the use of a Sage product. Personnel shall notify Sage within 24 hours by 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
37 forwarding the product complaint information via the contact information listed in Table 1  and in 
the Pharmacy Manual.  Where possible, personnel should segregate and retain  any product, 
materials, or packaging associated with the product complaint  until further instruction is 
provided by Sage or its designated representative(s) . 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
38 11. EFFICACY ASSESSMENTS AND CLINICAL PHARMACOLOGY 
ASSESSMENTS  
11.1. Efficacy Assessments  
11.1.1. The Essential Tremor Rating Assessment Scale 
TETRAS is a validated , comprehensive clinical assessment of essential tremor  (Elble 2013).  
Three different components of TETRAS will be assessed in this study. The TETRAS ADL 
subscale, total performance score, and performance subscale part 4 upper limb tremor  score will 
each be separately assessed  at each clinic visit as specified in the Schedule of Assessments 
(Table 2 ). 
The ADL subscale assesses how ET is impacting typical activities of daily living (ie, speech, 
eating, drinking, dressing, personal hygiene, writing, occupational impairment, social impact, 
and activities affected by upper limb tremor). It consists of 12 items that are  each  rated on a scale 
from 0  (normal activity)  to 4 (severe abnormality). The overall ADL score range is 0 to 48. 
The total performance score is based on overall rating  of tremor amplitude in the voice, limbs , 
head, face,  trunk, while performing pre -specified tasks, and also  measures functional task 
capabilities, ie, handwriting, spirography, and holding a pen over a dot. Each of these items is 
rated on a scale from 0  (no tremor) to 4 (severe tremor). Collectively, the performance items  
generate an  overall performance score from 0 to 64 .  
For the performance subscale part 4 upper limb tremor  score, a ll 3 maneuvers in the upper limb 
assessments of part 4 ( subscale items 4a, 4b, and 4c) will be completed for both arms, first for 
the right arm and then for the left. The part 4 subscale ordinally rates postural  (limbs extended 
forward  maneuver, and wing -beating  [elbows flexed] maneuver), and kinetic (finger-nose-finger 
maneuver) tremor on a 0 to 4  severity scale in 0.5- point increments.  
In this study, a videographer will videotape each TETRAS administration . 
11.1.2. Kinesia ONEâ„¢ Accelerometer Score 
Kinesia ONEâ„¢ is an ISO -certified wireless motion sensor worn distally on the index finger, 
which utilizes 3 orthogonal accelerometers and 3 orthogonal gyroscopes to monitor 3-dimensional motion. Data is transmitted wirelessly from the sensor to a Bluetooth technology -
enabled device to use with the Kinesia ONE software (eg,  Apple iPad or similar device with 
preinstalled Kinesia ONE software). The device has received FDA clearance.  
Via the Kinesia ONE software application, measures of 3-dimensional motion are converted to 
scores ranging from 0 to 4, per assessed maneuver; higher scores indicate greater tremor severity. Motion in both arms is captured. 
Participants will complete this assessment at each clinic visit as specified in the Schedule of 
Assessments (Table 2 ).  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
39 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
40 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
41 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
42 11.3. Other Patient- Reported Assessment s 
11.3.1. Patient Perception of Response Burden  
The Patient Perception of Response Burden Questionnaire is a patient -reported measure that 
assesses the multidimensional construct of response burden ( Atkinson 2019).  
Participants r espond to 6 items assessing 1) how well the questions related to their actual 
concerns, 2) how comfortable the participants were with answering the questions, 3) how well 
the survey characterized their health and well -being, 4) the length of time to comple te the 
questionnaires, 5) whether questions seemed unimportant or repetitive, and 6) what additional 
information should have been gathered. Items 1 to 3 are assessed on a 0 to 10 scale, item 4 is 
assessed on a 1 to 3 scale, and items 5 and 6 are open -ended. Items 1 and 4 are reverse scored. A 
composite score can be calculated to create a weighted representative index of relevance, 
comfort, and well-being relative to time to completion (ie, items 1, 2, and 3 were summed and 
multiplied by item 4) for a range of 0 to 72, with higher scores indicative of elevated endorsed 
response burden. The open- ended items will be summarized thematically. The Patient Perception 
of Response Burden Questionnaire will be performed as specified in the Schedule of Assessments (Table 2 ). 
 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
43 12. SAFETY ASSESSMENTS  
12.1. Safety Parameters  
All assessments will be conducted according to the Schedule of Assessments (Table 2 ). 
12.1.1. Demograph y and Medical History  
Demographic characteristics (age, race, sex, ethnicity) and a full medical history will be 
documented. Whether the participant is left -handed or right-handed w ill be recorded. This must 
also additionally include pa rticipant  recall of history of ET, disease duration, past treatments  
used, and responsiveness to alcohol and/ or other treatments  with use intended as off- label  
treatment of ET (eg, primidone or similar therapies). 
12.1.2. Weight and Height  
Height and weight wi ll be measured and documented . Body mass index (BMI) will be calculated 
and documented.  
12.1.3. Physical Examination  
Whenever possible, the same individual should perform all physical examinations . Phy sical 
examinations will include review  of systems (eg, head, eye, ear, nose and throat; heart; lungs; 
abdomen; and extremities) as well as comprehensive neurological examination and MSE. 
Unscheduled physical examinations may also be conducted per the Inves tigatorâ€™s discretion.  
Any abnormality in physical examinations will be interpreted by an investigator as abnormal, not 
clinically significant (NCS); or abnormal, clinically significant (CS) in source documents .  
12.1.4. Vital Signs  
Vital signs comprise blood pressure and heart rate  (supine and standing) , respiratory rate, and 
temperature. Systolic and diastolic blood pressure and heart rate are to be measured after the 
participant  has been supine for at least 5  minutes  and then repeated 1 minute and 3 minutes after 
standing.  
Vital signs are measured once at each timepoint with the exception of predose on Day 1, when 
blood pressure and heart rate are measured supine and standing in triplicate at least 15 minutes apart . 
Any abnormality in vital signs will be interpreted by an Investigator as abnormal, NCS; or abnormal, CS in source documents. 
12.1.5. Electrocardiogram  
A 12 -lead ECG will be performed . The standard intervals (heart rate, PR, QRS, QT, and QTcF ) 
as well as any rhythm abnormalities will be recorded.  
Electrocardiograms will be performed after the participant  has been resting in a supine position 
for at least 5 minutes. When ECG measurement s coincide with safety assessments, vital signs 
assessment or blood draws, procedures should be carried out in said order (vital signs , ECG, 
blood draw). 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
44 All abnormal ECGs wi ll be interpreted by an investigator as abnormal, NCS, or abnormal, CS in 
source documents. 
12.1.6. Laboratory Assessments  
Blood and urine samples for clinical labora tory assessments will be collected . Analytes to be 
evaluated are summarized in  Table  4. 
Table  4: Summary of Clinical Laboratory Analytes  
Biochemistry  Renal Panel : glucose, calcium, phosphorus, blood urea nitrogen, creatinine, 
sodium, potassium, chloride, bicarbonate  
Hepatic Panel : albumin, ALT, AST, total bilirubin, direct bilirubin, indirect 
bilirubin, alkaline phosphatase, total protein, lactate dehydrogenase, gamma 
glutamyl transferase  
Other: triglycerides, cholesterol (low density lipoprotein [LDL], high density lipoprotein [HDL]), creatine phosphokinase , thyroid stimulating hormone (TSH)  
Coagulation  activated partial thromboplastin time, prothrombin time, and international 
normalized ratio  
Hematology  red blood cell count, hemoglobin, hematocrit, white blood cell count with differential, platelet count, and if red blood count  indices are abnormal, reflex red 
blood cell  morphology a s indicated  
Urinalysis  protein, glucose, pH, blood, leukocyte este rase, urobilinogen, bilirubin, ketones, 
nitrite  
All clinical laboratory test results outside the reference range will be interpreted by the 
Investigator as abnormal, NCS; or abnormal, CS in source documents. 
Follicle stimulating hormone testing will be conducted to confirm whether a participant with 
â‰¥12 months of spontaneous amenorrhea meets the protocol- defined criteria for being 
postmenopausal ( Section  8.1).  
12.1.6.1. Drugs of Abuse, Alcohol, Nicotine  (Cotinine)  
A urine sample will be collected for assessment of the following selected drugs of abuse per the 
Schedule of Assessments  (Table 2 ): amphetamines, barbiturates, benzodiazepines, 
cannabinoids /THC, cocaine, methadone , MDMA, methamphetamines, opiates, oxycodone, 
tricyclic  antidepressants, and PCP . 
Urine samples will  be collected and tested for cotinin e. Either urine dipstick or breathalyzer will 
be used for alcohol testing. 
12.1.6.2. Pregnancy Screen  
A serum pregnancy test will be conducted for all female participants at Screening ; subsequently, 
a urine pregnancy t est will be conducted for all participants of childbearing potential as specified 
in the Schedule of Assessments (Table 2 ).  
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
 6DIHW\3KRQH&DOO
$SKRQHFDOOZLOOEHFRQGXFWHGRQFH SHUZHHNSUHIHUDEO\PLGZH HNLQEHWZHHQFOLQLFYLVLWVDV
VSHFLILHGLQ 7DEOHDQGDJDLQDW'D\WRFROOHFW LQIRUPDWLRQDERXWFXUUHQWKHD OWKVWDWXV
JHQHUDOZHOOEHLQJ,3FRPSOLDQFH RUWRJDWKHURWKHUSHUWLQHQW KHDOWKUHODWHGLQIRUPDWLRQDVSHU
LQYHVWLJDWRUMXGJHPHQW
$GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV
 $GYHUVH(YHQW'HILQLWLRQ
$Q$(LVDQ\XQWRZDUGPHGLFDORFFX UUHQFHLQDSDWLHQWRUFOLQLFDOLQYHVWLJDWLRQSDUWLFLSDQW
DGPLQLVWHUHGDSKDUPDF HXWLFDOSURGXFWDQGWKDWGRHVQRWQHFHVVD ULO\KDYHDFDXVDOUHODWLRQVKLS
ZLWKWKLVWUHDWPHQW$Q$(FDQWKHUHIRUHEHDQ\XQIDYRUDEOHDQG XQLQWHQGHGVLJQLQFOXGLQJDQ
DEQRUPDOODERUDWRU\ILQGLQJV\P SWRPRUGLVHDVHWHPSRUDOO\DVV RFLDWHGZLWKWKHXVHRID
PHGLFLQDOLQYHVWLJDWLRQDOSURGXFWZKHWKHURUQRWUHODWHGWRWKHPHGLFLQDOLQYHVWLJDWLRQDO
SURGXFW,QFOLQLFDOVWXGLHVD Q$(FDQLQFOXGHDQXQGHVLUDEOH PHGLFDOFRQGLWLRQRFFXUULQJDWDQ\
WLPHLQFOXGLQJEDVHOLQHRUZDVKRXWSHULRGVHYHQLIQRVWXG\W UHDWPHQWKDVEHHQDGPLQLVWHUHG
$7($(LVGHILQHGDVDQ$(ZLWKRQVHWDIWHUWKHVWDUWRI,3RUDQ\ZRUVHQLQJRIDSUHH[LVWLQJPHGLFDOFRQGLWLRQ$(ZLWKRQVHWDIWHUWKHVWDUWRI,3DQGWKURXJKRXWWKHVWXG\7KHWHUP,3LQFOXGHVDQ\6DJH,3DFRPSDUDWR URUDSODFHERD GPLQLVWHUHGL QDFOLQLFDOWULDO
/DERUDWRU\DEQRUPDOLWLHV DUHFRQVLGHUHG$(V
LIWKH\UHVXOWLQGLVFR QWLQXDWLRQRULQWHUUXSWLRQRIVWXG\WUHDWPHQWUHTXLUHWKHUDSHXWLFPHGLFDO
LQWHUYHQWLRQPHHWSURWRFROVSHFLILFFULWHULDLIDSSOLFDEOHR ULIWKHLQYHVWLJDWRUFRQVLGHUVWKHPWRPPD
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
EHFOLQLFDOO\VLJQLIL FDQW$Q\DEQRUPDOLWLHV WKDWPHHWWKHFULW HULDIRUDQ6$(VKRXOGEHUHSRUWHG
LQDQH[SHGLWHGPDQQHU/DERUDWRU\DEQRUPDOLWLHV 
WKDWDUHFOHDUO\DWWULEXWDEOHWRDQRWKHU$(GRQRWUHTXLUHGLV FUHWHUHSRUWLQJHJHOHFWURO\WH
GLVWXUEDQFHVLQWKHFRQWH[WRIGHK\GUDWLRQFKHPLVWU\DQGKHPDW RORJLFGLVWXUEDQFHVLQWKH
FRQWH[WRIVHSVLV
$OO$(VWKDWRFFXUDIWHUDQ\SDUWLFLSDQWK DVVLJQHGWKH,&)DQGWKURXJKRXWWKHGXUDWLRQRIWKH
VWXG\ZKHWKHURUQRWWKH\DUHUHODWHGWRWKHVWXG\PXVWEHUH SRUWHGWR6DJH7KHUDSHXWLFV
3DUWLFLSDQWVZKRGLVFRQWLQXHWKH,3GXHWRDQ$(UHJDUGOHVVRI LQYHVWLJDWRUGHWHUPLQHG
FDXVDOLW\VKRXOGEHIROORZHGXQWLOWKHHYHQWLVUHVROYHGFRQV LGHUHGVWDEOHRUWKHLQYHVWLJDWRU
GHWHUPLQHVWKHHYHQWLVQRORQJHUFOLQLFDOO\VLJQLILFDQW$Q\$ (VWKDWDUHXQUHVROYHGDWWKH
SDUWLFLSDQWÂ¶VODVW$(DVVHVVPHQWLQWKHVWXG\DUHIROORZHGXSE \WKHLQYHVWLJDWRUIRUDVORQJDV
PHGLFDOO\LQGLFDWHGEXWZLWKRXWI XUWKHUUHFRUGLQJLQWKHH&5) 7KHVSRQVRURULWVUHSUHVHQWDWLYH
UHWDLQVWKHULJKWWRUHTXHVWDGGL WLRQDOLQIRUPDWLRQIRUDQ\SDU WLFLSDQWZLWKRQJRLQJ$(V6$(V
DWWKHHQGRIWKHVWXG\LIMXGJHGQHFHVVDU\
 6HULRXV$GYHUVH(YHQW6$('HILQLWLRQ
$Q6$(LVDQ\XQWRZDUGPHGLFDORFFXUUHQFHWKDWDWDQ\GRVH
x5HVXOWVLQGHDWK
x3ODFHVWKHSDUWLFLSDQWDWLPPHGLDWHULVNRIGHDWKDOLIHWKUHD WHQLQJHYHQWKRZHYHU
WKLVGRHVQRWLQFOXGHDQHYHQWWKDWKDGLWRFFXUUHGLQDPRUH VHYHUHIRUPPLJKWKDYH
FDXVHGGHDWK
x5HTXLUHVLQSDWLHQWKRVSLWDOL]DWL RQRUSURORQJDWLRQRIH[LVWLQJ KRVSLWDOL]DWLRQ
x5HVXOWVLQSHUVLVWHQWRUVLJQLILFDQWGLVDELOLW\RULQFDSDFLW\
x5HVXOWVLQDFRQJHQLWDODEQRUPDOLW\RUELUWKGHIHFW
$Q6$(PD\DOVREHDQ\RWKHUPHGL FDOO\LPSRUWDQWHYHQWWKDWLQWKHRSLQLRQRIWKH,QYHVWLJDWRU
PD\MHRSDUGL]HWKHSDUWLFLSDQWRU PD\UHTXLUHPHG LFDOLQWHUYHQWLRQWRSUHYHQWRIWKHRXWFRPHV
OLVWHGDERYHH[DPSOHVRIVXFKHYHQWVLQFOXGHDOOHUJLFEURQFKRV SDVPUHTXLULQJLQWHQVLYH
WUHDWPHQWLQDQHPHUJHQF\URRP RUFRQYXOVLRQVRFFXUULQJDWKRPH WKDWGRQRWUHTXLUHDQ
LQSDWLHQWKRVSLWDOL]DWLRQ
$OO6$(VWKDWRFFXUDIWHUDQ\SDUWLFLSDQWKDVVLJQHGWKH,&)DQGWKURXJKRXWWKHGXUDWLRQRIWKH
VWXG\ZKHWKHURUQRWWKH\DUHUHODWHGWRWKHVWXG\PXVWEHUH FRUGHGRQWKH6$(UHSRUWIRUP
SURYLGHGE\6DJH7KHUDSHXWLFV$Q\6$(WKDWLVRQJRLQJZKHQWKH SDUWLFLSDQWFRPSOHWHVWKHLU
ILQDOVWXG\YLVLWZLOOEHIROORZHGE\WKHLQYHVWLJDWRUXQWLOW KHHYHQWKDVUHVROYHGVWDELOL]HG
UHWXUQHGWREDVHOLQHVWDWXVRUXQWLOWKHSDUWLFLSDQWGLHVRUL VORVWWRIROORZXS
$SUHVFKHGXOHGRUHOHFWLYHSURFHGXUHRUURXWLQHO\VFKHGXOHGWUH DWPHQWZLOOQRWEHFRQVLGHUHGDQ
6$(HYHQLIWKHSDUWLFLSDQW LVKRVSLWDOL]HG7KHVLWHPXVWGRF XPHQWDOORIWKHIROORZLQJ
x7KHSUHVFKHGXOHGRUHOHFWLYHSURFHG XUHRUURXWLQHO\VFKHGXOHGW UHDWPHQWZDV
VFKHGXOHGRURQDZDLWLQJOLVWWREHVFKHGXOHGSULRUWRREWDL QLQJWKHSDUWLFLSDQWÂ¶V
FRQVHQWWRSDUWLFLSDWHLQWKHVWXG\PPD
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
47 â€¢ The condition requiring the prescheduled or elective procedure or routinely scheduled 
treatment was present before and did not worsen or progress, in the opinion of an 
Investigator, between the participant â€™s consent to participate in the study and at the 
time of the procedure or treatment.  
12.2.3. Definition of Adverse Events of Special Interest  
There are no known adverse events of special inter est as of the date of signature approval of this 
clinical protocol.  
12.2.4. Relationship to Investigational Product 
The investigator must make the determination of relationship to the IP for each AE (not related, 
related ). The following definitions should be considered when evaluating the relationship of AEs 
and SAEs to the IP .  
Not Related  An AE will be considered â€œnot relatedâ€ to the use of the IP if there is not a reasonable 
possibility that the event has been caused by the IP. Factors pointing towards this 
assessment  include but are not limited to : the lack of temporal relationship between 
administration of the IP and the  event, the presence of biologically implausible 
relationship between the product and the AE, or the presence of a more likely 
alternative explanation for the AE 
Related  An AE will be considered â€œrelatedâ€ to the use of the IP if there is a reasonable 
possibility that the event may have been caused by the product under investigation. 
Factors that point towards this assessment include but are not limited to: a positive rechallenge, a reasonable temporal sequence between administration of the drug and 
the event, a known response pattern of the suspected drug, improvement following discontinuation or dose reduction, a biologically plausible relationship between the 
drug and the AE, or a lack of alternative explanation for the AE  
12.2.5. Recording Adverse Events  
AEs spontaneously reported by the participant  and/or in response to an open question from the 
study personnel or revealed by observation will be recorded during the study at the 
investigational site. The AE term should be reported in standard medical terminology  when 
possible. For each AE, the investigator will evaluate and report the onset (date and time), 
resolution (date and time), intensity, causality, action taken, outcome and seriousness (if 
applicable), and whether or not it caused the participant to discontinue the IP  or withdraw early 
from the study . 
Intensity will be assessed  according to the following scale: 
â€¢ Mild : symptom(s) barely noticeable to participant  or does not make participant 
uncomfortable; does not influence performance or functioning; prescription drug not 
ordinarily needed for relief of symptom(s)  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
48 â€¢ Moderate: symptom(s) of a sufficient severity to make participant uncomfortable; 
performance of daily activity is influenced; participant  is able to continue in study; 
treatment for symptom(s) may be needed  
â€¢ Severe: symptom(s) cause severe discomfort; symptoms cause incapacitation or 
significant impact on participantâ€™s daily life; severity may cause cessation of 
treatment with IP; treatment for symptom(s) may be given and/or participant 
hospitalized   
It is important to distinguish between serious and severe AEs . Severity is a measure of intensity 
whereas seriousness is defined by the criteria under Section  12.2.2. An AE of severe intensity 
may not necessarily be considered serious.  
12.2.6. Reporting Serious Adverse Events 
In order to adhere to all applicable laws and regulations for reporting an SAE(s), the study site must notify Sage or designee within 24 hours of the study site staff becoming aware of the 
SAE(s). The investigator must complete, sign and date the SAE report form, verify the accuracy 
of the information recorded on the SAE report form with the corresponding source documents, 
and send a copy to Sage or designee.  
Additional follow-up information, if required or available, should all be sent  to Sage or designee 
within 24 hours of receipt on a follow -up SAE report form and placed with the original SAE 
information and kept with the appropriate section of the eCRF and/or study file. 
SAEs occurring after the designated follow up time for the study, should be reported to Sage or 
designee according to the timelines noted above only if the i nvestigator considers the SAE 
related to IP .  
Sage , or designee, is responsible for notifying the relevant regulatory authorities of certain 
events. It is the principal investigatorâ€™s resp onsibility to notify the IRB/EC of all SAEs that occur 
at his or her site . Investigators will also be notified of all suspected unexpected serious adverse 
reactions  (SUSARs ) that occur during the clinical study. Each site is responsible for notifying its 
IRB of all  SUSARs .  
In addition, appropriate personnel in Sage  Drug Safety and Pharmacovigilance or designee will 
unblind SUSARs for the purpose of regulatory reporting. Sage  or designee will submit SUSARs 
(in blinded or unblinded fashion) to regulatory age ncies according to local law. Sage , or 
designee, will submit SUSARs to i nvestigators in a blinded fashion. 
12.3. Pregnancy 
If a participant becomes pregnant after the first administration of IP , pregnancy information must 
be collected and recorded on the pregnancy form and submitted to the sponsor within 24 hours of 
learning of the pregnancy. Details will be collected for all pregnancies for which conception was 
likely  to have occurr ed after the start of IP administration until 5 terminal half- lives following 
the last administration of IP  or until the completion of the study whichever is longer. Any 
pregnancy occurring in that time frame will be followed until delivery or termination of the 
pregnancy. The investigator will also attempt to collect pregnancy information on any 
participant â€™s partner who becomes pregnant after the participant has received the first 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
49 administration of IP . After obtaining the necessary signed informed consent from the pregnant 
partner directly, the investigator will follow the same pregnancy reporting procedures specified 
for pregnant participant s.  
The participant  or participant â€™s partner will be followed to determine the outcome of the 
pregnancy. The outcome of all preg nancies ( eg, spontaneous abortion, elective abortion, normal 
birth) must be followed and documented even if the participant was discontinued from the study. 
The investigator will collect follow -up information on the participant  or participantâ€™s partner and 
the neonate, and the information will be forwarded to Sage or designee. Generally, follow-up 
will not be required for longer than 6 to 8 weeks beyond the estimat ed delivery date. Any 
termination of pregnancy will be reported, regardless of fetal status (presence or absence of 
anomalies) or indication for the procedure. 
Pregnancy in itself is not regarded as an AE unless there is a suspicion that an IP  may have 
interfered with the effectiveness of a contraceptive medication. Any complication during 
pregnancy ( eg, anemia, infections, preeclampsia) should be reported as an AE/SAE. If the 
outcome of the pregnancy meets the criteria for immediate classification as an SA E (ie,  
spontaneous abortion, stillbirth, neonatal death), the investigator should follow the procedures 
for reporting an SAE.  
12.4. Overdose 
An overdose is any dose of IP  given to a participant or taken by a participant that exceeds the 
dose described in the protocol. Overdoses are not considered AEs and should not be recorded as 
an AE on the e CRF; however, all overdoses must be recor ded on an overdose form and sent to 
Sage or designee within 24 hours of the site becoming aware of the overdose. An overdose must be reported to Sage or designee even if the overdose does not result in an AE. If an overdose 
results in an AE, the AE must be recorded .  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
50 13. STATISTICS  
Detailed description of the analyses to be performed in the study will be provided in the 
statistical  analysis plan (SAP). The SAP will be finalized and approved prior to database lock. 
Any changes or additions to the SAP following database lock will be described in detail in the 
clinical study report. 
13.1. Data Analysis Sets  
The Randomized Set will include all participants who are randomized.  
The Safety Set will include all participants administered IP.  
The Full Analysis Set will include all randomized participant s who received any amount of IP  
and have a baseline and at least one postbaseline TETRAS performance subscale part 4 upper 
limb tremor score.  
 
 
The Per Protocol Set will include all participant s in the Full Analysis Set without any major 
protocol deviations that could affect efficacy. The review of major protocol deviations will be completed, and the decision on whether the deviation affects efficacy will be documented before database unblinding. Note that a positive cotinine te st on Days 1, 8, 15, 22 or 29 constitutes a 
major protocol deviation.  
13.2. Handling of Missing Data  
Every attempt will be made to avoid missing data . All participant s will be used in the analyses, 
as per the analysis populations, using all nonmissing data available. No imputation process will be used to estimate missing data .  
13.3. General Considerations  
All participant data, including those that are derived, that support the tables and figures will be 
presented in the participant data listings. Some data may be presented only in participant data listing, some may be presented with a corresponding table or figure; these will be indicated in 
relevant sections below. Participants will be summarized according to treatment received.  
For the purpose of all primary and secondary analyses where applicable, baseline is defined as the last measurement prior to receipt of IP .  
Continuous endpoints will be summarized with number (n), mean, standard deviation, median, minimum, and maximum. In addition, change from baseline values will be calculated at each time point and summarized descriptively. For categorical endpoints, descriptive summaries will 
include counts and percentages. 
13.4. Demographics and Baseline Characteristics  
Demographic data, such as age, race, and ethnicity, and baseline characteristics, such as height, weight, and BMI, will be summarized using the Safety Set .  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
51 Pregnancy test  results and drug screen results will be listed but not summarized .  
Medical history will be listed by participant .  
13.5. Efficacy Analysis  
The estimand for the primary efficacy analysis is the treatment difference between SAGE -324 
and placebo in mean cha nge from baseline in clinic -based TETRAS performance subscale part 4 
upper limb tremor  scores at Day 2 9 based on the Full Analysis Set. This will be analyzed using a 
mixed effects model for repeated measures (MMRM); the model will include treatment, baseline 
TETRAS performance subscale part 4 upper limb tremor score, assessment timepoint, and 
timepoint- by-treatment as explanatory variable s. All explanatory variables will be treated as 
fixed effects. All postbaseline clinic visits will be included in the model. The main comparison will be between SAGE -324 and placebo at the 29-day timepoint. Model- based point estimates 
(ie, least squares me ans, 5% confidence intervals, and p- values) will be reported where 
applicable. An unstructured covariance structure will be used to model the within- subject errors. 
If there is a convergence issue with the unstructured covariance model, Toeplitz compound symmetry or Autoregressive (1) [AR(1)] covariance structure will be used, following this 
sequence until convergence is achieved. If the model still does not converge with AR(1) structure, no results will be reported. When the covariance structure is not UN,  the sandwich 
estimator for the variance covariance matrix will be derived, using the EMPIRICAL option in 
the PROC MIXED statement in SAS.  
Similar to those methods described above for the primary endpoint, an MMRM will be used for 
the analysis of the chang e from baseline in TETRAS total performance score s, 
Kinesia ONE 
accelerometer  scores  and TETRAS ADL score s.  
Other efficacy analyses will be specified in the SAP. In general, data will be analyzed using 
appropriate descriptive statistics or prespecified statistical methods as applicable; participant  
listings will be provided for all efficacy data. Participants will be analyzed according to randomized treatment for the purpose of efficacy unless otherwise specified.  
Sensitivity analyses will be described in the S AP. 
13.6. Safety Analyses  
Safety and tolerability of SAGE -324 will be evaluated by AE s, concomitant medication usage, 
 
Safety data will be listed by participant  and summarized by treatment group . All 
safety summaries will be performed on the Safety Set using treatment received.   
13.6.1. Adverse Events  
AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 22.1 
or higher. A treatment- emergent adverse event (TEAE) is defined as an AE with onset after the 
first dose of IP . The analysis of AEs  will be based on the concept of TEAEs. The incidence of 
TEAEs will be summarized by System Organ Class (SOC) and preferred term. In addition, 
summaries will be provided by intensity (mild, moderate, severe) and by causality (related, not related) to IP.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
52 Any TEAEs leading to discontinuation of treatment or withdrawal from the study and any 
treatment- emergent SAEs  will be summarized.  
All AEs and SAEs (including those with onset or worsening before the start of IP ) through the 
end of the study will be listed.  
  
 
 
 
  
13.6.3. Physical Examinations  
The occurrence of a physical examination , including MSE, (yes/no) and the date performed will 
be listed by participant . 
13.6.6. Prior and Concomitant Medications 
Medications will be recorded at each study visit during the study and will be coded using World Health Organization -Drug dictionary (WHO -DD) September 2015, or later .  
All medications taken within 30 days prior to informed consent through the duration of the study 
will be recorded. In addition, all psychotropic medications taken in the previous 30 day s prior to 
screening will be recorded. Those medications taken prior to the ini tiation of the start of IP  will 
be denoted â€œPriorâ€. Those medications taken prior to the initiation of the IP and continuing 
beyond the initiation of the IP  or those medications started at the same time or after the initiation 
of the IP  will be denoted â€œConcomitantâ€.  
Medications will be presented according to whether they are â€œPriorâ€ or â€œConcomitantâ€ as defined above. If medication dates are incomplete and i t is not clear whether the medication was 
concomitant, it will be assumed to be concomitant.  
Details of prior and concomitant medications will be listed by participant, start date, and 
verbatim term.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
53 13.8. Sample Size  and Power 
The sample size of this study is based on the assumption of a 3 points difference in the change 
from baseline TETRAS performance subscale part 4 upper limb tremor score  between 
SAGE -324 and placebo with a standard deviation of 3.5 points. Under these assumptions, a 
sample size of 25 evaluable participants per group would provide 85% power for detecting a 
placebo -adjusted treatment difference of 3 points in TETRAS performance subscale part 4 upper 
limb tremor score assuming a 2- sided test at an alpha level  of 0.05. By including 2 treatment 
groups and using a 1:1 randomization, a total of 50 evaluable participants are required. Assuming 
a nonevaluability rate of 15%, approximately  60 participants  will be randomized.  Additional 
participants may be enrolled if the dropout rate is greater than 15%. 
13.8.1. Interim and Data Monitoring Committee (DMC) Analyses 
13.8.1.1. Interim Analysis  
The sponsor may conduct an interim analysis. Detailed descriptions of planned data analyses will 
be provided in a separate interim statistical analysis plan (SAP), if applicable . 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
54 13.8.1.2. DMC Analysis  
Not applicable 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
55 14. DIRECT ACCESS TO SOU RCE DATA/DOCUMENTS  
14.1. Study Monitoring  
Before an investigational site can enter a participant into the study, a representative of Sage 
Therapeutics will visit the investigational study site  per Sage SOPs  to: 
â€¢ Determine the adequacy of the facilities  
â€¢ Discuss with the investigator(s) and other personnel their responsibilities with regard to 
protocol adherence, and the responsibilities of Sage Therapeutics or its representatives . 
This will be documented in a Clinical Trial Agreement between Sage Therapeutics and 
the investigator.  
During the study, a monitor from Sage Therapeutics or representative will have regular contacts 
with the investigational site, for the following:  
â€¢ Provide information and support to the investigator(s)  
â€¢ Confirm that facilities remain acceptable  
â€¢ Confirm that the investigational team is adhering to the protocol, that data are being  
accurately recorded in the case report forms, and that IP accountability checks are being 
performed  
â€¢ Perform source data verification . This includes a comparison of the data in the case report 
forms with the participantâ€™s medical records at the hospital or  practice, and other records 
relevant to the study. This will require direct access to all original records for each 
participant  (eg, clinic charts).  
â€¢ Record and report any protocol deviations not previously sent to Sage Therapeutics. 
â€¢ Confirm AEs and SAEs have been properly documented on eCRFs and confirm any SAEs have been forwarded to Sage Therapeutics and those SAEs that met criteria for 
reporting have been forwarded to the IRB or EC. 
The monitor will be available between visits if the investigator(s) or other staff needs 
information or advice.  
14.2. Audits and Inspections  
Sage Therapeutics or authorized representatives of Sage Therapeutics, a regulatory authority, or an independent EC or an IRB may visit the site to perform an audit(s) or inspection(s), including 
source data verification . The purpose of a Sage Therapeutics audit or a regulatory authority 
inspection is to systematically and independently examine all study- related activities an d 
documents to determine whether these activities were conducted, and data were recorded, 
analyzed, and accurately reported according to the protocol, GCP/ICH GCP guidelines , and any 
applicable regulatory requirements . The investigator should contact Sage Therapeutics 
immediately if contacted by a regulatory agency  or IRB/EC  about an inspection. 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
56 14.3. Institutional Review Board or Ethics Committee 
The principal investigator must obtain IRB (or EC) approval for the clinical study  prior to 
enrolling a participant. Initial IRB (or EC) approval, and all materials approved by the IRB (or 
EC) for this study including the participant consent form and recruitment materials must be 
maintained by the investigator and made available for inspection. 
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
57 15. QUALITY C ONTROL AND QUALITY ASSURANCE 
To ensure compliance with Good Clinical Practice and all applicable regulatory requirements, 
Sage Therapeutics may conduct a quality assurance audit (s) at the clinical site . Please see 
Section  14.2  for more details regarding the audit process.  
The investigator must have adequate quality control practices to ensure that the study is 
performed in a manner consistent with the protocol, GCP/ICH GCP guidelines, and applicable 
regulatory requirements. The investigator is responsible for reviewing all ident ified protocol 
deviations. Significant protocol deviations should be reported to the IRB/EC per the IRB/ECâ€™s 
written procedures. 
The investigator is responsible for supervising any i ndividual or party to whom the investigator 
delegates trial-related duties  and functions conducted at the trial site. When the investigator 
retains the services of any individual or party to perform trial-related duties and functions, the 
investigator must ensure the individual or party is qualified to perform trial -related duties and 
functions and should implement procedures to ensure the integrity of the trial- related duties and 
functions performed, and any data generated.  
The investigator must maintain adequate and accurate source document s and trial records that 
include all pertinent observations on each of the siteâ€™s trial participants. Source data must be 
attributable, legible, contemporaneous, original, accurate, and complete. Changes to source data 
should be traceable, should not obscure the original entry, and should be explained, if necessary,  
to provide clarification . 
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
58 16. ETHICS  
16.1. Ethics Review  
The final study protocol, including the final version of the I CF, must be given a written and 
dated approval or favorable opinion by an IRB or EC as appropriate. The inves tigator must 
obtain and document approval before he or she can enroll any participant  into the study. The IRB 
or EC  must supply to the sponsor a list of the IRB /EC membership and a statement to confirm 
that the IRB /EC is organized and operates according to  GCP and applicable laws and 
regulations. 
The principal investigator is responsible for informing the IRB or EC of any amendment to the 
protocol in accordance with local requirements. In addition, the IRB or EC must approve all 
advertising used to recruit participants for the study. The protocol must be re-approved by the 
IRB or EC upon receipt of amendments and annually, as local regulations require. 
The principal investigator is also responsible for providing the IRB or EC with reports of any 
reportable s erious adverse drug reactions from any other study conducted with the IP. Sage 
Therapeutics will provide this information to the principal investigator.  
Progress reports and notifications of serious adverse drug reactions will be provided to the IRB 
or EC according to local regulations and guidelines. In addition, the prin cipal investigator must 
inform the IRB /EC and sponsor of any changes significantly affecting the conduct of the trial 
and/or increasing the risk to participants (eg, violations to the protocol or urgent safety measures 
taken for participant safety) . 
16.2. Ethical Conduct of the Study  
The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH  and GCP guidel ines, as well as all  
applicable regional or national regulatory requirements. 
16.3. Written Informed Consent 
Prior to enrolling a trial participant, t he investigator(s) will ensure that the participant  is given 
full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study. Participant s must also be notified that they are free to discontinue from the 
study at any time . The participant should be given the opportunity to ask questions and allowed 
time to consider the information provided.  
When the participant decides to participate in the trial, the participant (or the participantâ€™s, parent 
or legally authorized representative)  must provide  signed and dated informed consent. The 
written consent must be obtained before conducting any study procedures. The investigator must 
document the consent process in the participantâ€™s source records. The investigator  must maintain 
the original, si gned ICF . A copy of the signed ICF  must be given to the participant or to the 
participantâ€™s  parent or legal ly authorized representative. 
Throughout the trial participants should be informed of any changes made to the study  and as 
new safety and or risk information  becomes known . The provision of this information  will be 
documented in the participantâ€™s source records, and when applicable, an updated ICF will be 
provided. 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
59 17. DATA HANDLING AND RE CORDKEEPING  
17.1. Inspection of Records 
Sage Therapeutics or its representative(s) will be allowed to conduct site visit s at the 
investigation facilities for the purpose of monitoring any aspect of the study. The investigator 
agrees to allow the monitor to inspect the facility, drug storage area, drug accountability records, 
participant  charts and study source documents, and other records relative to study conduct. 
Inspection of the study by a regulatory authority may occur at any time. The investigator must 
agree to the inspection of study- related records and source documents by the regulatory authority 
representative (s).  
17.2. Retention of Records 
The principal investigator must maintain all documentation relating to the study for the period 
outlined in the site contract, or for a period of 2 years after the last marketing application 
approval, and until there are no pending or contemplated marketing application s in an ICH 
region or at least 2 years have elapsed since the formal discontinuation of clinical development 
of the investigational product. Sage is responsible to inform the investigator/institution as to 
when study documents no longer need to be retained.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
60 18. PUBLICATION POLICY 
All information concerning SAGE -324 is considered confidential and shall remain the sole 
property of Sage Therapeutics. The investigator agrees to use this information only in conducting 
the study and shall not use it for any other purposes without written approval from Sage 
Therapeutics. No publication or disclosure of study results will be permitted except as specified 
in a separate, written, agreement between Sage Therapeutics and the investigato r. 
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
/,672)5()(5(1&(6
$WNLQVRQ706FKZDUW]&(*ROGVWHLQ/HWDO$VVHVVPHQWVLQ2QFRORJ\9DOXHLQ+HDOWK

%HOHOOL'&DVXOD$/LQJ$/DPEHUW--7KHLQIOXHQFHRIVXEXQ LWFRPSRVLWLRQRQWKHLQWHUDFWLRQ
RIQHXURVWHURLGVZLWK*$%$$UHFHSWRUV1HXURSKDUPDFRORJ\
'HXVFKO*5DHWKMHQ-+HOOULHJHO+(OEOH57UHDWPHQWRISDWL HQWVZLWKHVVHQWLDOWUHPRU/DQFHW
1HXUR
(OEOH5%DLQ3)RUMD]0-HWDO7DVNIRUFHUHSRUWVFDOHVIR UVFUHHQLQJDQGHYDOXDWLQJWUHPRU
FULWLTXHDQGUHFRPPHQGDWLRQV0RY'LVRUG1RY 
*HQHWLFV+RPH5HIHUHQFH(VVHQWLDO7UHPRU/LVWHU+LOO1DWLRQDO &HQWHUIRU%LRPHGLFDO
&RPPXQLFDWLRQV861DWLRQDO/LEU DU\RI0HGLFLQH1DWLRQDO,QVWL WXWHVRI+HDOWK'HSDUWPHQWRI
+HDOWK	+XPDQ6HUYLFHV$YDLODEOHIURPKWWSVJKUQOPQLKJRYFRQGLWLRQHVVHQWLDOWUHPRU
$FFHVVHG6HSW
+RSIQHU)+DXEHQEHUJHU'*DOSHUQ:5HWDO.QRZOHGJHJDSVDQGUHVHDUFKUHFRPPHQGDWLRQV
IRUHVVHQWLDOWUHPRU3DUNLQVRQL VP5HODW'LVRUG
,QGHUDOÂŠSURSUDQROROK\GURFKORU LGH>SDFNDJHLQVHUW@3KLODGHOSKLD3$:\HWK
3KDUPDFHXWLFDOV,QF$FFHVVHGKWWSVZZZDFFHVVGDWDIGDJRYGU XJVDWIGDBGRFVODEHO VOEOSGI
.ROOHU:9HWHUH2YHUILHOG%$ FXWHDQGFKURQLFHIIHFWVRISURS UDQRORODQGSULPLGRQHLQ
HVVHQWLDOWUHPRU1HXURORJ\
/RXLV('2WWPDQ5+RZPDQ\SHRSOHLQWKH86$KDYHHVVHQWLDOW UHPRU"'HULYLQJD
SRSXODWLRQHVWLPDWHEDVHGRQHSLGH PLRORJLFDOGDWD7UHPRU2WKHU +\SHUNLQHW0RY1<
PPD
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 4 CONFIDENTIAL  
62 Olanow CW. Hyperkinetic Movement Disorders: Es sential Tremor. In: Harrison's Principles of 
Internal Medicine. Vol 2. 17th ed. New York, NY: McGraw Hill; 2008:2560. 
Zappia
 M, Albanese A, Bruno E, et al. T reatment of essential tremor: a systematic review of 
evidence and recommendations from the Italian Movement Disorders Association.  Epub 2012 
Aug 11. Review. Erratum in: J Neurol. 2013 Mar;260(3):741. 

 
1. TITLE PAGE A PHASE 2, DOUBLE -BLIND, PLACEBO -
CONTROLLED, RANDOMIZED STUDY EVALUATING 
THE EFFICACY, SAFETY, AND TOLERABILITY OF SAGE -324 IN THE TREATMENT OF INDIVIDUALS 
WITH ESSENTIAL TREMOR   
324-ETD -201  
 
Investigational Product  SAGE -324 Oral Table t  
Clinical Phase  Phase 2  
Sponsor  Sage Therapeutics , Inc.  
215 First Street 
Cambridge, MA 02142  
Sponsor Contact    
Phone : 
e-mail:  
Sponsor Medical Monitor  , MD, PhD  
Date of Original Protocol  23 October 2019  
Date of Amendment 1  20 December 2019  
Date of Amendment 2  24 February 2020  
Date of Amendment 3  10 June 2020  
Date of Amendment 4 17 December 2020  
 
 
Confidentiality Statement  
The confidential information in this document is provided to you as an investigator or consultant for 
review by you, your staff, and the applicable Institutional Review Board/Independent Ethics Committee . 
Your acceptance of this document constitutes agreem ent that you will not disclose the information 
contained herein to others without written authorization from Sage Therapeutics , Inc. 
 

Clinical Protocol Sage Therapeutics, Inc. 
324-ETD-201, Version 5 CONFIDENTIAL 
2 SPONSOR APPROVAL  
 
Protocol Number: 324-ETD-201 
Study Title: A Phase 2, Double-Blind, Placebo-Controlled, 
Randomized Study Evaluating the Efficacy, 
Safety, and Tolerability of SAGE-324 in the 
Treatment of Individuals with Essential Tremor 
Protocol Version and Date: Version 5, 17 December 2020  
 
 
 
 
 
_______________________________________________ ___________________________ 
Date 
 
 
 
 
 
_______________________________________________ ___________________________ 
, MD Date  
  
 
 
 
 
 
_______________________________________________ ___________________________ 
 MD Date  
 
  
DocuSign Envelope ID: F888EA4C-1D59-4EE2-89C0-33D8C6E572C6
18-Dec-2020 | 09:49 EST
18-Dec-2020 | 13:32 EST
17-Dec-2020 | 14:43 EST

Clinical Protocol Sage Therapeutics, Inc. 
324-ETD-201, Version 5 CONFIDENTIAL 
3  
 
 
 
 
_______________________________________________ ___________________________ 
Date  
 
 
 
 
 
_______________________________________________ ___________________________ 
, PhD Date  
 
 
 
 
 
 
______________________________________________ ___________________________ 
, PhD Date  
 
 
 
 
 
 
______________________________________________ ___________________________ 
 Date 
 
DocuSign Envelope ID: F888EA4C-1D59-4EE2-89C0-33D8C6E572C6
17-Dec-2020 | 14:19 EST
17-Dec-2020 | 15:19 EST
18-Dec-2020 | 12:07 EST
17-Dec-2020 | 14:16 EST

C ertifi c at e Of C o m pl eti o n
E n v el o p e I d: F 8 8 8 E A 4 C 1 D 5 9 4 E E 2 8 9 C 0 3 3 D 8 C 6 E 5 7 2 C 6 St at u s: C o m pl et e d
S u bj e ct: S A G E- E T D- 2 0 1 A m e n d m e nt 4 si g n at ur e p a g e v 2. p df
S o ur c e E n v el o p e: 
D o c u m e nt P a g e s: 2 Si g n at ur e s: 7 E n v el o p e Ori gi n at or: 
C ertifi c at e P a g e s: 3 I niti al s: 0
A ut o N a v: E n a bl e d
E n v el o p eI d St a m pi n g: E n a bl e d
Ti m e Z o n e: ( U T C- 0 5: 0 0) E a st er n Ti m e ( U S & C a n a d a)I P A d dr e s s:    
R e c or d Tr a c ki n g
St at u s: Ori gi n al
             1 7- D e c- 2 0 2 0 | 1 4: 0 5H ol d er: 
            L o c ati o n: D o c u Si g n
Si g n er E v e nt s Si g n at ur e Ti m e st a m p
S a g e T h er a p e uti c s - P art 1 1
S e c urit y L e v el: E m ail, A c c o u nt A ut h e nti c ati o n 
( R e q uir e d)Si g n at ur e A d o pti o n: Pr e- s el e ct e d St yl e
Si g n at ur e I D: 
A 0 A A C 4 E 8- 8 B 4 D- 4 3 6 C- A 2 1 1- 8 E 0 A C 6 D E B B 1 E
U si n g I P A d dr e s s: 
Wit h Si g ni n g A ut h e nti c ati o n vi a D o c u Si g n p a s s w or d
Wit h Si g ni n g R e a s o n s ( o n e a c h t a b): 
   I a p pr o v e t hi s d o c u m e ntS e nt: 1 7- D e c- 2 0 2 0 | 1 4: 0 8
Vi e w e d: 1 7- D e c- 2 0 2 0 | 1 4: 1 9 
Si g n e d: 1 7- D e c- 2 0 2 0 | 1 4: 1 9
El e ctr o ni c R e c or d a n d Si g n at ur e Di s cl o s ur e: 
      N ot Off er e d vi a D o c u Si g n
S a g e T h er a p e uti c s - P art 1 1
S e c urit y L e v el: E m ail, A c c o u nt A ut h e nti c ati o n 
( R e q uir e d)Si g n at ur e A d o pti o n: Pr e- s el e ct e d St yl e
Si g n at ur e I D: 
C 7 3 3 9 8 4 2- D 8 0 8- 4 F E E- A 2 F A- C 9 4 3 0 0 0 8 7 B C 1
U si n g I P A d dr e s s: 
Wit h Si g ni n g A ut h e nti c ati o n vi a D o c u Si g n p a s s w or d
Wit h Si g ni n g R e a s o n s ( o n e a c h t a b): 
   I a p pr o v e t hi s d o c u m e ntS e nt: 1 7- D e c- 2 0 2 0 | 1 4: 0 8
Vi e w e d: 1 7- D e c- 2 0 2 0 | 1 5: 1 8 
Si g n e d: 1 7- D e c- 2 0 2 0 | 1 5: 1 9
El e ctr o ni c R e c or d a n d Si g n at ur e Di s cl o s ur e: 
      N ot Off er e d vi a D o c u Si g n
S a g e T h er a p e uti c s - P art 1 1
S e c urit y L e v el: E m ail, A c c o u nt A ut h e nti c ati o n 
( R e q uir e d)Si g n at ur e A d o pti o n: Pr e- s el e ct e d St yl e
Si g n at ur e I D: 
4 C C D E 5 4 8- C 3 C A- 4 F 1 2- A E 6 0- B 1 5 F 6 F 5 9 0 0 A E
U si n g I P A d dr e s s: 
Wit h Si g ni n g A ut h e nti c ati o n vi a D o c u Si g n p a s s w or d
Wit h Si g ni n g R e a s o n s ( o n e a c h t a b): 
   I a p pr o v e t hi s d o c u m e ntS e nt: 1 7- D e c- 2 0 2 0 | 1 4: 0 8
R e s e nt: 1 8- D e c- 2 0 2 0 | 1 2: 0 4
Vi e w e d: 1 8- D e c- 2 0 2 0 | 1 2: 0 7 
Si g n e d: 1 8- D e c- 2 0 2 0 | 1 2: 0 7
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
5 CONTACT INFORMATION  
 
Table 1: E mergency Contact Information 
Role in Study  Name  Address and Telephone N umber  
Sage Study Physician  , MD Phone  
Sage Medical Monitor   , MD, PhD  Mobile:  
Office phone:  
E-mail:  
CRO Medical Monitor  and 
24-Hour Emergency Contact  , MD , 
MPH  Phone:  
E-
mail:  
SAE Reporting Information  IQVIA Lifecycle Safety   4820 Emperor Boulevard   
Durham, NC 27703  
E-mail: Sage.Safety@iqvia.com   
Fax: +1-855- 638-1674  
SAE Hotline: +1-855-564 -2229   
Product Complaints  Sage Therapeutics, Inc.  E-mail: productcomplaints@sagerx.com  
Phone: +1-833-554-7243  
 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
6 2. SYNOPSIS  
Name of Sponsor/Company:  
Sage Therapeutics, Inc. (hereafter referred to as Sage Therapeutics, or Sage)  
Name of Investigational Product: 
SAGE -324 Oral Tablet  
Name of Active Ingredient:  
SAGE -324 
Title of Study:  
A Phase 2, Double -blind, Placebo -controlled, Randomized Study Evaluating the Efficacy, Safety, and 
Tolerability of SAGE -324 in the Treatment of Individuals  with Essential Tremor  
Number of Sites and Study Location: This study will take place at  approximat ely 30 site s in the 
United States.  
Phase of D evelopment: Phase 2  
Planned Duration for each Study Participant:  
The duration of  participation (from Screening through the final follow -up visit) for each participant is 
estimated to be up to  71 days.  
Objectives and Endpoints : 
Objectives  Endpoints  
Primary   
To assess the effect of SAGE -324 compared to 
placebo on upper limb tremor reduction in 
individuals with essential tremor (ET) after 28 days of treatment  â€¢ Change from baseline compared to placebo in 
The Essential Tremor Rating Assessment (TETRAS) performance subscale part 4 upper limb tremor score on Day 29
 
Secondary   
To assess the effect of SAGE -324 compared to 
placebo on overall upper limb tremor reduction  â€¢ Change from baseline compared to placebo in 
TETRAS performance subscale part 4 upper limb tremor score at all other timepoints  
â€¢ Change from baseline compared to placebo in 
Kinesia ONE accelerometer scores  
To assess the effect of SAGE -324 compared to 
placebo on activities of daily living (ADLs)  â€¢ Change from baseline compared to placebo in 
TETRAS Scale ADL score  
To assess the effect of SAGE -324 compared to 
placebo on overall tremor  â€¢ Change from baseline compared to placebo in 
TETRAS total performance score  
To evaluate the safety and tolerability of SAGE -324 â€¢ Incidence of treatment-emergent adverse events 
(TEAEs)  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
7 Study Description : 
This is a randomized, double -blind, placebo -controlled, parallel group  study to evaluate the efficacy, 
safety, and tolerability of SAGE -324 in individuals with ET. Participants, site staff, and sponsor 
personnel will be masked to treatment allocation.  
This study includes a Screening Period of up to 28 days, a 29-day treatment period  (28 days of dosing) , 
and a 14 -day follow up period. After providing informed consent, participants will undergo screening 
assessments as outlined in Table 2  to determine eligibility.  
Screening Period: The Screening Period begins with the signing of the informed consent form (ICF). 
Eligible participants will visit the study center on Day 1 and complete additional eligibility  and baseline  
assessments, as specified in the Schedule of Assessments ( Table 2 ). Following completion of screening 
and Day 1  eligibility check s, participants will be randomized to 1 of 2 treatment groups ( SAGE -324 60 
mg daily , or placebo) in a 1:1 ratio.   
Double -Blind Treatment Period: Starting on Day 1, participants will receive a single dose of 
investigational product (IP) once daily for  28 days on an outpatient basis , to be taken  in the morning 
with food that comprises a minimum of 400 calories . Doses occurring on scheduled clinic visits will be 
administered in the clinic, and doses  occurring on all other days will be self-administered by the 
participant at home. During the Treatment Period, participants will return to the study center 
approximately once per week for efficacy and safety assessments as specified in  Table 2 . Participants 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
8 will be trained on the use of software applications and devices necessary to complete questionnaires or 
other assessments.  If on Day 1 or at any point during the treatment period participants experience 
moderate or severe AEs of somnolence, drowsiness, dizziness or similar, or have these events at any 
severity with associated symptoms such as confusion or balance impairment, they must have a dose 
interruption (drug holiday) of at l east 1 day (missing at least 1 dose). Following a drug holiday, the dose 
of study drug must then be reduced by 15 mg decrements to tolerability ( ie, from 60  mg to 45 mg to 
30 mg). The dose of IP may not be increased for the remainder of the study.  At the i nvestigatorâ€™s 
discretion, participants unable to tolerate the 30  mg dose may be discontinued from study drug. During 
the study, a phone call will be conducted at least once per week , preferably midw ay between clinic 
visits,  or as deemed appropriate by  the investigator, to review the current status of the participant .   
Follow -Up Period:  Follow -up visits will be conducted on an outpatient basis. Participants will continue 
to complete  questionnaires as indicated in Table 2  and will receive a phone call approximately 7 days 
after the last dose of IP (ie, Day 3 5) for safety monitoring. Participants will return to the s tudy center for 
an end of study  (EOS) v isit approximately 14 days following the last dose of IP (ie, Day 42). 
Number of Participants  (planned):  Approximately 60 participants, with approximately 30 per arm.  
Eligibility Criteria:  
Inclusion Criteria: 
1. Participant has signed an ICF before any study-specific procedures or washout of drugs i s 
performed. 
2. Participant is ambulatory and is 18 to 80 years of age, inclusive, at the time informed consent is 
obtained.  
3. Participant has a diagnosis of ET, a s defined by all of the following criteria:  
a. Isolated tremor syndrome consisting of bilateral upper limb action tremor 
b. At least 3 years duration  
c. With or without tremor in other locations (eg, head, voice, or lower limbs) 
d. Absence of other neurological signs, such as dystonia, ataxia, or parkinsonism , isolated 
focal tremors (eg, voice, head), task- and position-specific tremors, sudden tremor onset or 
evidence of stepwise deterioration of tremor  
4. Participant scores at least 1.5 for each of the six items that comprise the combined total upper 
limb TETRAS (total performance subscale p art 4)  with the total score for the dominant upper 
limb (the sum of the 3 items for either the right or left upper limb, whichever  is dominant) 
being at least 5.5, at both S creening and predose on Day 1. 
5. Participant is willing to  completely downtitrate  and discontinue  from medications taken for the 
treatment of ET at least  14 days or 5 half -lives (whichever is longer) prior to receiving  IP. 
Medications taken for the treatment of ET that were discontinued prior to receiving IP may be 
resumed following Day 29.   
6. Participant is willing to discontinue the use of alcohol and products that contain nicotine  within 
at least 1 week prior to Day 1  and through Day 29 of the study.   
7. Female participant agrees to use at least one method of highly effective contraception as listed 
in Section  9.2.4 during participation in the study and for 30 days following the last dose of 
study drug, unless she  is postmenopausal (at least 12 months of spontaneous amenorrhea 
without an alternative medical cause, with confirmatory follicle stimulating hormone 
>40 mIU/mL), and/or surgically sterile (bilateral oophorectomy, hysterectomy, and/or bilateral 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
9 salpingectomy), or does not engage in sexual relations which carry a risk of pregnancy (do es 
include abst inence).  
8. Male participant agrees to use an acceptable method of effective contraception for the duration 
of the study and for 13 weeks after receiving study drug, unless the participant does not engage 
in sexual relation(s) which carry a risk of pregnancy. Acceptable methods of effective 
contraception are listed in Section  9.2.4.  
9. Male participant is willing to abstain from sperm donation for the duration of the study and for 
13 weeks after receiving study drug.  
10. Participant has no clinically significant findings, as determined by the i nvestigator, on 
Screening and predose Day 1 physical examination  including mental state examination (MSE) 
and neurologic examination, 12 -lead ECG, or screening clinical laboratory tests.  
Exclusion Criteria:  
1. Participant has presence of known causes of enhanced physiological tremor.  
2. Participant has had recent exposure (14 days prior to Day 1) to tremorgenic drugs or presence of alcohol  withdrawal state.  
3. Participant has had direct or indirect injury or trauma to the nervous system within 3 months 
before the onset of tremor . 
4. Participant has had a previous procedure  for the treatment of ET, deep brain stimulation, brain 
lesioning, or magnetic resonance (MR) guided procedure, eg, MR -guided focused ultrasound. 
5. Participant has h istorical or clinical evidence of tremor with psychogenic origin (including but 
not limited to eating disorders, major depression, etc.) 
6. Participant has currently active, medically significant hepatic, renal, cardiovascular, pulmonary, 
gastrointestinal, hematological, immunologic, ophthalmologic, metabolic (hypothyroidism with 
stable thyroid replacement is acceptable), or oncological disease. 
7. Participant has history of substance abuse prior to Screening , has a positive screen for drugs of 
abuse at Screening or predose on Day 1 , or has a positive screen for alcohol or cotinine predose 
on Day 1. 
8. Participant has a k nown allergy to SAGE -324 or any excipient.  
9. Participant has had exposure to another investigational drug or device within 30 days  or 5 half -
lives (if known) of the investigational drug, whichever is longer,  prior to the Day 1 visit.  
10. Participant has h istory o f suicidal behavior within 2 years or answers â€œYESâ€ to questions 3, 4, 
or 5 on the C -SSRS at Screening or at Day 1 or is currently at risk of suicide in the opinion of 
the investigator . 
11. Participant has d onated one or more units (1 unit = 450 mL) of blood or experienced acute loss 
of an equivalent amount of blood within 60 days prior to Day 1.  
12. Participant has any condition or comorbidity that in the opinion of the investigator would limit 
or interfere with the participantâ€™s ability to complete or partake in the study.  
13. Participant is unwilling or unable to comply with study procedures  and required training. 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
10 14. Participant has used any known moderate or strong cytochrome P 450 3A4 inhibitors and/or 
inducers within 14 days or 5 half -lives (whichever is longer) prior to Day 1  or consumed 
grapefruit juice, grapefruit, Seville oranges, pomegranates, tangelos, or St. Johnâ€™s Wort or 
products containing these within 30 days prior to Day 1. Use of mild cytochrome inhibitors 
and/or inducers may be permitted.  
15. Participant has concurrent or recent exposure (14 days or five half -lives, whichever is longer, 
prior to the Day 1 visit) to sedative/hypnotic drugs, stimulants, highly caffeinated  beverages or 
dietary supplements containing high doses of caffeine , or recent increase above  regular daily  
consumption of caffeine . 
16. Participant plans to undergo elective surgery or relocate during participation in the study.  
17. Participant is investigative site personnel or a member of their immediate families (spouse, 
parent, child or sibling whether biological or legally adopted).   
18. [Removed ] 
19. Female p articipant has a positive pregnancy test  or confirmed pregnancy.  
Investigational Product  Dosage and Mode of Administration:  
SAGE -324 (60 mg) or matched placebo oral tablets will be administered in the clinic or self -
administer ed once  daily , in the morning, at approximately the same time each day , with food  that 
comprises a minimum of 400 calories .  
Duration of Treatment:  
Each participant will receive a single dose of SAGE -324 o ral tablets or matching placebo administered 
once  daily for 28 days.   
Statistical Methods:  
A separate statistical analysis plan (SAP) will provide a detailed description of the data analyses to be 
performed in the study. The SAP will be finalized and approved prior to database lock.  
General Considerations  
For the purpose of all efficacy and safety analyses where applicable, baseline is defined as the last 
measurement prior to the start of IP admini stration.  
Continuous endpoints will be summarized with number (n), mean, standard deviation, median, 
minimum, and maximum. In addition, change from baseline values will be calculated at each time point 
and summarized descriptively. For categorical endpoint s, descriptive summaries will include counts and 
percentages.  
Analysis Sets  
The Randomized Set is defined as all participants who are randomized.  
The Safety Set will include all participants who were administered IP.  
The Full Analysis Set will include all randomized participants who received any amount of IP and have 
a baseline and at least one postbaseline TETRAS performance subscale part 4 upper limb tremor score.  
 
The Per Protocol Set will include all participants in the F ull Analysis Set  without any major protocol 
deviations that could affect efficacy. The review of major protocol deviations will be com pleted, and 
the decision on whether the deviation affects efficacy will be documented before database unblinding.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
11 Determination of Sample Size  
The sample size of this study is based on the assumption of a 3 -point difference in the change from 
baseline TETRAS performance subscale part 4 upper limb tremor scores between  SAGE -324 and 
placebo with a standard deviation of 3.5 points. Under these assumptions, a sample size of 25 evaluable 
participants  per group would provide 85% power for detecting a placebo -adjusted treatment difference 
of 3 points in TETRAS performance subscale part 4 upper limb tremor score, assuming a  2-sided test at 
an alpha  level of 0.05. By including  2 treatment groups and using a 1:1 randomization, a total of 
50 evaluable participants  are required.  Assuming a nonevaluability rate of  15%, approximately 
60 participants will be randomized.  Additional participants  may be enrolled if the drop-out rate is hi gher 
than 15%.  
Analysis of Primary Efficacy Endpoint  
The estimand for the primary efficacy analysis is the treatment difference between SAGE -324 and 
placebo in mean change from baseline in clinic -based TETRAS performance subscale part 4 upper limb 
tremor s core at Day 2 9 based on the F ull Analysis Set. This will be analyzed using a mixed -effects 
model for repeated measures (MMRM); the model will include treatment, baseline TETRAS 
performance subscale part 4 upper limb tremor score , assessment timepoint, and timepoint-by- treatment 
as explanatory variables. All explanatory variables will be treated as fixed effects. All postbaseline 
clinic visits will be included in the model. The main comparison will be between SAGE -324 and 
placebo at the 2 9-day timepoint. Model-based point estimates (ie, least squares means, 95% confidence 
intervals, and p -values) will be reported where applicable. An unstructured covariance structure will be 
used to model the within -subject errors. If there is a convergence issue with the unstructured covariance 
model, Toeplitz compound symmetry or Autoregressive (1) [AR(1) ] covariance structure will be used, 
following this sequence until convergence is achieved. If the model still does not converge with AR(1) 
structure, no results will be reported. When the covariance structure is not unstructured , the sandwich 
estimator fo r the variance covariance matrix will be derived, using the EMPIRICAL option in the 
PROC MIXED statement in SAS.  
Analysis of Secondary Efficacy Endpoints  
Similar to those methods described above for the primary endpoint, an MMRM will be used to analyze 
of the change from baseline in TETRAS total performance score s, Kinesia ONE accelerometer scores 
and TETRAS ADL score s. Individual items of the TETRAS subscales will be summarized.  
Safety Analysis  
Safety and tolerability of study drug will be evaluated by incidence of TEAEs /serious adverse events, 
 
 
 
 
 
 
Interim Analysis  
The sponsor may conduct an interim analysis . Detailed descriptions of planned  data analyses will be 
provided in a  separate interim statistical analysis plan (SAP), if applicable .  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
12 Table 2: Schedule of Assessments  
Assessment Screening  Treatment Period  Follow -up Period  
Study Day  -28 to -1 1 5 (Â±1)  
Phone 
Call 8 (Â±1)  12 (Â±1) 
Phone 
Call 15(Â±1) 19 (Â±1) 
Phone 
Call 22 (Â±1)  26 (Â±1) 
Phone 
Call 29 (+1) 
EOT 
 35 (Â±1) 
Safety 
Phone Call  42 (Â±1) 
EOS/ETV  
Informed Consent X            
Inclusion/Exclusion  X X           
Demographics  X            
Medical History  X            
Pregnancy Test  X  
(serum;  all 
women ) X  
(urine ; 
WOCBP  
only)    
 X  
(urine ; 
WOCBP  
only)     X  
(urine ; 
WOCBP  
only)   X  
(urine ; 
WOCBP  only)  
FSH (postmenopausal 
women only)  X            
Randomizationa  X           
Alcohol /cotinine  screens   X  X  X  X  X   
Drug screen  X X           
Physical examinationb X X  X  X  X  X  X 
Neurological examination 
including MSEb X X  X  X  X  X  X 
Body height  X            
Body weight  X            
Vital signsc X X  X  X  X  X  X 
12-Lead ECGd X X  X  X  X  X  X 
Chemistry/hematology/  
coagulation/urinalysis  X X  X  X  X  X  X 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
13 Assessment Screening  Treatment Period  Follow -up Period  
Study Day  -28 to -1 1 5 (Â±1)  
Phone 
Call 8 (Â±1)  12 (Â±1) 
Phone 
Call 15(Â±1) 19 (Â±1) 
Phone 
Call 22 (Â±1)  26 (Â±1) 
Phone 
Call 29 (+1) 
EOT 
 35 (Â±1) 
Safety 
Phone Call  42 (Â±1) 
EOS/ETV  
Kinesia  ONEf X X  X  X  X  X  X 
TETRASg X X  X  X  X  X  X 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
14 Assessment Screening  Treatment Period  Follow -up Period  
Study Day  -28 to -1 1 5 (Â±1)  
Phone 
Call 8 (Â±1)  12 (Â±1) 
Phone 
Call 15(Â±1) 19 (Â±1) 
Phone 
Call 22 (Â±1)  26 (Â±1) 
Phone 
Call 29 (+1) 
EOT 
 35 (Â±1) 
Safety 
Phone Call  42 (Â±1) 
EOS/ETV  
Patient Perception of 
Response Burden          X  X 
Participant trainingh X X           
Dispense study drug  X   X  X  X     
IP administration  i  Administered once daily for 28 days  Not applicable  
AEs/SAEs X 
Prior and concomitant 
medication  and historyj X 
Abbreviations: ADL  = activities of daily living; AE  = adverse event;
; ECG  = electrocardiogram; EOS  = end of study; EOT  = end of treatment;  ; 
; ETV  = early termination visit; FSH = follicle stimulating hormone; HIV  = human immunodeficiency 
virus; ICF  = informed consent form; min  = minutes; IP = investigational product; MSE  = mental state examination;
; ; 
; ; SAE  = serious adverse event; TETRAS  = The Essential Tremor Rating Assessment 
Scale; WOCBP  = women of childbearing potential  
Note s:  
â€¢ The suggested order of assessments during clinic visits is: vital signs , TETRAS, Kinesia  ONE, ECG, blood sample collection for  and clinical 
laboratory assessments, and questionnaires . 
â€¢ All assessments will be performed predose  unless specified in a footnote . 
 
a Randomization  will occur on Day 1 after meeting all eligibility criteria.  
b Complete physical examinations (including MS E and comprehensive  neurologic examination) should be performed as specified and additionally as clinically 
necessary (see Section  12.1.3 ).  
c Predose on Day 1, supine and standing blood pressure and heart rate will be collected in triplicate at least 15 minutes apart, measur ed after the participant has 
been in the supine position for at least 5 minutes and then repeated 1 minute and 3 minutes after standing. Respiratory rate and temperature are collected once predose on Day 1. Vital signs will be collected once predose at all other visits. All postdose vital signs will be collected once at approximately 3 hours (Â±60 
min) after dosing . 
d ECGs will be collected and read centrally. ECGs will be performed predose and approximately 3 hours  (Â±60 min)  postdose. All ECGs must be performed after 
the participant has been in a supine position for at least 5 minutes.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
15  
f Kinesia ONE will be assessed subsequently to TETRAS P erformance subscale part 4 upper limb tremor .  
g The TETRAS Performance and TETRAS ADL subscales will be assessed at Screening and predose at each clinic visit. The TETRAS P erformance subscale 
part 4 upper limb tremor will be assessed before  Kinesia  ONE. In addition, on Day 15,  the TETRAS Performance  subscale will be assessed at 5 and 8 hours 
(Â±30 min) postdose . A videographer will record each TETRAS administration.  
h Participants will be trained by study personnel on the use of software applications , Investigational Product Diary,  and devices necessary for the conduct of the 
study.  
i On Day 1, participants will receive the first dose of IP  at the research site and  will be observed for AEs before leav ing the site. A phone call to follow up on any 
AE(s) will be conducted , if deemed  appropriate by the i nvestigator , to review the current status of the participant .  
j Prior medications will be recorded during Screening and will include all medications and supplements  taken within the 30 days prior to signing the ICF  through 
the first dose of IP , as well as a complete history of all treatments for ET since the year of di agnosis . Concomitant medications will be recorded thereafter 
throughout the duration of the study.  
   

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
16 3. TABLE OF CONTENTS  
1. TITLE PAGE ................................................................................................................1  
INVESTIGATORâ€™S AGREEMENT  ...............................................................................................4  
CONTACT INFORMATION  ..........................................................................................................5  
2. SYNOPSIS  ...................................................................................................................6  
3. TABLE OF CONTENTS  ...........................................................................................16  
LIST OF TABLES  .........................................................................................................................20  
LIST OF FIGURES  .......................................................................................................................20  
4. LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  .............................21  
5. INTRODUCTION  ......................................................................................................23  
5.1. Dose Justification  ........................................................................................................23  
5.2. Benefit/Risk Assessment  ............................................................................................24  
6. STUDY OBJECTIVES AND ENDPOINTS  ..............................................................25  
7. INVESTIGATIONAL PLAN  .....................................................................................27  
7.1. Overall Study Design  ..................................................................................................27  
7.2. Number of Participants  ...............................................................................................28  
7.3. Treatment Assignment  ................................................................................................28  
7.4. Dose Adjustment Criteria  ...........................................................................................28  
7.5. Criteria for Study Termination  ...................................................................................29  
8. SELECTION AND WITHDRAWAL OF PARTICIPANTS  .....................................30  
8.1. Participant Inclusion Criteria  ......................................................................................30  
8.2. Participant Exclusion Criteria  .....................................................................................31  
8.3. Screen Failures  ............................................................................................................32  
8.4. Investigational Product Discontinuation and Early Termination from the 
Study ...........................................................................................................................32  
8.4.1.  Investigational Product Discontinuation .....................................................................32  
8.4.2.  Early Termination from the Study  ..............................................................................32  
8.4.3.  Loss to Follow-up .......................................................................................................33  
8.4.4.  Replacement of Participants  .......................................................................................33  
9. TREATMENT OF PARTICIPANTS  .........................................................................34  
9.1. Description of Investigational Product .......................................................................34  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
17 9.2. Prior Medications, Concomitant Medications, Restrictions, and 
Contraception Requirements ......................................................................................34  
9.2.1.  Prior and Concomitant Medications and/or Supplements ..........................................34  
9.2.2.  Prohibited Medications  ...............................................................................................34  
9.2.3.  Other Restrictions  .......................................................................................................35  
9.2.4.  Acceptable Forms of Contraception  ...........................................................................35  
9.3. Intervention after the End of the Study  .......................................................................36  
9.4. Treatment Adherence  ..................................................................................................36  
9.5. Randomization and Blinding ......................................................................................36  
9.5.1.  Emergency Unblinding  ...............................................................................................36  
10. INVESTIGATIONAL PRODUCT MATERIALS AND MANAGEMENT  .............37  
10.1.  Investigational Product ...............................................................................................37  
10.2.  Investigational Product Packaging and Labeling .......................................................37  
10.3.  Investigational Product Storage  ..................................................................................37  
10.4.  Investigational Product Preparation  ............................................................................38  
10.5.  Investigational Product Administration  ......................................................................38  
10.6.  Investigational Product Accountability, Handling, and Disposal ...............................38  
10.7.  Product Complaints ....................................................................................................39  
11. EFFI CACY ASSESSMENTS AND CLINICAL PHARMACOLOGY 
ASSESSMENTS  .........................................................................................................40  
11.1.  Efficacy Assessments  .................................................................................................40  
11.1.1.  The Essential Tremor Rating Assessment Scale  ........................................................40  
11.1.2.  Kinesia ONEâ„¢ Accelerometer Score ..........................................................................40  
 41 
 41 
 41 
 41 
 42 
 42 
 42 
 43 
 43 
 43 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
18  43 
 43 
 43 
11.3.  Other Patient -Reported Assessments  ..........................................................................44  
11.3.1.  Patient Perception of Response Burden  ......................................................................44  
12. SAFETY ASSESSMENTS ........................................................................................45  
12.1.  Safety Parameters  .......................................................................................................45  
12.1.1.  Demography and Medical History ..............................................................................45  
12.1.2.  Weight and Height  ......................................................................................................45  
12.1.3.  Physical Examination  .................................................................................................45  
12.1.4.  Vital Signs  ..................................................................................................................45  
12.1.5.  Electr ocardiogram .......................................................................................................45  
12.1.6.  Laboratory Assessments  .............................................................................................46  
12.1.6.1.  Drugs of Abuse, Alcohol, Nicotine (Cotinine) ...........................................................46  
12.1.6.2.  Pregnancy Screen  ........................................................................................................46  
 47 
 47 
12.1.9.  Safety Phone Call  .......................................................................................................47  
12.2.  Adverse Events and Serious Adverse Events .............................................................47  
12.2.1.  Adverse Event Definition  ...........................................................................................47  
12.2.2.  Serious Adverse Event (SAE) Definition  ...................................................................48  
12.2.3.  Definition of Adverse Events of Special Interest  .......................................................49  
12.2.4.  Relationship to Investigational Product  ......................................................................49  
12.2.5.  Recording Adverse Events  .........................................................................................49  
12.2.6.  Reporting Serious Adverse Events .............................................................................50  
12.3.  Pregnancy ...................................................................................................................50  
12.4.  Overdose .....................................................................................................................51  
13. STATISTICS ..............................................................................................................52  
13.1.  Data Analysis Sets  ......................................................................................................52  
13.2.  Handling of Missing Data ...........................................................................................52  
13.3.  General Considerations  ...............................................................................................52  
13.4.  Demographics and Baseline Characteristics  ...............................................................52  
13.5.  Efficacy Analysis  ........................................................................................................53  

&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
  6DIHW\$QDO\VHV  
  $GYHUVH(YHQWV  
  
  3K\VLFDO([DPLQDWLRQV  
  
  
  3ULRUDQG&RQFRPLWDQW0HGLFDWLRQV  
  
  
  
  6DPSOH6L]HDQG3RZHU  
  ,QWHULPDQG'DWD0RQLWRULQJ&R PPLWWHH'0&$QDO\VHV  
  ,QWHULP$QDO\VLV  
  '0&$QDO\VLV  
 ',5(&7$&&(66726285&('$7$'2&80(176   
  6WXG\0RQLWRULQJ   
  $XGLWVDQG,QVSHFWLRQV  
  ,QVWLWXWLRQDO5HYLHZ%RDUGRU(WKLFV&RPPLWWHH   
 48$/,7<&21752/$1'48$/,7<$6685$1&(   
 (7+,&6   
  (WKLFV5HYLHZ   
  (WKLFDO&RQGXFWRIWKH6WXG\   
  :ULWWHQ,QIRUPHG&RQVHQW  
 '$7$+$1'/,1*$1'5(&25'.((3,1*   
  ,QVSHFWLRQRI5HFRUGV   
  5HWHQWLRQRI5HFRUGV   
 38%/,&$7,2132/,&<  
 /,672)5()(5(1&(6   

 PPD
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
20 LIST OF TABLES  
Table 1:  Emergency Contact Information  ...................................................................................5  
Table 2:  Schedule of Assessments  ............................................................................................12  
Table 3:  Investigational Product ...............................................................................................37  
Table  4: Summary of Clinical Laboratory Analytes  .................................................................46  
 
LIST OF FIGURES  
Figure 1:  Study Design ...............................................................................................................28  
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
21 4. LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  
 
Abbreviation  Definition  
AE adverse event  
ADL  activities of daily living  
ADR  adverse drug reaction  
AUC inf area under the curve from 0 to infinity  
AUC 0-tau area under the concentration-time curve from 0 to end of the dosing period 
BMI  body mass index  
  
Cmax maximum observed concentration  
CRO  contract research organization  
EC ethics committee  
ECG  electrocardiogram  
eCRF  electronic case report form  
EOS  End-of-Study  
  
  
ET essential tremor  
  
ETV  early termination visit 
FDA  Food and Drug Administration 
GCP  Good Clinical Practice  
GMP  Good Manufacturing Practice 
IB investigatorâ€™s brochure 
ICF informed consent form  
ICH International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use  
IP investigational product 
IRB institutional review board 
MedDRA  Medical Dictionary for Regulatory Activities  
  
PD pharmacodynamic 
  
PI principal investigator  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
22 Abbreviation  Definition  
PK pharmacokinetic 
PV Pharmacovigilance 
QTcF  QT corrected according to Fridericiaâ€™s formula  
SAE  serious adverse event  
SAP statistical analysis plan 
SOP standard operating procedure  
tÂ½  terminal elimination half- life  
TEAE  treatment- emergent adverse event  
TETRAS  The Essential Tremor Rating Assessment Scale  
tmax time of occurrence of C max 
WHO  World Health Organization 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
23 5. INTRODUCTION  
SAGE -324 is a positive allosteric modulator (PAM) of A -type Î³- aminobutyric acid -gated 
chloride channel (GABA A) receptors, the major class of inhibitory neurotransmitter receptors in 
the brain. In addition to being developed as an adjunctive therapy in epilepsy and other seizure 
disorders under IND 139201, SAGE -324 is also being developed for the treatment of Essential 
Tremor (ET).  
Essential tremor is a permanently debilitating, neurologically determined, common movement disorder characterized by involuntary rhythmi c oscillation of a body part due to intermittent 
muscle contractions typically occurring when not at rest, thus interfering with fine motor skills 
associated with daily activities (Olanow 2008, Deuschl 2011, Hopfner 2016, NIH 2019).  
Although the pathophysiology and etiology of ET is not fully understood, it is postulated that 
approximately 50% of ET patients feature an autosomal dominant pattern of familial inheritance 
and that non- inherited cases may have toxin -based or other causality ( Olanow 2008, Hopfner 
2016). ET is the most common movement disorder in the US, with prevalence estimated to be 
approximately 2.2% of the population, representing a substantial societal medical burden with 
over an estimated 7 million ET patients in the US alone ( Louis 2014).  
In general, active tasks of daily life are adversely impacted by ET, including but not limited to 
speech, handwriting, household tasks, and occupational demands, contributing negatively to 
psychosocial well-being, general anxiety, and overall quality of life  (Koller, 1989). Although 
benign in term of its effect on life expectancy, ET is a progressive neurodegenerative condition 
whose symptoms are typically disabling, often forcing patients to change jobs or seek early 
retirement ( Zapp ia, 2013). In some cases, serious disability may ensue.   
The pharmacological profile of SAGE -324 is theorized to  induce therapeutic effect in the 
treatment of ET. Based on preclinical studies of  SAGE -324, which features a different 
mechanism of action than  that of propranolol, the pharmacokinetic (PK)/ pharmacodynamic (PD) 
profile suggests SAGE -324 may safely ameliorate symptoms in patients suffering from ET, 
regardless of propranolol use . 
There are currently ongoing Phase 1 clinical studies of SAGE -324 in healthy adults and in adults 
with ET . These studies, in addition to preclinical studies of SAGE -324, are detailed in the 
investigatorâ€™s brochure. 
With a GABA
A receptor -based mechanism of action  featuring  positive allosteric modulation  
capability , SAGE -324 represents a novel approach to the treatment of ET, which may help 
address the unmet medical need of the ET population, warranting further study of SAGE -324 as 
a potential treatment for this common movement disorder.  
Henceforth, this double -blind, placebo-controlled efficacy and safety study of SAGE -324 will be 
conducted in adults and is designed to assess the effect of SAGE -324 on a variety of outcome 
measures specific to ET disease characteristics and associate d quality of life domains. 
5.1. Dose Justification  
The d ose of SAGE -324 planned for this study is 60 mg given as oral tablets, to be administered 
once daily in the morning with food. The dose w as selected based on preliminary data from 
3 active studies of SAGE -324, which included : unblinded data from completed cohorts in 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
24 324-CLP-101 Part A (oral solution SAGE -324 doses of 3 mg, 10 mg, 30 mg, 45 mg, 60 mg); 
Part C (oral solution SAGE -324 doses of 30 mg); Part D (oral suspension SAGE -324 doses of 
30 mg) in healthy subjects ; and preliminary data from open- label Part E (oral suspension 
SAGE -324 doses of 45 mg and 60 mg) in participants with ET; additional preliminary data from 
324-CLP-102 cohorts 1 through 6 (cohorts 1 to 5 unblinded, cohort 6 blinded) , which evaluated 
oral suspension doses ranging from 5 mg to 60 mg; and preliminary unblinded data from 
324-CLP-104, which compared the relative bioavailability of the oral tablet (30 mg) vs oral 
suspension (30 mg) formulations of SAGE -324 and separately the effect of food on the PK of the 
SAGE -324 oral tablet. In 324- CLP-101 and 324- CLP-102 studies , doses were administered in a 
fasted state. The preliminary data from all of these active studies collectively informed the route 
of administration (oral) and dose strength of 60 mg as oral tablets planned for further evaluation 
in this study .  
SAGE -324 w as generally well -tolerated in participants with ET and in healthy volunteers, as was 
shown in the preliminary data of 324- CLP-101 Part E at single administration doses of 45 mg 
and 60 mg, and in 324- CLP-102 through once- daily administered doses of up to 60 mg for 
14 days. In addition, tremor reduction was observed at both doses on TETRAS and Kinesia ONE 
accelerometry, with greater improvement seen at 60  mg compared to 45 mg.  
In the clinically complete  study 324- CLP-104, preliminary data showed that SAGE -324 oral 
tablets, when coadministered with a meal, resulted in exposures approximately equivalent to that of SAGE -324 oral suspension under fasted conditions. Therefore, the SAGE -324 oral tablets are 
recommended to be admi nistered with food.  
5.2. Benefit/Risk Assessment  
Based on the mechanism of action of SAGE -324 and the results of completed nonclinical studies 
and preliminary data of currently ongoing clinical studies of SAGE -324, it is theorized that 
participants  may have sym ptomatic amelioration, ie, tremor reduction and possibly improved 
quality of life from potentially stabilizing disease characteristics associated with ET. 
Potential risks anticipated in this study are based on available data from toxicology studies of SAGE -324 in addition to preliminary data from 3 ongoing, currently active Phase 1 clinical 
studies of SAGE -324.  
Available preliminary clinical data are summarized in the SAGE -324 Investigatorâ€™s Brochure.  
There have been no deaths or SAEs related to IP , and based on the preliminary clinical data 
available, there have been  no confirmed  clinically significant trends in clinical laboratory 
evaluations, vital signs, or physical examinations.  
Based on available preliminary clinical data from SAGE -324 active clinical studies, AEs of 
somnolence and feeling of relaxation are considered adverse drug reactions (ADRs) . In addition 
to scheduled clinic visits, the current status of study participants will be reviewed via phone calls 
in between clinic visits , or more frequen tly for AE monitoring . 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
25 6. STUDY  OBJECTIVES AND ENDPOINTS  
Objectives  Endpoints  
Primary   
To assess the effect of SAGE -324 compared to 
placebo on upper limb tremor reduction in 
individuals with essential tremor (ET) after 
28 days of treatment  â€¢ Change from baseline compared to placebo in 
The Essential Tremor Rating Assessment (TETRAS) performance subscale part 4 upper limb tremor score on Day 29  
Secondary   
To assess the effect of SAGE -324 compared to 
placebo on overall upper limb tremor reduction  â€¢ Change from baseline compared to placebo in 
TETRAS performance subscale part 4 upper limb tremor score at all other timepoints  
â€¢ Change from baseline compared to placebo in 
Kinesia ONE accelerometer scores  
To assess the effect of SAGE -324 compared to 
placebo on activities of daily living (ADLs)  â€¢ Change from baseline compared to placebo in 
TETRAS Scale ADL score  
To assess the effect of SAGE -324 compared to 
placebo on overall tremor  â€¢ Change from  baseline compared to placebo in 
TETRAS total performance score  
To evaluate the safety and tolerability of SAGE -324 â€¢ Incidence of treatment-emergent adverse events (TEAEs)  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
26  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
27 7. INVESTIGATIONAL PLAN  
7.1. Overall Study Design 
This is a randomized, double -blind, placebo-controlled, parallel group study to evaluate the 
efficacy, safety, and tolerability of SAGE -324 in individuals with ET. Participants, site staff, and 
sponsor personnel will be masked to treatment allocation  (see Section  9.5). 
This study includes a Screening Period of up to 28 days, a 29-day treatment period consisting of 
28 days of dosing with the end of treatment visit intended to be on Day 29 at trough, and a 14-day follow-up period relative to final dose  (Figure 1). After providing informed consent, 
participants will undergo screening assessments as outlined in Table 2  to determine eligibility .  
The Screening Perio d begins with the signing of the informed consent form (ICF). Eligible 
participants will visit the study center on Day 1 and complete additional eligibility assessments 
of safety and efficacy, as specified in the Schedule of Assessments ( Table 2 ). Following 
completion of screening and Day 1 eligibility checks, participants will be randomized to 1 of 
2 treatment groups (SAGE -324 60 mg daily, or placebo) in a 1:1 ratio.   
During the double-blind T reatment Period, s tarting on Day 1, participants will receive a single 
dose of investigational product (IP) once daily in the morning with food for 28 days on an 
outpatient basis (see Section  10.5) . Doses occurring on scheduled clinic visits will be 
administered in the clinic,  and doses occurring on all other days will be self -administered by the 
participant at home as specified in Table 2. During the T reatment Period, participants will return 
to the study center approximately once per week for efficacy and safety assessments as specified 
in Table 2 . If on Day 1 or at any point during the treatment period, participants experience 
moderate or severe AEs of somnolence, drowsiness, dizziness or similar, or experience these 
events at any severity with associated symptoms such as confusion or balance impairment , they 
must have a dose interruption (drug holiday) of at least 1 day (missing at least 1 dose). Following a drug holiday, the dose of study drug must then be reduced by 15 mg decrements to tolerability (ie, from 60  mg to 45 mg to 30 mg). The dose of IP may not be increased for the remainder of 
the study. At the investigatorâ€™s discretion, participants unable to tolerate the 30- mg dose will be 
discontinued from IP. During the study, a phone call will be conducted once per week, preferably 
midw ay between clinic visits,  or more frequently if deemed appropriate by the investigator, to 
review the current status of the participant.  Details regarding dose adjustment criteria and procedures are provided in Section  7.4. 
In addition to Kinesia ONE- specific training, c linical study center staff and study p articipants 
will be trained on the use of software applications and devices necessary to complete 
questionnaires or other assessments as required.  During in -clinic visits, clinical study center staff 
will be available to assist participants as needed , to ensure they can  access and use the software  
applications and devices  correctly according to the training . 
During the follow -up period, visits will be condu cted on an outpatient basis. In addition to the 
phone calls to review current status, participants will receive a phone call approximately 7 days 
after the last dose of IP (ie, Day 35) for safety monitoring. Participants will return to the study center for an end of study visit approximately 14 days following the last dose of IP (ie, Day 42). 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
28 Figure 1: Study Design
Abbreviation:  EOT = end of treatment  
7.2. Number of Participants 
Approximately 60 participants  are planned , with approximately 30 participants enrolled per arm, 
to produce 25  evaluable participants per arm  for primary efficacy  analysis. Additional 
participants may be randomized if the drop-out rate is higher than anticipated (ie, >15 %). 
7.3. Treatment Assignment 
Participants will be assigned to IP  (active or placebo) in accordance with the randomization 
schedule on Day 1. Additional details on randomization and blinding are provided in Section  9.5. 
7.4. Dose Adjustment Criteria 
If a part icipant reports moderate or  severe adverse eve nts (as defined i n Section  12.2.5 ) of 
somnolen
ce, drowsiness, dizziness, o r similar eve nts or expe riences th ese events at an y seve rity 
with associated symptom s such as confusion  or balance impairment  on Day 1 or at any point 
during the treatment period, the participant must 
have a drug holiday (dose interruption) of at 
least 1 d ay (missing at least 1 dose) (Table 2 ). The drug holiday must be followed by reducing 
the dose of IP from 60 mg to 45 mg (i e, from 4 tablets of 15 mg to 3 tablets of 15 mg).   
If the events persist and continue to be moderate or severe, despite the drug holiday and dose 
reduction, or the participant experi ences a new moderate or severe AE of somnolence, 
drowsiness, dizziness or similar, the participant must have a further drug holiday  of at least 1 
day and a further dose reduction from 45 mg to 30 m g (from 3 t ablets 
to 2 tablets).  
The participantâ€™s condition must be closely monitored via phone calls or in-person visits to 
assess the impact of any drug holiday and dose reduction. 
The reduced dose 
of IP will continue to be administered once daily at the same schedule as 
specified in
 the Schedule of Assessments (Table 2). The dose of IP may not be increased for the 
remainder of the study.  
Following a second drug holiday and dose reduction 
to 30 m g, if the events persist or recur and 
are 
moderate or severe, the 
investigator must discontinue the participant from the IP. The dose 
may not be reduced below 30 mg. 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
29 The investigator will continue to institute drug holidays, dose reductions, or IP discontinuation 
over and above this minimum as clinically appropriate.  
7.5. Criteria for Study Termination  
Sage Therapeutics may terminate this study or any portion of the study at any time for safety 
reasons including the occurrence of AEs or other findings suggesting unacceptable risk to 
participant s, or for administrative reasons . In the event of study termination, Sage Therapeutics 
will provide written notification to the investigator. Investigational sites must promptly notify 
their IRB, where required, and initiate withdrawal procedures for participating participants.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
30 8. SELECTION AND WITHDRAWAL OF PARTICIPANT S 
8.1. Participant Inclusion Criteria 
Participants must meet all of the following criteria to qualify for participation in this study: 
1. Participant has signed an ICF before any study -specific procedures or washout of drugs is 
performed. 
2. Participant  is ambulatory and is 18 to 80 years of age, inclusive, at the time informed 
consent is obtained.  
3. Participant has a diagnosis of ET, as defined by all of the following criteria:  
a. Isolated tremor syndrome consisting of bilateral upper limb action tremor 
b. At least 3 years duration  
c. With or without tremor in other locations (eg, head, voice, or lower limbs) 
d. Absence of other neurological signs, such as dystonia, ataxia, or parkinsonism, 
isolated focal tremors (eg, voice, head), task - and position -specific tremors, sudden 
tremor on set or evidence of stepwise deterioration of tremor  
4. Participant scores at least 1.5 for each of the six items that comprise the combined total 
upper limb  TETRAS (total performance subscale part 4) with the total score for the 
dominant upper limb (the sum of the three items for either the right or left upper limb, 
whichever is dominant) being at least 5.5, at both Screening and predose on Day 1. 
5. Participant is willing to completely downtitrate and discontinue from medications taken 
for the treatment of ET at least  14 days or 5 half- lives (whichever is longer) prior to 
receiving IP.  Medications taken for the treatment of ET that were discontinued prior to 
receiving IP may be resumed following Day 29. 
6. Participant is willing to discontinue the use of alcohol and products that contain nicotine within at least 1 week prior to Day 1 and through Day 29 of the study. 
7. Female participant agrees to use at least one method of highly effective contraception as 
listed in Section  9.2.4 during participation in the study and for 30 days following the last 
dose of study drug, unless she is postmenopausal (at least 12 months of spontaneous amenorrhea without an alternative medical cause, with confirmatory follicle stimulating hormone >40 mIU/mL), and/or surgically sterile (bilateral oophorectomy, hysterectomy, 
and/or bilateral salpingectomy), or does not engage in sexual relations which carry a risk 
of pregnancy (does include abstinence).  
8. Male participant agrees to use an acceptable method of effective contraception for the 
duration of the study and for 13 weeks after receiving study drug, unless the participant 
does not engage in sexual relation(s) which carry a risk of pregnancy. Acceptable methods of effective contraception are listed in Section  9.2.4.  
9. Male participant is willing to abstain from sperm donation for the duration of the study 
and for 13 weeks after receiving study drug. 
10. Participant has no clinically significant findings, as determined by the investigator, on 
Screening and predose Day 1 physical examination including mental state examination 
(MSE) and neurologic examination, 12-lead ECG, or screening clinical laboratory tests.   
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
31 8.2. Participant Exclusion Criteria  
Participant s who meet any of the following criteria are disqualified from participation in this 
study: 
1. Participant has presence of known causes of enhan ced physiological tremor.  
2. Participant has had recent exposure (14 days prior to Day 1) to tremorgenic drugs or 
presence of alcohol withdrawal state.  
3. Participant has had direct or indirect injury or trauma to the nervous system within 3 
months before the onset of tremor.  
4. Participant has had a previous procedure for the treatment of ET, deep brain stimulation, brain lesioning, or magnetic resonance (MR) guided procedure, eg, MR-guided focused ultrasound. 
5. Participant has historical or clinical evidence of tremor with psychogenic origin (including but not limited to eating disorders, major depression, etc.) 
6. Participant has currently active, medically
 significant hepatic, renal, cardiovascular, 
pulmonary, gastrointestinal, hematological, immunologic, ophthalmologic, metabolic (hypothyroidism with stable thyroid replacement is acceptable), or oncological disease.  
7. Participant has history of substance abuse prior to Screening  or has  a positive screen for 
drugs of abuse at Screening or predose on Day 1 or has a positi ve screen for alcohol or 
cotinine  predose on Day 1. 
8. Participant has a known allergy to SAGE -324 or any excipient.  
9. Participant has had exposure to another investigational drug or device within 30 days or 5 half-lives (if known) of the investigational drug, whichever is longer, prior to the Day 1 visit.  
10. Participant has history or suicidal behavior within 2 years or answ ers â€œYESâ€ to questions 
3, 4, or 5 on the C- SSRS at Screening or at Day 1 or is currently at risk o f suicide in the 
opinion of the investigator. 
11. Participant has donated one or more units (1 unit = 450 mL) of blood or experienced 
acute loss of an equivalent amount of blood within 60 days prior to Day 1.  
12. Participant has any condition or comorbidity that in the opinion of the investigator would 
limit or interfere with the participantâ€™s ability to complete or partake in the study.  
13. Participant is unwilling or un able to comply with study procedures and required training. 
14. Participant has used any known moderate or strong cytochrome P450 3A4 inhibitors and/or inducers within 14 days or 5 half-lives (whichever is longer) prior to Day 1 or 
consumed grapefruit juice, grapefruit, Seville oranges, pomegranates, tangelos, or St. Johnâ€™s Wort or products containing these within 30 days prior to Day 1. Use of mild 
cytochrome inhibitors and/or inducers may be permitted.  
15. Participant has concurrent or recent exposure (14 days or 5 half -lives, whichever is 
longer, prior to the Day 1 visit) to sedative/hypnotic drugs, stimulants, highly caffeinated 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
32 beverages or dietary supplements containing high doses of caffeine, or recent increase 
above regular daily consumption of caffeine . 
16. Participant plans to undergo elective surgery or relocate during participation in the study.  
17. Participant is investigative si te personnel or a member of their immediate families 
(spouse, parent, child or sibling whether biological or legally adopted).  
18. [Removed] 
19. Female participant has a positive pregnancy test or confirmed pregnancy. 
8.3. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study but are not subsequently assigned IP or entered in the study, ie , a participant who does not meet 1 or 
more of the eligibility criteria  after providing consent  and prior to randomization  (Day 1). A 
minimal set of screen failure information will be collected, including demography, screen failure 
details, eligibility criteria, and any SAE.  
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened.  
8.4. Investigational Product Discontinuation and Early Termination from 
the Study  
8.4.1.  Investigational Product Discontinuation  
A participant may discontinue IP at any time at his/her own request for any reason. The 
investigator may discontinue a participant from IP for safety, behavioral, compliance, or 
administrative reasons. Participants who discontinue IP will be encouraged by the i nvestigator to 
remain on study and complete the EOT visit, the safety phone call 7 days later, and then, after a 
further 7  days, the End of Study/ Early Termination visit (EOS/ETV) , as specified in the 
Schedule of Assessments ( Table 2 ). If the participant withdraw s consent to collect protected 
health information , the EOS/ETV will be conducted . 
The reason for IP discontinuation must be documented in the participantâ€™s study record and 
recorded in the participantâ€™s electronic case report form (eCRF).  
The investigator must notify the sponsor and/or the m edical monitor when a participant stops IP  
for any reason.  
Participant s who discontinue IP  due to an AE, regardless of i nvestigator -determined causality, 
should be followed until the event is resolved, considered stable , or the i nvestigator determines 
the event is no longer clinically significant.  
8.4.2.  Early Termination from the Study  
A participant may withdraw from the study at any time at his/her own request for any reason. 
The investigator may discontinue a participant fro m the study for safety, behavioral, compliance, 
or administrative reasons.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
33 The reason for early termination from the study must be documented in the participantâ€™s study 
record and recorded in the participantâ€™s electronic case report form (eCRF).  
The investigator must notify the sponsor and/or the m edical monitor when a participant stops 
participation in the study for any reason.  
If a participant is persistently noncompliant, the investigator should discuss with the sponsor the 
potential discontinuation of the participant. Any reasons for unwillingness or inability to adhere 
to the protocol must be recorded in the participantâ€™s eCRF, including: 
â€¢ missed visits;  
â€¢ interruptions in the schedule of study drug administration;  
â€¢ non-permitted medications  
If the participant withdraws from the study after completing 28 days of dosing with IP, they will 
be encouraged to attend follow -up visits for safety assessments at Day 35 and Day 42 , as 
specified in the Schedule of Assessments ( Table 2 ). If the participant withdraw s their consent to 
collect protected health information , the EOS/ETV  visit will be conducted and the participant 
will be permanently discontinued from the study at that time . 
If the participant withdraws consent for disclosure of future information, the sponsor will retain 
and continue to use any data collected before such a withdrawal of consent. 
If a participant withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the i nvestigator must document this in the site study records.  
8.4.3. Loss to Follow- up 
A participant will be deemed lost to follow -up after 3 attempts at contacting the participant have 
been unsuccessful .  
8.4.4. Replacement of Participants  
Participants will not be replaced.  However, a dditional participants may be enrolled if the drop-
out rate is higher than 15%. 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
34 9. TREATMENT OF PARTICIPANT S 
9.1. Description of Investigational Product  
SAGE -324 is an orally administered tablet provided in  15 mg dose strengths. Participants will 
receive IP (60 mg total dose of SAGE -324 tablets , or appearance- matched placebo tablets) 
according to the randomization schedule. Additional details regarding IP preparation, 
formulation, and storage are included in Section  10. 
9.2. Prior Medications, Concomitant Medications, Restrictions, and 
Contraception Requirements  
9.2.1. Prior and Concomitant Medications and/or Supplements  
The start and end dates, route, dose/units, frequency, and indication for all medications and/or 
supplements taken within 30 days prior to signing the informed consent through the first dose of 
IP will be recorded .  
All medications and/or supplements taken from the first dose of IP  through the Day 42 (Â± 1 days) 
visit (including start and end dates route, dose/units, frequency, and indication) will be recorded 
on the eCRF. Any concomitant medication determined necessary for the welfare of the 
participant  may be given at the discretion of the investigator at any time during the study.  
9.2.2. Prohibited Medications  
Use or consumption of the following is prohibited for the timeframes specified:  
â€¢ Treatment with an investigational drug or device during the 30 days or 5 half- lives (if 
known) of the investigational drug, whichever is longer, prior to Day 1  or during the 
study.  
â€¢ Use of tremorgenic drugs within the 14 days or 5 half- lives (whichever is longer) of 
Day 1  or during the study. 
â€¢ Use of  agents known to affect SAGE -324 drug metabolism (any known cytochrome 
P450 3A4 inhibitors and/or inducers) within the 14 days or 5 half- lives (whichever is 
longer) of Day 1  and through Day 29 of the study period. Use of mild cytochrome P 
inhibitors and/or inducers may be permitted. 
â€¢ Concomitant use of sedative/hypnotic drugs for 14 da ys or 5 half-lives prior to Day 1 
and during the 28-day dosing period.  
â€¢ Any prior ET medications must be discontinued prior to the Screening TETRAS: 
âˆ’ There must be 14 days or 5 half-lives (whichever is longer) washout period prior to the Day 1 (baseline) visit.    
âˆ’ For drugs requiring downtitration , there must be the required number of days for 
downtitration plus 14 days or 5 half- lives (whichever is lon ger) prior to the Day 1 
(baseline) visit.   
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
35 9.2.3. Other Restrictions  
â€¢ Use of any drugs of abuse during the study period is prohibited. Note: participants 
with a history of drug abuse prior to screening should not be enrolled in the study. 
â€¢ Use of alcohol within 1 week prior to Day 1 and through Day 29 of the study period is prohibited . If the alcohol test is positive on Days 1, 8, 15, 22, or 29, the participant 
will not be administered further IP and will be withdrawn from the study; no further 
efficacy assessments such as TETRAS will be undertaken.  
â€¢ Use of products that contain nicotine within 1 week prior to Day 1 and through Day 29 of the study period is prohibited. Positive cotinine testing on Days 8, 15, 22, 
or 29 would be considered a major protocol deviation and the participant will be excluded from the Per Protocol Analysis Set. Positive cotinine testing on Day 1 is exclusionary. 
â€¢ Consumption of grapefruit juice, grapefruit, Seville oranges, pomegranates, tangelos, or St. Johnâ€™s Wort or products containing these within 30 days prior to Day 1 and through Day 29 of the study period is prohibited.  
â€¢ Use of stimulants, highly caffeinated beverages or dietary supplements containing 
high doses of caffeine within 14 days prior to the Day 1 visit and through Day 29 of the study period is prohibited . Note: participants should not increase their regular 
daily consumption of caffeine during the study period.  
9.2.4. Acceptable Forms of Contraception  
Acceptable forms of highly effective contraception for participants of childbearing potential or 
for partners of male participants who are of childbearing potential include:  
â€¢ Combined (estrogen and progestogen containing) oral, intravaginal, or transdermal hormonal contraception associated with inhibition of ovulation  
â€¢ Oral, injectable, o r implantable progestogen- only hormonal contraception associated 
with inhibition of ovulation  
â€¢ Intrauterine device  
â€¢ Intrauterine hormone -releasing system  
â€¢ Bilateral tubal ligation  or bilateral tubal occlusion (performed at least 3 months prior 
to Screening)  
â€¢ Vasectomized partner  (performed at least 3 months prior to Screening)  
â€¢ Sexual abstinence (no sexual intercourse)  
Acceptable forms of contraception for male participants include:  
â€¢ Sexual abstinence (no sexual intercourse)  
â€¢ History of vasectomy  (performed at le ast 3 months prior to S creening)  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
36 â€¢ Condom with spermicide used together with highly effective female contraceptive 
methods if the female partner(s) is of childbearing potential (see above for list of 
acceptable female contraceptive methods)  
9.3. Intervention after the End of the Study  
There is n o planned intervention following the end of the study. 
9.4. Treatment Adherence  
The first dose of IP  will be received and administered by participants in the clinic . Participants 
will be dispensed a 7-day supply of IP  to orally self- administer  at home with instructions 
specifying to administer in the morning with food. Treatment adherence will be monitored by the 
site staff at each in -clinic visit by direct questioning and counting returned tablets  and will be 
documented. Details on drug accountability are included in Section  10.6. 
Patients will be asked to record the dates and times of their IP dose administrations at home in a 
diary. They will also record details around how well they complied with the study instructions 
for self-administering IP  at home. 
9.5. Randomization and Blinding 
This is a randomized, double-blind, placebo-controlled study. Participants will be randomized in 
a 1:1 ratio  to treatment group s (SAGE -324, 60 mg  or placebo). Participants, site staff, and the 
sponsor will be blinded to treatment allocation. Randomization  schedules will be generated by an 
independent statistician . The randomization schedules will be kept strictly confidential, 
accessible only to authorized  personnel until the time of unblinding. The blinding of the study 
will be broken after the database has been locked.  
9.5.1. Emergency Unblinding  
During the study, the blind is to be broken only when the safety of a participant  is at risk and the 
treatment plan is dependent on the study treatment received. Unless a participant is at immediate 
risk, the investigator should make diligent attempts to contact Sage prior to unblinding the study 
treatment administered to a participant. R equest s from the investigator about the treatment 
administered to study participant s should be discussed with the Sage  Medical Monitor . If the 
unblinding occurs without Sageâ€™s knowledge, the investigator must notify Sage within 24 hours of breaking the blind. All circumstances surrounding a premature unblinding must be clearly documented in the source recor ds.  
In all cases where the IP allocation for a participant is unblinded, pertinent information 
(including the reason for unblinding) must be documented in the participantâ€™s records and on the eCRF.  
If a participant or any study personnel become unblinded to treatment, the participant will be 
excluded from the Per Protocol analysis set, as detailed further in the statistical analysis plan. 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
37 10. INVESTIGATIONAL PRODUCT  MATERIALS AND 
MANAGEMENT  
10.1. Investigational Product 
Table 3: Investigational Product  
 Investigational Product 
Product Name:  SAGE -324 Placebo  
Dosage Form:  Tablet Tablet  
Tablet Strength  15 mg  0 mg, appearance-matched to 15 
mg, respectively  
Route of Administration  Oral Oral 
Physical Description Immediate release white to off -
white, round, film -coated tablet 
containing 15 mg  of SAGE -324 
drug substance, and composed 
of lactose, microcrystalline 
cellulose, croscarmellose sodium, sodium stearyl fumarate and fumed silica, featuring  
OpadryÂ® II white as the coating 
agent.  White to off -white, round, film -
coated tablet containing no drug substance, composed of lactose, 
microcrystalline cellulose, 
croscarmellose sodium, sodium stearyl fumarate and fumed silica, featuring  OpadryÂ® II 
white as the coating agen t.  
Manufacturer  Sage Therapeutics, Inc.  
10.2. Investigational Product Packaging and Labeling 
SAGE -324 Oral Tablets and Placebo Tablets will be  packaged in blinded, high density 
polyethylene (HDPE) containers.  The containers used for SAGE -324 and placebo will be 
identical in appearance.  The package labeling conforms to FDA and GMP requirements. 
10.3. Investigational Product Storage  
Upon receipt of the IP , the investigator, or the responsible pharmacist or designee, will inspect 
the product and acknowledge receipt in accordance with the study -specific process.  
The IP must be carefully stored at the temperature specified in the investigatorâ€™s brochure, 
securely and separately from other drugs. The IP  may not be used for any purpose other than the 
present study. Any  unused IP  must be returned per the sponsorâ€™s instructions or destroyed locally  
per the siteâ€™s procedure(s). IP may not be destroyed until accountability and reconciliation 
procedures have been completed  and monitored . 
The investigator or designee will be responsible for ensuring appropriate storage, dispensing, 
inventory, and accountability of the IP. An accurate, timely record of the disposition of the IP  
must be maintained.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
38 10.4. Invest igational Product Preparation  
The IP will be in tablet form and  provided in blinded packaging. No preparation is required for 
the tablet , which is administered orally as described below . 
10.5. Invest igational Product Administration 
The IP will be administered in the clinic or at home as specified in the Schedule of Assessments 
(Table 2 ). The IP will be provided as tablets , sufficient in number to achieve a dose of 60 mg. IP  
will be orally administered once daily  in the morning, with food. Participants will be instructed 
to take the IP with food that comprises a minimum of 400 calories , and to take the IP at 
approximately the same time each morning .  
If a participant reports moderate or seve re adverse events (as defined in Section  12.2.5 ) of 
somnolence, drowsiness, dizziness, or similar events, or experiences these events at any severity 
with associated symptoms such as confusion or balance impairment  on Day 1 or at any point 
during the treatment period, the dose m ust be adjusted per the criteria in Section  7.4. 
10.6. Invest igational Product Accountability , Handling, and Disposal  
Upon receipt of IP , the investigator(s), or the responsible pharmacist or designee, will inspect the 
IP and complete and follow the instructions regarding receipt and storage in the i nvestigatorâ€™s 
brochure and (where applicable) in the Pharmacy Manual. A copy of the shipping documentation 
will be kept in the study files.  
The designated site staff will dispense the supplied participant -specific kits to participants at the 
planned dispensation visit intervals outlined in  the Schedule of Assessments ( Table 2 ). 
An interactive response technology (IRT) will be used to capture participant- identifying 
information. The IRT will be used to randomize the eligible participant into the study and 
provides the kit number of the IP to be dispensed to that participant.  
If dispensing errors or discrepancies are discovered by site staff or sponsorâ€™s designee, the 
sponsor must be notified immediately.  
The IP provided is for use only as directed in this protocol. The investigator or designee must 
keep a record of all IP  received, used and returned/discarded.  
Sage Therapeutics will be permitted access to the study supplies at any time with appropriate 
notice during or after completion of the study to perform drug accountability reconciliation.   
The investigator, pharmacist, or qualified designee is responsible for drug accountability, 
reconciliat ion, and record maintenance (ie, receipt, reconciliation, and final disposition records). 
At the end of the study, any unused IP  tablets will be returned to Sage Therapeutics for 
destruction or destroyed locally per the siteâ€™s procedures ; disposition of IP will be documented. 
IP may not be destroyed until accountability and reconciliation procedures have been completed 
and monitored. 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
39 10.7. Product Complaints  
A product complaint is any written, electronic, or verbal expression of dissatisfaction regarding 
the iden tity, quality, reliability, safety, purity, potency, effectiveness or performance (applicable 
for approved marketed products) of a drug product after it is released for distribution.  
In the course of conduct of the study, study personnel may become aware of a product complaint 
associated with the use of a Sage product. Personnel shall notify Sage within 24 hours by 
forwarding the product complaint information via the contact information listed in Table 1  and in 
the Pharmacy Manual.  Where possible, personnel should segregate and retain  any product, 
materials, or packaging associated with the product complaint  until further instruction is 
provided by Sage or its designated representative(s) . 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
40 11. EFFICACY ASSESSMENTS AND CLINICAL PHARMACOLOGY 
ASSESSMENTS  
11.1. Efficacy Assessments  
11.1.1. The Essential Tremor Rating Assessment Scale 
TETRAS is a validated , comprehensive clinical assessment of essential tremor  (Elble 2013).  
Three different components of TETRAS will be assessed in this study. The TETRAS ADL 
subscale, total performance score, and performance subscale part 4 upper limb tremor  score will 
each be separately assessed  at each clinic visit as specified in the Schedule of Assessments 
(Table 2 ). 
The ADL subscale assesses how ET is impacting typical activities of daily living (ie, speech, 
eating, drinking, dressing, personal hygiene, writing, occupational impairment, social impact, 
and activities affected by upper limb tremor). It consists of 12 items that are  each  rated on a scale 
from 0  (normal activity)  to 4 (severe abnormality). The overall ADL score range is 0 to 48. 
The total performance score is based on overall rating  of tremor amplitude in the voice, limbs , 
head, face,  trunk, while performing pre -specified tasks, and also  measures functional task 
capabilities, ie, handwriting, spirography, and holding a pen over a dot. Each of these items is 
rated on a scale from 0  (no tremor) to 4 (severe tremor). Collectively, the performance items  
generate an  overall performance score fr om 0 to 64.  
For the performance subscale part 4 upper limb tremor  score, a ll 3 maneuvers in the upper limb 
assessments of part 4 ( subscale items 4a, 4b, and 4c) will be completed for both arms, first for 
the right arm and then for the left. The part 4 sub scale ordinally rates postural (limbs extended 
forward  maneuver, and wing -beating  [elbows flexed] maneuver), and kinetic (finger-nose-finger 
maneuver) tremor on a 0 to 4  severity scale in 0.5- point increments.  
In this study, a videographer will videotape each TETRAS administration . 
Prior medications for ET  must be discontinued prior to Screening TETRAS rating s (see 
Section  9.2.2 for w ashout periods). 
11.1.2. Kinesia ONEâ„¢ Accelerometer Score 
Kinesia ONEâ„¢ is an ISO -certified wireless motion sensor worn distally on the index finger, 
which utilizes 3 orthogonal accelerometers and 3 orthogonal gyroscopes to monitor 3-dimensional motion. Data is tra nsmitted wirelessly from the sensor to a Bluetooth technology -
enabled device to use with the Kinesia ONE software (eg,  Apple iPad or similar device with 
preinstalled Kinesia ONE software). The device has received FDA clearance.  
Via the Kinesia ONE software  application, measures of 3-dimensional motion are converted to 
scores ranging from 0 to 4, per assessed maneuver; higher scores indicate greater tremor severity. 
Motion in both arms is captured. 
Participants will complete this assessment at each clinic visit as specified in the Schedule of 
Assessments ( Table 2 ).  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
41 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
42 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
43 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
44 11.3. Other Patient- Reported Assessment s 
11.3.1. Patient Perception of Response Burden  
The Patient Perception of Response Burden Questionnaire is a patient -reported measure that 
assesses the multidimensional construct of response burden ( Atkinson 2019).  
Participants respond to 6 items assessing 1) how well the questions related to their actual 
concerns, 2) how comfortable the participants were with answering the questions, 3) how well 
the survey characterized their health and well -being, 4) the length of time to complete the 
questionnaires, 5) whether questions seemed unimportant or repetitive, and 6) what additional 
information should have been gathered. Items 1 to 3 are assessed on a 0 to 10 scale, item 4 is 
assessed on a 1 to 3 scale, and items 5 and 6 are open -ended. Items 1 and 4 are reverse scored. A 
composite score can be calculated to create a weighted representative index of relevance, 
comfort, and well-being relative to time to completion (ie, items 1, 2, and 3 were summed and 
multiplied by item 4) for a range of 0 to 72, with higher scores indicative of elevated endorsed response burden. The open- ended items will be summarized thematically. The Patient Perception 
of Response Burden Questionnaire will be performed as specified in the Schedule of Assessments ( Table 2 ). 
 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
45 12. SAFETY ASSESSMENTS  
12.1. Safety Parameters  
All assessments will be conducted according to the Schedule of Assessments (Table 2 ). 
12.1.1. Demograph y and Medical History  
Demographic characteristics (age, race, sex, ethnicity) and a full medical history will be 
documented. Whether the participant is left -handed or right-handed will be recorded. This must 
also additionally include pa rticipant  recall of history of ET, disease duration, past treatments  
used, and responsiveness to alcohol and/ or other treatments  with use intended as off- label  
treatment of ET (eg, primidone or similar therapies). 
12.1.2. Weight and Height  
Height and weight wi ll be measured and documented . Body mass index (BMI) will be calculated 
and documented.  
12.1.3. Physical Examination  
Whenever possible, the same individual should perform all physical examinations . Physical 
examinations will include review  of systems (eg, head, eye, ear, nose and throat; heart; lungs; 
abdomen; and extremities) as well as comprehensive neurological examination and MSE. 
Unscheduled physical examinations may also be conducted per the Investigatorâ€™s discretion. 
Any abnormality in physical examinations will be interpreted by an investigator as abnormal, not 
clinically significant (NCS); or abnormal, clinically significant (CS) in source documents .  
12.1.4. Vital Signs  
Vital signs comprise blood pressure and heart rate  (supine and standing) , respiratory rate, and 
temperature. Systolic and diastolic blood pressure and heart rate are to be measured after the 
participant  has been supine for at least 5  minutes  and then repeated 1 minute and 3 minutes after 
standing.  
Vital signs are measured once at each timepoint with the exception of predose on Day 1, when 
blood pressure and heart rate are measured supine and standing in triplicate at least 15 minutes apart . 
Any abnormality in vital signs will be interpreted by an Investigator as abnormal, NCS; or abnormal, CS in source documents. 
12.1.5. Electrocardiogram  
A 12 -lead ECG will be performed . The standard intervals (heart rate, PR, QRS, QT, and QTcF ) 
as well as any  rhythm abnormalities will be recorded.  
Electrocardiograms will be performed after the participant  has been resting in a supine position 
for at least 5 minutes. When ECG measurement s coincide with safety assessments, vital signs 
assessment or blood draws, procedures should be carried out in said order (vital signs , ECG, 
blood draw). 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
46 All abnormal ECGs will be interpreted by an investigator as abnormal, NCS, or abnormal, CS in 
source documents. 
12.1.6. Laboratory Assessments  
Blood and urine samples for clinical labora tory assessments will be collected . Analytes to be 
evaluated are summarized in Table  4. 
Table  4: Summary of Clinical Laboratory Analytes  
Biochemistry  Renal Panel : glucose, calcium, phosphorus, blood urea nitrogen, creatinine, 
sodium, potassium, chloride, bicarbonate  
Hepatic Panel : albumin, ALT, AST, total bilirubin, direct bilirubin, indirect 
bilirubin, alkaline phosphatase, total protein, lactate dehydrogenase, gamma 
glutamyl transferase  
Other: triglycerides, cholesterol (low density lipoprotein [LDL], high density lipoprotein [HDL]), creatine phosphokinase , thyroid stimulating hormone (TSH)  
Coagulation  activated partial thromboplastin time, prothrombin time, and international 
normalized ratio  
Hematology  red blood cell count, hemoglobin, hematocrit, white blood cell count with differential, platelet count, and if red blood count  indices are abnormal, reflex red 
blood cell  morphology a s indicated  
Urinalysis  protein, glucose, pH, blood, leukocyte este rase, urobilinogen, bilirubin, ketones, 
nitrite  
All clinical laboratory test results outside the reference range will be interpreted by the 
Investigator as abnormal, NCS; or abnormal, CS in source documents. 
Follicle stimulating hormone testing will be conducte d to confirm whether a participant with 
â‰¥12 months of spontaneous amenorrhea meets the protocol- defined criteria for being 
postmenopausal ( Section  8.1).  
12.1.6.1. Drugs of Abuse, Alcohol, Nicotine  (Cotinine)  
A urine sample will be collected for assessment of the following selected drugs of abuse per the 
Schedule of Assessments  (Table 2 ): amphetamines, barbiturates, benzodiazepines, 
cannabinoids /THC, cocaine, methadone , MDMA, methamphetamines, opiates, oxycodone, 
tricyclic  antidepressants, and PCP . 
Urine samples will  be collected and tested for cotinin e. Either urine dipstick or breathalyzer will 
be used for alcohol testing. 
12.1.6.2. Pregnancy Screen  
A serum pregnancy test will be conducted for all female participants at Screening ; subsequently, 
a urine pregnancy test will be conducted for all participants of childbearing potential as specified 
in the Schedule of Assessments ( Table 2 ).  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
47 12.1.9. Safety Phone Call  
A phone call will be conduct ed once per week , preferably mid -week in between clinic visits  (as 
specified in  Table 2 ), and again at Day 35, to collect information  about current health status, 
general well -being, IP compliance, or to gather other pertinent health -related information as per 
investigator judgem ent. 
If a dose interruption (drug holiday) followed by a dose reduction is  required , the investigator 
will speak with the participant to provide instructions  via the phone or the participant will have 
an in-person visit.  
12.2. Adverse Events and Serious Adverse Events 
12.2.1. Adverse Event  Definition  
An AE is any untoward medical occurrence in a patient or clinical investigation participant 
administered a pharmaceutical product and that does not necessarily have a causal relationship  
with this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom or disease temporally associated with the use of a 
medicinal (investigational) product whether or not related to the medicinal (investigational) 
product. In clinical studies, an AE can include an undesirable medical condition occurring at any time, including baseline or washout periods, even if no study treatment has been administered.  
A TEAE is defined as an AE with onset after the start of IP , or any worsening of a preexisting 
medical condition/AE  with onset after the start of IP  and throughout the study. The term IP  
includes any Sage IP, a comparator, or a placebo administered in a clinical trial.  

&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
/DERUDWRU\DEQRUPDOLWLHV DUHFRQVLGHUHG$(V
LIWKH\UHVXOWLQGLVFR QWLQXDWLRQRULQWHUUXSWLRQRIVWXG\WUHDWPHQWUHTXLUHWKHUDSHXWLFPHGLFDO
LQWHUYHQWLRQPHHWSURWRFROVSHFLILFFULWHULDLIDSSOLFDEOHR ULIWKHLQYHVWLJDWRUFRQVLGHUVWKHPWR
EHFOLQLFDOO\VLJQLIL FDQW$Q\DEQRUPDOLWLHV WKDWPHHWWKHFULW HULDIRUDQ6$(VKRXOGEHUHSRUWHG
LQDQH[SHGLWHGPDQQHU/DERUDWRU\DEQRUPDOLWLHV 
WKDWDUHFOHDUO\DWWULEXWDEOHWRDQRWKHU$(GRQRWUHTXLUHGLV FUHWHUHSRUWLQJHJHOHFWURO\WH
GLVWXUEDQFHVLQWKHFRQWH[WRIGHK\GUDWLRQFKHPLVWU\DQGKHPDW RORJLFGLVWXUEDQFHVLQWKH
FRQWH[WRIVHSVLV
$OO$(VWKDWRFFXUDIWHUDQ\SDUWLFLSDQWK DVVLJQHGWKH,&)DQGWKURXJKRXWWKHGXUDWLRQRIWKH
VWXG\ZKHWKHURUQRWWKH\DUHUHODWHGWRWKHVWXG\PXVWEHUH SRUWHGWR6DJH7KHUDSHXWLFV
3DUWLFLSDQWVZKRGLVFRQWLQXHWKH,3GXHWRDQ$(UHJDUGOHVVRI LQYHVWLJDWRUGHWHUPLQHG
FDXVDOLW\VKRXOGEHIROORZHGXQWLOWKHHYHQWLVUHVROYHGFRQV LGHUHGVWDEOHRUWKHLQYHVWLJDWRU
GHWHUPLQHVWKHHYHQWLVQRORQJHUFOLQLFDOO\VLJQLILFDQW$Q\$ (VWKDWDUHXQUHVROYHGDWWKH
SDUWLFLSDQWÂ¶VODVW$(DVVHVVPHQWLQWKHVWXG\DUHIROORZHGXSE \WKHLQYHVWLJDWRUIRUDVORQJDV
PHGLFDOO\LQGLFDWHGEXWZLWKRXWI XUWKHUUHFRUGLQJLQWKHH&5) 7KHVSRQVRURULWVUHSUHVHQWDWLYH
UHWDLQVWKHULJKWWRUHTXHVWDGGL WLRQDOLQIRUPDWLRQIRUDQ\SDU WLFLSDQWZLWKRQJRLQJ$(V6$(V
DWWKHHQGRIWKHVWXG\LIMXGJHGQHFHVVDU\
 6HULRXV$GYHUVH(YHQW6$('HILQLWLRQ
$Q6$(LVDQ\XQWRZDUGPHGLFDORFFXUUHQFHWKDWDWDQ\GRVH
x5HVXOWVLQGHDWK
x3ODFHVWKHSDUWLFLSDQWDWLPPHGLDWHULVNRIGHDWKDOLIHWKUHD WHQLQJHYHQWKRZHYHU
WKLVGRHVQRWLQFOXGHDQHYHQWWKDWKDGLWRFFXUUHGLQDPRUHVHYHUHIRUPPLJKWKDYH
FDXVHGGHDWK
x5HTXLUHVLQSDWLHQWKRVSLWDOL]DWL RQRUSURORQJDWLRQRIH[LVWLQJ KRVSLWDOL]DWLRQ
x5HVXOWVLQSHUVLVWHQWRUVLJQLILFDQWGLVDELOLW\RULQFDSDFLW\
x5HVXOWVLQDFRQJHQLWDODEQRUPDOLW\RUELUWKGHIHFW
$Q6$(PD\DOVREHDQ\RWKHUPHGL FDOO\LPSRUWDQWHYHQWWKDWLQWKHRSLQLRQRIWKH,QYHVWLJDWRU
PD\MHRSDUGL]HWKHSDUWLFLSDQWRU PD\UHTXLUHPHG LFDOLQWHUYHQWLRQWRSUHYHQWRIWKHRXWFRPHV
OLVWHGDERYHH[DPSOHVRIVXFKHYHQWVLQFOXGHDOOHUJLFEURQFKRV SDVPUHTXLULQJLQWHQVLYH
WUHDWPHQWLQDQHPHUJHQF\URRP RUFRQYXOVLRQVRFFXUULQJDWKRPH WKDWGRQRWUHTXLUHDQ
LQSDWLHQWKRVSLWDOL]DWLRQ
$OO6$(VWKDWRFFXUDIWHUDQ\SDUWLFLSDQWKDVVLJQHGWKH,&)DQGWKURXJKRXWWKHGXUDWLRQRIWKH
VWXG\ZKHWKHURUQRWWKH\DUHUHODWHGWRWKHVWXG\PXVWEHUH FRUGHGRQWKH6$(UHSRUWIRUP
SURYLGHGE\6DJH7KHUDSHXWLFV$Q\6$(WKDWLVRQJRLQJZKHQWKH SDUWLFLSDQWFRPSOHWHVWKHLU
ILQDOVWXG\YLVLWZLOOEHIROORZHGE\WKHLQYHVWLJDWRUXQWLOW KHHYHQWKDVUHVROYHGVWDELOL]HG
UHWXUQHGWREDVHOLQHVWDWXVRUXQWLOWKHSDUWLFLSDQWGLHVRUL VORVWWRIROORZXS
$SUHVFKHGXOHGRUHOHFWLYHSURFHGXUHRUURXWLQHO\VFKHGXOHGWUH DWPHQWZLOOQRWEHFRQVLGHUHGDQ
6$(HYHQLIWKHSDUWLFLSDQW LVKRVSLWDOL]HG7KHVLWHPXVWGRF XPHQWD
OORIWKHIROORZLQJPPD
PPD
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
49 â€¢ The prescheduled or elective procedure or routinely scheduled treatment was 
schedu led (or on a waiting list to be scheduled) prior to obtaining the participant â€™s 
consent to participate in the study.  
â€¢ The condition requiring the prescheduled or elective procedure or routinely scheduled treatment was present before and did not worsen or progress, in the opinion of an 
Investigator, between the participant â€™s consent to participate in the study and at the 
time of the procedure or treatment.  
12.2.3. Definition of Adverse Events of Special Interest  
There are no known adverse events of special interest as of the date of signature approval of this clinical protocol.  
12.2.4. Relationship to Investigational Product 
The investigator must make the determination of relationship to the IP for each AE (not related, 
related ). The following definitions should be considered when evaluating the relationship of AEs 
and SAEs to the IP .  
Not Related  An AE will be considered â€œnot relatedâ€ to the use of the IP if there is not a reasonable 
possibility that the event has been caused by t he IP. Factors pointing towards this 
assessment  include but are not limited to : the lack of temporal relationship between 
administration of the IP and the event, the presence of biologically implausible 
relationship between the product and the AE, or the presence of a more likely 
alternative explanation for the AE 
Related  An AE will be considered â€œrelatedâ€ to the use of the IP if there is a reasonable 
possibility that the event may have been caused by the product under investigation. 
Factors that point towards this assessment include but are not limited to: a positive 
rechallenge, a reasonable temporal sequence between administ ration of the drug and 
the event, a known response pattern of the suspected drug, improvement following 
discontinuation or dose reduction, a biologically plausible relationship between the 
drug and the AE, or a lack of alternative explanation for the AE  
12.2.5. Recording Adverse Events  
AEs spontaneously reported by the participant  and/or in response to an open question from the 
study personnel or revealed by observation will be recorded during the study at the 
investigational site. The AE term should be reported in standard medical terminology when possible. For each AE, the investigator will evaluate and report the onset (date and time), 
resolution (date and time), intensity, causality, action taken, outcome and seriousness (if 
applicable), and whether or not it c aused the participant to discontinue the IP  or withdraw early 
from the study . 
Intensity will be assessed  according to the following scale: 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
50 â€¢ Mild : symptom(s) barely noticeable to participant  or does not make participant 
uncomfortable; does not influence performance or functioning; prescription drug not 
ordinarily needed for relief of symptom(s)  
â€¢ Moderate: symptom(s) of a sufficient severity to make participant uncomfortable; 
performance of daily activity is influenced; participant  is able to continue in study; 
treatment for symptom(s) may be needed  
â€¢ Severe: symptom(s) cause severe discomfort; symptoms cause incapacitation or 
significant impact on participantâ€™s daily life; severity may cause cessation of 
treatment with IP; treatment for symptom(s) may be given and/or participant 
hospitalized   
It is important to distinguish between serious and severe AEs . Severity is a measure of intensity 
whereas seriousness is defined by the criteria under Section  12.2.2. An AE of severe intensity 
may not necessarily be considered serious.  
12.2.6. Reporting Serious Adverse Events 
In order to adhere to all applicable laws and regulations for reporting an SAE(s), the study site must notify Sage or designee within 24 hours of the study site staff becoming aware of the 
SAE(s). The investigator must complete, sign and date the SAE report form, verify the accuracy 
of the information recorded on the SAE r eport form with the corresponding source documents, 
and send a copy to Sage or designee.  
Additional follow-up information, if required or available, should all be sent  to Sage or designee 
within 24 hours of receipt on a follow -up SAE report form and placed with the original SAE 
information and kept with the appropriate section of the eCRF and/or study file. 
SAEs occurring after the designated follow up time for the study, should be reported to Sage or 
designee according to the timelines noted above only if the i nvestigator considers the SAE 
related to IP .  
Sage , or designee, is responsible for notifying the relevant regulatory authorities of certain 
events. It is the principal investigatorâ€™s responsibility  to notify the IRB/EC of all SAEs that occur 
at his or her site . Investigators will also be notified of all suspected unexpected serious adverse 
reactions  (SUSARs ) that occur during the clinical study. Each site is responsible for notifying its 
IRB of all  SUSARs .  
In addition, appropriate personnel in Sage  Drug Safety and Pharmacovigilance or designee will 
unblind SUSARs for the purpose of regulatory reporting. Sage  or designee will submit SUSARs 
(in blinded or unblinded fashion) to regulatory agencies according to local law. Sage , or 
designee, will submit SUSARs to i nvestigators in a blinded fashion. 
12.3. Pregnancy 
If a participant becomes pregnant after the first administration of IP , pregnancy information must 
be collected and recorded on the pregnancy form and submitted to the sponsor within 24 hours of 
learning of the pregnancy. Details will be collected for all pregnancies for which conception was 
likely  to have occurr ed after the start of IP administration until 5 terminal half- lives following 
the last administration of IP  or until the completion of the study whichever is longer. Any 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
51 pregnancy occurring in that time frame will be followed until delivery or termination of the 
pregnancy. The investigator will also attempt to collect pregnancy informatio n on any 
participant â€™s partner who becomes pregnant after the participant has received the first 
administration of IP . After obtaining the necessary signed informed consent from the pregnant 
partner directly, the investigator will follow the same pregnancy  reporting procedures specified 
for pregnant participant s.  
The participant  or participant â€™s partner will be followed to determine the outcome of the 
pregnancy. The outcome of all pregnancies (eg, spontaneous abortion, elective abortion, normal 
birth) must be followed and documented even if the participant was discontinued from the study. 
The investigator will collect follow -up information on the participant  or participantâ€™s partner and 
the neonate, and the information will be forwarded to Sage or designee. Generally, follow-up 
will not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any 
termination of pregnancy will be reported, regardless of fetal status (presence or ab sence of 
anomalies) or indication for the procedure. 
Pregnancy in itself is not regarded as an AE unless there is a suspicion that an IP  may have 
interfered with the effectiveness of a contraceptive medication. Any complication during 
pregnancy ( eg, anemia, infections, preeclampsia) should be reported as an AE/SAE. If the 
outcome of the pregnancy meets the criteria for immediate classification as an SAE (ie,  
spontaneous abortion, stillbirth, neonatal death), the investigator should follow the procedures for reporting an SAE.  
12.4. Overdose 
An overdose is any dose of IP  given to a participant or taken by a participant that exceeds the 
dose described in the protocol. Overdoses are not considered AEs and should not be recorded as 
an AE on the e CRF; however, all overdoses must be recor ded on an overdose form and sent to 
Sage or designee within 24 hours of the site becoming aware of the overdose. An overdose must be reported to Sage or designee even if the overdose does not result in an AE. If an overdose 
results in an AE, the AE must be recorded .  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
52 13. STATISTICS  
Detailed description of the analyses to be performed in the study will be provided in the 
statistical analysis plan (SAP). The SAP will be finalized and approved prior to database lock. 
Any changes or additions to the SAP following database lock will be described in detail in the clinical study report. 
13.1. Data Analysis Sets  
The Randomized Set wil l include all participants who are randomized.  
The Safety Set will include all participants administered IP.  
The Full Analysis Set will include all randomized participant s who received any amount of IP  
and have a baseline and at least one postbaseline TETRAS performance subscale part 4 upper 
limb tremor score.  
 
 
The Per Protocol Set will in clude all participant s in the Full Analysis Set without any major 
protocol deviations that could affect efficacy. The review of major protocol deviations will be completed, and the decision on whether the deviation affects efficacy will be documented befor e 
database unblinding. Note that a positive cotinine test on Days 1, 8, 15, 22 or 29 constitutes a 
major protocol deviation.  
13.2. Handling of Missing Data  
Every attempt will be made to avoid missing data . All participant s will be used in the analyses, 
as per th e analysis populations, using all nonmissing data available. No imputation process will 
be used to estimate missing data .  
13.3. General Considerations  
All participant data, including those that are derived, that support the tables and figures will be 
presented in the participant data listings. Some data may be presented only in participant data 
listing, some may be presented with a corresponding table or figure; these will be indicated in 
relevant sections below. Participants will be summarized according to treatment received.  
For the purpose of all primary and secondary analyses where applicable, baseline is defined as the last measurement prior to receipt of IP .  
Continuous endpoints will be summarized with number (n), mean, standard deviation, median, minimum, and maximum. In addition, change from baseline values will be calculated at each time point and summarized descriptively. For categorical endpoints, descriptive summaries will 
include counts and percentages. 
13.4. Demographics and Baseline Characteristics  
Demographic data, such as age, race, and ethnicity, and baseline characteristics, such as height, weight, and BMI, will be summarized using the Safety Set .  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
53 Pregnancy test  results and drug screen results will be listed but not summarized .  
Medical history will be listed by participant .  
13.5. Efficacy Analysis  
The estimand for the primary efficacy analysis is the treatment difference between SAGE -324 
and placebo in mean cha nge from baseline in clinic -based TETRAS performance subscale part 4 
upper limb tremor scores at Day 2 9 based on the Full Analysis Set. This will be analyzed using a 
mixed effects model for repeated measures (MMRM); the model will include treatment, baseline 
TETRAS performance subscale part 4 upper limb tremor score, assessment timepoint, and 
timepoint- by-treatment as explanatory variable s. All explanatory variables will be treated as 
fixed effects. All postbaseline clinic visits will be included in the model. The main comparison will be between SAGE -324 and placebo at the 29-day timepoint. Model- based point estimates 
(ie, least squares me ans, 5% confidence intervals, and p- values) will be reported where 
applicable. An unstructured covariance structure will be used to model the within- subject errors. 
If there is a convergence issue with the unstructured covariance model, Toeplitz compound symmetry or Autoregressive (1) [AR(1)] covariance structure will be used, following this 
sequence until convergence is achieved. If the model still does not converge with AR(1) structure, no results will be reported. When the covariance structure is not UN,  the sandwich 
estimator for the variance covariance matrix will be derived, using the EMPIRICAL option in 
the PROC MIXED statement in SAS.  
Similar to those methods described above for the primary endpoint, an MMRM will be used for 
the analysis of the chang e from baseline in TETRAS total performance score s, 
Kinesia ONE 
accelerometer  scores  and TETRAS ADL score s.  
Other efficacy analyses will be specified in the SAP. In general, data will be analyzed using 
appropriate descriptive statistics or prespecified statistical methods as applicable; participant  
listings will be provided for all efficacy data. Participants will be analyzed according to randomized treatment for the purpose of efficacy unless otherwise specified.  
Sensitivity analyses will be described in the SAP. 
13.6. Safety Analyses  
Safety and tolerability of SAGE -324 will be evaluated by AE s, concomitant medication usage, 
 
 Safety data will be listed by participant  and summarized by treatment group . All 
safety summaries will be performed on the Safety Set using treatment r eceived.   
13.6.1. Adverse Events  
AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 22.1 
or higher. A treatment- emergent adverse event (TEAE) is defined as an AE with onset after the 
first dose of IP . The analysis of AEs  will be based on the concept of TEAEs. The incidence of 
TEAEs will be summarized by System Organ Class (SOC) and preferred term. In addition, summaries will be provided by intensity (mild, moderate, severe) and by causality (related, not related) to IP.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
54 Any TEAEs  leading to discontinuation of treatment or withdrawal from the study and any 
treatment- emergent SAEs  will be summarized.  
All AEs and SAEs (including those with onset or worsening before the start of IP ) through the 
end of the study will be listed.  
13.6.3. Physical Examinations  
The occurrence of a physical examination , including MSE, (yes/no) and the date performed will 
be listed by participant . 
13.6.6. Prior and Concomitant Medications 
Medications will be recorded at each study visit  during the study and will be coded using World 
Health Organization -Drug dictionary (WHO -DD) September 2015, or later .  
All medications taken within 30 days prior to informed consent through the duration of the study 
will be recorded. In addition, all psychotropic medications taken in the previous 30 day s prior to 
screening will be recorded. Those medications taken prior to the initiation of the start of IP  will 
be denoted â€œPriorâ€. Those medications taken prior to the initiation of the IP and continuing 
beyond the initiation of the IP  or those medications started at the same time or after the initiation 
of the IP  will be denoted â€œConcomitantâ€.  
Medications will be presented according to whether they are â€œPriorâ€ or â€œConcomitantâ€ as 
defined above. If medication dates are incomplete and it is not clear whether the medication was 
concomitant, it will be assumed to be concomitant.  
Details of prior an d concomitant medications will be listed by participant, start date, and 
verbatim term.  

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
55 13.8. Sample Size  and Power  
The sample size of this study is based on the assumption of a 3 points difference in the change 
from baseline TETRAS performance subscale part 4 upper limb tremor score  between 
SAGE -324 and placebo with a standard deviation of 3.5 points. Under these assumptions, a 
sample size of 25 evaluable participants per group would provide 85% power for detecting a 
placebo -adjusted treatment difference of 3 points in TETRAS performance subscale part 4 upper 
limb tremor score assuming a 2- sided test at an alpha level  of 0.05. By including 2 treatment 
groups and using a 1:1 randomization, a total of 50 evaluable participants are required. Assuming 
a nonevaluability rate of 15%, approximately  60 participants  will be randomized.  Additional 
participants may be enrolled if the dropout rate is greater than 15%.  
13.8.1. Interim and Data Monitoring Committee (DMC) Analyses 
13.8.1.1. Interim Analysis  
The sponsor may conduct an interim analysis. Detailed descriptions of planned data analyses will be provided in a separate interim statistical analysis plan (SAP), if applicable . 

Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
56 13.8.1.2. DMC Analysis  
Not applicable 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
57 14. DIRECT ACCESS TO SOURCE DATA/DOCUMENTS  
14.1. Study Moni toring  
Before an investigational site can enter a participant into the study, a representative of Sage 
Therapeutics will visit the investigational study site  per Sage SOPs  to: 
â€¢ Determine the adequacy of the facilities  
â€¢ Discuss with the investigator(s) and ot her personnel their responsibilities with regard to 
protocol adherence, and the responsibilities of Sage Therapeutics or its representatives . 
This will be documented in a Clinical Trial Agreement between Sage Therapeutics and 
the investigator.  
During the study, a monitor from Sage Therapeutics or representative will have regular contacts 
with the investigational site, for the following:  
â€¢ Provide information and support to the investigator(s)  
â€¢ Confirm that facilities remain acceptable  
â€¢ Confirm that the investig ational team is adhering to the protocol, that data are being 
accurately recorded in the case report forms, and that IP accountability checks are being 
performed  
â€¢ Perform source data verification . This includes a comparison of the data in the case report 
forms with the participantâ€™s medical records at the hospital or practice, and other records relevant to the study. This will require direct access to all original records for each participant  (eg, clinic charts).  
â€¢ Record and report any protocol deviations not previously sent to Sage Therapeutics. 
â€¢ Confirm AEs and SAEs have been properly documented on eCRFs and confirm any SAEs have been forwarded to Sage Therapeutics and those SAEs that met criteria for 
reporting have been forwarded to the IRB or EC. 
The monitor will be available between visits if the investigator(s) or other staff needs 
information or advice.  
14.2. Audits and Inspections  
Sage Therapeutics or authorized representatives of Sage Therapeutics, a regulatory authority, or an independent EC or an I RB may visit the site to perform an audit(s) or inspection(s), including 
source data verification . The purpose of a Sage Therapeutics audit or a regulatory authority 
inspection is to systematically and independently examine all study -related activities and 
documents to determine whether these activities were conducted, and data were recorded, 
analyzed, and accurately reported according to the protocol, GCP/ICH GCP guidelines , and any 
applicable regulatory requirements . The investigator should contact Sage Therapeutics 
immediately if contacted by a regulatory agency  or IRB/EC  about an inspection. 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
58 14.3. Institutional Review Board or Ethics Committee 
The principal investigator must obtain IRB (or EC) approval for the clinical study  prior to 
enrolling a participant. Initial IRB (or EC) approval, and all materials approved by the IRB (or 
EC) for this study including the participant consent form and recruitment materials must be 
maintained by the investigator and made available for inspection. 
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
59 15. QUALITY C ONTROL AND QUALITY ASSURANCE 
To ensure compliance with Good Clinical Practice and all applicable regulatory requirements, 
Sage Therapeutics may conduct a quality assurance audit (s) at the clinical site . Please see 
Section  14.2  for more details regarding the audit process.  
The investigator must have adequate quality control practices to ensure that the study is 
performed in a manner consistent with the protocol, GCP/ICH GCP guidelines, and applicable 
regulatory requirements. The investigator is responsible for reviewing all ident ified protocol 
deviations. Significant protocol deviations should be reported to the IRB/EC per the IRB/ECâ€™s 
written procedures. 
The investigator is responsible for supervising any i ndividual or party to whom the investigator 
delegates trial-related duties  and functions conducted at the trial site. When the investigator 
retains the services of any individual or party to perform trial-related duties and functions, the 
investigator must ensure the individual or party is qualified to perform trial -related duties and 
functions and should implement procedures to ensure the integrity of the trial- related duties and 
functions performed, and any data generated.  
The investigator must maintain adequate and accurate source document s and trial records that 
include all pertinent observations on each of the siteâ€™s trial participants. Source data must be 
attributable, legible, contemporaneous, original, accurate, and complete. Changes to source data 
should be traceable, should not obscure the original entry, and should be explained, if necessary,  
to provide clarification . 
 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
60 16. ETHICS  
16.1. Ethics Review  
The final study protocol, including the final version of the I CF, must be given a written and 
dated approval or favorable opinion by an IRB or EC as appropriate. The inves tigator must 
obtain and document approval before he or she can enroll any participant  into the study. The IRB 
or EC  must supply to the sponsor a list of the IRB /EC membership and a statement to confirm 
that the IRB /EC is organized and operates according to  GCP and applicable laws and 
regulations. 
The principal investigator is responsible for informing the IRB or EC of any amendment to the 
protocol in accordance with local requirements. In addition, the IRB or EC must approve all 
advertising used to recruit participants for the study. The protocol must be re-approved by the 
IRB or EC upon receipt of amendments and annually, as local regulations require. 
The principal investigator is also responsible for providing the IRB or EC with reports of any 
reportable s erious adverse drug reactions from any other study conducted with the IP. Sage 
Therapeutics will provide this information to the principal investigator.  
Progress reports and notifications of serious adverse drug reactions will be provided to the IRB 
or EC according to local regulations and guidelines. In addition, the prin cipal investigator must 
inform the IRB /EC and sponsor of any changes significantly affecting the conduct of the trial 
and/or increasing the risk to participants (eg, violations to the protocol or urgent safety measures 
taken for participant safety) . 
16.2. Ethical Conduct of the Study  
The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH  and GCP guidel ines, as well as all  
applicable regional or national regulatory requirements. 
16.3. Written Informed Consent 
Prior to enrolling a trial participant, t he investigator(s) will ensure that the participant  is given 
full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study. Participant s must also be notified that they are free to discontinue from the 
study at any time . The participant should be given the opportunity to ask questions and allowed 
time to consider the information provided.  
When the participant decides to participate in the trial, the participant (or the participantâ€™s, parent 
or legally authorized representative)  must provide  signed and dated informed consent. The 
written consent must be obtained before conducting any study procedures. The investigator must 
document the consent process in the participantâ€™s source records. The investigator  must maintain 
the original, si gned ICF . A copy of the signed ICF  must be given to the participant or to the 
participantâ€™s  parent or legal ly authorized representative. 
Throughout the trial participants should be informed of any changes made to the study  and as 
new safety and or risk information  becomes known . The provision of this information will be 
documented in the participantâ€™s source records, and when applicable, an updated ICF will be 
provided. 
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
61 17. DATA HANDLING AND RECORDKEEPING  
17.1. Inspection of Records 
Sage Therapeutics or its representative(s) will be allowed to conduct site visits at the 
investigation facilities for the purpose of monitoring any aspect of the study. The investigator 
agrees to allow the monitor to inspect the facility, drug storage area, drug accountability records, 
participant  charts and study source documents, and other records relative to study conduct. 
Inspection of the study by a regulatory authority may occur at any time. The investigator must 
agree to the inspection of study- related records and source documents by the r egulatory authority 
representative (s).  
17.2. Retention of Records 
The principal investigator must maintain all documentation relating to the study for the period 
outlined in the site contract, or for a period of 2 years after the last marketing application 
approval, and until there are no pending or contemplated marketing applications in an ICH 
region or at least 2 years have elapsed since the formal discontinuation of clinical development 
of the investigational product. Sage i s responsible to inform the investigator/institution as to 
when study documents no longer need to be retained.  
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
62 18. PUBLICATION POLICY 
All information concerning SAGE -324 is considered confidential and shall remain the sole 
property of Sage Therapeutics. The investigator agrees to use this information only in conducting 
the study and shall not use it for any other purposes without written approval from Sage Therapeutics. No publication or disclosure of study results will be permitted except as specified 
in a separate, written, agreement between Sage Therapeutics and the investigator. 
&OLQLFDO3URWRFRO 6DJH7KHUDSHXWLFV,QF
(7'9HUVLRQ &21),'(17,$/
/,672)5()(5(1&(6
$WNLQVRQ706FKZDUW]&(*ROGVWHLQ/HWDO$VVHVVPHQWVLQ2QFRORJ\9DOXHLQ+HDOWK

%HOHOOL'&DVXOD$/LQJ$/DPEHUW--7KHLQIOXHQFHRIVXEXQ LWFRPSRVLWLRQRQWKHLQWHUDFWLRQ
RIQHXURVWHURLGVZLWK*$%$$UHFHSWRUV1HXURSKDUPDFRORJ\
'HXVFKO*5DHWKMHQ-+HOOULHJ HO+(OEOH57UHDWPHQWRISDWL HQWVZLWKHVVHQWLDOWUHPRU/DQFHW
1HXUR
(OEOH5%DLQ3)RUMD]0-HWDO7DVNIRUFHUHSRUWVFDOHVIR UVFUHHQLQJDQGHYDOXDWLQJWUHPRU
FULWLTXHDQGUHFRPPHQGDWLRQV0RY'LVRUG1RY 
*HQHWLFV+RPH5HIHUHQFH(VVHQWLDO7UHPRU/LVWHU+LOO1DWLRQDO &HQWHUIRU%LRPHGLFDO
&RPPXQLFDWLRQV861DWLRQDO/LEUDU\RI0HGLFLQH1DWLRQDO,QVWL WXWHVRI+HDOWK'HSDUWPHQWRI
+HDOWK	+XPDQ6HUYLFHV$YDLODEOHIURPKWWSVJKUQOPQLKJRYFRQGLWLRQHVVHQWLDOWUHPRU
$FFHVVHG6HSW
+RSIQHU)+DXEHQEHUJHU'*DOSHUQ:5HWDO.QRZOHGJHJDSVDQGUHVHDUFKUHFRPPHQGDWLRQV
IRUHVVHQWLDOWUHPRU3DUNLQV RQLVP5HODW'LVRUG
,QGHUDOÂŠSURSUDQROROK\GURFKORU LGH>SDFNDJHLQVHUW@3KLODGHO SKLD3$:\HWK
3KDUPDFHXWLFDOV,QF$FFHVVHGKWWSVZZZDFFHVVGDWDIGDJRYGU XJVDWIGDBGRFVODEHO VOEOSGI
.ROOHU:9HWHUH2YHUILHOG%$ FXWHDQGFKURQLFHIIHFWVRISURS UDQRORODQGSULPLGRQHLQ
HVVHQWLDOWUHPRU1HXURORJ\
/RXLV('2WWPDQ5+RZPDQ\SHRSOHLQWKH86$KDYHHVVHQWLDOW UHPRU"'HULYLQJD
SRSXODWLRQHVWLPDWHEDVHGRQHSLGH PLRORJLFDOGDWD7UHPRU2WKHU +\SHUNLQHW0RY1<
PPD
Clinical Protocol  Sage Therapeutics, Inc.  
324-ETD -201, Version 5 CONFIDENTIAL  
64 Olanow CW. Hyperkinetic Movement Disorders: Essential Tremor. In: Harrison's Principles of 
Internal Medicine. Vol 2. 17th ed. New York, NY: McGraw Hill; 2008:2560. 
Zappia M, Albanese A, Bruno E, et al. T reatment of essential tremor: a systematic review of 
evidence and recommendations from the Italian Movement Disorders Association.  Epub 2012 
Aug 11. Review. Erratum in: J Neurol. 2013 Mar;260(3):741. 

 
 o (617) 949.4256    f (617) 299.8379  
215 First Street, Cambridge, MA 02142  
www.sagerx.com  
  
 
 
324-ETD-201_Protocol Administrative Letter #1_16Nov2020     Page 1 of 3 
 
 
324-ETD-201 Protocol Administrative Letter # 1 
 
The purpose of this letter is to notify Investigators of an upcoming protocol amendment on the 
management of participants  experiencing adverse events of somnolence or similar events.   
 
This letter should be submitted to the local Independent Review Board (IRB) and filed within 
the Investigator Site File.  
 
The following represents the minimum action  an investigator must take in response to an 
experience of somnolence or similar adverse events experienced by a participant .  The 
investigator should, as always, continue to use their clinical judgement and institute drug 
holidays, dose reductions and IP discontinuations over and above these instructions  to ensure 
the safety and well -being of all participants . 
 
If a participant  experiences moderate or severe  adverse events of somnolence, drowsiness, 
dizziness or similar on Day 1 or at any point during the treatment period:  
ï‚· The Investigator must c arefully assess the participant before they leave the clinic  
ï‚· The Investigator must instruct the participant  prior to resuming study drug dosing via 
phone  call or in person  to ensure that:  
o The participant  has a drug holiday of at least one day (they must miss at least 
one dose)  
o The participant â€™s daily dose of study d rug must then be reduced from 60 mg to 
45 mg  when study drug dosing resumes  
ï‚· The Investigator must closely monitor the participant â€™s condition via phone call  or in 
person visit  to assess the effectiveness of the drug holiday and dose reduction.  
 
Following the first  drug holiday and dose reduction,  if the events persist and continue to be 
moderate or severe , or the participant  experiences a new moderate or severe AE of 
somnolence, drowsiness, dizziness or similar :  
ï‚· The Investigator must instruct the particip ant prior to resuming study drug dosing via 
phone  call or in person  to ensure that:  
o The participant  has another  drug holiday of at least one day (they must miss at 
least one dose)  
o The participant â€™s daily dose of study drug must then be further reduced from 45  
mg to 30 mg when study drug dosing resumes  
ï‚· The Investigator must closely monitor the participan tâ€™s condition via phone call  or in 
person visit  to assess the effectiveness of the drug holiday an d dose reduction  
 
DocuSign Envelope ID: 32AFE171-CE9C-45E4-B67E-71C2F2C1BDDD
 
 o (617) 949.4256    f (617) 299.8379  
215 First Street, Cambridge, MA 02142  
www.sagerx.com  
  
 
 
324-ETD-201_Protocol Administrative Letter #1_16Nov2020     Page 2 of 3 
 
Following the  second drug holiday and  dose reduction to 30 mg , if the events persist or recur 
and are moderate or severe : 
ï‚· The investigator must discontinue the participant from the Investigational Product (See 
Section 8.4.1 of Protocol: I nvestigational Product Discontinuation)  
  
If at any time somnolence, drowsiness, dizziness or similar  events of any severity are also 
associated with symptoms such as confusion or balance impairment:  
ï‚· The Investigator must f ollow the instructions as above  on drug holidays , dose reductions  
and IP discontinuation .  
 
 
 
 
 
 
 
 
 
____________________________________________                _________________________  
         Date  
 
 
 
 
 
 
 
 
 
 
 
 
____________________________________________                _________________________  
         Date  
, MD   
    
 
 
 
 
DocuSign Envelope ID: 32AFE171-CE9C-45E4-B67E-71C2F2C1BDDD
16-Nov-2020 | 21:03 EST16-Nov-2020 | 14:09 EST

 
 o (617) 949.4256    f (617) 299.8379  
215 First Street, Cambridge, MA 02142  
www.sagerx.com  
  
 
 
324-ETD-201_Protocol Administrative Letter #1_16Nov2020     Page 3 of 3 
 
 
 
 
 
_____________________________________                 _________________________  
         Date  
  
  
 
 
  
 
 
 
 
____________________________________________                _________________________  
         Date  
, MD , 
   
DocuSign Envelope ID: 32AFE171-CE9C-45E4-B67E-71C2F2C1BDDD
16-Nov-2020 | 13:14 EST
16-Nov-2020 | 14:54 EST

C ertifi c at e Of C o m pl eti o n
E n v el o p e I d: 3 2 A F E 1 7 1 C E 9 C 4 5 E 4 B 6 7 E 7 1 C 2 F 2 C 1 B D D D St at u s: C o m pl et e d
S u bj e ct: Pl e a s e D o c u Si g n: 3 2 4- E T D- 2 0 1 A d mi n L ett er 1 _ 1 6 N o v 2 0 2 0. d o c x
S o ur c e E n v el o p e: 
D o c u m e nt P a g e s: 3 Si g n at ur e s: 4 E n v el o p e Ori gi n at or: 
C ertifi c at e P a g e s: 2 I niti al s: 0
A ut o N a v: E n a bl e d
E n v el o p eI d St a m pi n g: E n a bl e d
Ti m e Z o n e: ( U T C- 0 5: 0 0) E a st er n Ti m e ( U S & C a n a d a)I P A d dr e s s:    
R e c or d Tr a c ki n g
St at u s: Ori gi n al
             1 6- N o v- 2 0 2 0 | 1 3: 0 2H ol d er: 
             L o c ati o n: D o c u Si g n
Si g n er E v e nt s Si g n at ur e Ti m e st a m p
S a g e T h er a p e uti c s - P art 1 1
S e c urit y L e v el: E m ail, A c c o u nt A ut h e nti c ati o n 
( R e q uir e d)Si g n at ur e A d o pti o n: Pr e- s el e ct e d St yl e
Si g n at ur e I D: 
U si n g I P A d dr e s s: 
Wit h Si g ni n g A ut h e nti c ati o n vi a D o c u Si g n p a s s w or d
Wit h Si g ni n g R e a s o n s ( o n e a c h t a b): 
   I h a v e r e vi e w e d t hi s d o c u m e ntS e nt: 1 6- N o v- 2 0 2 0 | 1 3: 0 4
R e s e nt: 1 6- N o v- 2 0 2 0 | 1 6: 1 9
Vi e w e d: 1 6- N o v- 2 0 2 0 | 2 0: 5 2 
Si g n e d: 1 6- N o v- 2 0 2 0 | 2 1: 0 3
El e ctr o ni c R e c or d a n d Si g n at ur e Di s cl o s ur e: 
      N ot Off er e d vi a D o c u Si g n
S a g e T h er a p e uti c s - P art 1 1
S e c urit y L e v el: E m ail, A c c o u nt A ut h e nti c ati o n 
( R e q uir e d)Si g n at ur e A d o pti o n: Pr e- s el e ct e d St yl e
Si g n at ur e I D: 
U si n g I P A d dr e s s: 
Wit h Si g ni n g A ut h e nti c ati o n vi a D o c u Si g n p a s s w or d
Wit h Si g ni n g R e a s o n s ( o n e a c h t a b): 
   I a p pr o v e t hi s d o c u m e ntS e nt: 1 6- N o v- 2 0 2 0 | 1 3: 0 4
Vi e w e d: 1 6- N o v- 2 0 2 0 | 1 4: 0 9 
Si g n e d: 1 6- N o v- 2 0 2 0 | 1 4: 0 9
El e ctr o ni c R e c or d a n d Si g n at ur e Di s cl o s ur e: 
      N ot Off er e d vi a D o c u Si g n
S a g e T h er a p e uti c s - P art 1 1
S e c urit y L e v el: E m ail, A c c o u nt A ut h e nti c ati o n 
( R e q uir e d)Si g n at ur e A d o pti o n: Pr e- s el e ct e d St yl e
Si g n at ur e I D: 
U si n g I P A d dr e s s: 
Wit h Si g ni n g A ut h e nti c ati o n vi a D o c u Si g n p a s s w or d
Wit h Si g ni n g R e a s o n s ( o n e a c h t a b): 
   I a p pr o v e t hi s d o c u m e ntS e nt: 1 6- N o v- 2 0 2 0 | 1 3: 0 4
Vi e w e d: 1 6- N o v- 2 0 2 0 | 1 3: 1 2 
Si g n e d: 1 6- N o v- 2 0 2 0 | 1 3: 1 4
Si g n er E v e nt s Si g n at ur e Ti m e st a m p
El e ctr o ni c R e c or d a n d Si g n at ur e Di s cl o s ur e: 
      N ot Off er e d vi a D o c u Si g n
S a g e T h er a p e uti c s - P art 1 1
S e c urit y L e v el: E m ail, A c c o u nt A ut h e nti c ati o n 
( R e q uir e d)Si g n at ur e A d o pti o n: Pr e- s el e ct e d St yl e
Si g n at ur e I D: 
U si n g I P A d dr e s s: 
Wit h Si g ni n g A ut h e nti c ati o n vi a D o c u Si g n p a s s w or d
Wit h Si g ni n g R e a s o n s ( o n e a c h t a b): 
   I a p pr o v e t hi s d o c u m e ntS e nt: 1 6- N o v- 2 0 2 0 | 1 3: 0 4
Vi e w e d: 1 6- N o v- 2 0 2 0 | 1 4: 5 3 
Si g n e d: 1 6- N o v- 2 0 2 0 | 1 4: 5 4
El e ctr o ni c R e c or d a n d Si g n at ur e Di s cl o s ur e: 
      N ot Off er e d vi a D o c u Si g n
I n P er s o n Si g n er E v e nt s Si g n at ur e Ti m e st a m p
E dit or D eli v er y E v e nt s St at u s Ti m e st a m p
A g e nt D eli v er y E v e nt s St at u s Ti m e st a m p
I nt er m e di ar y D eli v er y E v e nt s St at u s Ti m e st a m p
C ertifi e d D eli v er y E v e nt s St at u s Ti m e st a m p
C ar b o n C o p y E v e nt s St at u s Ti m e st a m p
Wit n e s s E v e nt s Si g n at ur e Ti m e st a m p
N ot ar y E v e nt s Si g n at ur e Ti m e st a m p
E n v el o p e S u m m ar y E v e nt s St at u s Ti m e st a m p s
E n v el o p e S e nt H a s h e d/ E n cr y pt e d 1 6- N o v- 2 0 2 0 | 1 3: 0 4
C ertifi e d D eli v er e d S e c urit y C h e c k e d 1 6- N o v- 2 0 2 0 | 1 4: 5 3
Si g ni n g C o m pl et e S e c urit y C h e c k e d 1 6- N o v- 2 0 2 0 | 1 4: 5 4
C o m pl et e d S e c urit y C h e c k e d 1 6- N o v- 2 0 2 0 | 2 1: 0 3
P a y m e nt E v e nt s St at u s Ti m e st a m p s